http://fasb.org/us-gaap/2022#UnrealizedGainLossOnInvestmentshttp://fasb.org/us-gaap/2022#UnrealizedGainLossOnInvestments639,4130http://fasb.org/us-gaap/2022#RealizedInvestmentGainsLosses--12-310http://fasb.org/us-gaap/2022#RealizedInvestmentGainsLosses0000012807840FY00false00001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:SeniorSecuredDebtMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2021-01-012021-12-310001280784htgc:SoftwareMemberhtgc:DispatchTechnologiesIncMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMemberhtgc:MajorityOwnedControlInvestmentsMember2021-01-012021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:EnGeneIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ShadowDragonLLCMember2021-12-310001280784htgc:DividendDeclaredFourMember2020-08-172020-08-170001280784us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberstpr:IL2021-01-012021-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:EqualityHealthLLCMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:DoorDashIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784us-gaap:CommonStockMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:TricidaIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2021-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:BetterTherapeuticsIncMemberus-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMember2022-01-012022-12-310001280784htgc:GeronCorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:LastOutWithSecurityInterestInAllOfTheAssetsMemberus-gaap:SalesRevenueNetMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:SeniorSecuredFirstLienMember2021-01-012021-12-310001280784us-gaap:SeriesEPreferredStockMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:WorldremitGroupLimitedOneMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MinimumMemberhtgc:ExpectedRealizableValueMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:SolarSpectrumHoldingsLLCMember2021-01-012021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:ScynexisIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SMBCFacilityMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2020-12-310001280784htgc:DividendDeclaredOneMember2022-03-162022-03-160001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMember2022-01-012022-12-310001280784htgc:ZappiIncMemberhtgc:SoftwareMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:WeMayNotHaveTheFundsOrAbilityToMakeAdditionalInvestmentsInOurPortfolioCompaniesMember2022-01-012022-12-310001280784us-gaap:CommonStockMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:CloudBoltSoftwareIncorporationMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:CodiakBiosciencesIncMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:LogicworksMember2021-12-310001280784htgc:InvestmentMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:CloudBoltSoftwareIncorporationMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:CommunicationsAndNetworkingMember2021-12-310001280784htgc:ConvertibleNoteDiscountsAmortizationMember2022-01-012022-12-310001280784htgc:ConvoyIncorporationMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:DividendDeclaredSixMember2021-08-182021-08-180001280784htgc:AssetBackedNotes2027Member2020-01-012020-12-310001280784htgc:AryakaNetworksIncMemberhtgc:SeniorSecuredDebtMemberhtgc:CommunicationsAndNetworkingMember2022-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:DebtInvestmentsMember2021-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:PreferredStockMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:NuvoloTechnologiesCorporationMember2022-12-310001280784us-gaap:RestrictedStockMemberus-gaap:CommonStockMember2022-01-012022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMember2021-01-012021-12-310001280784htgc:DistributableEarningsLossMember2020-01-012020-12-310001280784htgc:StockholdersMayIncurDilutionIfWeSellSharesOfCommonStockInOneOrMoreOfferingsAtPricesBelowThenCurrentNavPerShareOfCommonStockOrIssueSecuritiesToSubscribeToConvertToOrPurchaseSharesOfOurCommonStockMember2022-01-012022-12-310001280784us-gaap:PreferredStockMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:EquityInvestmentsMemberhtgc:BlackCrowAIIncMember2021-12-310001280784htgc:SeatGeekIncMemberus-gaap:CommonStockMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:SeriesCPreferredStockMemberhtgc:NorthSeaTherapeuticsMemberhtgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SMBCFacilityMemberus-gaap:SubsequentEventMember2023-01-130001280784htgc:XFourPharmaceuticalsIncMemberus-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:UnsecuredMemberhtgc:GibraltarBusinessCapitalLLCOneMember2021-12-310001280784htgc:SoftwareMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:FortifiedHealthSecurityMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:EscrowReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:SoftwareMemberhtgc:PymetricsIncorporationMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:FulfilSolutionsIncMember2021-12-310001280784htgc:SBADebenturesIssuedOnJulyTwentyEightTwoThousandAndTwentyOneMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:BiomXINCMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2022-01-012022-12-310001280784us-gaap:FairValueInputsLevel1Memberhtgc:MarchTwoThousandTwentySixANotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784us-gaap:SubsequentEventMemberhtgc:SupplementalDividendMember2023-02-092023-02-090001280784htgc:ChemocentryxIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:ElectronicsComputerHardwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMemberhtgc:INMOBIIncMember2021-12-310001280784htgc:HerculesAdviserLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberus-gaap:MemberUnitsMember2021-01-012021-12-310001280784htgc:PromissoryNotesMemberhtgc:BlackCrowAIIncMember2022-12-3100012807842020-04-012020-06-300001280784htgc:ForbionGrowthOpportunitiesFundIICVMemberhtgc:InvestmentFundsAndVehiclesMember2021-12-310001280784htgc:IfWeDefaultOnOurObligationsImposedUponUsByOurIndebtednessWeMayNotBeAbleToMakePaymentsOnOurOutstandingNotesAndCreditFacilitiesMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:HilleVaxIncMember2021-12-310001280784htgc:TheRespectiveIndenturesUnderWhichTheNotesWereIssuedContainLimitedProtectionsForTheHoldersOfTheNotesMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:ProventionBioIncMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:HalioIncPKKinestralTechnologiesIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:TGTherapeuticsIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:ElectronicsComputerHardwareMember2022-12-310001280784htgc:ThreeGTMSLLCMemberhtgc:DebtInvestmentsMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:TwoThousandTwentyTwoConvertibleNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:CommonStockMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:SmallBusinessAdministrationDebenturesHtIiiMember2020-01-012020-12-310001280784htgc:SoftwareMemberhtgc:EsmeLearningSolutionsIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMember2022-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:DebtInvestmentsMemberhtgc:GibraltarBusinessCapitalLLCMember2021-12-310001280784htgc:TwoThousandThirtyThreeNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:LocusBiosciencesIncMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:TwoThousandThirtyThreeNotesMember2021-01-012021-12-310001280784htgc:CommonStockParValueZeroPointZeroZeroOnePerShareMember2022-01-012022-12-310001280784htgc:KuraOncologyIncMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SoftwareMemberhtgc:ElationHealthIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SBADebenturesIssuedOnNovemberThirtyTwoThousandAndTwentyOneMember2022-12-310001280784htgc:ThePhaseOutOfLiborAndTheUseOfReplacementRatesForLiborMayAdverselyAffectTheValueOfOurPortfolioSecuritiesMember2022-01-012022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:GryphonNetworksCorporationMember2021-12-310001280784htgc:AxsomeTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:AffiliateInvestmentsMember2020-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMember2021-12-310001280784us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-12-310001280784htgc:TwoThousandTwentyTwoNotesMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMember2021-01-012021-12-310001280784htgc:ConsumerAndBusinessProductsMemberhtgc:EquityInvestmentsMemberus-gaap:CommonClassAMemberhtgc:SavageXHoldingLLCMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:ImpossibleFoodsIncMemberhtgc:SeriesEOnePreferredStockMemberhtgc:EquityInvestmentsMember2021-12-310001280784us-gaap:WarrantMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:CommunicationsAndNetworkingMember2022-12-310001280784htgc:PerformanceDeuMember2022-01-012022-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:FlightScheduleProLlcMember2022-12-310001280784htgc:TwoThousandTwentyTwoConvertibleNotesMember2022-01-012022-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:HilleVaxIncMember2022-12-310001280784htgc:HumanigenIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SmallBusinessAdministrationDebenturesHtIiiMember2016-01-012016-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:MarchTwoThousandTwentySixANotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:InformationServicesMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberus-gaap:PrimeRateMemberhtgc:ImpossibleFoodsIncMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:SoftwareMemberhtgc:AutomationAnyWhereIncMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:CommonGrossProceedsMember2021-01-012021-12-310001280784htgc:SeptemberTwoThousandTwentySixNotesMember2021-01-012021-12-310001280784us-gaap:SeriesEPreferredStockMemberhtgc:SoftwareMemberhtgc:EquityInvestmentsMemberhtgc:VeranaHealthIncMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:AldeyraTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:IncomeApproachValuationTechniqueMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMember2021-12-310001280784us-gaap:CommonStockMemberhtgc:PDSBiotechnologyCorporationMemberhtgc:DrugDeliveryMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:SeriesFPreferredStockMemberhtgc:ElectronicsComputerHardwareMemberhtgc:EquityInvestmentsMemberhtgc:LocusRoboticsCorporationMember2022-12-310001280784htgc:InformationServicesMemberhtgc:YipitLLCMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:ControlInvestmentsMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2020-01-012020-12-310001280784htgc:DebtInvestmentsMember2022-01-012022-12-310001280784us-gaap:CommonStockMemberhtgc:ScynexisIncMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2022-12-310001280784htgc:PDSBiotechnologyCorporationPKEdgeTherapeuticsIncMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMemberhtgc:DrugDeliveryMember2021-12-310001280784htgc:EquityInvestmentsMemberhtgc:SurgicalDevicesMember2021-12-310001280784htgc:SMBCFacilityMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001280784us-gaap:WarrantMembersrt:MaximumMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2022-12-310001280784htgc:Notes2025Member2019-01-012019-12-310001280784htgc:SumitomoMitsuiBankingCorporationFacilityMember2022-12-310001280784htgc:SoftwareMemberhtgc:SingleStoreIncMemberhtgc:EquityInvestmentsMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SeresTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:SeniorSecuritiesMember2016-01-012016-12-3100012807842021-01-012021-03-310001280784srt:MaximumMemberus-gaap:SubsequentEventMemberhtgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2023-01-132023-01-130001280784htgc:SixPointTwoFiveNotesDueTwoThousandThirtyThreeMember2022-01-012022-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMember2022-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputEbitdaMultipleMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784htgc:SoftwareMemberhtgc:SeriesAThreePreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:CapLinkedIncMember2021-12-310001280784us-gaap:CommonStockMember2020-01-012020-12-310001280784htgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMembersrt:MinimumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMember2022-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2022-12-310001280784htgc:SoftwareMemberhtgc:LogicSourceMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SnagajobcomIncMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:SeriesBPreferredStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:DividendDeclaredSevenMember2022-01-012022-12-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:PreferredStockMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:BetterTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784htgc:SeriesAAPreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:FlowonixMedicalIncorporatedMember2022-12-310001280784htgc:KuraOncologyIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:FairValueInputsLevel1Memberhtgc:SBADebenturesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:PreferredStockMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2021-01-012021-12-310001280784htgc:SyndaxPharmaceuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:ViridianTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:PollenIncOneMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:CommonStockMemberhtgc:ScynexisIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SBADebenturesIssuedOnJanuaryTwentyOneTwoThousandAndTwentyTwoMember2021-12-310001280784htgc:InternetConsumerAndBusinessServicesMember2022-12-310001280784htgc:KuraOncologyIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2022-12-310001280784htgc:BiotechnologyToolsMemberhtgc:SeniorSecuredDebtMemberhtgc:PathaiIncMember2022-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:CommunicationsAndNetworkingMember2021-01-012021-12-310001280784htgc:EvernoteCorporationMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:ConsumerAndBusinessServicesMemberhtgc:LendioIncMemberus-gaap:SeriesDPreferredStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:ConsumerAndBusinessProductsMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:TheFailureInCyberSecuritySystemsAsWellAsTheOccurrenceOfEventsUnanticipatedInOurDisasterRecoverySystemsAndManagementContinuityPlanningCouldImpairOurAbilityToConductBusinessEffectivelyMember2022-01-012022-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:MixpanelIncMemberhtgc:ExitFeeMember2021-12-310001280784htgc:DebtAndEquitySecuritiesUnrealizedGainLossMemberus-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-12-310001280784htgc:TwoThousandTwentyEightAssetBackedNotesMemberhtgc:UnusedFacilityOtherFeesMember2021-01-012021-12-310001280784htgc:CarwowLimitedMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:HerculesCapitalFourLPMember2021-01-012021-12-310001280784htgc:DebtInvestmentsMemberhtgc:VidaHealthMember2022-12-310001280784htgc:September2019NotesMember2014-01-012014-12-310001280784htgc:RecurringFeeIncomeMember2021-01-012021-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:SeniorSecuredDebtMemberhtgc:CarbonHealthTechnologiesIncMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:CodiakBiosciencesIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:CapRateMemberhtgc:GritstoneBioIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:CellarityIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:IncomeApproachValuationTechniqueMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:SustainableAndRenewableTechnologyMemberhtgc:DebtInvestmentsMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:VidaHealthIncMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:ElectronicsComputerHardwareMember2022-12-310001280784us-gaap:PreferredStockMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:BlackCrowAIIncMember2022-01-012022-12-310001280784htgc:CampaignMonitorLimitedMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:CommunicationsAndNetworkingMemberhtgc:CytracomHoldingsLLCMember2022-12-310001280784htgc:MarchTwoThousandTwentySixANotesMember2021-12-310001280784htgc:LiborMemberhtgc:SeniorSecuredDebtMemberhtgc:CommunicationsAndNetworkingMemberhtgc:CytracomHoldingsLLCMember2022-12-310001280784htgc:ElectronicsComputerHardwareMemberhtgc:SeniorSecuredDebtMemberhtgc:LocusRoboticsCorporationMemberhtgc:ExitFeeMember2022-12-310001280784htgc:TGTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:LyftIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:ThumbtackIncorporationMemberus-gaap:CommonStockMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:SkywordIncorporatinMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:IncludingCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784htgc:UniQureBVMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2013-01-012013-12-310001280784us-gaap-supplement:InvestmentUnaffiliatedIssuerMember2022-01-012022-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel1Member2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:AtaiLifeSciencesNVMember2022-12-310001280784htgc:Notes2024Member2019-01-012019-12-310001280784htgc:DebtInvestmentsMemberhtgc:AgilenceIncorporationMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:NextrollIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:SubsequentEventMemberhtgc:BaseDividendMember2023-02-090001280784us-gaap:WarrantMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMembersrt:MaximumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:DebtMaturingWithinOneYearMember2022-12-310001280784htgc:SignalMediaLimitedMemberhtgc:DebtInvestmentsMember2022-12-310001280784htgc:ManufacturingTechnologyMemberhtgc:MacroFabIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:HighRoadsIncMemberhtgc:EquityInvestmentsMember2021-12-310001280784htgc:TheNeatCompanyMemberhtgc:ConsumerAndBusinessProductsMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:DiversifiedFinancialServicesMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784us-gaap:FairValueInputsLevel1Memberhtgc:MarchTwoThousandTwentySixANotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:EloxxPharmaceuticalsIncMemberus-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SoftwareMemberhtgc:BrainCorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:EnGeneIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputRevenueMultipleMembersrt:MinimumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784htgc:SemiconductorsMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:MarchTwoThousandTwentySixBNotesMember2022-01-012022-12-310001280784htgc:SoftwareMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:SeniorSecuredDebtMemberhtgc:AlchemerLLCMember2022-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:SustainableAndRenewableTechnologyMemberhtgc:DebtInvestmentsMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784htgc:AppDirectIncorporationMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:BrainCorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:ConvoyIncorporationMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:SBADebenturesIssuedOnJanuaryFourteenTwoThousandAndTwentyTwoMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerMemberhtgc:ControlAndAffiliateInvestmentsMember2022-12-310001280784htgc:LiborMemberhtgc:EPayPolicyHoldingsLLCMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:DermavantSciencesLtdMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:TactAiTechnologiesIncMemberus-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:DynavaxTechnologiesMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-3100012807842020-10-012020-12-310001280784us-gaap:PreferredStockMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-12-310001280784us-gaap:ConvertibleDebtMemberhtgc:HouzzIncorporationMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784us-gaap:WarrantMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberhtgc:ValuationTechniqueMarketAdjustedOpmBacksolveMember2021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:SeriesCOnePreferredStockMemberhtgc:FulcrumBioenergyIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:MedicalDevicesAndEquipmentMember2022-12-310001280784htgc:SyndaxPharmaceuticsIncMemberhtgc:DebtInvestmentsMember2022-12-310001280784htgc:CarwowLimitedMemberus-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:SoftwareMemberhtgc:CloudNineSoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:BlueSprigPediatricsIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:WarrantMemberhtgc:ValuationTechniqueOtherMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784us-gaap:CommonStockMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:TelaBioIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784htgc:OperatingUnderTheConstraintsImposedOnUsAsABdcAndRicMayHinderTheAchievementOfOurInvestmentObjectivesMember2022-01-012022-12-310001280784us-gaap:ConvertibleDebtMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:BlackCrowAIIncMember2021-01-012021-12-310001280784htgc:ThreeGTMSLLCMemberhtgc:DebtInvestmentsMember2021-12-310001280784htgc:SoftwareMemberhtgc:EsmeLearningSolutionsIncMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:MedicalDevicesAndEquipmentMemberhtgc:WarrantInvestmentMemberhtgc:PhathomPharmaceuticalsIncMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:EnmarkSystemsIncorporationMember2022-12-310001280784htgc:IvericBioIncMemberhtgc:SeniorSecuredDebtMemberhtgc:CapRateMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SurgicalDevicesMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:FinchTherapeuticsGroupIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:XFourPharmaceuticalsIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:RealizedGainLossMember2019-01-012019-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2022-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputRevenueMultipleMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:GritstoneBioIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:OtherControlInvestmentsMember2022-01-012022-12-310001280784htgc:SignalMediaLimitedMemberhtgc:InformationServicesMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784srt:MinimumMemberhtgc:SumitomoMitsuiBankingCorporationFacilityMember2022-01-012022-12-310001280784htgc:EscrowReceivableMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-12-310001280784htgc:ALackOfIpoOrMergerAndAcquisitionOpportunitiesMayCauseCompaniesToStayInOurPortfolioLongerLeadingToLowerReturnsUnrealizedDepreciationOrRealizedLossesMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:OmedaHoldingsLlcMember2021-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:SecondLienMember2021-01-012021-12-310001280784htgc:OmedaHoldingsLlcMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SoftwareMemberhtgc:FortifiedHealthSecurityMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMembersrt:MinimumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:InternetConsumerAndBusinessServicesMemberus-gaap:CommonStockMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2021-12-310001280784htgc:WorldremitGroupLimitedMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:DebtInvestmentsMember2021-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:SustainableAndRenewableTechnologyMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2022-12-310001280784htgc:InformationServicesMemberhtgc:EquityInvestmentsMemberhtgc:PlanetLabsIncMemberus-gaap:CommonStockMember2022-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:TwoThousandThirtyThreeNotesMember2022-01-012022-12-310001280784us-gaap:SeriesEPreferredStockMemberhtgc:MedroboticsCorporationMemberhtgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2021-12-310001280784htgc:SonaCareMedicalLLCMemberhtgc:MedicalDevicesAndEquipmentMemberus-gaap:SeriesAPreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:AdviserFundsMember2021-01-012021-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMembersrt:WeightedAverageMemberhtgc:ValuationTechniqueMarketAdjustedOpmBacksolveMember2021-12-310001280784us-gaap:CommonStockMemberhtgc:ParatekPharmaceuticalsIncMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:IvericBioIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:ConsumerAndBusinessProductsMember2022-01-012022-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:SBADebenturesMember2020-01-012020-12-310001280784htgc:LiborMemberhtgc:WorldremitGroupLimitedMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:UniQureBVMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:ChemocentryxIncOneMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784htgc:SpilloveramountpershareMember2022-12-310001280784us-gaap:SubsequentEventMemberhtgc:SumitomoMitsuiBankingCorporationFacilityMember2023-01-132023-01-130001280784htgc:SmallBusinessAdministrationDebenturesHtIiMember2015-01-012015-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberus-gaap:CommonStockMember2021-12-310001280784htgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MinimumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerMemberhtgc:ControlAndAffiliateInvestmentsMember2020-01-012020-12-310001280784htgc:SeriesATwoPreferredStockMemberhtgc:CoronadoAestheticsLLCMemberhtgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2022-12-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CostApproachValuationTechniqueMember2021-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:AllAssetsIncludingIntellectualPropertyMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:SeniorSecuredFirstLienMember2022-01-012022-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:TwoThousandThirtyThreeNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:TwoThousandTwentyEightAssetBackedNotesMember2021-01-012021-12-310001280784htgc:ProvisionsOfTheMarylandGeneralCorporationLawAndOfOurCharterAndBylawsCouldDeterTakeoverAttemptsAndHaveAnAdverseImpactOnThePriceOfOurCommonStockMember2022-01-012022-12-310001280784htgc:TheMarketPriceOfOurSecuritiesMayBeVolatileAndFluctuateSignificantlyMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:AxsomeTherapeuticsIncMember2022-12-310001280784htgc:CommunicationsAndNetworkingMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:RealizedGainLossMemberhtgc:DistributableEarningsLossMember2022-01-012022-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2022-12-310001280784htgc:HerculesAdviserLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:MemberUnitsMemberhtgc:MajorityOwnedControlInvestmentsMember2022-01-012022-12-310001280784us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:CA2022-01-012022-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:DebtMemberhtgc:AppreciationMember2021-01-012021-12-310001280784htgc:TaxableSubsidiaryMember2022-01-012022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2021-01-012021-12-310001280784htgc:NextrollIncorporationMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784htgc:MUFGBankFacilityMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:OmedaHoldingsLlcMemberhtgc:SoftwareMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:PollenIncOneMemberus-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:CommonGrossProceedsMember2022-01-012022-12-310001280784htgc:SoftwareMemberhtgc:DemandbaseIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:CenturyTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:BlackCrowAIIncMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:ConstructorIoCorporationMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:TGTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberhtgc:ExpectedRealizableValueMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMember2021-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001280784htgc:ThumbtackIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:ExitFeeMember2022-12-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:SeniorSecuredDebtMemberhtgc:CarbonHealthTechnologiesIncMemberhtgc:ExitFeeMember2021-12-310001280784country:DE2022-12-310001280784htgc:MarchTwoThousandTwentySixANotesMember2020-01-012020-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:LiabilityClassifiedAwardsMember2022-12-310001280784htgc:GeronCorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:CommonStockMemberhtgc:BioQPharmaIncorporatedMemberhtgc:DrugDeliveryMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:WarrantMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:LastOutWithSecurityInterestInAllOfTheAssetsMemberus-gaap:SalesRevenueNetMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:SeniorSecuredFirstLienMember2022-01-012022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:PhathomPharmaceuticalsIncMemberhtgc:ExitFeeMember2022-12-310001280784htgc:UnvestedRestrictedStockAwardsMember2021-01-012021-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:WarrantInvestmentMemberhtgc:AppreciationMember2021-01-012021-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2021-12-310001280784htgc:FailureToComplyWithApplicableLawsOrRegulationsAndChangesInLawsOrRegulationsGoverningOurOperationsMayAdverselyAffectOurBusinessOrCauseUsToAlterOurBusinessStrategyMember2022-01-012022-12-310001280784htgc:AkeroTherapeuticsIncMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:EquitySecuritiesMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2022-12-310001280784us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:CA2021-01-012021-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:UnsecuredMember2021-12-310001280784htgc:DividendDeclaredFiveMember2021-01-012021-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2021-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784us-gaap:CommonStockMemberhtgc:BrickellBiotechIncMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:Notes2022Member2019-01-012019-12-310001280784htgc:MarchTwoThousandTwentySixANotesMember2022-01-012022-12-310001280784htgc:YumanityTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-3100012807842020-12-310001280784htgc:SoftwareMemberus-gaap:PreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:BlackCrowAIIncMember2022-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:CommonStockMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:CommonUnitsMemberhtgc:EquityInvestmentsMemberhtgc:NantEnergyLLCMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:InformationServicesMemberhtgc:CapellaSpaceCorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2022-12-310001280784htgc:SoftwareMemberhtgc:RivieraPartnersLLCMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:CybermaxxIntermediateHoldingsIncorporationMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:TactAiTechnologiesIncMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:February2025NotesMember2021-01-012021-12-310001280784htgc:AssetBackedNotes2028Member2020-01-012020-12-310001280784htgc:LiborMemberhtgc:ThreeGTMSLLCMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:AdviserSubsidiaryMember2022-12-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMemberhtgc:UnusedFacilityOtherFeesMember2022-01-012022-12-310001280784htgc:AdviserFundsMember2021-12-310001280784htgc:AeramiTherapeuticsHoldingsIncMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMemberhtgc:DrugDeliveryMember2022-12-310001280784htgc:TecturaCorporationTwoMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:CommonStockMemberhtgc:ValoHealthLLCPKIntegralHealthHoldingsLLCMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:RedshiftBioanalyticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SeniorSecuritiesMember2013-01-012013-12-310001280784us-gaap:CommonStockMemberhtgc:TransMedicsGroupIncPKTransmedicsIncMemberhtgc:SurgicalDevicesMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:BiotechnologyToolsMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:RVShareLimitedLiabilityCompanyMember2021-12-310001280784htgc:ManufacturingTechnologyMemberus-gaap:PrimeRateMemberhtgc:BrightMachinesIncorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:PIKInterestMember2020-01-012020-12-310001280784htgc:AcceleratedFeeIncomeEarlyRepaymentsMember2020-01-012020-12-310001280784htgc:SoftwareMemberhtgc:EsmeLearningSolutionsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2022-12-310001280784htgc:SoftwareMemberhtgc:DronedeployIncorporationMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:DebtAndEquitySecuritiesUnrealizedGainLossMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:OtherControlInvestmentsMemberhtgc:PreferredSeriesBBMemberhtgc:TecturaCorporationMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:ThumbtackIncorporationMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:CommunicationsAndNetworkingMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SBADebenturesIssuedOnJulyTwentyEightTwoThousandAndTwentyOneMember2021-12-310001280784us-gaap:SubsequentEventMemberus-gaap:CommonStockMember2023-01-012023-01-310001280784htgc:ReplimuneGroupIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:DiversifiedFinancialServicesMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:GibraltarBusinessCapitalLLCMember2022-12-310001280784htgc:InternetConsumerAndBusinessServicesMemberhtgc:SeriesGThreePreferredStockMemberhtgc:InteractionsCorporationMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001280784srt:MaximumMemberhtgc:SumitomoMitsuiBankingCorporationFacilityMember2022-01-012022-12-310001280784htgc:MedicalDevicesAndEquipmentMemberhtgc:WarrantInvestmentMember2021-12-310001280784country:US2021-12-310001280784htgc:DelphixCorporationMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784htgc:PerformanceVestingAwardMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:FebruaryTwoThousandTwentyFiveNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784us-gaap:SeriesCPreferredStockMemberhtgc:ContentfulGlobalIncMemberhtgc:EquityInvestmentsMemberhtgc:InternetConsumerAndBusinessServicesMember2021-12-310001280784htgc:CenturyTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:SeriesEPreferredStockMemberhtgc:SoftwareMemberhtgc:SingleStoreIncMemberhtgc:EquityInvestmentsMember2022-12-310001280784htgc:RhinoLabsIncorporationMemberus-gaap:CommonStockMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:UnionBankFacilityMember2021-12-310001280784us-gaap:SeriesCPreferredStockMemberhtgc:SoftwareMemberhtgc:DNAnexusIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:PrivateEquityFundsForeignMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ZimperiumIncMember2021-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:BetterTherapeuticsIncMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:BiotechnologyToolsMemberus-gaap:CommonStockMemberhtgc:PathaiIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001280784htgc:AveoPharmaceuticalsIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:DividendDeclaredThreeMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:ConvertibleNotes2022Member2022-01-012022-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:EquityInvestmentsMemberus-gaap:SeriesAPreferredStockMemberhtgc:GibraltarBusinessCapitalLLCMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:DashlaneIncorporationMember2021-12-310001280784htgc:EigenTechnologiesLimitedMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MinimumMemberhtgc:ExpectedRealizableValueMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:LogicworksMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:ViridianTherapeuticsIncMember2022-12-310001280784htgc:WeMayInTheFutureDetermineToIssuePreferredStockWhichCouldAdverselyAffectTheMarketValueOfOurCommonStockMember2022-01-012022-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:CouchbaseIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2020-01-012020-12-310001280784htgc:SBADebenturesIssuedOnMarchTwentySixTwoThousandAndTwentyOneMember2022-12-310001280784htgc:AppliedGeneticTechnologiesCorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784srt:MaximumMemberus-gaap:SubsequentEventMemberhtgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2023-01-130001280784htgc:SoftwareMember2022-12-310001280784htgc:AssetBackedNotes2017Member2013-01-012013-12-310001280784us-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:ParatekPharmaceuticalsIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:HerculesAdviserLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2022-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputEbitdaMultipleMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:VideoAmpIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SoftwareMemberhtgc:EquityInvestmentsMemberhtgc:DruvaHoldingsIncMember2022-12-310001280784htgc:DebtAndEquitySecuritiesUnrealizedGainLossMemberus-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310001280784htgc:OportunMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:InternetConsumerAndBusinessServicesMember2021-12-310001280784htgc:InternetConsumerAndBusinessServicesMemberus-gaap:SeriesDPreferredStockMemberhtgc:LendioIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:PreferredStockMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001280784htgc:SoftwareMemberhtgc:MobileSolutionsServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:ReplimuneGroupIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:UberTechnologiesIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:WorldremitGroupLimitedMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:EnmarkSystemsIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:RecurringFeeIncomeMember2020-01-012020-12-310001280784htgc:DeteriorationInTheEconomyAndFinancialMarketsCouldImpairOurPortfolioCompaniesFinancialPositionsAndOperatingResultsAndAffectTheIndustriesInWhichWeInvestWhichCouldInTurnHarmOurOperatingResultsMember2022-01-012022-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:TwentyThreeAndMeIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMember2022-12-310001280784us-gaap:CommonStockMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:TelaBioIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:SeniorSecuredDebtMember2021-01-012021-12-310001280784htgc:ThereMayBeCircumstancesWhereOurDebtInvestmentsCouldBeSubordinatedToClaimsOfOtherCreditorsOrWeCouldBeSubjectToLenderLiabilityClaimsMember2022-01-012022-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:BicycleTherapeuticsPLCMember2021-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:UnsecuredDebtOneMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784us-gaap:WarrantMemberhtgc:DebtAndEquitySecuritiesUnrealizedGainLossMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-12-310001280784htgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMember2022-01-012022-12-310001280784htgc:WeAreSubjectToRisksAssociatedWithTheCurrentInterestRateEnvironmentAndChangesInInterestRatesWillAffectOurCostOfCapitalNetInvestmentIncomeAndTheValueOfOurInvestmentsMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:AlchemerLLCMember2022-12-310001280784htgc:TheLackOfLiquidityInOurInvestmentsMayAdverselyAffectOurBusinessMember2022-01-012022-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:DebtInvestmentsMemberhtgc:GibraltarBusinessCapitalLLCMember2022-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:ConstructorIoCorporationMember2022-12-310001280784us-gaap:WarrantMemberhtgc:DebtAndEquitySecuritiesUnrealizedGainLossMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310001280784us-gaap:SubsequentEventMemberhtgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2023-01-012023-01-130001280784htgc:SemiconductorsMember2022-12-310001280784htgc:InformationServicesMemberus-gaap:CommonStockMemberhtgc:CapellaSpaceCorporationMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2017-01-012017-12-310001280784us-gaap:CommonStockMemberhtgc:ADMABiologicsIncMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMemberhtgc:UnusedFacilityOtherFeesMember2022-01-012022-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMember2022-01-012022-12-310001280784us-gaap:PrimeRateMemberhtgc:ElationHealthIncMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SoftwareMemberhtgc:MobileSolutionsServicesMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:UnsecuredDebtMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784htgc:AssetBackedNotes2027Member2019-01-012019-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerMemberhtgc:ControlAndAffiliateInvestmentsMember2021-01-012021-12-310001280784htgc:DebtInvestmentsMemberhtgc:KuraOncologyIncMember2022-12-310001280784htgc:MarchTwoThousandTwentySixANotesMember2022-12-310001280784htgc:InformationServicesMemberhtgc:CapellaSpaceCorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:DividendDeclaredFiveMember2021-08-182021-08-180001280784htgc:UnusedFacilityOtherFeesMemberhtgc:TwoThousandTwentyTwoNotesMember2021-01-012021-12-310001280784htgc:DiversifiedFinancialServicesMemberus-gaap:UnsecuredDebtMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784htgc:SoftwareMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:BabelStreetMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:DronedeployIncorporationMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2021-12-310001280784htgc:SBADebenturesIssuedOnNovemberFifteenTwoThousandAndTwentyOneMember2022-12-310001280784htgc:AppDirectIncorporationMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:FailureToMaintainOurStatusAsABdcWouldReduceOurOperatingFlexibilityMember2022-01-012022-12-310001280784htgc:PineappleEnergyLLCMemberhtgc:SustainableAndRenewableTechnologyMemberhtgc:SeniorSecuredDebtOneMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2021-12-310001280784htgc:WorldremitGroupLimitedMemberus-gaap:SeriesEPreferredStockMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SumitomoMitsuiBankingCorporationFacilityMember2022-01-012022-12-310001280784htgc:SBADebenturesMember2020-01-012020-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:RocketLabGlobalServicesLLCMemberhtgc:CommunicationsAndNetworkingMember2022-12-310001280784us-gaap:FairValueInputsLevel1Memberhtgc:JanuaryTwoThousandTwentySevenNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:VideoAmpIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:RedshiftBioanalyticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:EquityInvestmentsMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeriesSeedPreferredStockMemberhtgc:BlackCrowAIIncMember2021-12-310001280784htgc:InternetConsumerAndBusinessServicesMemberhtgc:EquityInvestmentsMember2021-12-310001280784us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMember2022-01-012022-12-3100012807842022-10-012022-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:IkonScienceLimitedMember2021-12-310001280784htgc:ConsumerAndBusinessProductsMemberhtgc:TechStyleIncPKJustFabulousIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMember2021-12-310001280784us-gaap:RestrictedStockMember2021-01-012021-12-310001280784htgc:ConvertibleNotes2016Member2015-01-012015-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:ChemocentryxIncTwoMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2020-02-050001280784us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:DiversifiedFinancialServicesMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:SeriesAPreferredStockMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:MadrigalPharmaceuticalIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:PollenIncTwoMember2021-12-310001280784us-gaap:UnsecuredDebtMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784htgc:SoftwareMemberhtgc:AlchemerLLCMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:EquitySecuritiesMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2021-12-310001280784htgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMemberhtgc:TechnologyMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:CytracomHoldingsLLCMember2022-12-310001280784htgc:ThreeMonthLIBORMember2022-12-310001280784htgc:SoftwareMemberhtgc:AutomationAnyWhereIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SeriesATwoPreferredStockMemberhtgc:CoronadoAestheticsLlcOneMemberhtgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2021-12-310001280784htgc:HibercellIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MaximumMemberhtgc:ExpectedRealizableValueMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:DividendDeclaredEightMember2021-11-172021-11-170001280784htgc:DividendDeclaredSixMember2020-11-162020-11-160001280784us-gaap:PrimeRateMemberhtgc:YumanityTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:CarwowLimitedMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:SoftwareMemberhtgc:CatchpointSystemsIncorporationMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:AveoPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:DividendDeclaredSixMember2022-01-012022-12-310001280784htgc:Notes2022Member2021-01-012021-12-310001280784htgc:WeMayBeTheTargetOfLitigationMember2022-01-012022-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMember2020-01-012020-12-310001280784us-gaap:CommonStockMemberhtgc:KinetaIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:GelesisIncMemberhtgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2021-12-310001280784htgc:ConsumerAndBusinessProductsMember2021-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:UnsecuredDebtOneMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784htgc:PineappleEnergyLLCMemberhtgc:DebtInvestmentsMember2022-12-310001280784htgc:TwoThousandThirtyThreeNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:PerformanceAwardsMember2021-01-012021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:LocusBiosciencesIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SBADebenturesIssuedOnOctoberTwentyOneTwoThousandAndTwentyOneMember2021-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyThreeTwoThousandAndTwentyOneMember2022-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:HerculesAdviserLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784htgc:DividendDeclaredOneMember2020-03-092020-03-090001280784htgc:TwoThousandTwentyEightAssetBackedNotesMemberhtgc:UnusedFacilityOtherFeesMember2020-01-012020-12-310001280784htgc:G1TherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:RevolvingCreditFacilityMember2022-01-012022-12-310001280784htgc:EquityAndWarrantInvestmentsMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:GelesisIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:MedicalDevicesAndEquipmentMember2022-12-310001280784htgc:SoftwareMemberhtgc:SeriesJuniorOnePreferredMemberhtgc:SignPostIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2021-12-310001280784htgc:CellarityIncMemberus-gaap:SeriesBPreferredStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:HtgcDebtAndEquitySecuritiesRealizedGainLossMember2021-01-012021-12-310001280784us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:GB2022-01-012022-12-310001280784htgc:MarchTwoThousandTwentySixANotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2022-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:EqualityHealthLLCMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:CommonStockMember2022-01-012022-12-310001280784htgc:AdviserSubsidiaryMember2022-01-012022-12-310001280784us-gaap:PreferredStockMemberhtgc:EquityInvestmentsMember2022-12-310001280784htgc:PharmaceuticalsMemberhtgc:DebtInvestmentsMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMemberhtgc:MeasurementInputHypotheticalMarketYieldMember2021-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DockerIncMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:OakStreetHealthIncMember2022-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMember2020-01-012020-12-310001280784country:GB2021-12-310001280784htgc:CapitalGainsMember2019-01-012019-12-310001280784us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:JobandtalentUSAIncorporationMember2022-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMemberhtgc:TechnologyMember2021-12-310001280784htgc:ManufacturingTechnologyMember2021-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:UnionBankFacilityMember2021-12-310001280784htgc:TwoThousandTwentyTwoConvertibleNotesMemberhtgc:AdditionalFaceAmountMember2017-01-250001280784htgc:ReischlingPressIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:SMBCFacilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:September2019NotesMember2017-01-012017-12-310001280784htgc:DividendDeclaredThreeMember2020-01-012020-12-310001280784htgc:TactAiTechnologiesIncMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:LogicSourceMember2022-12-310001280784us-gaap:PreferredStockMemberhtgc:EquityInvestmentsMember2021-12-310001280784htgc:SmallBusinessAdministrationDebenturesHtIiiMember2013-01-012013-12-310001280784htgc:AcceleratedFeeIncomeEarlyRepaymentsMember2021-01-012021-12-310001280784htgc:CertainOfOurAssetsAreSubjectToSecurityInterestsUnderOurSeniorSecuritiesAndIfWeDefaultOnOurObligationsUnderOurSeniorSecuritiesWeMaySufferAdverseConsequencesIncludingForeclosureOnThoseAssetsMember2022-01-012022-12-310001280784us-gaap:EquitySecuritiesMembersrt:MaximumMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784us-gaap:RestrictedStockMember2020-01-012020-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeriesThreePreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:DruvaHoldingsIncMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:CutoverIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:CoriumIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberus-gaap:CommonStockMember2020-12-310001280784htgc:EquityInvestmentsMemberhtgc:CommunicationsAndNetworkingMember2021-12-310001280784htgc:ContractualInterestIncomeMember2020-01-012020-12-310001280784us-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:RocketPharmaceuticalsLtdMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:EnmarkSystemsIncorporationMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:ReltioIncMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:AmplifybioLlcMemberus-gaap:CommonClassAMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2021-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap:ConvertibleDebtMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2022-01-012022-12-310001280784us-gaap:SeriesCPreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:SurgicalDevicesMemberhtgc:GynesonicsIncMember2022-12-310001280784htgc:UnionBankFacilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784us-gaap:ConvertibleDebtMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:BlackCrowAIIncMember2020-12-310001280784htgc:EquityAndWarrantInvestmentsMember2022-01-012022-12-310001280784htgc:DebtAndEquitySecuritiesUnrealizedGainLossMemberus-gaap:CommonStockMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-12-310001280784htgc:PerformanceVestingAwardMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:BlueSprigPediatricsIncMember2021-12-310001280784htgc:BiotechnologyToolsMember2021-12-310001280784us-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:DebtMaturingWithinOneYearMember2021-12-310001280784htgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyThreeTwoThousandAndTwentyOneMember2022-01-012022-12-310001280784htgc:LiabilityClassifiedAwardsMember2021-01-012021-12-310001280784us-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:BridgeBioPharmaIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:DeferredFeesMember2021-01-012021-12-310001280784htgc:InvestmentFundsVehiclesMember2022-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2022-12-310001280784us-gaap:SubsequentEventMemberhtgc:BaseAndSupplementalDividendMember2023-02-090001280784htgc:DividendDeclaredOneMember2021-03-152021-03-150001280784us-gaap:RestrictedStockMemberhtgc:CapitalInExcessOfParValueMember2020-01-012020-12-310001280784htgc:AvaloTherapeuticsIncPKCerecorIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputRevenueMultipleMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:HerculesAdviserLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberus-gaap:MemberUnitsMember2021-12-310001280784htgc:SignalMediaLimitedMemberhtgc:InformationServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:CapRateMember2022-12-310001280784htgc:CapitalInExcessOfParValueMember2022-12-310001280784htgc:SoftwareMemberhtgc:CampaignMonitorLimitedMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:SeniorSecuredDebtMember2022-12-3100012807842022-01-012022-03-310001280784htgc:IvericBioIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2022-12-310001280784srt:MaximumMemberhtgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:HalioIncPKKinestralTechnologiesIncMemberus-gaap:SeriesBPreferredStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:HerculesAdviserLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2021-12-310001280784htgc:EquityAndWarrantInvestmentsMember2021-01-012021-12-310001280784htgc:DebtInvestmentsMemberhtgc:IkonScienceLimitedMember2021-12-310001280784htgc:SkywordIncorporatinMemberus-gaap:CommonStockMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2022-12-310001280784country:NLus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001280784htgc:EquityInvestmentsMemberus-gaap:SeriesDPreferredStockMemberhtgc:GynesonicsIncMemberhtgc:SurgicalDevicesMember2022-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:CommonStockMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:ReplimuneGroupIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:TecturaCorporationOneMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:ScynexisIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:WarrantInvestmentMemberhtgc:DrugDeliveryMember2021-12-310001280784htgc:EquityInvestmentsMemberhtgc:DrugDeliveryMember2022-12-310001280784htgc:PineappleEnergyLLCMemberhtgc:SustainableAndRenewableTechnologyMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMember2022-12-310001280784htgc:ConsumerAndBusinessProductsMemberhtgc:TechStyleIncPKJustFabulousIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMember2022-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:UdacityIncMember2021-12-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CostApproachValuationTechniqueMemberus-gaap:MeasurementInputDiscountRateMemberhtgc:TechnologyMember2022-12-3100012807842022-04-012022-06-300001280784us-gaap:CommonStockMember2022-12-310001280784htgc:DividendDeclaredFourMember2022-01-012022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:CodiakBiosciencesIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784country:IEus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:AryakaNetworksIncMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-12-310001280784htgc:SoftwareMemberhtgc:ConstructorIoCorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:EquityInvestmentsMemberhtgc:ConsumerAndBusinessServicesMember2021-12-310001280784htgc:BiotechnologyToolsMember2022-12-310001280784htgc:DareBiosciencesIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:TwoThousandTwentySevenAssetBackedNotesMember2021-01-012021-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:MarchTwoThousandTwentySixANotesMember2020-01-012020-12-310001280784us-gaap:FairValueInputsLevel1Memberhtgc:FebruaryTwoThousandTwentyFiveNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:CapitalGainsMember2020-01-012020-12-310001280784htgc:AppliedGeneticTechnologiesCorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784htgc:HibercellIncMemberhtgc:EquityInvestmentsMemberus-gaap:SeriesBPreferredStockMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:TwoThousandTwentyTwoConvertibleNotesMember2017-01-250001280784htgc:SeniorSecuredDebtMemberhtgc:BicycleTherapeuticsPLCMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SoftwareMemberhtgc:SalaryComLlcMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:ProterraIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMember2021-12-310001280784us-gaap:WarrantMembersrt:MinimumMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:MixpanelIncMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:FortifiedHealthSecurityMember2022-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:AllAssetsWithNegativePledgeOnIntellectualPropertyMemberhtgc:SeniorSecuredFirstLienMember2022-01-012022-12-310001280784htgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784htgc:CarwowLimitedMemberhtgc:InternetConsumerAndBusinessServicesMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:ReltioIncMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:MUFGBankFacilityMember2022-12-310001280784htgc:DistributableEarningsLossMember2022-12-310001280784us-gaap:CommonStockMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMemberhtgc:LandingHoldingsIncMember2021-12-310001280784htgc:DividendDeclaredSixMember2022-08-162022-08-160001280784htgc:HerculesAdviserLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:UnsecuredDebtMemberhtgc:MajorityOwnedControlInvestmentsMember2021-01-012021-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001280784srt:MaximumMemberhtgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2023-01-130001280784htgc:DebtInvestmentsMemberhtgc:ShadowDragonLLCMember2022-12-310001280784htgc:SecurityTypeMember2022-01-012022-12-310001280784htgc:RegulationsGoverningOurOperationAsABdcWillAffectOurAbilityToAndTheWayInWhichWeRaiseAdditionalCapitalMember2022-01-012022-12-310001280784htgc:AprilTwoThousandTwentyFiveNotesMember2020-01-012020-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:ThreeGtmsLlcOneMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:UnsecuredDebtMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2020-12-310001280784htgc:CellarityIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:TactAiTechnologiesIncMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:RocketLabGlobalServicesLLCMemberhtgc:CommunicationsAndNetworkingMember2021-12-310001280784htgc:WeAreSubjectToRisksRelatedToCorporateSocialResponsibilityMember2022-01-012022-12-310001280784htgc:InformationServicesMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMemberhtgc:INMOBIIncMember2021-12-310001280784htgc:AmplifybioLlcMemberus-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerMemberhtgc:ControlAndAffiliateInvestmentsMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:ZimperiumIncMember2022-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:HerculesAdviserLLCMemberhtgc:EquityInvestmentsMemberus-gaap:MemberUnitsMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:CloudBoltSoftwareIncorporationMember2022-12-310001280784htgc:FinchTherapeuticsGroupIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:NuvoloTechnologiesCorporationMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:BlackCrowAIIncMember2021-12-310001280784htgc:ConvertibleNotes2022Member2017-01-012017-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:SeniorSecuredDebtMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2020-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:InternetConsumerAndBusinessServicesMember2022-01-012022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:RocketLabGlobalServicesLLCMemberhtgc:CommunicationsAndNetworkingMember2022-12-310001280784htgc:SBADebenturesIssuedOnJanuaryFourteenTwoThousandAndTwentyTwoMember2022-01-012022-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:CellarityIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SemiconductorsMemberhtgc:SeniorSecuredDebtMemberhtgc:FungibleIncorporationMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:CommonUnitsMemberhtgc:EquityInvestmentsMemberhtgc:NantEnergyLLCMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:SeniorSecuredDebtMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2022-12-310001280784htgc:AkeroTherapeuticsIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:ZimperiumIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:TwoThousandThirtyThreeNotesMember2020-01-012020-12-310001280784htgc:AryakaNetworksIncMemberhtgc:SeniorSecuredDebtMemberhtgc:CommunicationsAndNetworkingMemberhtgc:ExitFeeMember2022-12-310001280784htgc:MUFGBankFacilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:ConsumerAndBusinessProductsMember2021-01-012021-12-310001280784htgc:ConsumerAndBusinessProductsMemberhtgc:EquityInvestmentsMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:CerosIncorporationMember2022-12-310001280784htgc:SmallBusinessAdministrationDebenturesHtIiiMember2014-01-012014-12-310001280784country:NL2022-12-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2022-12-310001280784htgc:NuvoloTechnologiesCorporationMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784htgc:ThreeGTMSLLCMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:YumanityTherapeuticsIncMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:HibercellIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:InvestmentTypeConcentrationRiskMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMember2022-01-012022-12-310001280784htgc:WeAreDependentUponSeniorManagementPersonnelForOurFutureSuccessParticularlyScottBluesteinMember2022-01-012022-12-310001280784htgc:SyndaxPharmaceuticsIncMemberus-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:ConvertibleNoteDiscountsAmortizationMember2021-01-012021-12-310001280784htgc:EscrowReceivableMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:EvernoteCorporationMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784us-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310001280784htgc:PDSBiotechnologyCorporationPKEdgeTherapeuticsIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDeliveryMember2021-12-310001280784htgc:SharesOfClosedEndInvestmentCompaniesIncludingBdcsMayTradeAtADiscountToTheirNavMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:VidaHealthMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:BiomXINCMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:InvestingInOurSecuritiesMayInvolveAHighDegreeOfRiskMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:AlamarBiosciencesIncorporationMember2022-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:CloudNineSoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2021-01-012021-12-310001280784htgc:DebtInvestmentsMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:G1TherapeuticsIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarBusinessCapitalLLCMember2021-01-012021-12-310001280784htgc:HumanigenIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:DiversifiedFinancialServicesMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784htgc:DiscountsAmortizationMember2022-01-012022-12-310001280784htgc:WeMayExperienceFluctuationsInOurOperatingResultsMember2022-01-012022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:OtherControlInvestmentsMemberhtgc:PreferredSeriesBBMemberhtgc:TecturaCorporationMember2021-12-310001280784htgc:CommunicationsAndNetworkingMember2022-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMemberhtgc:TechnologyMember2022-12-310001280784htgc:AxsomeTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:UnusedFacilityOtherFeesMember2020-01-012020-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:TwoThousandTwentyTwoNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:EquityInvestmentsMember2022-12-310001280784htgc:EquityInvestmentsMemberus-gaap:SeriesBPreferredStockMemberhtgc:GynesonicsIncMemberhtgc:SurgicalDevicesMember2022-12-310001280784htgc:WeGenerallyWillNotControlOurPortfolioCompaniesMember2022-01-012022-12-310001280784htgc:InvestmentFundsVehiclesMemberhtgc:ForbionGrowthOpportunitiesFundICVMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:ReplimuneGroupIncMemberhtgc:SeniorSecuredDebtMemberhtgc:CapRateMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarBusinessCapitalLLCMember2021-12-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2022-12-310001280784htgc:EloxxPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:RVShareLimitedLiabilityCompanyMember2022-12-310001280784htgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2021-12-310001280784htgc:PerformanceAwardsMember2022-01-012022-12-310001280784htgc:SBADebenturesIssuedOnAugustTwentyTwoThousandAndTwentyOneMember2022-12-310001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:SioGeneTherapiesIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:MacroFabIncorporationMember2022-12-310001280784htgc:RecurringFeeIncomeMember2022-01-012022-12-310001280784htgc:DependingOnFundingRequirementsWeMayNeedToRaiseAdditionalCapitalToMeetOurUnfundedCommitmentsThroughAdditionalBorrowingsMember2022-01-012022-12-310001280784htgc:AeramiTherapeuticsHoldingsIncMemberus-gaap:CommonStockMemberhtgc:DrugDeliveryMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:CommonOfferingExpensesMember2020-01-012020-12-310001280784htgc:EloxxPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SoftwareMemberhtgc:DashlaneIncorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:SeptemberTwoThousandTwentySixNotesMemberhtgc:UnusedFacilityOtherFeesMember2021-01-012021-12-310001280784htgc:TwoThousandTwentyTwoConvertibleNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:ImpervaIncMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:NewfrontInsuranceHoldingsIncMemberhtgc:DiversifiedFinancialServicesMemberhtgc:SeriesDTwoPreferredStockMemberhtgc:EquityInvestmentsMember2022-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandTwentyTwoConvertibleNotesMember2021-12-310001280784us-gaap:PreferredStockMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:BlackCrowAIIncMember2021-01-012021-12-310001280784us-gaap:CommonStockMemberhtgc:EquityInvestmentsMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:TwoThousandThirtyThreeNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2022-01-012022-12-310001280784htgc:EquityInvestmentsMemberhtgc:SurgicalDevicesMember2022-12-310001280784htgc:SemiconductorsMemberhtgc:SeniorSecuredDebtMemberhtgc:FungibleIncorporationMember2022-12-310001280784us-gaap:CommonStockMember2019-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:FulfilSolutionsIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:RedshiftBioanalyticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:EvofemBiosciencesIncMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:PreferredStockMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784us-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixANotesMember2021-12-310001280784htgc:MUFGBankFacilityMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:SmallBusinessAdministrationDebenturesHtIiMember2014-01-012014-12-310001280784htgc:MarchTwoThousandTwentySixANotesMember2021-01-012021-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:BiotechnologyToolsMember2021-01-012021-12-310001280784htgc:RoyaltyContractMemberhtgc:PhathomPharmaceuticalsIncMember2022-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001280784srt:MinimumMemberus-gaap:SubsequentEventMemberhtgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2023-01-130001280784htgc:CarwowLimitedMemberus-gaap:CommonStockMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:CarwowLimitedMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:UnityBiotechnologyIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:DividendDeclaredSixMember2021-01-012021-12-310001280784us-gaap:CommonStockMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:RumbleONIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SBADebenturesMember2021-12-310001280784htgc:SingleStoreIncMemberhtgc:SoftwareMemberus-gaap:SeriesDPreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:IkonScienceLimitedMember2022-12-310001280784htgc:SoftwareMemberhtgc:PymetricsIncorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:GeronCorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:OtherTemporaryDifferencesMember2022-12-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberus-gaap:CommonStockMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:HerculesAdviserLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:NerdyIncMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ZimperiumIncMember2021-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:BetterTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:SeptemberTwoThousandTwentySixNotesMemberhtgc:UnusedFacilityOtherFeesMember2022-01-012022-12-310001280784us-gaap:PreferredStockMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:DruvaHoldingsIncOneMemberhtgc:SoftwareMemberhtgc:SeriesThreePreferredStockMemberhtgc:EquityInvestmentsMember2021-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SBADebenturesMember2022-12-310001280784us-gaap-supplement:InvestmentUnaffiliatedIssuerMember2020-01-012020-12-310001280784htgc:SecuritizedCreditFacilityWithWellsFargoCapitalFinanceMember2016-01-012016-12-310001280784us-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:TFGHoldingIncMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:MobileSolutionsServicesMember2022-12-310001280784htgc:SmallBusinessAdministrationDebenturesHtIiiMember2021-01-012021-12-310001280784htgc:SoftwareMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:SeniorSecuredDebtMemberhtgc:FlightScheduleProLlcMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-12-310001280784htgc:InformationServicesMemberus-gaap:CommonStockMemberhtgc:CapellaSpaceCorporationMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:SeriesAOnePreferredStockMemberhtgc:OfferUpIncMemberhtgc:EquityInvestmentsMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:UdacityIncMemberhtgc:ExitFeeMember2021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:DebtInvestmentsMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMemberhtgc:MeasurementInputHypotheticalMarketYieldMember2022-12-310001280784htgc:SoftwareMemberhtgc:ImpervaIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SoftwareMemberhtgc:AgilenceIncorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:InterestIncomeMember2020-01-012020-12-310001280784htgc:ElectronicsComputerHardwareMember2021-12-310001280784htgc:ThreeMonthLIBORMember2021-12-310001280784htgc:HumanigenIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784htgc:StockholdersMayHaveCurrentTaxLiabilityOnDividendsTheyElectToReinvestInOurCommonStockButWouldNotReceiveCashFromSuchDividendsToPaySuchTaxLiabilityMember2022-01-012022-12-310001280784htgc:AldeyraTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:NabrivaTherapeuticsMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2022-12-310001280784htgc:OfferUpIncMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:EquityInvestmentsMemberus-gaap:SeriesAPreferredStockMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:OtherControlInvestmentsMember2020-12-310001280784htgc:Notes2024Member2016-01-012016-12-310001280784htgc:TarsusPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:NextdoorComIncMemberhtgc:EquityInvestmentsMemberhtgc:InternetConsumerAndBusinessServicesMemberus-gaap:CommonStockMember2021-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMember2019-07-160001280784htgc:OurWhollyOwnedSubsidiaryIsLicensedByTheSbaAndThereforeSubjectToSbicRegulationsMember2022-01-012022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:PreferredStockMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2020-12-310001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2022-01-012022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarBusinessCapitalLLCMember2022-12-310001280784htgc:ReltioIncMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784htgc:ConsumerAndBusinessProductsMemberus-gaap:CommonClassAMemberhtgc:SavageXHoldingLLCMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:TwoThousandTwentyTwoConvertibleNotesMember2022-02-010001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2022-12-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberus-gaap:CommonStockMemberhtgc:MajorityOwnedControlInvestmentsMember2022-01-012022-12-310001280784htgc:SBADebenturesMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberhtgc:ExpectedRealizableValueMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputHypotheticalMarketYieldMembersrt:WeightedAverageMember2021-12-310001280784htgc:TactAiTechnologiesIncMemberus-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:TwoThousandTwentyTwoConvertibleNotesMemberhtgc:UnusedFacilityOtherFeesMember2020-01-012020-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:EquityInvestmentsMemberhtgc:GibraltarBusinessCapitalLLCMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784htgc:SeniorSecuritiesMember2015-01-012015-12-310001280784htgc:WeMayNotBeAbleToPayDistributionsToStockholdersDistributionsMayNotGrowOverTimeAndAPortionOfDistributionsPaidToStockholdersMayBeAReturnOfCapitalWhichIsADistributionOfTheStockholdersInvestedCapitalMember2022-01-012022-12-3100012807842023-02-090001280784htgc:SpringMobileSolutionsIncMemberus-gaap:CommonStockMemberhtgc:CommunicationsAndNetworkingMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:HerculesAdviserLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberus-gaap:MemberUnitsMember2020-12-310001280784htgc:SoftwareMemberhtgc:ContentfulGlobalIncMemberhtgc:EquityInvestmentsMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:PhathomPharmaceuticalsIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:AxsomeTherapeuticsIncMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:DividendDeclaredEightMember2022-01-012022-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputEbitdaMultipleMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2022-12-310001280784htgc:OurSuccessDependsOnAttractingAndRetainingQualifiedPersonnelInACompetitiveEnvironmentMember2022-01-012022-12-310001280784htgc:ViridianTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:InvestmentsInSecuritiesMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:PreferredStockMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2020-12-310001280784us-gaap:WarrantMembersrt:MaximumMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2022-12-310001280784htgc:ThreeGTMSLLCMemberhtgc:SoftwareMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:OmedaHoldingsLlcMember2022-12-310001280784htgc:SkywordIncorporatinMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:SeriesBPreferredStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-3100012807842019-01-012019-12-310001280784htgc:MedicalDevicesAndEquipmentMember2021-12-310001280784htgc:MUFGBankFacilityMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:SeniorSecuredDebtTwoMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2022-12-310001280784htgc:AssetBackedNotes2017Member2014-01-012014-12-310001280784us-gaap:PrimeRateMemberhtgc:KaleidoBiosciencesIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:CommonStockMemberhtgc:AlbireoPharmaIncMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:NetInvestmentIncomeMemberhtgc:DistributableEarningsLossMember2022-01-012022-12-310001280784htgc:MUFGBankFacilityMemberhtgc:UnusedFacilityOtherFeesMember2021-01-012021-12-310001280784us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:EquitySecuritiesMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784htgc:September2019NotesMember2013-01-012013-12-310001280784htgc:ControlAndAffiliateInvestmentsMember2021-01-012021-12-310001280784htgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MinimumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:DeferredFeesMember2021-12-310001280784htgc:BiomXINCMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:ManufacturingTechnologyMemberhtgc:BrightMachinesIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:SoftwareMemberhtgc:EquityInvestmentsMember2021-12-310001280784htgc:LiborMemberhtgc:HealthcareServicesOtherMemberhtgc:BlueSprigPediatricsIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:AkeroTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:EnGeneIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:ConvertibleNotes2016Member2014-01-012014-12-310001280784htgc:EscrowReceivableMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:MajorityOwnedControlInvestmentsMember2022-01-012022-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:SeniorSecuredDebtMember2021-01-012021-12-310001280784htgc:CellarityIncMemberus-gaap:SeriesBPreferredStockMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:CommonStockInvestmentMemberus-gaap:FairValueInputsLevel3Memberhtgc:AppreciationMember2022-01-012022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:BridgeBioPharmaIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:ManufacturingTechnologyMemberhtgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:MixpanelIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SingleStoreIncMemberhtgc:SoftwareMemberhtgc:EquityInvestmentsMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2021-12-310001280784us-gaap:RestrictedStockMemberus-gaap:CommonStockMember2021-01-012021-12-310001280784htgc:SolarSpectrumHoldingsLlcPKASungevityIncMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberus-gaap:CommonStockMember2020-12-310001280784htgc:ReltioIncMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:SBADebenturesIssuedOnOctoberTwentyOneTwoThousandAndTwentyOneMember2022-01-012022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:PreferredStockMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:BabelStreetMember2022-12-310001280784htgc:CapitalInExcessOfParValueMember2020-01-012020-12-310001280784htgc:DiversifiedFinancialServicesMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ThreatConnectIncMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:CytracomHoldingsLLCMember2021-12-310001280784htgc:PenumbraBrandsLLCMemberhtgc:ConsumerAndBusinessProductsMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:VeemIncorporationMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2020-01-012020-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:BlueSprigPediatricsIncMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMemberus-gaap:MeasurementInputDiscountRateMember2022-12-310001280784htgc:UnrealizedGainLossMember2018-01-012018-12-310001280784htgc:SoftwareMemberhtgc:DemandbaseIncorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:RivieraPartnersLLCMember2021-12-310001280784htgc:TheNotesAreUnsecuredAndThereforeEffectivelySubordinatedToAnyCurrentOrFutureSecuredIndebtednessMember2022-01-012022-12-310001280784htgc:SeatGeekIncMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMemberhtgc:TechnologyMember2022-12-310001280784htgc:UndistributedOrdinaryIncomeMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:InformationServicesMemberhtgc:CapellaSpaceCorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:StealthBioTherapeuticsCorpMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:DebtInvestmentsMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:TechnologyMember2021-12-310001280784htgc:InternetConsumerAndBusinessServicesMemberus-gaap:SeriesBPreferredStockMemberhtgc:CloudpayIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMemberhtgc:UnusedFacilityOtherFeesMember2020-01-012020-12-310001280784us-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:LegislativeOrRegulatoryTaxChangesCouldAdverselyAffectOurStockholdersMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:FortifiedHealthSecurityMember2021-12-310001280784htgc:SBADebenturesIssuedOnNovemberFifteenTwoThousandAndTwentyOneMember2021-12-310001280784us-gaap:PrivateEquityFundsForeignMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:SMBCFacilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:CapitalGainsMember2018-01-012018-12-310001280784us-gaap:PrimeRateMemberhtgc:RhinoLabsIncorporationMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:VeemIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:XFourPharmaceuticalsIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SkywordIncorporatinMemberhtgc:InternetConsumerAndBusinessServicesMemberus-gaap:SeriesBPreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:LiabilityClassifiedAwardsMember2021-12-310001280784us-gaap:EquitySecuritiesMembersrt:MaximumMemberus-gaap:MeasurementInputRevenueMultipleMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784htgc:ManufacturingTechnologyMemberhtgc:MacroFabIncorporationMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SoftwareMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:ZeroFoxIncMember2022-12-310001280784htgc:UnrealizedGainLossMember2022-01-012022-12-310001280784htgc:ValoHealthLLCMemberus-gaap:SeriesCPreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SeriesAAPreferredStockMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:FlowonixMedicalIncorporatedMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:ForbionGrowthOpportunitiesFundICVMemberhtgc:InvestmentFundsAndVehiclesMember2021-12-310001280784htgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:DividendDeclaredTwoMember2020-03-092020-03-090001280784htgc:NuvoloTechnologiesCorporationMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:ProviMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:SignalMediaLimitedMemberhtgc:InformationServicesMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:July2024NotesMember2020-01-012020-12-310001280784htgc:SeniorSecuritiesMember2021-01-012021-12-310001280784htgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2022-12-310001280784htgc:PDSBiotechnologyCorporationPKEdgeTherapeuticsIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDeliveryMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:MarchTwoThousandTwentySixANotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:SeniorSecuredDebtMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2021-12-310001280784htgc:ThreeGTMSLLCMemberhtgc:DebtInvestmentsMemberhtgc:SoftwareMember2022-12-310001280784htgc:TheDispositionOfOurInvestmentsMayResultInContingentLiabilitiesMember2022-01-012022-12-310001280784htgc:SBADebenturesIssuedOnMarchTwentySixTwoThousandAndTwentyOneMember2021-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-12-310001280784htgc:SMBCFacilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2020-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784us-gaap:SeriesCPreferredStockMemberhtgc:SurgicalDevicesMemberhtgc:GynesonicsIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:BrigadeGroupIncMember2021-12-310001280784us-gaap:EquitySecuritiesMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarBusinessCapitalLLCMember2020-12-310001280784htgc:DividendDeclaredSevenMember2021-11-172021-11-170001280784htgc:DebtInvestmentsMemberhtgc:AryakaNetworksIncMember2021-12-310001280784htgc:WeMayInTheFutureChooseToPayDistributionsInOurOwnStockInWhichCaseYouMayBeRequiredToPayTaxInExcessOfTheCashYouReceiveMember2022-01-012022-12-310001280784htgc:PerformanceAwardsMember2020-01-012020-12-310001280784htgc:CarwowLimitedMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:ExitFeeMember2022-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310001280784htgc:DebtInvestmentsMemberhtgc:ProventionBioIncMember2021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:HalioIncPKKinestralTechnologiesIncMemberus-gaap:SeriesAPreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784srt:MaximumMemberhtgc:ForeignCurrencyBorrowingMemberhtgc:SumitomoMitsuiBankingCorporationFacilityMember2022-12-310001280784htgc:HerculesAdviserLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberus-gaap:MemberUnitsMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:CopperCRMIncorporationMember2022-12-310001280784us-gaap-supplement:InvestmentUnaffiliatedIssuerMember2021-01-012021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMember2021-01-012021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:ChemocentryxIncTwoMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784htgc:DiversifiedFinancialServicesMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:UnsecuredDebtMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784htgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:RVShareLimitedLiabilityCompanyMember2021-12-310001280784htgc:EquityAndWarrantInvestmentsMember2020-01-012020-12-310001280784us-gaap:PrimeRateMemberhtgc:SkywordIncorporatinMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:BrainCorporationMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMemberhtgc:MajorityOwnedControlInvestmentsMember2020-12-310001280784htgc:SBADebenturesIssuedOnNovemberThirtyTwoThousandAndTwentyOneMember2021-12-310001280784htgc:Notes2022Member2020-01-012020-12-310001280784us-gaap:EquitySecuritiesMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784htgc:SoftwareMemberhtgc:ElationHealthIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:InvestingInPubliclyTradedCompaniesCanInvolveAHighDegreeOfRiskAndCanBeSpeculativeMember2022-01-012022-12-310001280784htgc:NetInvestmentIncomeMemberhtgc:DistributableEarningsLossMember2021-01-012021-12-310001280784htgc:AldeyraTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMemberhtgc:UnusedFacilityOtherFeesMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:ElationHealthIncMember2022-12-310001280784htgc:TwoThousandTwentyTwoConvertibleNotesMember2021-01-012021-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2022-12-310001280784htgc:MUFGBankFacilityMember2021-12-310001280784htgc:TaxableSubsidiaryMember2020-01-012020-12-310001280784us-gaap:WarrantMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:InformationServicesMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:ZetaGlobalCorpMember2021-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:PreferredStockMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:JobandtalentUSAIncorporationMemberhtgc:ExitFeeMember2022-12-310001280784htgc:SeriesThreePreferredStockMemberhtgc:EnGeneIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:DistributableEarningsLossMember2021-12-310001280784htgc:AcelRxPharmaceuticalsIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDeliveryMember2022-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:SemiconductorsMember2021-01-012021-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:UnityBiotechnologyIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SeniorSecuritiesMember2014-01-012014-12-310001280784htgc:LightbendIncMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMember2022-12-310001280784htgc:SoftwareMemberhtgc:EsentireIncorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:GeronCorporationMemberus-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:NuvoloTechnologiesCorporationMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:ControlAndAffiliateInvestmentsMember2021-12-310001280784htgc:ManufacturingTechnologyMemberhtgc:BrightMachinesIncorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:IncomeApproachValuationTechniqueMemberhtgc:SustainableAndRenewableTechnologyMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:SoftwareMember2021-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:HerculesAdviserLLCMemberhtgc:UnsecuredMember2022-12-310001280784htgc:SoftwareMemberhtgc:DemandbaseIncorporationMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:FairValueInputsLevel1Memberhtgc:TwoThousandTwentyTwoConvertibleNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMember2021-12-310001280784htgc:SMBCFacilityMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:SeptemberTwoThousandTwentySixNotesMember2022-12-310001280784htgc:IncludedInCostMember2021-12-310001280784htgc:FirstInsightIncMemberhtgc:SoftwareMemberus-gaap:SeriesBPreferredStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2022-01-012022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:CodiakBiosciencesIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SeresTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:LiborMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:RVShareLimitedLiabilityCompanyMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:ProventionBioIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:XFourPharmaceuticalsIncMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:PineappleEnergyLLCMemberhtgc:DebtInvestmentsMember2021-12-310001280784htgc:LightbendIncMemberhtgc:SoftwareMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMember2021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:SeriesCOnePreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:FulcrumBioenergyIncMember2022-12-310001280784us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001280784htgc:InvestmentFundsVehiclesMemberhtgc:SoftwareMemberhtgc:LibertyZimCoInvestLPMember2022-12-310001280784htgc:HerculesCapitalFourLPMember2022-01-012022-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SBADebenturesMember2022-12-310001280784htgc:SemiconductorsMemberhtgc:SeniorSecuredDebtMemberhtgc:FungibleIncorporationMemberhtgc:ExitFeeMember2022-12-310001280784htgc:HealthcareServicesOtherMemberus-gaap:SeriesCPreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:CarbonHealthTechnologiesIncMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:BiotechnologyToolsMember2022-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SBADebenturesMember2021-12-310001280784htgc:DividendDeclaredOneMember2022-01-012022-12-310001280784htgc:ConsumerAndBusinessServicesMemberhtgc:VeemIncorporationOneMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784country:IE2021-12-310001280784htgc:TheNeatCompanyMemberhtgc:ConsumerAndBusinessProductsMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:CapRateMemberhtgc:CopperCRMIncorporationMember2022-12-310001280784htgc:CommonOfferingExpensesMember2021-01-012021-12-310001280784htgc:Notes2024Member2015-01-012015-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:PhathomPharmaceuticalsIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784us-gaap:ConvertibleDebtMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:BlackCrowAIIncMember2021-12-310001280784htgc:SoftwareMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:GeographicalLocationMember2022-01-012022-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyThreeTwoThousandAndTwentyOneMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:AxsomeTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:MarchTwoThousandTwentySixANotesMember2022-01-012022-12-310001280784htgc:SmallBusinessAdministrationDebenturesHcIvMember2021-01-012021-12-310001280784htgc:NabrivaTherapeuticsMemberus-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:WellsFacilityMember2020-01-012020-12-310001280784us-gaap:PrimeRateMemberhtgc:ThumbtackIncorporationMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:MeasurementInputEbitdaMultipleMemberus-gaap:EquitySecuritiesMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784htgc:OptiscanBiomedicalCorpMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2020-12-310001280784htgc:ThreeGTMSLLCMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:HtgcDebtAndEquitySecuritiesRealizedGainLossMember2022-01-012022-12-310001280784htgc:AspireBariatricsIncMemberus-gaap:CommonStockMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:DebtAndEquitySecuritiesUnrealizedGainLossMemberus-gaap:CommonStockMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310001280784us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:LocusBiosciencesIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:ConsumerAndBusinessProductsMember2022-12-310001280784htgc:SMBCFacilityMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:MedicalDevicesAndEquipmentMember2021-01-012021-12-3100012807842020-01-012020-03-310001280784htgc:ManufacturingTechnologyMemberhtgc:DebtInvestmentsMember2022-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyOneMember2021-12-310001280784htgc:WorldremitGroupLimitedMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:SeriesDPreferredStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:SeriesAPreferredStockMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMemberhtgc:UnusedFacilityOtherFeesMember2020-01-012020-12-310001280784htgc:SmallBusinessAdministrationDebenturesHtIiiMember2015-01-012015-12-310001280784htgc:Notes2024Member2017-01-012017-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2021-01-012021-12-310001280784htgc:AveoPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:WorldremitGroupLimitedMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:ExitFeeMember2022-12-310001280784htgc:PIKInterestMember2022-01-012022-12-310001280784us-gaap:PrimeRateMemberhtgc:ChemocentryxIncOneMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2021-12-310001280784htgc:AcceleratedFeeIncomeExpiredCommitmentsMember2022-01-012022-12-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2022-06-220001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:HilleVaxIncMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:HilleVaxIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:HalioIncPKKinestralTechnologiesIncMemberus-gaap:SeriesBPreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SBADebenturesMember2021-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:EscrowReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:InvestmentFundsAndVehiclesMember2022-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:EquityInvestmentsMemberhtgc:GibraltarBusinessCapitalLLCMember2022-12-310001280784htgc:SnagajobcomIncMemberhtgc:InternetConsumerAndBusinessServicesMemberus-gaap:SeriesAPreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:AnnexCloudMemberhtgc:DebtInvestmentsMember2022-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:BetterTherapeuticsIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:WeThroughOurWhollyOwnedSubsidiaryIssueDebtSecuritiesGuaranteedByTheSbaAndSoldInTheCapitalMarketsMember2022-01-012022-12-310001280784us-gaap:SeriesFPreferredStockMemberhtgc:SingleStoreIncMemberhtgc:SoftwareMemberhtgc:EquityInvestmentsMember2022-12-310001280784htgc:SoftwareMemberhtgc:VideoAmpIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:BiotechnologyToolsMemberhtgc:SeniorSecuredDebtMemberhtgc:PathaiIncMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:AlbireoPharmaIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMemberhtgc:TechnologyMember2021-12-310001280784htgc:DividendDeclaredEightMember2021-01-012021-12-310001280784htgc:DebtInvestmentsMemberhtgc:ConsumerAndBusinessProductsMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:IvericBioIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001280784htgc:DiscountsAmortizationMember2020-01-012020-12-310001280784htgc:March2026BNotesMember2022-01-012022-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberus-gaap:CommonStockMember2022-01-012022-12-310001280784htgc:CommonUnitsMemberhtgc:ValoHealthLLCPKIntegralHealthHoldingsLLCMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SurgicalDevicesMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:ThumbtackIncorporationMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:OrdinaryIncomeMember2020-01-012020-12-310001280784htgc:IncludedInCostMember2022-01-012022-12-310001280784htgc:CenterForBreakthroughMedicinesHoldingsLLCMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:TGTherapeuticsIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SecuritizedCreditFacilityWithWellsFargoCapitalFinanceMember2019-01-012019-12-310001280784htgc:MedicalDevicesAndEquipmentMemberhtgc:FlowonixMedicalIncorporatedMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-01-012022-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:InvestmentTypeConcentrationRiskMember2022-01-012022-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2021-12-310001280784htgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:TecturaCorporationThreeMember2021-12-310001280784htgc:PineappleEnergyLLCMemberhtgc:SustainableAndRenewableTechnologyMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberus-gaap:CommonStockMember2021-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310001280784us-gaap:SeriesFPreferredStockMemberhtgc:SoftwareMemberhtgc:SingleStoreIncOneMemberhtgc:EquityInvestmentsMember2021-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:TwoThousandTwentyTwoConvertibleNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:AprilTwoThousandTwentyFiveNotesMemberhtgc:UnusedFacilityOtherFeesMember2021-01-012021-12-310001280784us-gaap:WarrantMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:AssetBackedNotes2021Member2016-01-012016-12-310001280784htgc:DebtInvestmentsMemberhtgc:SemiconductorsMember2021-12-310001280784htgc:ManufacturingTechnologyMemberhtgc:DebtInvestmentsMember2021-12-310001280784htgc:TapjoyIncMemberhtgc:InternetConsumerAndBusinessServicesMemberus-gaap:SeriesDPreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:March2026ANotesMember2020-01-012020-12-310001280784htgc:SixMonthLIBORMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:BlueSprigPediatricsIncMember2022-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMember2022-12-310001280784htgc:SeriesFOnePreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:SurgicalDevicesMemberhtgc:GynesonicsIncMember2021-12-310001280784htgc:HerculesAdviserLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2021-01-012021-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:MarchTwoThousandTwentySixBNotesMember2021-01-012021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:CouchbaseIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:AxsomeTherapeuticsIncMember2021-12-310001280784htgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2022-12-310001280784htgc:EquityInvestmentsMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:TecturaCorporationMember2021-12-310001280784htgc:MUFGBankFacilityMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001280784htgc:EquityInvestmentsMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:JulyTwoThousandTwentyFourNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:AgrividaIncMemberus-gaap:SeriesDPreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:IncomeApproachValuationTechniqueMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMember2022-12-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:PreferredStockMemberhtgc:MajorityOwnedControlInvestmentsMember2022-01-012022-12-310001280784htgc:SMBCFacilityMemberus-gaap:SubsequentEventMember2023-01-132023-01-130001280784htgc:ConsumerAndBusinessProductsMemberus-gaap:CommonStockMemberhtgc:GadgetGuardLLCMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:G1TherapeuticsIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:InvestmentMember2022-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:CloudBoltSoftwareIncorporationMember2022-12-310001280784htgc:TwoThousandThirtyThreeNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784us-gaap:CommonStockMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:LandingHoldingsIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SoftwareMemberhtgc:SeriesAThreePreferredStockMemberhtgc:CapLinkedIncMemberhtgc:EquityInvestmentsMember2022-12-310001280784us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:EquitySecuritiesMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2022-12-310001280784htgc:XFourPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:InternetConsumerAndBusinessServicesMember2021-12-310001280784htgc:SustainableAndRenewableTechnologyMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:AlbireoPharmaIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784htgc:AdviserSubsidiaryMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:EqualityHealthLLCMember2022-12-310001280784htgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2018-01-012018-12-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2022-01-012022-12-310001280784htgc:SoftwareMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:DockerIncMember2021-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:FebruaryTwoThousandTwentyFiveNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMember2021-01-012021-12-310001280784htgc:DiversifiedFinancialServicesMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784us-gaap:CommonStockMemberhtgc:TGTherapeuticsIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:ChemocentryxIncOneMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:GryphonNetworksCorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:SeniorSecuredDebtMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2022-01-012022-12-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2022-01-200001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:InformationServicesMember2022-01-012022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:MadrigalPharmaceuticalIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2022-12-310001280784htgc:AlladaptImmunotherapeuticsincMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMember2020-06-030001280784htgc:UniQureBVMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2022-12-310001280784htgc:SmallBusinessAdministrationDebenturesHtIiMember2013-01-012013-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMember2022-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:MobileSolutionsServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:PharmaceuticalsMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2021-12-310001280784htgc:BiotechnologyToolsMemberhtgc:SeniorSecuredDebtMemberhtgc:PathaiIncMemberhtgc:ExitFeeMember2022-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:ElectronicsComputerHardwareMember2021-01-012021-12-310001280784htgc:SoftwareMemberhtgc:EnmarkSystemsIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:TechnologicalInnovationsAndIndustryDisruptionsMayNegativelyImpactUsMember2022-01-012022-12-310001280784htgc:AcaciaPharmaIncMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:LogicSourceMember2021-12-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2022-01-202022-01-200001280784htgc:HealthcareServicesOtherMemberus-gaap:PrimeRateMemberhtgc:OakStreetHealthIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:WeWillBeSubjectToUSFederalIncomeTaxIfWeAreUnableToQualifyAsARicUnderSubchapterMOfTheCodeMember2022-01-012022-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:CommonStockMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:AssetBackedNotes2028Member2021-01-012021-12-310001280784htgc:IntuityMedicalIncMemberhtgc:SeriesBOnePreferredStockMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784us-gaap:PrimeRateMemberhtgc:AlladaptImmunotherapeuticsincMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:DividendDeclaredThreeMember2021-01-012021-12-310001280784htgc:RealizedGainLossMemberhtgc:DistributableEarningsLossMember2021-01-012021-12-310001280784htgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMember2021-12-310001280784us-gaap:CommonStockMember2020-12-310001280784htgc:LeaseAndLicenseObligationsMember2021-12-310001280784htgc:SMBCFacilityMember2021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:ImpossibleFoodsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784htgc:SeniorSecuritiesMember2020-01-012020-12-310001280784htgc:AsAnInternallyManagedBdcWeAreSubjectToCertainRestrictionsThatMayAdverselyAffectOurBusinessMember2022-01-012022-12-310001280784htgc:TactAiTechnologiesIncMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ShadowDragonLLCMember2021-12-310001280784htgc:HumanigenIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SmallBusinessAdministrationDebenturesHtIiMember2016-01-012016-12-310001280784htgc:DividendDeclaredThreeMember2020-05-212020-05-210001280784htgc:SeniorSecuredDebtMemberhtgc:LocusBiosciencesIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:ReischlingPressIncMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:CarbonHealthTechnologiesIncMember2021-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMember2021-03-042021-03-040001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2022-12-310001280784us-gaap:SeriesCPreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:SurgicalDevicesMemberhtgc:GynesonicsIncMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeriesJuniorOnePreferredMemberhtgc:SignPostIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SemiconductorsMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2021-01-012021-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CostApproachValuationTechniqueMember2021-12-310001280784htgc:DividendDeclaredTwoMember2021-01-012021-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:UnionBankFacilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:InformationServicesMemberhtgc:YipitLLCMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:SeriesEPreferredStockMemberhtgc:InformationServicesMemberhtgc:YipitLLCMemberhtgc:EquityInvestmentsMember2021-12-310001280784htgc:InformationServicesMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:ZetaGlobalCorpMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:YipitLLCMember2021-12-310001280784htgc:TheNotesAreStructurallySubordinatedToTheIndebtednessAndOtherLiabilitiesOfOurSubsidiariesMember2022-01-012022-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001280784htgc:HealthcareServicesOtherMemberus-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:CarbonHealthTechnologiesIncMember2022-12-310001280784htgc:GroveCollaborativeIncMemberhtgc:ConsumerAndBusinessProductsMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784htgc:EquityInvestmentsMemberhtgc:MedroboticsCorporationTwoMemberhtgc:MedicalDevicesAndEquipmentMemberus-gaap:SeriesGPreferredStockMember2021-12-310001280784htgc:DelphixCorporationMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMemberhtgc:MeasurementInputHypotheticalMarketYieldMembersrt:WeightedAverageMember2022-12-310001280784us-gaap:IncomeApproachValuationTechniqueMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:TGTherapeuticsIncMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:AmplifybioLlcMemberhtgc:SeniorSecuredDebtMemberhtgc:CapRateMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMemberhtgc:UnusedFacilityOtherFeesMember2022-01-012022-12-310001280784htgc:GroveCollaborativeIncMemberhtgc:ConsumerAndBusinessProductsMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:CodiakBiosciencesIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:JanuaryTwoThousandTwentySevenNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:RocketLabGlobalServicesLLCMemberhtgc:CommunicationsAndNetworkingMember2021-12-310001280784htgc:SeniorSecuredDebtOneMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2021-12-310001280784htgc:Notes2033Member2020-01-012020-12-310001280784htgc:SecuredCreditFacilityWithSumitomoMitsuiBankingCorporationSMBCMember2022-01-012022-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMembersrt:MinimumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:FlightScheduleProLlcMember2022-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:HerculesAdviserLLCMemberhtgc:EquityInvestmentsMemberus-gaap:MemberUnitsMember2021-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:FebruaryTwoThousandTwentyFiveNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:SeresTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:TerroristAttacksActsOfWarPublicHealthCrisesOrNaturalDisastersMayAffectAnyMarketForOurSecuritiesImpactTheBusinessesInWhichWeInvestAndHarmOurBusinessOperatingResultsAndFinancialConditionMember2022-01-012022-12-310001280784htgc:SoftwareMember2021-12-310001280784htgc:VeemIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:DemandbaseIncorporationMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2020-12-310001280784htgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:AnnexCloudMemberhtgc:SoftwareMemberhtgc:BloombergShorttermBankYieldIndexMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:SeriesEPreferredStockMemberhtgc:RedshiftBioanalyticsIncMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SBADebenturesIssuedOnJuneTwentyFiveTwoThousandAndTwentyOneMember2022-12-310001280784htgc:SoftwareMemberhtgc:BrainCorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:DebtInvestmentsMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:UdacityIncMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:ElationHealthIncMember2021-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputRevenueMultipleMembersrt:MaximumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:EquitySecuritiesMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:PhathomPharmaceuticalsIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784htgc:WorldremitGroupLimitedMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784us-gaap:PreferredStockMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:BlackCrowAIIncMember2022-12-310001280784htgc:EscrowReceivableMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsImminentPayoffsMember2022-12-310001280784htgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MaximumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:SkywordIncorporatinMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMember2020-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyEightTwoThousandAndTwentyOneMember2021-12-310001280784us-gaap:SeriesFPreferredStockMemberhtgc:FuzeIncMemberhtgc:SoftwareMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:ViewRayIncMemberhtgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2021-12-310001280784us-gaap:SalesRevenueNetMemberus-gaap:PreferredStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:EquityInvestmentsMember2021-01-012021-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:SeniorSecuredDebtMember2022-12-3100012807842018-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:HilleVaxIncMember2022-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001280784htgc:SoftwareMemberhtgc:CutoverIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:DepreciationMemberus-gaap:FairValueInputsLevel3Memberhtgc:PreferredStockInvestmentMember2021-01-012021-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:TwentyThreeAndMeIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMember2021-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784us-gaap:IncomeApproachValuationTechniqueMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMember2022-12-310001280784us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2022-12-310001280784htgc:EloxxPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:EPayPolicyHoldingsLLCMember2021-12-310001280784htgc:DareBiosciencesIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberstpr:IL2022-01-012022-12-310001280784htgc:SBADebenturesIssuedOnNovemberFifteenTwoThousandAndTwentyOneMember2022-01-012022-12-310001280784htgc:DividendDeclaredFiveMember2020-11-162020-11-160001280784htgc:DermavantSciencesLtdMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:AlbireoPharmaIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:ReltioIncMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMember2022-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:AgilenceIncorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:BicycleTherapeuticsPLCMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:HibercellIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:UnionBankFacilityMember2020-01-012020-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:HealthcareServicesOtherMemberus-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:CarbonHealthTechnologiesIncMember2021-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberus-gaap:CommonStockMember2021-01-012021-12-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:MajorityOwnedControlInvestmentsMember2020-12-310001280784htgc:SubstantiallyAllOfOurPortfolioInvestmentsAreRecordedAtFairValueAsDeterminedInAccordanceWithOurValuationGuidelinesAndAsAResultThereMayBeUncertaintyAsToTheValueOfOurPortfolioInvestmentsMember2022-01-012022-12-310001280784htgc:PharmaceuticalsMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2022-12-310001280784htgc:DividendDeclaredSevenMember2021-01-012021-12-310001280784htgc:DebtInvestmentsMemberhtgc:FlightScheduleProLlcMember2021-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:CommonStockMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:ControlInvestmentsMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2021-12-310001280784htgc:OurInvestmentsAreConcentratedInCertainTechnologyRelatedIndustriesWhichSubjectsUsToTheRiskOfSignificantLossIfAnyOneOrMoreOfSuchIndustriesExperiencesADownturnMember2022-01-012022-12-310001280784htgc:InformationServicesMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMembersrt:WeightedAverageMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:CopperCRMIncorporationMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:ScynexisIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SoftwareMemberhtgc:NextdoorComIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:DelphixCorporationMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:MeasurementInputEbitdaMultipleMemberus-gaap:EquitySecuritiesMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784htgc:SeriesThreeClassCPreferredStockMemberhtgc:EnGeneIncMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:TarsusPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:BicycleTherapeuticsPLCMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:MadrigalPharmaceuticalIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2021-12-3100012807842020-01-012020-12-310001280784htgc:MediaContentInfoMember2021-12-310001280784htgc:AppDirectIncorporationMemberhtgc:DebtInvestmentsMember2021-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SBADebenturesMember2022-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001280784htgc:EquityInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:PreferredSeriesBBMemberhtgc:TecturaCorporationMember2022-12-310001280784htgc:DebtAndEquitySecuritiesUnrealizedGainLossMemberus-gaap:PreferredStockMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-12-310001280784htgc:UnvestedRestrictedStockAwardsMember2022-01-012022-12-310001280784us-gaap:CommonStockMemberhtgc:WarrantInvestmentMemberhtgc:PhathomPharmaceuticalsIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:DebtAndEquitySecuritiesUnrealizedGainLossMemberus-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-12-310001280784htgc:LiborMemberhtgc:CampaignMonitorLimitedMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:SeptemberTwoThousandTwentySixNotesMember2022-01-012022-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:MarchTwoThousandTwentySixBNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMemberhtgc:MeasurementInputHypotheticalMarketYieldMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:EnGeneIncMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:PineappleEnergyLLCMemberhtgc:SeniorDebtMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2022-01-012022-12-310001280784htgc:CenterForBreakthroughMedicinesHoldingsLLCMemberus-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:CoriumIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:AlladaptImmunotherapeuticsincMember2022-12-310001280784htgc:ElationHealthIncMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:March2026ANotesMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberhtgc:ExpectedRealizableValueMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:SoftwareMemberhtgc:SeriesTwoPreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:DruvaHoldingsIncMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:ChemocentryxIncTwoMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:SeniorSecuredDebtMember2020-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:UniQureBVMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:MeasurementInputEbitdaMultipleMemberus-gaap:EquitySecuritiesMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784htgc:SoftwareMemberhtgc:ImpervaIncMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:SeriesEPreferredStockMemberhtgc:InformationServicesMemberhtgc:YipitLLCMemberhtgc:EquityInvestmentsMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:ConvoyIncorporationMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:MarchTwoThousandTwentySixANotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:ManufacturingTechnologyMemberhtgc:MacroFabIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:SustainableAndRenewableTechnologyMemberhtgc:DebtInvestmentsMembersrt:MinimumMemberhtgc:ExpectedRealizableValueMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:GenoceaBiosciencesIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:EquitySecuritiesMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784htgc:OurSbicSubsidiaryMayBeUnableToMakeDistributionsToUsThatWillEnableUsToMeetOrMaintainRicStatusWhichCouldResultInTheImpositionOfAnEntityLevelTaxMember2022-01-012022-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:UnsecuredMemberhtgc:GibraltarBusinessCapitalLLCMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:PolyeraCorporationMemberus-gaap:SeriesCPreferredStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:ScynexisIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001280784us-gaap:RestrictedStockMemberus-gaap:CommonStockMember2020-01-012020-12-310001280784htgc:DebtInvestmentsMemberhtgc:MadrigalPharmaceuticalIncMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:ScynexisIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:InformationServicesMember2022-12-310001280784htgc:CybermaxxIntermediateHoldingsIncorporationMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:ViridianTherapeuticsIncMember2021-12-310001280784htgc:DebtInvestmentsMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:ValuationTechniqueMarketComparableCompaniesMemberhtgc:TechnologyMember2022-12-310001280784htgc:DiversifiedFinancialServicesMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:EqualityHealthLLCMember2021-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:MarchTwoThousandTwentySixANotesMember2021-01-012021-12-310001280784us-gaap:CommonStockMemberhtgc:ParatekPharmaceuticalsIncMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:AtaiLifeSciencesNVMember2022-12-310001280784us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:EquitySecuritiesMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784htgc:SoftwareMemberhtgc:DashlaneIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:ContractualInterestIncomeMember2021-01-012021-12-310001280784us-gaap:FairValueInputsLevel1Memberhtgc:FebruaryTwoThousandTwentyFiveNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:SkydioIncorporationMember2022-12-310001280784htgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2016-01-012016-12-310001280784htgc:PalantirTechnologiesMemberhtgc:SoftwareMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMember2021-12-310001280784htgc:InvestmentFundsVehiclesMemberus-gaap:SalesRevenueNetMemberhtgc:InvestmentTypeConcentrationRiskMember2022-01-012022-12-310001280784htgc:EquityInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:TecturaCorporationMember2022-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:NewfrontInsuranceHoldingsIncMemberus-gaap:ConvertibleDebtMember2021-12-310001280784htgc:PerformanceVestingAwardMember2021-12-310001280784htgc:InternetConsumerAndBusinessServicesMemberhtgc:EquityInvestmentsMemberus-gaap:CommonClassAMemberhtgc:SavageXHoldingLLCMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:GroveCollaborativeIncMemberhtgc:ConsumerAndBusinessProductsMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:PreferredStockMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2021-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:TwoThousandTwentySevenAssetBackedNotesMember2020-01-012020-12-310001280784htgc:SMBCFacilityMember2022-01-012022-12-310001280784htgc:ThumbtackIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2022-12-310001280784htgc:EvofemBiosciencesIncMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:AspireBariatricsIncMemberus-gaap:CommonStockMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:LiborMemberhtgc:SeniorSecuredDebtMemberhtgc:CommunicationsAndNetworkingMemberhtgc:CytracomHoldingsLLCMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerMemberhtgc:ControlAndAffiliateInvestmentsMember2021-12-310001280784us-gaap:SeriesEPreferredStockMemberhtgc:SoftwareMemberhtgc:EquityInvestmentsMemberhtgc:VeranaHealthIncMember2021-12-310001280784htgc:ExitFeesAmortizationMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMember2022-12-310001280784htgc:BioQPharmaIncorporatedMemberhtgc:EquityInvestmentsMemberus-gaap:SeriesDPreferredStockMemberhtgc:DrugDeliveryMember2022-12-310001280784htgc:InformationServicesMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:WarrantMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberhtgc:ValuationTechniqueMarketAdjustedOpmBacksolveMember2021-12-310001280784us-gaap:MeasurementInputEbitdaMultipleMemberus-gaap:EquitySecuritiesMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMember2021-12-310001280784htgc:UnsecuredMember2022-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001280784htgc:EquityInvestmentsMemberhtgc:SemiconductorsMember2022-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:CutoverIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SoftwareMemberhtgc:SeriesCOnePreferredStockMemberhtgc:ZeroFoxIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:SignalMediaLimitedMemberhtgc:InformationServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:SeriesAPreferredStockMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784us-gaap:RevolvingCreditFacilityMember2021-01-012021-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:CellarityIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2022-06-230001280784htgc:HealthcareServicesOtherMemberus-gaap:PrimeRateMemberhtgc:EqualityHealthLLCMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2022-01-012022-12-310001280784htgc:EquityInvestmentsMemberus-gaap:SeriesDPreferredStockMemberhtgc:SurgicalDevicesMemberhtgc:GynesonicsIncMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2020-12-310001280784htgc:SecuritizedCreditFacilityWithWellsFargoCapitalFinanceMember2020-01-012020-12-310001280784htgc:TechStyleIncMemberhtgc:ConsumerAndBusinessProductsMemberus-gaap:SeriesBPreferredStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SemiconductorsMemberhtgc:EquityInvestmentsMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeriesTwoPreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:DruvaHoldingsIncMember2022-12-310001280784us-gaap:CommonStockMember2021-01-012021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:BridgeBioPharmaIncMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:ImpossibleFoodsIncMemberhtgc:SeriesEOnePreferredStockMemberhtgc:EquityInvestmentsMember2022-12-310001280784htgc:ZappiIncMemberhtgc:DebtInvestmentsMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2022-12-310001280784htgc:MotifBioPLCMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputRevenueMultipleMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784htgc:WarrantInvestmentMemberhtgc:DrugDeliveryMember2022-12-310001280784htgc:DebtInvestmentsMember2021-12-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberus-gaap:MarketApproachValuationTechniqueMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:UnityBiotechnologyIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:OurBusinessModelDependsToASignificantExtentUponStrongReferralRelationshipsMember2022-01-012022-12-310001280784htgc:LiborMemberhtgc:KazooIncPKYouEarnedItIncMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2020-01-012020-12-310001280784htgc:PineappleEnergyLLCMemberhtgc:SustainableAndRenewableTechnologyMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2021-12-310001280784htgc:ManufacturingTechnologyMemberus-gaap:CommonStockMemberhtgc:XometryIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2021-12-310001280784htgc:DividendDeclaredTwoMember2020-01-012020-12-310001280784us-gaap:PrimeRateMemberhtgc:ValoHealthLLCPKIntegralHealthHoldingsLLCMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-3100012807842021-04-012021-06-300001280784htgc:SoftwareMemberhtgc:ContentfulGlobalIncMemberhtgc:EquityInvestmentsMemberus-gaap:SeriesDPreferredStockMember2022-12-310001280784htgc:OfferUpIncMemberhtgc:EquityInvestmentsMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:DelphixCorporationMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:FeverLabsIncMemberhtgc:DebtInvestmentsMember2021-12-310001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:HighRoadsIncMemberhtgc:SurgicalDevicesMember2021-12-310001280784htgc:SpringMobileSolutionsIncMemberus-gaap:CommonStockMemberhtgc:CommunicationsAndNetworkingMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310001280784htgc:CarwowLimitedMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:DividendDeclaredFiveMember2022-08-162022-08-160001280784htgc:February2025NotesMember2020-01-012020-12-310001280784us-gaap:IncomeApproachValuationTechniqueMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMember2022-12-310001280784country:IE2022-12-310001280784us-gaap:SeriesCPreferredStockMemberhtgc:SoftwareMemberhtgc:DNAnexusIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:InvestmentFundsVehiclesMemberhtgc:ForbionGrowthOpportunitiesFundICVMember2021-12-310001280784htgc:UnusedFacilityOtherFeesMember2022-01-012022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2020-12-310001280784us-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:ConcertPharmaceuticalsIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:TwoThousandThirtyThreeNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001280784htgc:ServiceVestingAwardsMember2020-01-012020-12-310001280784htgc:BiotechnologyToolsMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:TwoThousandTwentyTwoNotesMember2022-02-220001280784htgc:SeniorSecuredDebtMemberhtgc:CapRateMemberhtgc:HilleVaxIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-3100012807842022-01-012022-12-310001280784htgc:AytuBioScienceIncPKNeosTherapeuticsIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDeliveryMember2022-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:CollateralTypeConcentrationRiskMember2021-01-012021-12-310001280784htgc:DebtInvestmentsMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:TechnologyMemberus-gaap:MarketApproachValuationTechniqueMember2022-12-310001280784htgc:DividendDeclaredFiveMember2022-01-012022-12-310001280784us-gaap:PreferredStockMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:BlackCrowAIIncMember2021-12-310001280784htgc:OurInvestmentsInForeignSecuritiesOrInvestmentsDenominatedInForeignCurrenciesMayInvolveSignificantRisksInAdditionToTheRisksInherentInUSAndUSDenominatedInvestmentsMember2022-01-012022-12-310001280784srt:MinimumMemberus-gaap:SubsequentEventMemberhtgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2023-01-132023-01-130001280784us-gaap:EquitySecuritiesMemberhtgc:ValuationTechniqueOtherMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784htgc:AssetBackedNotes2031Member2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:PathaiIncMember2022-12-310001280784htgc:SemiconductorsMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:CommonStockMemberhtgc:TGTherapeuticsIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:Notes2025Member2021-01-012021-12-310001280784htgc:WeMayNotBeAbleToPrepayTheNotesOrCreditFacilitiesUponAChangeInControlMember2022-01-012022-12-310001280784htgc:TheNotesMayOrMayNotHaveAnEstablishedTradingMarketIfATradingMarketInTheNotesIsDevelopedItMayNotBeMaintainedMember2022-01-012022-12-310001280784us-gaap:PrimeRateMemberhtgc:CenturyTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ThreatConnectIncMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:CenturyTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:TwoThousandTwentyTwoNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:UnfundedDebtCommitmentsMember2022-01-012022-12-310001280784htgc:CenturyTherapeuticsIncMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:SeriesEPreferredStockMemberhtgc:MedroboticsCorporationMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784htgc:PharmaceuticalsMemberhtgc:DebtInvestmentsMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784us-gaap:CommonStockMemberhtgc:SemiconductorsMemberhtgc:FungibleIncorporationMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:CommonStockMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:BlackCrowAIIncMember2021-01-012021-12-310001280784htgc:UnrealizedGainLossMember2019-01-012019-12-310001280784htgc:DistributableEarningsLossMember2020-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:SeniorSecuredDebtTwoMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2021-12-310001280784htgc:MUFGBankFacilityMembersrt:MaximumMember2023-01-130001280784htgc:SmallBusinessAdministrationDebenturesHtIiiMember2017-01-012017-12-310001280784htgc:AppDirectIncorporationMemberus-gaap:PrimeRateMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:AkeroTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyOneMember2022-01-012022-12-310001280784htgc:ConsumerAndBusinessProductsMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:EsmeLearningSolutionsIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberhtgc:ExpectedRealizableValueMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMember2021-12-310001280784htgc:ElectronicsComputerHardwareMemberhtgc:SkydioIncorporationMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarBusinessCapitalLLCMember2022-01-012022-12-310001280784htgc:EquityInvestmentsMemberhtgc:GynesonicsIncMemberhtgc:SurgicalDevicesMember2021-12-310001280784htgc:ThreeGTMSLLCMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMember2021-12-310001280784htgc:BiotechnologyToolsMemberhtgc:AlamarBiosciencesIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:EquitySecuritiesMembersrt:MaximumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784htgc:September2019NotesMember2015-01-012015-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:DemandbaseIncorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:DividendDeclaredFourMember2021-05-192021-05-190001280784us-gaap:PrimeRateMemberhtgc:ValoHealthLLCPKIntegralHealthHoldingsLLCMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:G1TherapeuticsIncMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:PollenIncTwoMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:ManufacturingTechnologyMemberhtgc:BrightMachinesIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:ConcertPharmaceuticalsIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:April2019NotesMember2013-01-012013-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:AllAssetsIncludingIntellectualPropertyMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:SeniorSecuredFirstLienMember2021-01-012021-12-310001280784htgc:ConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap-supplement:InvestmentUnaffiliatedIssuerMember2021-12-310001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMember2021-12-310001280784us-gaap:SeriesEPreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:SurgicalDevicesMemberhtgc:GynesonicsIncMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:IkonScienceLimitedMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:BicycleTherapeuticsPLCMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:SeniorSecuredDebtMemberhtgc:CarbonHealthTechnologiesIncMemberhtgc:ExitFeeMember2022-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMember2022-01-012022-12-310001280784htgc:SurgicalDevicesMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:OtherInterestIncomeMember2020-01-012020-12-310001280784us-gaap:WarrantMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784htgc:UnionBankFacilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:LocusBiosciencesIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:CommonStockMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:RumbleONIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:UnsecuredMemberhtgc:GibraltarBusinessCapitalLLCMember2022-12-310001280784htgc:PerformanceVestingAwardMember2020-12-310001280784htgc:ConsumerAndBusinessProductsMemberhtgc:EquityInvestmentsMember2022-12-310001280784htgc:ViridianTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2022-12-310001280784htgc:ConsumerAndBusinessProductsMemberhtgc:TechStyleIncPKJustFabulousIncMemberus-gaap:SeriesBPreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:SoftwareMemberhtgc:EnmarkSystemsIncorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:DebtInvestmentsMember2022-12-310001280784htgc:KazooIncPKYouEarnedItIncMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputEbitdaMultipleMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:TecturaCorporationMember2021-12-310001280784htgc:UnusedFacilityOtherFeesMember2021-01-012021-12-310001280784htgc:SoftwareMemberhtgc:BitsightTechnologiesIncMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SBADebenturesMember2021-12-310001280784htgc:SeniorSecuredDebtMember2021-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ThreatConnectIncMember2021-12-310001280784htgc:CybermaxxIntermediateHoldingsIncorporationMemberhtgc:SoftwareMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap-supplement:InvestmentUnaffiliatedIssuerMember2022-12-310001280784htgc:SmallBusinessAdministrationDebenturesHcIvMember2022-01-012022-12-310001280784htgc:InternetConsumerAndBusinessServicesMemberus-gaap:CommonStockMemberhtgc:XometryIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:Notes2025Member2018-01-012018-12-310001280784htgc:UberTechnologiesIncMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMember2021-12-310001280784htgc:RealizedGainLossMemberhtgc:DistributableEarningsLossMember2020-01-012020-12-310001280784htgc:MUFGBankFacilityMember2022-01-012022-12-310001280784us-gaap:SeriesFPreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:GynesonicsIncMemberhtgc:SurgicalDevicesMember2021-12-310001280784htgc:AveoPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SeriesAAPreferredStockMemberhtgc:TheFactionGroupLLCMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:MUFGBankFacilityMember2022-01-012022-12-310001280784htgc:NetInvestmentIncomeMemberhtgc:DistributableEarningsLossMember2020-01-012020-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MinimumMemberhtgc:ExpectedRealizableValueMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputHypotheticalMarketYieldMember2021-12-310001280784htgc:MedicalDevicesAndEquipmentMemberhtgc:FlowonixMedicalIncorporatedMemberhtgc:PreferredSeriesBBMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SemiconductorsMemberhtgc:SeniorSecuredDebtMemberhtgc:FungibleIncorporationMember2021-12-310001280784htgc:SMBCFacilityMember2021-12-310001280784htgc:TwoThousandThirtyThreeNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:TwoThousandTwentyTwoConvertibleNotesMember2021-12-310001280784htgc:OusterIncorporationMemberhtgc:ManufacturingTechnologyMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:AssetBackedNotes2021Member2014-01-012014-12-310001280784htgc:AssetBackedNotes2017Member2015-01-012015-12-310001280784htgc:CommonStockInvestmentMemberus-gaap:FairValueInputsLevel3Memberhtgc:AppreciationMember2021-01-012021-12-310001280784htgc:DebtInvestmentsMemberhtgc:MobileSolutionsServicesMember2021-12-310001280784htgc:OrdinaryIncomeMember2019-01-012019-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMemberhtgc:UnusedFacilityOtherFeesMember2021-01-012021-12-310001280784htgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:UdacityIncMember2022-12-310001280784htgc:MarchTwoThousandTwentySixANotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:XFourPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:ConvoyIncorporationMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMemberhtgc:UnusedFacilityOtherFeesMember2020-01-012020-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784us-gaap:IncomeApproachValuationTechniqueMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMember2021-12-310001280784htgc:DebtAndEquitySecuritiesUnrealizedGainLossMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:CommunicationsAndNetworkingMember2022-12-310001280784htgc:TecturaCorporationOneMemberhtgc:EquityInvestmentsMemberhtgc:InternetConsumerAndBusinessServicesMemberus-gaap:CommonStockMember2021-12-310001280784country:CA2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:AmpionPBCMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:SBADebenturesMember2021-01-012021-12-310001280784htgc:MyovantSciencesLtdMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SkywordIncorporatinMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:Notes2022Member2018-01-012018-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:EnmarkSystemsIncorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:CommonGrossProceedsMember2020-01-012020-12-310001280784htgc:ConvertibleNotes2016Member2013-01-012013-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:CoriumIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:RestrictedStockMemberhtgc:CapitalInExcessOfParValueMember2022-01-012022-12-310001280784htgc:DebtAndEquitySecuritiesUnrealizedGainLossMemberus-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310001280784htgc:DebtInvestmentsMemberhtgc:MacroFabIncorporationMember2021-12-310001280784htgc:PineappleEnergyLLCMemberhtgc:SustainableAndRenewableTechnologyMemberhtgc:EquityInvestmentsMemberus-gaap:CommonClassAMember2021-12-310001280784htgc:SeatGeekIncMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:SecuritizedCreditFacilityWithWellsFargoCapitalFinanceMember2018-01-012018-12-310001280784us-gaap:PrimeRateMemberhtgc:HibercellIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:ManufacturingTechnologyMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-01-012021-12-310001280784htgc:DividendDeclaredSevenMember2022-11-172022-11-170001280784htgc:ManufacturingTechnologyMemberhtgc:BrightMachinesIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784htgc:ValoHealthLLCPKIntegralHealthHoldingsLLCMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:ModumetalIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMember2021-12-310001280784us-gaap:CommonStockMemberhtgc:MadrigalPharmaceuticalIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:DepreciationMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DebtMember2022-01-012022-12-310001280784htgc:SeriesATwoPreferredStockMemberhtgc:GelesisIncTwoMemberhtgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2021-12-310001280784htgc:OurInvestmentsInPortfolioCompaniesInvolveHigherLevelsOfRiskAndWeCouldLoseAllOrPartOfOurInvestmentMember2022-01-012022-12-310001280784htgc:SyndaxPharmaceuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:EigenTechnologiesLimitedMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:AnyInabilityToRenewExtendOrReplaceOurCreditFacilitiesCouldAdverselyImpactOurLiquidityAndAbilityToFindNewInvestmentsOrMaintainDistributionsToOurStockholdersMember2022-01-012022-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:CommonStockMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:SmallBusinessAdministrationDebenturesHtIiMember2018-01-012018-12-310001280784us-gaap:PrimeRateMemberhtgc:AxsomeTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:BridgeBioPharmaIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:ScynexisIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:ImpervaIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:LiborMemberhtgc:WorldremitGroupLimitedMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:AkeroTherapeuticsIncMember2021-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SBADebenturesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:DebtAndEquitySecuritiesUnrealizedGainLossMemberhtgc:EscrowReceivableMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:FebruaryTwoThousandTwentyFiveNotesMember2021-12-310001280784htgc:SoftwareMemberhtgc:BloombergShorttermBankYieldIndexMemberhtgc:AgilenceIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerMemberhtgc:ControlAndAffiliateInvestmentsMember2020-12-310001280784htgc:OneMonthLIBORMember2021-12-310001280784htgc:InformationServicesMemberhtgc:EquityInvestmentsMember2022-12-310001280784htgc:UnvestedRestrictedStockAwardsMember2020-01-012020-12-310001280784htgc:SoftwareMemberhtgc:BrainCorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:SBADebenturesIssuedOnJanuaryTwentyOneTwoThousandAndTwentyTwoMember2022-01-012022-12-310001280784htgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMembersrt:MaximumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:AffiliateInvestmentsMember2022-12-310001280784htgc:SoftwareMemberhtgc:SingleStoreIncMemberus-gaap:SeriesDPreferredStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:RhinoLabsIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:TarsusPharmaceuticalsIncMemberhtgc:DebtInvestmentsMember2022-12-310001280784htgc:ViridianTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:CapRateMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:SurgicalDevicesMember2022-01-012022-12-310001280784htgc:TwoThousandTwentyTwoNotesMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:AlchemerLLCMember2021-12-310001280784us-gaap:EquitySecuritiesMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784htgc:LiborMemberhtgc:CerosLLCMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:AppDirectIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:AytuBioScienceIncPKNeosTherapeuticsIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDeliveryMember2021-12-310001280784htgc:TwoThousandTwentyTwoEquityDistributionAgreementMemberus-gaap:CommonStockMember2022-05-090001280784htgc:AkeroTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:TwoThousandThirtyThreeNotesMemberhtgc:UnderwritingMember2022-12-310001280784us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001280784htgc:CommonOfferingExpensesMember2022-01-012022-12-310001280784htgc:SemiconductorsMemberus-gaap:CommonStockMemberhtgc:FungibleIncorporationMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:MedicalDevicesAndEquipmentMember2022-01-012022-12-310001280784htgc:SMBCFacilityMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:AryakaNetworksIncMemberhtgc:SeniorSecuredDebtMemberhtgc:CommunicationsAndNetworkingMember2022-12-310001280784htgc:SoftwareMemberhtgc:AutomationAnyWhereIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:MarchTwoThousandTwentySixANotesMember2020-11-040001280784us-gaap:PreferredStockMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:BlackCrowAIIncMember2020-12-310001280784htgc:Notes2025Member2020-01-012020-12-310001280784us-gaap:PrimeRateMemberhtgc:AveoPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:IncomeApproachValuationTechniqueMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMemberhtgc:TechnologyMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2020-01-012020-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMember2020-01-012020-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:UnsecuredMemberhtgc:CollateralTypeConcentrationRiskMember2021-01-012021-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:CloudBoltSoftwareIncorporationMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:SoftwareMemberhtgc:RivieraPartnersLLCMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:CloudBoltSoftwareIncorporationMemberhtgc:ExitFeeMember2021-12-310001280784htgc:AdviserSubsidiaryMember2021-01-012021-12-310001280784htgc:SemiconductorsMember2021-12-310001280784us-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:PreferredStockMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2022-01-012022-12-310001280784htgc:SnagajobcomIncMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SBADebenturesMember2021-01-012021-12-310001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:SioGeneTherapiesIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-3100012807842022-06-300001280784htgc:September2019NotesMember2016-01-012016-12-310001280784htgc:DistributableEarningsLossMember2022-01-012022-12-310001280784htgc:CloudianIncMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SeriesBBPreferredStockMemberhtgc:TecturaCorporationOneMemberhtgc:EquityInvestmentsMemberhtgc:InternetConsumerAndBusinessServicesMember2021-12-310001280784htgc:InformationServicesMemberus-gaap:CommonStockMemberhtgc:INMOBIIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:NuvoloTechnologiesCorporationMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:AlbireoPharmaIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:MUFGBankFacilityMemberhtgc:UnusedFacilityOtherFeesMember2022-01-012022-12-310001280784us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:GB2021-01-012021-12-310001280784us-gaap:FairValueInputsLevel1Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:HibercellIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:ExitFeeMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:PathaiIncMember2021-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputRevenueMultipleMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMember2021-12-310001280784htgc:CoronadoAestheticsLLCMemberhtgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2021-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixANotesMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMember2021-12-310001280784htgc:PineappleEnergyLLCMemberhtgc:SustainableAndRenewableTechnologyMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:UdacityIncMember2022-12-310001280784us-gaap:CommonStockMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:UdacityIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:PharmaceuticalsMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2022-12-310001280784htgc:SeptemberTwoThousandTwentySixNotesMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:AutomationAnyWhereIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:ServiceVestingAwardsMember2022-01-012022-12-310001280784us-gaap:IncomeApproachValuationTechniqueMemberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMember2021-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2022-12-310001280784htgc:CarwowLimitedMemberhtgc:EquityInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:SeriesDFourPreferredStockMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:InternetConsumerAndBusinessServicesMember2021-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMemberhtgc:TechnologyMember2021-12-310001280784htgc:AnnexCloudMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:EquityInvestmentsMemberhtgc:DrugDeliveryMember2021-12-310001280784htgc:WarrantInvestmentMember2022-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2022-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMembersrt:WeightedAverageMember2022-12-310001280784htgc:SolarSpectrumHoldingsLlcPKASungevityIncMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberus-gaap:CommonStockMember2021-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:EquityInvestmentsMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:SkydioIncorporationMember2021-12-310001280784htgc:SecuritizedCreditFacilityWithWellsFargoCapitalFinanceMember2015-01-012015-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:CommunicationsAndNetworkingMember2021-12-310001280784htgc:MedicalDevicesAndEquipmentMemberhtgc:FlowonixMedicalIncorporatedMemberhtgc:PreferredSeriesBBMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:CapitalInExcessOfParValueMember2021-01-012021-12-310001280784htgc:EscrowReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:DoorDashIncMemberhtgc:EquityInvestmentsMemberhtgc:InternetConsumerAndBusinessServicesMemberus-gaap:CommonStockMember2021-12-310001280784htgc:ConvertibleNotes2022Member2020-01-012020-12-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberus-gaap:CommonStockMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784htgc:SecuritizedCreditFacilityWithWellsFargoCapitalFinanceMember2013-01-012013-12-310001280784htgc:DepreciationMemberus-gaap:FairValueInputsLevel3Memberhtgc:PreferredStockInvestmentMember2022-01-012022-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:LogicworksMember2021-12-310001280784htgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMembersrt:MaximumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMember2022-12-310001280784htgc:PeerlessNetworkHoldingsIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:CommunicationsAndNetworkingMember2021-12-310001280784htgc:WeOperateInAHighlyCompetitiveMarketForInvestmentOpportunitiesMember2022-01-012022-12-310001280784us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMemberus-gaap:MeasurementInputDiscountRateMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:LogicworksMember2022-12-310001280784htgc:CenturyTherapeuticsIncMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:RocketLabGlobalServicesLLCMemberhtgc:CommunicationsAndNetworkingMemberhtgc:ExitFeeMember2022-12-310001280784us-gaap:SeriesFPreferredStockMemberhtgc:MedroboticsCorporationOneMemberhtgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2021-12-310001280784htgc:AxsomeTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:CapRateMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SecuredCreditFacilityWithSumitomoMitsuiBankingCorporationSMBCMember2021-01-012021-12-310001280784htgc:KaleidoBiosciencesIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:UdacityIncMember2022-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:AllAssetsWithNegativePledgeOnIntellectualPropertyMemberhtgc:SeniorSecuredFirstLienMember2021-01-012021-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:CloudBoltSoftwareIncorporationMember2021-12-310001280784htgc:Notes2022Member2022-01-012022-12-310001280784htgc:SeriesAAPreferredStockMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:FlowonixMedicalIncorporatedMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:AcelRxPharmaceuticalsIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDeliveryMember2021-12-310001280784htgc:ProviMemberus-gaap:CommonStockMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SeniorSecuredDebtOneMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2022-12-310001280784htgc:TGTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2022-12-310001280784htgc:DividendDeclaredFourMember2021-01-012021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:KhorosMember2022-12-310001280784htgc:UnrealizedGainLossMember2021-01-012021-12-310001280784us-gaap:ConvertibleDebtSecuritiesMember2020-01-012020-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:ModumetalIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:NuvoloTechnologiesCorporationMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:HibercellIncMemberhtgc:EquityInvestmentsMemberus-gaap:SeriesBPreferredStockMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:RhinoLabsIncorporationMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:LiborMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:RVShareLLCMember2022-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:GibraltarBusinessCapitalLLCMember2021-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784htgc:DividendDeclaredTwoMember2021-03-152021-03-150001280784htgc:June20253YearNotesMember2022-01-012022-12-310001280784htgc:CommonUnitsMemberhtgc:CoronadoAestheticsLLCMemberhtgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2021-12-310001280784htgc:AppliedMolecularTransportMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:EquityInvestmentsMemberus-gaap:SeriesBPreferredStockMemberhtgc:SurgicalDevicesMemberhtgc:GynesonicsIncMember2021-12-310001280784htgc:KhorosPKLithiumTechnologiesMemberhtgc:DebtInvestmentsMember2021-12-310001280784htgc:September2026NotesMember2021-01-012021-12-310001280784htgc:G1TherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784htgc:ElectronicsComputerHardwareMemberhtgc:NineZeroEightDevicesIncMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:CommonStockMemberhtgc:AlbireoPharmaIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:UdacityIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:HealthcareServicesOtherMember2021-12-310001280784stpr:IL2021-12-310001280784us-gaap:FairValueInputsLevel1Memberhtgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2022-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:SprinklrIncMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:RegentEducationMemberhtgc:ExitFeeMember2021-12-310001280784htgc:ControlInvestmentsMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2021-01-012021-12-310001280784htgc:Notes2033Member2018-01-012018-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CostApproachValuationTechniqueMemberus-gaap:MeasurementInputDiscountRateMember2021-12-310001280784htgc:SoftwareMemberus-gaap:SeriesBPreferredStockMemberhtgc:CloudpayIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:WellsFacilityMember2020-01-012020-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:DefaultsByOurPortfolioCompaniesWillHarmOurOperatingResultsMember2022-01-012022-12-310001280784htgc:AcaciaPharmaIncMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:LuciraHealthIncMemberus-gaap:CommonStockMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SkywordIncorporatinMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:LyftIncMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMember2021-12-310001280784htgc:InvestmentsInTheAdviserFundsManagedByOurAdviserSubsidiaryMayCreateConflictsOfInterestsMember2022-01-012022-12-310001280784htgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CostApproachValuationTechniqueMemberus-gaap:MeasurementInputDiscountRateMember2021-12-310001280784us-gaap:CommonStockMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:OutsetMedicalIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:PineappleEnergyLLCMemberhtgc:SustainableAndRenewableTechnologyMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:SeatGeekIncOneMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:ControlAndAffiliateInvestmentsMember2022-12-310001280784htgc:Notes2024Member2018-01-012018-12-310001280784htgc:SoftwareMemberhtgc:CampaignMonitorLimitedMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:AdviserFundsMember2022-01-012022-12-310001280784htgc:WeMayBeExposedToHigherRisksWithRespectToOurInvestmentsThatIncludePikInterestOrExitFeesMember2022-01-012022-12-310001280784htgc:TwoThousandTwentyTwoNotesMember2020-01-012020-12-310001280784htgc:ForbionGrowthOpportunitiesFundIICVMemberhtgc:InvestmentFundsAndVehiclesMember2022-12-310001280784htgc:Notes2022Member2017-01-012017-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:SecondLienMember2022-01-012022-12-310001280784us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001280784htgc:EquityInvestmentsMemberhtgc:BioQPharmaIncorporatedMemberus-gaap:SeriesDPreferredStockMemberhtgc:DrugDeliveryMember2021-12-310001280784htgc:TwoThousandTwentyTwoConvertibleNotesMember2020-01-012020-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:EquityInvestmentsMemberus-gaap:SeriesAPreferredStockMemberhtgc:GibraltarBusinessCapitalLLCOneMember2021-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:SoftwareMember2021-01-012021-12-310001280784htgc:ManufacturingTechnologyMemberus-gaap:PrimeRateMemberhtgc:OusterIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SeniorSecuritiesMember2017-01-012017-12-310001280784htgc:SurgicalDevicesMember2021-12-310001280784htgc:SoftwareMemberhtgc:ThreeGtmsLlcOneMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:WeThroughTheAdviserSubsidiaryDeriveRevenuesFromManagingThirdPartyFundsPursuantToManagementAgreementsThatMayBeTerminatedMember2022-01-012022-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputEbitdaMultipleMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784htgc:WeMayExperienceFluctuationsInOurQuarterlyOperatingResultsMember2022-01-012022-12-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2022-12-310001280784htgc:ElectronicsComputerHardwareMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:PreferredStockMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:PIKInterestMember2021-01-012021-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:EquityInvestmentsMember2021-12-310001280784htgc:OtherTemporaryDifferencesMember2020-12-310001280784us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:EquitySecuritiesMembersrt:MinimumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784htgc:ConvertibleNotes2016Member2016-01-012016-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MaximumMemberhtgc:ExpectedRealizableValueMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:SoftwareMemberhtgc:PymetricsIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:SBADebenturesMember2022-01-012022-12-310001280784htgc:BecauseWeHaveSubstantialBorrowingsThePotentialForGainOrLossOnAmountsInvestedInUsIsMagnifiedAndMayIncreaseTheRiskOfInvestingInUsMember2022-01-012022-12-310001280784us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:DE2022-01-012022-12-310001280784htgc:InformationServicesMemberhtgc:CapellaSpaceCorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:IncludedInCostMember2022-12-310001280784htgc:PollenIncOneMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784htgc:AldeyraTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784country:NL2021-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputRevenueMultipleMembersrt:MaximumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784us-gaap:MeasurementInputEbitdaMultipleMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2022-12-310001280784htgc:LiborMemberhtgc:CybermaxxIntermediateHoldingsIncorporationMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:GritstoneBioIncMember2022-12-310001280784htgc:MediaContentInfoMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:AppDirectIncorporationMemberus-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMemberhtgc:TechnologyMember2022-12-310001280784htgc:UniQureBVMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SeriesFOnePreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:SurgicalDevicesMemberhtgc:GynesonicsIncMember2022-12-310001280784htgc:SoftwareMemberhtgc:DispatchTechnologiesIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:GeronCorporationMemberus-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:ReplimuneGroupIncMember2022-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:CollateralTypeConcentrationRiskMember2022-01-012022-12-310001280784htgc:Notes2024Member2014-01-012014-12-310001280784htgc:TwoThousandTwentyTwoNotesMemberhtgc:DebtIssuanceCostMember2022-02-222022-02-220001280784htgc:UnrealizedGainLossMember2020-01-012020-12-310001280784htgc:UniQureBVMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:KazooIncPKYouEarnedItIncMemberhtgc:SoftwareMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001280784htgc:SoftwareMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:SalaryComLlcMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:CloudBoltSoftwareIncorporationMemberhtgc:ExitFeeMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:BrainCorporationMember2022-12-310001280784htgc:DiversifiedFinancialServicesMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:SeriesAPreferredStockMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:BicycleTherapeuticsPLCMemberhtgc:CapRateMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2021-12-310001280784htgc:CenturyTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:KuraOncologyIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:SeniorSecuritiesMember2022-01-012022-12-310001280784htgc:AprilTwoThousandTwentyFiveNotesMemberhtgc:UnusedFacilityOtherFeesMember2020-01-012020-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2022-12-310001280784htgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:BetterTherapeuticsIncMemberhtgc:DebtInvestmentsMember2021-12-310001280784htgc:EquityAndWarrantInvestmentsMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784country:DE2021-12-310001280784htgc:InternetConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:OtherMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001280784htgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMember2022-12-310001280784htgc:ZappiIncMemberhtgc:DebtInvestmentsMember2022-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:PoplicusIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:UndistributedOrdinaryIncomeMember2020-12-310001280784htgc:BiomXINCMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2020-01-012020-12-310001280784htgc:CoronadoAestheticsLLCMemberhtgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:DashlaneIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SoftwareMemberhtgc:BrainCorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:PolyeraCorporationMemberus-gaap:SeriesCPreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:ManufacturingTechnologyMemberhtgc:OusterIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:CutoverIncMember2021-12-310001280784htgc:AssetBackedNotes2027Member2021-01-012021-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueOtherMember2021-12-310001280784htgc:AprilTwoThousandTwentyFiveNotesMember2021-01-012021-12-310001280784htgc:BiotechnologyToolsMemberhtgc:AlamarBiosciencesIncorporationMemberus-gaap:SeriesBPreferredStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SoftwareMemberhtgc:DashlaneIncorporationMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:TwoThousandTwentyTwoNotesMember2017-10-230001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:PreferredStockMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2022-12-310001280784htgc:SnagajobcomIncMemberus-gaap:CommonStockMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMemberhtgc:ConcertPharmaceuticalsIncMember2021-12-310001280784us-gaap:FairValueInputsLevel1Memberhtgc:TwoThousandTwentyTwoNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:OneMonthLIBORMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:SeatGeekIncMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:JulyTwoThousandTwentyFourNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784us-gaap:SeriesCPreferredStockMemberhtgc:NorthSeaTherapeuticsMemberhtgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-3100012807842022-07-012022-09-300001280784htgc:SeniorSecuredDebtMemberhtgc:RocketLabGlobalServicesLLCMemberhtgc:CommunicationsAndNetworkingMemberhtgc:ExitFeeMember2021-12-310001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:OtherControlInvestmentsMember2021-12-310001280784htgc:WellsFacilityMember2021-01-012021-12-310001280784htgc:DebtInvestmentsMemberhtgc:FulfilSolutionsIncMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784htgc:EscrowReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:MUFGBankFacilityMember2021-01-012021-12-310001280784htgc:UniQureBVMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SemiconductorsMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:ValoHealthLLCMemberhtgc:EquityInvestmentsMemberus-gaap:SeriesBPreferredStockMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:OtherControlInvestmentsMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:ValoHealthLLCPKIntegralHealthHoldingsLLCMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:ShadowDragonLLCMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:DemandbaseIncorporationMember2022-12-310001280784htgc:NabrivaTherapeuticsMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:EquityInvestmentsMemberhtgc:SurgicalDevicesMemberhtgc:GynesonicsIncMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:GryphonNetworksCorporationMember2022-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:ParatekPharmaceuticalsIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:EPayPolicyHoldingsLLCMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:TwoThousandTwentyEightAssetBackedNotesMember2020-01-012020-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2022-12-310001280784htgc:DividendDeclaredEightMember2022-11-172022-11-170001280784htgc:DistributableEarningsLossMember2021-01-012021-12-310001280784us-gaap:SeriesCPreferredStockMemberhtgc:LogicSourceMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ZimperiumIncMember2022-12-310001280784htgc:TaxableSubsidiaryMember2021-01-012021-12-310001280784htgc:NabrivaTherapeuticsMemberus-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:LiborMemberhtgc:InformationServicesMemberhtgc:YipitLLCMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:SBADebenturesIssuedOnMarchTwentySixTwoThousandAndTwentyOneMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CostApproachValuationTechniqueMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:UniQureBVMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001280784htgc:SMBCFacilityMember2021-01-012021-12-310001280784us-gaap:SeriesEPreferredStockMemberhtgc:SoftwareMemberhtgc:SingleStoreIncMemberhtgc:EquityInvestmentsMember2021-12-310001280784us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:SemiconductorsMember2022-01-012022-12-310001280784htgc:HerculesAdviserLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:UnsecuredDebtMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784us-gaap:ConvertibleDebtSecuritiesMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:ThreatConnectIncMember2022-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyEightTwoThousandAndTwentyOneMember2022-01-012022-12-310001280784us-gaap:PrimeRateMemberhtgc:BiotechnologyToolsMemberhtgc:AlamarBiosciencesIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:CreditConcentrationRiskMember2021-12-3100012807842017-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:UnityBiotechnologyIncMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:OrdinaryIncomeMember2022-01-012022-12-310001280784htgc:SoftwareMemberhtgc:ConstructorIoCorporationMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:SolarSpectrumHoldingsLLCMember2020-12-310001280784htgc:ExitFeesAmortizationMember2021-01-012021-12-310001280784htgc:SecuritizedCreditFacilityWithWellsFargoCapitalFinanceMember2021-01-012021-12-310001280784htgc:DebtInvestmentsMemberhtgc:InformationServicesMember2021-12-310001280784htgc:ProventionBioIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:AppDirectIncorporationMemberhtgc:DebtInvestmentsMember2022-12-310001280784htgc:LenderMemberhtgc:MUFGBankFacilityMember2021-12-310001280784htgc:CommonUnitsMemberhtgc:CoronadoAestheticsLLCMemberhtgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2022-12-310001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:RocketPharmaceuticalsLtdMember2022-12-310001280784htgc:HealthcareServicesOtherMemberus-gaap:SeriesCPreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:CarbonHealthTechnologiesIncMember2021-12-310001280784us-gaap:PreferredStockMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:SemiconductorsMemberhtgc:SeniorSecuredDebtMemberhtgc:FungibleIncorporationMember2021-12-310001280784htgc:CerosLLCMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:SolarSpectrumHoldingsLlcPKASungevityIncMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberus-gaap:CommonStockMember2021-01-012021-12-310001280784htgc:DebtInvestmentsMemberhtgc:ZimperiumIncMember2021-12-310001280784us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:EquitySecuritiesMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMember2021-12-310001280784htgc:WeAreANonDiversifiedInvestmentCompanyWithinTheMeaningOfThe1940ActAndThereforeWeAreNotLimitedWithRespectToTheProportionOfOurAssetsThatMayBeInvestedInSecuritiesOfASingleIssuerMember2022-01-012022-12-310001280784stpr:IL2022-12-310001280784htgc:SeptemberTwoThousandTwentySixNotesMember2021-09-160001280784us-gaap:FairValueInputsLevel2Memberhtgc:JuneTwoThousandTwentyFiveThreeYearNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:DemandbaseIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:AchronixSemiconductorCorporationMemberhtgc:SemiconductorsMemberhtgc:EquityInvestmentsMember2021-12-310001280784htgc:TwoThousandTwentyTwoNotesMember2021-12-310001280784htgc:SyndaxPharmaceuticsIncMemberhtgc:DebtInvestmentsMember2021-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel1Member2021-12-310001280784htgc:ManufacturingTechnologyMemberhtgc:MacroFabIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:OurBoardMayChangeOurOperatingPoliciesAndStrategiesWithoutPriorNoticeOrStockholderApprovalTheEffectsOfWhichMayBeAdverseMember2022-01-012022-12-310001280784htgc:SeniorSecuritiesMember2019-01-012019-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2021-01-012021-12-310001280784htgc:SignalMediaLimitedMemberus-gaap:PrimeRateMemberhtgc:InformationServicesMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:AssetBackedNotes2027Member2018-01-012018-12-310001280784us-gaap:EquitySecuritiesMembersrt:MaximumMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:VeemIncorporationOneMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:ExitFeeMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:ThumbtackIncorporationMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:EnGeneIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:SolarSpectrumHoldingsLLCMember2020-01-012020-12-310001280784us-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:TransMedicsGroupIncPKTransmedicsIncMemberhtgc:SurgicalDevicesMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:EPayPolicyHoldingsLLCMember2022-12-310001280784htgc:WorldremitGroupLimitedMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:MedicalDevicesAndEquipmentMemberhtgc:FlowonixMedicalIncorporatedMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:July2024NotesMember2022-01-012022-12-310001280784htgc:SBADebenturesIssuedOnJulyTwentyEightTwoThousandAndTwentyOneMember2022-01-012022-12-310001280784htgc:LightbendIncMemberhtgc:SoftwareMemberus-gaap:SeriesDPreferredStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:AppliedGeneticTechnologiesCorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:MedroboticsCorporationMemberhtgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2021-12-310001280784htgc:ElectronicsComputerHardwareMemberhtgc:NineZeroEightDevicesIncMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:AdviserFundsMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeatGeekIncMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:BetterTherapeuticsIncMemberhtgc:DebtInvestmentsMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMember2020-01-012020-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:AlladaptImmunotherapeuticsincMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:UnsecuredMemberhtgc:InvestmentTypeConcentrationRiskMember2022-01-012022-12-310001280784htgc:HerculesCapitalFourLPMember2020-10-272020-10-270001280784htgc:ManufacturingTechnologyMember2022-12-310001280784htgc:TricidaIncMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:AldeyraTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784us-gaap:FairValueInputsLevel1Memberhtgc:UnionBankFacilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:BridgeBioPharmaIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:KuraOncologyIncMember2021-12-310001280784htgc:EscrowReceivableMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:PreferredStockMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:MarchTwoThousandTwentySixANotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:CellarityIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:CommunicationsAndNetworkingMemberhtgc:CytracomHoldingsLLCMember2021-12-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2021-12-310001280784htgc:ElectronicsComputerHardwareMemberhtgc:EquityInvestmentsMember2022-12-310001280784htgc:CapitalGainsMember2021-01-012021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:AffiliateInvestmentsMember2021-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:BrainCorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:PrepaymentFeesMemberhtgc:TwoThousandTwentyTwoNotesMember2022-02-222022-02-220001280784us-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2021-12-310001280784country:US2022-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueOtherMember2021-12-310001280784htgc:G1TherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2022-12-310001280784htgc:February2025NotesMember2022-01-012022-12-310001280784htgc:CapitalInExcessOfParValueMember2020-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:AffiliateInvestmentsMember2022-01-012022-12-310001280784htgc:MediaContentInfoMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:IncludedInCostMember2021-01-012021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2022-01-012022-12-310001280784htgc:SMBCFacilityMemberhtgc:UnusedFacilityOtherFeesMember2021-01-012021-12-310001280784htgc:SMBCFacilityMember2022-12-310001280784htgc:SeatGeekIncOneMemberus-gaap:PrimeRateMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:InformationServicesMemberhtgc:YipitLLCMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputRevenueMultipleMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMemberhtgc:TechnologyMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:LocusBiosciencesIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:PreferredStockMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2022-01-012022-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784us-gaap:CommonStockMember2021-12-310001280784htgc:ValoHealthLLCMemberhtgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SoftwareMemberhtgc:BrainCorporationMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:FeverLabsIncMemberhtgc:DebtInvestmentsMember2022-12-310001280784htgc:CellarityIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:EquityInvestmentsMemberus-gaap:SeriesDPreferredStockMemberhtgc:PivotBioIncMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:CopperCRMIncorporationMemberhtgc:ExitFeeMember2022-12-310001280784htgc:CapitalInExcessOfParValueMember2021-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001280784htgc:ConsumerAndBusinessProductsMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:TFGHoldingIncMember2022-12-310001280784htgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:RVShareLLCMember2022-12-310001280784htgc:EquityInvestmentsMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:DebtInvestmentsMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2022-12-310001280784htgc:AcceleratedFeeIncomeEarlyRepaymentsMember2022-01-012022-12-310001280784htgc:ContentfulGlobalIncMemberhtgc:EquityInvestmentsMemberhtgc:InternetConsumerAndBusinessServicesMember2021-12-310001280784htgc:UnsecuredDebtOneMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784htgc:InvestmentFundsVehiclesMember2021-12-310001280784htgc:InvestmentFundsVehiclesMemberus-gaap:SalesRevenueNetMemberhtgc:InvestmentTypeConcentrationRiskMember2021-01-012021-12-310001280784htgc:DistributableEarningsLossMember2019-12-310001280784htgc:SoftwareMemberhtgc:CutoverIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:IncomeApproachValuationTechniqueMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMemberhtgc:TechnologyMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:G1TherapeuticsIncMember2022-12-310001280784htgc:TwoThousandThirtyThreeNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001280784htgc:DividendDeclaredTwoMember2022-03-162022-03-160001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:AffiliateInvestmentsMember2021-01-012021-12-310001280784htgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMemberhtgc:TechnologyMember2021-12-310001280784htgc:June2025NotesMember2020-01-012020-12-310001280784htgc:BiomXINCMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:EquityInvestmentsMemberhtgc:AveoPharmaceuticalsIncMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:WeMayNotRealizeGainsFromOurEquityOrWarrantInvestmentsMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:AlladaptImmunotherapeuticsincMember2021-12-310001280784htgc:AlladaptImmunotherapeuticsincMemberhtgc:SeniorSecuredDebtMemberhtgc:CapRateMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:ProventionBioIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMemberhtgc:UnusedFacilityOtherFeesMember2022-01-012022-12-310001280784us-gaap:PreferredStockMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:PymetricsIncorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2021-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:MixpanelIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:RhinoLabsIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:ZappiIncMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:FairValueInputsLevel1Memberhtgc:EscrowReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:DiscountsAmortizationMember2021-01-012021-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyOneMember2022-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2021-12-310001280784htgc:SMBCFacilityMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:DividendDeclaredThreeMember2021-05-192021-05-190001280784htgc:RealizedGainLossMember2018-01-012018-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputRevenueMultipleMembersrt:MinimumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:ServiceVestingAwardsMember2021-01-012021-12-310001280784htgc:DebtInvestmentsMemberhtgc:ThreatConnectIncMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:CarbonHealthTechnologiesIncMember2022-12-310001280784us-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:CapitalInExcessOfParValueMember2019-12-310001280784htgc:GeronCorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:MediaContentInfoMember2021-01-012021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:NuvoloTechnologiesCorporationMember2021-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:SeniorSecuredDebtMember2022-01-012022-12-310001280784htgc:WeMayHaveDifficultyPayingTheDistributionsRequiredToMaintainRicStatusUnderTheCodeIfWeRecognizeIncomeBeforeOrWithoutReceivingCashRepresentingSuchIncomeMember2022-01-012022-12-310001280784htgc:EquityInvestmentsMember2021-12-310001280784htgc:SMBCFacilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:InvestmentFundsVehiclesMemberhtgc:ForbionGrowthOpportunitiesFundIICVMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:HouzzIncorporationMemberus-gaap:CommonStockMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:WellsFacilityMember2021-01-012021-12-310001280784htgc:ControlAndAffiliateInvestmentsMember2022-01-012022-12-310001280784htgc:FeverLabsIncMemberhtgc:SeriesEOnePreferredStockMemberhtgc:MediaContentInfoMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2022-12-310001280784htgc:SBADebenturesIssuedOnNovemberThirtyTwoThousandAndTwentyOneMember2022-01-012022-12-310001280784htgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:TecturaCorporationThreeMember2022-12-310001280784htgc:HerculesAdviserLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2022-01-012022-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2022-12-310001280784htgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputRevenueMultipleMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMember2022-12-310001280784htgc:SeriesAAPreferredStockMemberhtgc:SoftwareMemberhtgc:TheFactionGroupLLCMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:InformationServicesMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:PlanetLabsIncMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMember2022-12-310001280784htgc:ExciseTaxMember2021-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:OakStreetHealthIncMemberhtgc:SeniorSecuredDebtMemberhtgc:CapRateMember2022-12-310001280784htgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2022-01-012022-12-310001280784htgc:Notes2033Member2022-01-012022-12-310001280784us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:BlackCrowAIIncMember2022-01-012022-12-310001280784us-gaap:SeriesFPreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:GynesonicsIncMemberhtgc:SurgicalDevicesMember2022-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:KhorosMember2021-12-310001280784us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784htgc:HerculesCapitalFourLPMember2020-10-270001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:InternetConsumerAndBusinessServicesMember2021-01-012021-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:KhorosMember2021-12-310001280784us-gaap:EquitySecuritiesMembersrt:MinimumMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:CodiakBiosciencesIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784country:IEus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001280784htgc:InformationServicesMember2021-12-310001280784htgc:EigenTechnologiesLimitedMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CostApproachValuationTechniqueMemberhtgc:TechnologyMember2021-12-310001280784htgc:SoftwareMemberhtgc:LogicSourceMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:PineappleEnergyLLCOneMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:NextrollIncorporationMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:OportunMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:DispatchTechnologiesIncMember2021-12-310001280784htgc:SoftwareMemberhtgc:CatchpointSystemsIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:BetterTherapeuticsIncMemberus-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:CloudianIncMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:DispatchTechnologiesIncMember2022-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ShadowDragonLLCMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:MarchTwoThousandTwentySixBNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:OrdinaryIncomeMember2021-01-012021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:GritstoneBioIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2022-12-310001280784htgc:VeemIncorporationMemberus-gaap:CommonStockMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:EnGeneIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784htgc:KaleidoBiosciencesIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:SeriesEPreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:GynesonicsIncMemberhtgc:SurgicalDevicesMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:BicycleTherapeuticsPLCMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SeatGeekIncMemberus-gaap:CommonStockMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMembersrt:MaximumMemberhtgc:ExpectedRealizableValueMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:AkeroTherapeuticsIncMember2022-12-310001280784htgc:MUFGBankFacilityMemberhtgc:ThreeMonthSecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-01-012022-12-310001280784htgc:SeriesOnePreferredStockMemberhtgc:InformationServicesMemberhtgc:WarrantInvestmentMemberhtgc:NetBaseSolutionsIncMember2021-12-310001280784htgc:AvaloTherapeuticsIncPKCerecorIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:SoftwareMember2022-01-012022-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputRevenueMultipleMembersrt:MinimumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784htgc:SoftwareMemberhtgc:VideoAmpIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberus-gaap:PrimeRateMemberhtgc:AmpionPBCMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:DebtInvestmentsMemberhtgc:ExpectedRealizableValueMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:Notes2033Member2021-01-012021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:OtherControlInvestmentsMember2021-01-012021-12-310001280784htgc:ContentfulGlobalIncOneMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:EquityInvestmentsMemberus-gaap:SeriesDPreferredStockMember2021-12-310001280784htgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:LogicworksMember2022-12-310001280784htgc:SoftwareMemberhtgc:DashlaneIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:EloxxPharmaceuticalsIncMemberus-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeatGeekIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:SeniorSecuredDebtMemberhtgc:CarbonHealthTechnologiesIncMember2021-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:OakStreetHealthIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:TarsusPharmaceuticalsIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SoftwareMemberhtgc:NextrollIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784country:CA2021-12-310001280784htgc:TwoThousandEighteenPlanAndDirectorPlanMember2018-06-280001280784us-gaap:CreditConcentrationRiskMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:ThumbtackIncorporationMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:TecturaCorporationMember2021-12-310001280784htgc:AryakaNetworksIncMemberus-gaap:CommonStockMemberhtgc:CommunicationsAndNetworkingMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:LightbendIncMemberhtgc:SoftwareMemberus-gaap:SeriesDPreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:TecturaCorporationOneMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:DemandbaseIncorporationMember2021-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:SeniorSecuredFirstLienMember2021-01-012021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMember2020-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:HerculesAdviserLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:MemberUnitsMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784htgc:DividendDeclaredOneMember2020-01-012020-12-310001280784htgc:SoftwareMemberhtgc:DemandbaseIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-3100012807842021-12-310001280784htgc:RealizedGainLossMember2021-01-012021-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:CommonStockMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001280784us-gaap:EquitySecuritiesMembersrt:MaximumMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMember2022-12-310001280784htgc:KhorosPKLithiumTechnologiesMemberhtgc:DebtInvestmentsMember2022-12-310001280784htgc:ForbionGrowthOpportunitiesFundICVMemberhtgc:InvestmentFundsAndVehiclesMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2022-01-012022-12-310001280784htgc:ProventionBioIncMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SnagajobcomIncMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:SeriesAPreferredStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:DividendDeclaredThreeMember2022-05-242022-05-240001280784htgc:ConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:AutomationAnyWhereIncMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:ValoHealthLLCPKIntegralHealthHoldingsLLCMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:DividendDeclaredFourMember2020-01-012020-12-310001280784htgc:ChemocentryxIncMemberhtgc:DebtInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:AveoPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:CapRateMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:ConvertibleDebtMemberhtgc:HouzzIncorporationMemberhtgc:InternetConsumerAndBusinessServicesMember2021-12-310001280784htgc:TwoThousandThirtyThreeNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:HerculesCapitalFourLPMember2021-12-310001280784us-gaap:WarrantMemberus-gaap:SalesRevenueNetMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:WarrantInvestmentMember2022-01-012022-12-310001280784htgc:ThumbtackIncorporationMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2021-12-310001280784htgc:NuvoloTechnologiesCorporationMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:BiomXINCMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784htgc:ConvertibleNotes2022Member2021-01-012021-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:MobileSolutionsServicesMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMemberhtgc:MeasurementInputHypotheticalMarketYieldMembersrt:WeightedAverageMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:SeriesCOnePreferredStockMemberhtgc:FulcrumBioenergyIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:LiabilityClassifiedAwardsMember2022-01-012022-12-310001280784htgc:RapidMinerIncMemberhtgc:SoftwareMemberhtgc:SeriesCOnePreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:GritstoneBioIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:RegentEducationMember2021-12-310001280784htgc:AldeyraTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:ViewRayIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2021-12-310001280784us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001280784htgc:SoftwareMemberhtgc:BitsightTechnologiesIncMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:CommonStockMemberhtgc:PhathomPharmaceuticalsIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:SignalMediaLimitedMemberhtgc:DebtInvestmentsMember2021-12-310001280784us-gaap:SubsequentEventMemberhtgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2023-01-132023-01-130001280784htgc:SmallBusinessAdministrationDebenturesHtIiiMember2018-01-012018-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:PollenIncTwoMemberhtgc:ExitFeeMember2021-12-310001280784htgc:SoftwareMemberhtgc:AgilenceIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2014-01-012014-12-310001280784us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:EquitySecuritiesMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784htgc:BrickellBiotechIncMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:TermsRelatingToRedemptionMayMateriallyAdverselyAffectYourReturnOnAnyDebtSecuritiesThatWeMayIssueMember2022-01-012022-12-310001280784htgc:April2019NotesMember2015-01-012015-12-310001280784htgc:MyovantSciencesLtdMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:AcceleratedFeeIncomeExpiredCommitmentsMember2020-01-012020-12-310001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:SavaraIncMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:RivieraPartnersLLCMember2022-12-310001280784htgc:MUFGBankFacilityMemberhtgc:OneMonthSecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-01-012022-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001280784us-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:TecturaCorporationMember2022-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2021-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:SeniorSecuredFirstLienMember2022-01-012022-12-310001280784htgc:WhoopIncMemberus-gaap:SeriesCPreferredStockMemberhtgc:ConsumerAndBusinessProductsMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:BicycleTherapeuticsPLCMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:RestrictedStockMemberhtgc:CapitalInExcessOfParValueMember2021-01-012021-12-310001280784htgc:WarrantInvestmentMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:PreferredStockMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2021-01-012021-12-310001280784htgc:SoftwareMemberhtgc:DashlaneIncorporationMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2021-01-012021-12-310001280784htgc:OtherInterestIncomeMember2022-01-012022-12-310001280784htgc:WeMayExposeOurselvesToRisksIfWeEngageInHedgingTransactionsMember2022-01-012022-12-310001280784htgc:EigenTechnologiesLimitedMemberus-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:FairValueInputsLevel1Memberhtgc:EscrowReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:InformationServicesMemberhtgc:CapellaSpaceCorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784htgc:SoftwareMemberhtgc:DashlaneIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784htgc:YumanityTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:KaleidoBiosciencesIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784htgc:LeaseAndLicenseObligationsMember2022-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2018-09-240001280784htgc:ElectronicsComputerHardwareMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:PreferredStockMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:BlackCrowAIIncMember2021-12-310001280784htgc:AssetBackedNotes2021Member2015-01-012015-12-310001280784htgc:CenterForBreakthroughMedicinesHoldingsLLCMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:CommunicationsAndNetworkingMember2022-01-012022-12-310001280784htgc:March2026ANotesMember2021-01-012021-12-310001280784htgc:GroveCollaborativeIncMemberus-gaap:PrimeRateMemberhtgc:ConsumerAndBusinessProductsMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:RestrictedStockMember2022-01-012022-12-310001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:GritstoneBioIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:AdviserFundsMember2022-05-312022-05-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputRevenueMultipleMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784htgc:SBADebenturesMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:JobandtalentUSAIncorporationMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:ProviMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:IntuityMedicalIncMemberhtgc:SeriesBOnePreferredStockMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:TactAiTechnologiesIncMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784htgc:SecuritizedCreditFacilityWithWellsFargoCapitalFinanceMember2014-01-012014-12-310001280784htgc:SoftwareMemberhtgc:NextrollIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:AgilenceIncorporationMember2022-12-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:EloxxPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:KazooIncPKYouEarnedItIncMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:ManufacturingTechnologyMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:ThumbtackIncorporationMemberus-gaap:CommonStockMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:EquitySecuritiesMembersrt:MaximumMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMember2021-12-310001280784htgc:ProviMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:ExitFeeMember2022-12-310001280784htgc:DeferredFeesMember2022-01-012022-12-310001280784htgc:ViewRayIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:MedicalDevicesAndEquipmentMember2022-12-310001280784htgc:PharmaceuticalsMemberhtgc:DebtInvestmentsMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMemberhtgc:MeasurementInputHypotheticalMarketYieldMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMemberhtgc:MajorityOwnedControlInvestmentsMember2021-01-012021-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:UnsecuredMemberhtgc:CollateralTypeConcentrationRiskMember2022-01-012022-12-310001280784htgc:ControlAndAffiliateInvestmentsMember2020-12-310001280784htgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:DE2021-01-012021-12-310001280784htgc:TwoThousandTwentySevenAssetBackedNotesMember2020-01-012020-12-310001280784us-gaap:SeriesEPreferredStockMemberhtgc:MedroboticsCorporationMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:ElectronicsComputerHardwareMemberhtgc:SkydioIncorporationMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SecuritizedCreditFacilityWithWellsFargoCapitalFinanceMember2017-01-012017-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:EquityInvestmentsMember2021-12-310001280784htgc:DividendDeclaredFiveMember2020-01-012020-12-310001280784us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:EquitySecuritiesMembersrt:MinimumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:LogicworksMember2021-12-310001280784htgc:AcceleratedFeeIncomeExpiredCommitmentsMember2021-01-012021-12-310001280784htgc:WhoopIncMemberus-gaap:SeriesCPreferredStockMemberhtgc:ConsumerAndBusinessProductsMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:GelesisIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:MedicalDevicesAndEquipmentMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:UnityBiotechnologyIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:MUFGBankFacilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:TwoThousandTwentyTwoConvertibleNotesMemberhtgc:UnusedFacilityOtherFeesMember2022-01-012022-12-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2020-01-012020-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:SBADebenturesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:SnagajobcomIncMemberhtgc:InternetConsumerAndBusinessServicesMemberus-gaap:SeriesBPreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:RealizedGainLossMember2022-01-012022-12-310001280784htgc:TwoThousandEighteenPlanAndDirectorPlanMemberus-gaap:RestrictedStockMember2018-06-280001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:AmpionPBCMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:March2026BNotesMember2021-01-012021-12-310001280784htgc:CapitalInExcessOfParValueMember2022-01-012022-12-310001280784us-gaap:PrimeRateMemberhtgc:SoftwareMemberhtgc:DashlaneIncorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2022-12-310001280784htgc:UndistributedOrdinaryIncomeMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:PhathomPharmaceuticalsIncMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:PhathomPharmaceuticalsIncMember2022-12-310001280784htgc:HibercellIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2022-12-310001280784htgc:ValoHealthLLCPKIntegralHealthHoldingsLLCMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:LiborMemberhtgc:ThreeGTMSLLCMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:DividendDeclaredFourMember2022-05-242022-05-240001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:NerdyIncMember2022-12-310001280784htgc:ExitFeesAmortizationMember2020-01-012020-12-310001280784htgc:RhinoLabsIncorporationMemberus-gaap:CommonStockMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:TwoThousandTwentyTwoNotesMember2020-01-012020-12-310001280784us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMember2022-12-310001280784us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:US2021-01-012021-12-310001280784htgc:XFourPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:TwoThousandTwentyTwoNotesMember2021-01-012021-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:CerosIncorporationMember2022-12-310001280784htgc:LiborMemberhtgc:HealthcareServicesOtherMemberhtgc:BlueSprigPediatricsIncMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:SoftwareMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:SeniorSecuredDebtMemberhtgc:KhorosMember2022-12-310001280784htgc:ContractualInterestIncomeMember2022-01-012022-12-310001280784htgc:OurFinancialResultsCouldBeNegativelyAffectedIfASignificantPortfolioInvestmentFailsToPerformAsExpectedMember2022-01-012022-12-310001280784htgc:AxsomeTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:G1TherapeuticsIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:InvestmentFundsVehiclesMemberhtgc:SoftwareMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:MadrigalPharmaceuticalIncMember2021-12-310001280784htgc:SoftwareMemberhtgc:EquityInvestmentsMember2022-12-310001280784htgc:SMBCFacilityMemberhtgc:UnusedFacilityOtherFeesMember2022-01-012022-12-310001280784us-gaap:CommonStockMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:OutsetMedicalIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:ElectronicsComputerHardwareMemberhtgc:LocusRoboticsCorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:HerculesCapitalFourLPMember2022-12-310001280784htgc:SBADebenturesIssuedOnAugustTwentyTwoThousandAndTwentyOneMember2021-12-310001280784htgc:June2025NotesMember2021-01-012021-12-310001280784htgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:TecturaCorporationTwoMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:AmplifybioLlcMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:BiotechnologyToolsMember2022-01-012022-12-310001280784htgc:PeerlessNetworkHoldingsIncMemberhtgc:EquityInvestmentsMemberhtgc:CommunicationsAndNetworkingMember2021-12-310001280784htgc:TricidaIncMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:SubsequentEventMemberhtgc:BaseAndSupplementalDividendMember2023-02-092023-02-090001280784htgc:SeptemberTwoThousandTwentySixNotesMember2021-09-162021-09-160001280784htgc:JuneTwoThousandTwentyFiveNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:PharmaceuticalsMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2021-12-310001280784htgc:FinchTherapeuticsGroupIncMemberhtgc:SeniorSecuredDebtMemberhtgc:CapRateMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:RhinoLabsIncorporationMemberhtgc:SeriesBTwoPreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:SeresTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784us-gaap:EquitySecuritiesMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784htgc:InvestmentFundsAndVehiclesMember2021-12-310001280784htgc:SoftwareMemberhtgc:DemandbaseIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:April2019NotesMember2014-01-012014-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:ProterraIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMember2022-12-310001280784htgc:TarsusPharmaceuticalsIncMemberhtgc:DebtInvestmentsMember2021-12-310001280784htgc:FirstInsightIncMemberhtgc:InternetConsumerAndBusinessServicesMemberus-gaap:SeriesBPreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyEightTwoThousandAndTwentyOneMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:EquityInvestmentsMember2022-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMember2021-01-012021-12-310001280784htgc:CybermaxxIntermediateHoldingsIncorporationMemberhtgc:DebtInvestmentsMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:BicycleTherapeuticsPLCMember2022-12-310001280784htgc:April2019NotesMember2017-01-012017-12-310001280784htgc:CommonUnitsMemberhtgc:ValoHealthLLCPKIntegralHealthHoldingsLLCMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:JuneTwoThousandTwentyFiveThreeYearNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:WeAreCurrentlyOperatingInAPeriodOfCapitalMarketsDisruptionAndEconomicUncertaintyAndCapitalMarketsMayExperiencePeriodsOfDisruptionAndInstabilityInTheFutureMember2022-01-012022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:BicycleTherapeuticsPLCMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2021-12-310001280784htgc:AxsomeTherapeuticsIncMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:GelesisIncOneMemberhtgc:SeriesAOnePreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2021-12-310001280784htgc:AveoPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:NuvoloTechnologiesCorporationMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:PhathomPharmaceuticalsIncMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:YipitLLCMember2022-12-310001280784htgc:SeriesAAPreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMemberhtgc:FlowonixMedicalIncorporatedMember2021-12-310001280784htgc:Notes2033Member2019-01-012019-12-3100012807842020-07-012020-09-300001280784htgc:SemiconductorsMemberhtgc:SeniorSecuredDebtMemberhtgc:FungibleIncorporationMemberhtgc:ExitFeeMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMemberhtgc:HilleVaxIncMember2022-12-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2021-12-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784htgc:OtherMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001280784htgc:SBADebenturesIssuedOnJanuaryFourteenTwoThousandAndTwentyTwoMember2022-12-310001280784htgc:AxsomeTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:DebtInvestmentsMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:ValuationTechniqueMarketComparableCompaniesMemberhtgc:TechnologyMember2021-12-310001280784htgc:ZoomMediaGroupIncMemberhtgc:MediaContentInfoMemberus-gaap:SeriesAPreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:SolarSpectrumHoldingsLLCMember2021-12-310001280784htgc:January2027NotesMember2022-01-012022-12-310001280784htgc:DividendDeclaredTwoMember2022-01-012022-12-310001280784htgc:SBADebenturesIssuedOnJanuaryTwentyOneTwoThousandAndTwentyTwoMember2022-12-310001280784htgc:SmallBusinessAdministrationDebenturesHtIiMember2017-01-012017-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:ManufacturingTechnologyMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMemberhtgc:UnusedFacilityOtherFeesMember2021-01-012021-12-310001280784htgc:CapitalGainsMember2022-01-012022-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputRevenueMultipleMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMember2022-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2022-12-310001280784htgc:DebtAndEquitySecuritiesUnrealizedGainLossMemberus-gaap:PreferredStockMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310001280784htgc:SolarSpectrumHoldingsLlcPKASungevityIncMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:SeniorSecuredDebtMember2021-01-012021-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:EsentireIncorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:OfferUpIncMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:EquityInvestmentsMember2021-12-310001280784htgc:DrugDeliveryMember2022-12-310001280784htgc:ExitFeeMember2021-01-012021-12-310001280784htgc:CarwowLimitedMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:EquityInvestmentsMemberhtgc:SeriesDFourPreferredStockMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMember2021-01-012021-12-310001280784htgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2015-01-012015-12-310001280784htgc:SnagajobcomIncMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2021-12-310001280784htgc:AssetBackedNotes2021Member2017-01-012017-12-310001280784htgc:NextrollIncorporationMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2022-01-012022-12-310001280784htgc:SoftwareMemberhtgc:EquityInvestmentsMemberhtgc:DruvaHoldingsIncMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:SemiconductorsMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:ReplimuneGroupIncMember2021-12-310001280784htgc:BiotechnologyToolsMemberhtgc:AlamarBiosciencesIncorporationMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMemberhtgc:MeasurementInputHypotheticalMarketYieldMember2021-12-310001280784us-gaap:FairValueInputsLevel1Memberhtgc:SBADebenturesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:EquitySecuritiesMembersrt:MaximumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ThreatConnectIncMember2021-12-310001280784htgc:InformationServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:XFourPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:HalioIncPKKinestralTechnologiesIncMemberus-gaap:SeriesAPreferredStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:CenturyTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784htgc:HouzzIncorporationMemberhtgc:InternetConsumerAndBusinessServicesMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:FairValueInputsLevel1Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:IkonScienceLimitedMember2021-12-3100012807842022-12-310001280784htgc:NabrivaTherapeuticsMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:EquitySecuritiesMembersrt:MinimumMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMember2022-12-310001280784htgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:PoplicusIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:ConsumerAndBusinessProductsMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:AffiliateInvestmentsMember2020-01-012020-12-310001280784htgc:TarsusPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:VeemIncorporationOneMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:CoriumIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:HalioIncPKKinestralTechnologiesIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:SoftwareMemberhtgc:EsentireIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SBADebenturesIssuedOnJuneTwentyFiveTwoThousandAndTwentyOneMember2022-01-012022-12-310001280784htgc:SBADebenturesIssuedOnAugustTwentyTwoThousandAndTwentyOneMember2022-01-012022-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:TwoThousandTwentySevenAssetBackedNotesMember2021-01-012021-12-310001280784us-gaap:SeriesCPreferredStockMemberhtgc:GynesonicsIncMemberhtgc:SurgicalDevicesMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SoftwareMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:SprinklrIncMember2022-12-310001280784htgc:July2024NotesMember2021-01-012021-12-310001280784htgc:InformationServicesMemberhtgc:WarrantInvestmentMember2022-12-3100012807842019-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:AmpionPBCMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:DebtAndEquitySecuritiesUnrealizedGainLossMemberhtgc:EscrowReceivableMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310001280784us-gaap:CommonStockMemberhtgc:ADMABiologicsIncMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:DepreciationMemberus-gaap:FairValueInputsLevel3Memberhtgc:WarrantInvestmentMember2022-01-012022-12-310001280784htgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMember2020-12-310001280784htgc:ValoHealthLLCMemberhtgc:EquityInvestmentsMemberus-gaap:SeriesBPreferredStockMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:September2026NotesMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:BabelStreetMember2021-12-310001280784htgc:HerculesAdviserLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberus-gaap:MemberUnitsMember2022-12-310001280784htgc:PalantirTechnologiesMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMember2022-12-3100012807842021-07-012021-09-300001280784htgc:TricidaIncMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:SeriesCPreferredStockMemberhtgc:TheNeatCompanyMemberhtgc:ConsumerAndBusinessProductsMemberus-gaap:CommonStockMember2021-12-310001280784htgc:PeerlessNetworkHoldingsIncMemberhtgc:EquityInvestmentsMemberus-gaap:SeriesAPreferredStockMemberhtgc:CommunicationsAndNetworkingMember2021-12-310001280784htgc:DelphixCorporationMemberhtgc:SoftwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:ConsumerAndBusinessProductsMemberus-gaap:CommonStockMemberhtgc:TFGHoldingIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2022-12-310001280784htgc:InformationServicesMemberhtgc:EquityInvestmentsMember2021-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:DrugDeliveryMember2021-01-012021-12-310001280784htgc:SmallBusinessAdministrationDebenturesHtIiiMember2019-01-012019-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784htgc:ElectronicsComputerHardwareMemberhtgc:LocusRoboticsCorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SolarSpectrumHoldingsLlcPKASungevityIncMemberhtgc:SeniorDebtMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2021-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMember2021-03-040001280784us-gaap:CommonStockMemberhtgc:BioQPharmaIncorporatedMemberhtgc:DrugDeliveryMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:CutoverIncMember2022-12-310001280784htgc:OtherMember2021-12-310001280784htgc:ExitFeeMember2020-01-012020-12-310001280784htgc:DividendDeclaredSixMember2020-01-012020-12-310001280784htgc:DiversifiedFinancialServicesMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:TecturaCorporationOneMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:VeemIncorporationMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:OrdinaryIncomeMember2018-01-012018-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:ManufacturingTechnologyMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001280784us-gaap:WarrantMemberus-gaap:SalesRevenueNetMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:WarrantInvestmentMember2021-01-012021-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:CommonStockMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:EquitySecuritiesMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2021-12-310001280784htgc:OtherMember2022-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2022-12-310001280784htgc:HealthcareServicesOtherMemberus-gaap:PrimeRateMemberhtgc:EqualityHealthLLCMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SoftwareMemberhtgc:BrainCorporationMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:FinchTherapeuticsGroupIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2022-12-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2021-01-012021-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001280784htgc:WeAreHighlyDependentOnInformationSystemsAndSystemsFailuresCouldSignificantlyDisruptOurBusinessWhichMayInTurnNegativelyAffectTheMarketPriceOfOurCommonStockAndOurAbilityToPayDividendsMember2022-01-012022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2021-01-012021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:MixpanelIncMember2021-12-310001280784htgc:ConvertibleNotes2022Member2018-01-012018-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:BlackCrowAIIncMember2022-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:InvestmentTypeConcentrationRiskMember2021-01-012021-12-310001280784htgc:MUFGBankFacilityMembersrt:MinimumMember2022-12-310001280784htgc:SeresTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2022-12-310001280784htgc:SolarSpectrumHoldingsLlcPKASungevityIncMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:SeniorSecuredDebtMember2020-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:HerculesAdviserLLCMemberhtgc:UnsecuredMember2021-12-310001280784htgc:April2019NotesMember2016-01-012016-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberhtgc:SeniorSecuredDebtMember2022-01-012022-12-310001280784htgc:DeferredFeesMember2022-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:OakStreetHealthIncMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:TactAiTechnologiesIncMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2022-12-310001280784htgc:CybermaxxIntermediateHoldingsIncorporationMemberhtgc:DebtInvestmentsMember2021-12-310001280784htgc:SoftwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:PreferredStockMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:SurgicalDevicesMember2021-01-012021-12-310001280784htgc:AchronixSemiconductorCorporationMemberhtgc:SeriesDTwoPreferredStockMemberhtgc:SemiconductorsMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap:CommonStockMemberhtgc:SurgicalDevicesMemberhtgc:TransMedicsGroupIncPKTransmedicsIncMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:DebtInvestmentsMember2022-12-310001280784htgc:ConvertibleNoteDiscountsAmortizationMember2020-01-012020-12-310001280784htgc:OurExecutiveOfficersAndEmployeesThroughTheAdviserSubsidiaryAreExpectedToManageTheAdviserFundsOrSeparatelyManagedAccountsMember2022-01-012022-12-310001280784htgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:DynavaxTechnologiesMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:OfferUpIncMemberhtgc:EquityInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:SeriesAPreferredStockMember2022-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputEbitdaMultipleMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2021-12-310001280784htgc:SecuredCreditFacilityWithMUFGBankLtdMUFGMember2019-01-012019-12-310001280784us-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:SavaraIncMember2022-12-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMemberhtgc:UnusedFacilityOtherFeesMember2021-01-012021-12-310001280784htgc:ControlInvestmentsMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2022-12-310001280784us-gaap:SeriesEPreferredStockMemberhtgc:ElectronicsComputerHardwareMemberhtgc:SkydioIncorporationMemberhtgc:EquityInvestmentsMember2022-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:CoriumIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:AchronixSemiconductorCorporationMemberus-gaap:SeriesCPreferredStockMemberhtgc:EquityInvestmentsMemberhtgc:SemiconductorsMember2022-12-310001280784htgc:AxsomeTherapeuticsIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784country:NLus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001280784htgc:InvestmentsInSecuritiesMember2022-12-310001280784htgc:PharmaceuticalsMemberhtgc:DebtInvestmentsMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMemberhtgc:MeasurementInputHypotheticalMarketYieldMember2021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:ImpossibleFoodsIncMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:XFourPharmaceuticalsIncMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:OptiscanBiomedicalCorpMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2020-01-012020-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784htgc:RealizedGainLossMember2020-01-012020-12-310001280784htgc:TwoThousandTwentyTwoConvertibleNotesMemberhtgc:UnusedFacilityOtherFeesMember2021-01-012021-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MaximumMemberhtgc:ExpectedRealizableValueMemberhtgc:MeasurementInputHypotheticalMarketYieldMember2021-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:EsentireIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:IndustrySectorMember2022-01-012022-12-310001280784htgc:SoftwareMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhtgc:SeniorSecuredDebtMemberhtgc:ZimperiumIncMember2022-12-310001280784htgc:SoftwareMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:MediaContentInfoMember2022-12-310001280784htgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MaximumMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:PreferredStockMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:SeniorSecuredDebtMemberhtgc:PhathomPharmaceuticalsIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SkywordIncorporatinMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMember2021-12-310001280784htgc:SeresTherapeuticsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:SoftwareMemberhtgc:PollenIncMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:BicycleTherapeuticsPLCMemberhtgc:DrugDiscoveryAndDevelopmentMemberhtgc:ExitFeeMember2021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:DebtInvestmentsMemberhtgc:ExpectedRealizableValueMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMember2021-12-310001280784htgc:AnnexCloudMemberhtgc:DebtInvestmentsMember2021-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:FebruaryTwoThousandTwentyFiveNotesMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:AlamarBiosciencesIncorporationMember2021-12-310001280784htgc:AriaSystemsIncMemberhtgc:InternetConsumerAndBusinessServicesMemberus-gaap:SeriesGPreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:MeasurementInputEbitdaMultipleMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMembersrt:WeightedAverageMember2021-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:UnsecuredMemberhtgc:GibraltarBusinessCapitalLLCOneMember2022-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMember2021-01-012021-12-310001280784htgc:TwoThousandTwentyTwoNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:XFourPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:SoftwareMemberhtgc:GryphonNetworksCorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:FatcaWithholdingMayApplyToPaymentsMadeToCertainForeignEntitiesMember2022-01-012022-12-310001280784htgc:PRIMEInterestRateMember2021-12-310001280784htgc:LocusRoboticsCorpMemberhtgc:ElectronicsComputerHardwareMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:SBADebenturesIssuedOnOctoberTwentyOneTwoThousandAndTwentyOneMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberhtgc:ValuationTechniqueLiquidationMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:ElectronicsComputerHardwareMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:BridgeBioPharmaIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:PrepaymentsOfOurDebtInvestmentsByOurPortfolioCompaniesCouldAdverselyImpactOurResultsOfOperationsAndReduceOurReturnOnEquityMember2022-01-012022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:UnsecuredDebtMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2021-01-012021-12-310001280784htgc:AmplifybioLlcMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:US2022-01-012022-12-310001280784us-gaap:PrimeRateMemberhtgc:AveoPharmaceuticalsIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:UnsecuredMember2021-12-310001280784htgc:SkywordIncorporatinMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:ExitFeeMember2022-12-310001280784htgc:ControlInvestmentsMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2022-01-012022-12-310001280784htgc:SBADebenturesIssuedOnJuneTwentyFiveTwoThousandAndTwentyOneMember2021-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:ElectronicsComputerHardwareMember2022-01-012022-12-310001280784htgc:SustainableAndRenewableTechnologyMemberus-gaap:SeriesDPreferredStockMemberhtgc:IngredientwerksHoldingsIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:CommonStockMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2021-12-310001280784us-gaap:SalesRevenueNetMemberus-gaap:PreferredStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:EquityInvestmentsMember2022-01-012022-12-310001280784htgc:TwoThousandTwentyTwoConvertibleNotesMember2022-12-310001280784htgc:GroveCollaborativeIncMemberhtgc:ConsumerAndBusinessProductsMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:SoftwareMemberhtgc:HighRoadsIncMemberus-gaap:CommonStockMemberhtgc:EquityInvestmentsMember2022-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784country:GB2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:CerosIncorporationMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberhtgc:FebruaryTwoThousandTwentyFiveNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:ControlInvestmentsMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMember2020-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:CoriumIncMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:DrugDeliveryMember2022-01-012022-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2022-01-012022-12-310001280784us-gaap:SeriesCPreferredStockMemberhtgc:ShareThisIncMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:InformationServicesMember2021-01-012021-12-310001280784htgc:AdditionalGrantMemberhtgc:PerformanceVestingAwardMember2022-01-012022-12-310001280784htgc:AchronixSemiconductorCorporationMemberhtgc:SeriesDTwoPreferredStockMemberhtgc:SemiconductorsMemberhtgc:WarrantInvestmentMember2021-12-310001280784us-gaap:ConvertibleDebtSecuritiesMember2021-01-012021-12-310001280784htgc:TwoThousandTwentyTwoNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784us-gaap:CommonStockMemberhtgc:EquityInvestmentsMemberhtgc:AlbireoPharmaIncMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:GenoceaBiosciencesIncMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784us-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:SBADebenturesIssuedOnNovemberOneTwoThousandAndTwentyOneMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:CerosIncorporationMember2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:DronedeployIncorporationMember2022-12-310001280784htgc:June2025NotesMember2022-01-012022-12-3100012807842021-10-012021-12-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2021-12-310001280784us-gaap:PrimeRateMemberhtgc:HumanigenIncMemberhtgc:SeniorSecuredDebtMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:CommunicationsAndNetworkingMember2021-12-310001280784htgc:IncludingCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280784htgc:SBADebenturesIssuedOnNovemberOneTwoThousandAndTwentyOneMember2021-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:EquityInvestmentsMember2021-12-310001280784htgc:ManufacturingTechnologyMemberhtgc:BrightMachinesIncorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:TwoThousandThirtyThreeNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:OtherTemporaryDifferencesMember2021-12-310001280784htgc:SeriesOnePreferredStockMemberhtgc:InformationServicesMemberhtgc:NetBaseSolutionsIncMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:LongTermCapitalGainsMember2022-01-012022-12-310001280784us-gaap:SeriesCPreferredStockMemberhtgc:AchronixSemiconductorCorporationMemberhtgc:EquityInvestmentsMemberhtgc:SemiconductorsMember2021-12-310001280784htgc:AnyUnrealizedDepreciationWeExperienceOnInvestmentPortfolioMayBeAnIndicationOfFutureRealizedLossesWhichCouldReduceOurIncomeAvailableForDistributionAndCouldImpairOurAbilityToServiceOurBorrowingsMember2022-01-012022-12-310001280784htgc:July2024NotesMember2019-01-012019-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMember2022-01-012022-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:WorldremitGroupLimitedMemberhtgc:SeniorSecuredDebtMemberhtgc:ConsumerAndBusinessServicesMember2022-12-310001280784htgc:AppliedMolecularTransportMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:WorldremitGroupLimitedMemberhtgc:InternetConsumerAndBusinessServicesMemberus-gaap:SeriesDPreferredStockMemberhtgc:WarrantInvestmentMember2021-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:TwoThousandTwentyTwoNotesMember2022-01-012022-12-310001280784us-gaap:UnsecuredDebtMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarBusinessCapitalLLCMemberhtgc:MajorityOwnedControlInvestmentsMember2022-01-012022-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CostApproachValuationTechniqueMemberus-gaap:MeasurementInputDiscountRateMembersrt:WeightedAverageMember2021-12-310001280784us-gaap:SeriesCPreferredStockMemberhtgc:SoftwareMemberhtgc:ContentfulGlobalIncMemberhtgc:EquityInvestmentsMember2022-12-3100012807842021-01-012021-12-310001280784htgc:LiborMemberhtgc:SoftwareMemberhtgc:SeniorSecuredDebtMemberhtgc:ShadowDragonLLCMember2022-12-310001280784us-gaap:PrimeRateMemberhtgc:InformationServicesMemberhtgc:CapellaSpaceCorporationMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:EquityInvestmentsMemberus-gaap:CommonStockMember2021-01-012021-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:GritstoneBioIncMember2021-12-310001280784htgc:MeasurementInputPremiumDiscountMemberhtgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueMarketComparableCompaniesMember2021-12-310001280784us-gaap:WarrantMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMembersrt:WeightedAverageMember2022-12-310001280784htgc:SBADebenturesIssuedOnNovemberOneTwoThousandAndTwentyOneMember2022-01-012022-12-310001280784us-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarBusinessCapitalLLCMember2020-01-012020-12-310001280784htgc:MedicalDevicesAndEquipmentMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:DashlaneIncorporationMember2022-12-310001280784us-gaap:SalesRevenueNetMemberhtgc:UnsecuredMemberhtgc:InvestmentTypeConcentrationRiskMember2021-01-012021-12-310001280784htgc:NabrivaTherapeuticsMemberhtgc:SeniorSecuredDebtMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:ManufacturingTechnologyMemberhtgc:BrightMachinesIncorporationMemberus-gaap:CommonStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:DebtInvestmentsMemberhtgc:AutomationAnyWhereIncMember2022-12-310001280784htgc:PineappleEnergyLLCMemberhtgc:SustainableAndRenewableTechnologyMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:DividendDeclaredOneMember2021-01-012021-12-310001280784htgc:SixMonthLIBORMember2022-12-310001280784htgc:InvestmentFundsVehiclesMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhtgc:MediaContentInfoMember2022-01-012022-12-3100012807842018-01-012018-12-310001280784htgc:AssetBackedNotes2028Member2019-01-012019-12-310001280784htgc:AriaSystemsIncMemberhtgc:SoftwareMemberus-gaap:SeriesGPreferredStockMemberhtgc:WarrantInvestmentMember2022-12-310001280784htgc:OtherInterestIncomeMember2021-01-012021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:OfferupIncOneMemberhtgc:SeriesAOnePreferredStockMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:EquityInvestmentsMember2021-12-310001280784htgc:SeniorSecuritiesMember2018-01-012018-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:UnityBiotechnologyIncMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2021-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:EquityInvestmentsMemberus-gaap:SeriesDPreferredStockMemberhtgc:PivotBioIncMember2022-12-310001280784htgc:AppDirectIncorporationMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2021-12-310001280784htgc:ADowngradeSuspensionOrWithdrawalOfTheCreditRatingAssignedByARatingAgencyToUsOrOurDebtSecuritiesMember2022-01-012022-12-310001280784htgc:SoftwareMemberhtgc:BabelStreetMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784us-gaap:IncomeApproachValuationTechniqueMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:SustainableAndRenewableTechnologyMemberhtgc:DebtInvestmentsMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280784htgc:DebtInvestmentsMemberhtgc:OakStreetHealthIncMember2021-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:AtaiLifeSciencesNVMemberhtgc:ExitFeeMemberhtgc:DrugDiscoveryAndDevelopmentMember2022-12-310001280784htgc:DrugDeliveryMember2021-12-310001280784htgc:HealthcareServicesOtherMember2022-12-310001280784htgc:UnusedFacilityOtherFeesMemberhtgc:UnionBankFacilityMember2020-01-012020-12-310001280784htgc:TecturaCorporationOneMemberhtgc:InternetConsumerAndBusinessServicesMemberhtgc:EquityInvestmentsMemberhtgc:PreferredSeriesBBMember2021-12-310001280784htgc:SMBCFacilityMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001280784htgc:PineappleEnergyLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerNoncontrolledMemberus-gaap:CommonStockMember2022-12-310001280784htgc:ConvertibleNotes2022Member2019-01-012019-12-310001280784htgc:HerculesAdviserLLCMemberus-gaap-supplement:InvestmentAffiliatedIssuerControlledMemberus-gaap:UnsecuredDebtMemberhtgc:MajorityOwnedControlInvestmentsMember2022-12-310001280784htgc:SnagajobcomIncMemberus-gaap:CommonStockMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:WarrantInvestmentMember2022-12-31xbrli:pureiso4217:USDxbrli:sharesxbrli:sharesiso4217:GBPiso4217:USDhtgc:Firm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 814-00702

 

HERCULES CAPITAL, INC.

(Exact name of Registrant as specified in its charter)

 

 

Maryland

 

74-3113410

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification Number)

400 Hamilton Avenue, Suite 310

Palo Alto, California 94301

(Address of principal executive offices)

Registrant’s telephone number, including area code: (650) 289-3060

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Shares, par value $0.001 per share

6.25% Notes due 2033

HTGC

HCXY

New York Stock Exchange

New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with a new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $1.68 billion based upon a closing price of $13.49 reported for such date on the New York Stock Exchange. Common shares held by each executive officer and director and by each person who owns 5% or more of the outstanding common shares have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not intended and shall not be deemed to be an admission that, such persons are affiliates of the Registrant.

On February 9, 2023, there were 136,480,361 shares outstanding of the registrant’s common stock, $0.001 par value.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s Proxy Statement for its 2023 Annual Meeting of Stockholders to be filed within 120 days after the close of the registrant’s year end are incorporated by reference into Part III of this Annual Report on Form 10-K.

Auditor Firm Id:

238

Auditor Name:

PricewaterhouseCoopers, LLP

Auditor Location:

San Francisco, CA

 

 

 

1


HERCULES CAPITAL, INC.

FORM 10-K

ANNUAL REPORT

 

 

 

Page

 

Part I.

 

Item 1.

Business

3

Item 1A.

Risk Factors

25

Item 1B.

Unresolved SEC Staff Comments

47

Item 2.

Properties

47

Item 3.

Legal Proceedings

47

Item 4.

Mine Safety Disclosures

47

 

 

Part II.

 

 

Item 5.

 

Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

48

Item 6.

Reserved

50

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

51

Item 7A.

Quantitative and Qualitative Disclosure About Market Risk

66

Item 8.

Financial Statements and Supplementary Data

67

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

130

Item 9A.

Controls and Procedures

130

Item 9B.

Other Information

131

Item 9C

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

134

 

 

Part III.

 

 

Item 10.

 

Directors, Executive Officers and Corporate Governance

135

Item 11.

Executive Compensation

135

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

135

Item 13.

Certain Relationships and Related Transactions and Director Independence

135

Item 14.

Principal Accountant Fees and Services

135

 

 

Part IV.

 

 

Item 15.

 

Exhibits and Financial Statement Schedules

136

Item 16.

Form 10-K Summary

143

Signatures

144

 

Hercules Capital, Inc., our logo and other trademarks of Hercules Capital, Inc. are the property of Hercules Capital, Inc. All other trademarks or trade names referred to in this Annual Report on Form 10-K are the property of their respective owners.

 

2


In this Annual Report on Form 10-K, or Annual Report, the “Company,” “Hercules,” “we,” “us,” and “our” refer to Hercules Capital, Inc., its wholly owned subsidiaries, and its affiliated securitization trust unless the context otherwise requires.

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements that involve substantial risks and uncertainties that are within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can identify these statements using forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “target,” “estimate,” “intend,” “continue” or “believe” or the negatives of, or other variations on, these terms or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects, and expectations concerning our business, operating results, financial condition, and other similar matters. We believe that it is important to communicate our future expectations to our investors. Our forward-looking statements include information in this report regarding general domestic and global economic conditions, our future financing plans, our ability to operate as a business development company (“BDC”) and the expected performance of, and the yield on, our portfolio companies. There may be events in the future, however, that we are not able to predict accurately or control. The factors listed under “Risk Factors” in this annual report on Form 10-K, as well as any cautionary language in this report, provide examples of risks, uncertainties and events that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. The occurrence of the events described in these risk factors and elsewhere in this report could have a material adverse effect on our business, results of operations and financial position. Any forward-looking statement made by us in this report speaks only as of the date of this report. Factors or events that could cause our actual results to differ from our forward-looking statements may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable law.

PART I

Item 1. Business

GENERAL

Hercules Capital, Inc. is a specialty finance company focused on providing financing solutions to high-growth, innovative venture capital-backed and institutional-backed companies in a variety of technology, life sciences and sustainable and renewable technology industries. Our goal is to be the leading Structured Debt financing provider for venture capital-backed and institutional-backed companies in technology-related industries requiring sophisticated and customized financing solutions. We use the term “Structured Debt” to refer to a debt investment that is structured with an equity, warrant, option, or other right to purchase or convert into common or preferred stock. Our strategy is to evaluate and invest in a broad range of technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology and to offer a full suite of growth capital products.

Our primary business objectives are to increase our net income, net investment income, and net asset value (“NAV”) through our investments in primarily Structured Debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. We aim to achieve our business objectives by maximizing our portfolio total return through generation of current income from our debt investments and capital appreciation from our warrant and equity investments. Our equity ownership in our portfolio companies may exceed 25% of the voting securities of such companies, which represents a controlling interest under the Investment Company Act of 1940 (“1940 Act”). In some cases, we receive the right to make additional equity investments in our portfolio companies in connection with future equity financing rounds. Capital that we provide is generally used for growth and general working capital purposes as well as in select cases for acquisitions or recapitalizations. We invest primarily in private companies but also have investments in public companies.

Our investments are focused in companies that are active in a variety of technology industry sub-sectors or are characterized by products or services that require advanced technologies, including, but not limited to, computer software and hardware, networking systems, semiconductors, semiconductor capital equipment, information technology infrastructure or services, consumer and business services, telecommunications, telecommunications equipment, media, life sciences, and renewable or alternative energy. Within the life sciences sub-sector, we generally focus on medical devices, bio-pharmaceutical, drug discovery and development, drug delivery, health care services and information systems companies. Within the sustainable and renewable technology sub-sector, we focus on sustainable and renewable energy technologies and energy efficiency and monitoring technologies. We refer to all of these companies as “technology-related” companies and intend, under normal circumstances, to invest at least 80% of the value of our total assets in such businesses.

 

3


We, our subsidiaries or our affiliates, may also agree to manage certain other funds that invest in debt, equity or provide other financing or services to companies in a variety of industries for which we may earn management or other fees for our services. We may also invest in the equity of these funds, along with other third parties, from which we would seek to earn a return and/or future incentive allocations. Some of these transactions could be material to our business. Consummation of any such transaction will be subject to completion of due diligence, finalization of key business and financial terms (including price) and negotiation of final definitive documentation as well as a number of other factors and conditions, which may include, depending on the transaction and without limitation, the approval of our Board of Directors (the "Board"), required regulatory or third-party consents, and/or the approval of our stockholders. Accordingly, there can be no assurance that any such transaction would be consummated. Any of these transactions or funds may require significant management resources either during the transaction phase or on an ongoing basis depending on the terms of the transaction.

CORPORATE STRUCTURE

We are an internally managed, non-diversified closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the 1940 Act. As a BDC, we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in “qualifying assets,” including securities of private U.S. companies, cash, cash equivalents, U.S. government securities and high-quality debt investments that mature in one year or less. As a BDC, we must also maintain a coverage ratio of total assets to total senior securities, which include all of our borrowings (including accrued interest payable) except for debentures issued by the Small Business Administration (the “SBA”) and any preferred stock we may issue in the future, of at least 150% subsequent to each borrowing or issuance of senior securities. Certain of our wholly owned subsidiaries are licensed to operate as a small business investment company (a “SBIC” or “SBICs”) under the authority of the SBA. Through SBIC licensed vehicles we may access capital from the SBA debenture program. See “Regulation” for additional information related to our capital requirements.

We are internally managed under the supervision of our Board. We do not pay management or advisory fees, but instead incur costs customary for an operating company. Some of those costs include recruiting and marketing expenses as well as the costs associated with employing management, investment and portfolio management professionals, and technology, secretarial and other support personnel. In connection with our recruiting, branding and marketing efforts, we may, among other things, make charitable contributions in amounts we believe to be immaterial and that do not exceed $500 thousand in the aggregate in any year. We believe that many of these contributions help us raise our profile in the communities and benefit us in attracting and retaining talent and investment opportunities.

Effective January 1, 2006, we elected to be treated for U.S. federal tax purposes as a regulated investment company (“RIC”) under the Internal Revenue Code of 1986, as amended (“the Code”). As a RIC, we generally will not be subject to U.S. federal income tax on the portion of our investment company taxable income and net capital gain (i.e., net realized long-term capital gains in excess of net realized short-term capital losses) we distribute (or are deemed to distribute) as dividends for U.S. federal income tax purposes to stockholders with respect to that taxable year. We will be subject to a 4% non-deductible U.S. federal excise tax on certain undistributed income and gains unless we make distributions treated as dividends for U.S. federal income tax purposes in a timely manner to our stockholders in respect of each calendar year subject to certain requirements as defined for RICs. See “Certain United States Federal Income Tax Considerations” for additional information. Additionally, we have established wholly owned subsidiaries that are not consolidated for U.S. federal tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments.

In May 2020, Hercules Adviser LLC (the “Adviser Subsidiary”) was formed as a wholly owned Delaware limited liability subsidiary to provide investment advisory and related services to investment vehicles (“Adviser Funds”) owned by one or more unrelated third-party investors (“External Parties”). The Adviser Subsidiary receives fee income for the services provided to the Adviser Funds. The Company was granted no-action relief by the staff of the Securities and Exchange Commission (“SEC”) to allow the Adviser Subsidiary to register as a registered investment adviser under the Investment Advisers Act of 1940, as amended (“Advisers Act”). See “— Regulation—No-action and Exemptive Relief Obtained” for additional information regarding our Adviser Subsidiary.

CORPORATE HISTORY AND OFFICES

We are a Maryland corporation formed in December 2003 that began investment operations in September 2004. On February 25, 2016, we changed our name from “Hercules Technology Growth Capital, Inc.” to “Hercules Capital, Inc.” Our principal executive offices are located at 400 Hamilton Avenue, Suite 310, Palo Alto, California 94301, and our telephone number is (650) 289-3060. We also have offices in Boston, MA, New York, NY, Bethesda, MD, Westport, CT, Chicago, IL, San Diego, CA, and London, United Kingdom.

 

4


AVAILABLE INFORMATION

We file with or submit to the SEC our annual, quarterly, current reports, proxy statements and other information meeting the informational requirements of the Securities Exchange Act of 1934, as amended (“the Exchange Act”). We make available, free of charge, on our website our proxy statement, annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports and other publicly filed information available as soon as reasonably practicable after we electronically file such material with, or furnish it to the SEC. Our Internet address where these documents and other information can be found is www.htgc.com. Information contained on our website is not incorporated by reference into this Annual Report, and you should not consider that information to be part of this Annual Report. Our annual, quarterly, periodic and current reports, proxy statements and other public filings are also available free of charge on the EDGAR Database on the SEC's Internet website at www.sec.gov.

OUR MARKET OPPORTUNITY

We believe that technology-related companies compete in one of the largest and most rapidly growing sectors of the U.S. economy and that continued growth is supported by ongoing innovation and performance improvements in technology products as well as the adoption of technology across virtually all industries in response to competitive pressures. We believe that an attractive market opportunity exists for a specialty finance company focused primarily on investments in Structured Debt, senior debt, and equity securities in technology-related companies for the following reasons:

technology-related companies have generally been underserved by traditional lending sources;
unfulfilled demand exists for Structured Debt financing to technology-related companies due to the complexity of evaluating risk in these investments; and
Structured Debt products are less dilutive and complement equity financing from venture capital and private equity funds.

Technology-Related Companies are Underserved by Traditional Lenders.

We believe many viable technology-related companies backed by financial sponsors have been unable to obtain sufficient growth financing from traditional lenders, including financial services companies such as commercial banks and finance companies because traditional lenders have continued to consolidate and have adopted a more risk-averse approach to lending. More importantly, we believe traditional lenders are typically unable to underwrite the risk associated with these companies effectively.

The unique cash flow characteristics of many technology-related companies typically include significant research and development expenditures and high projected revenue growth thus often making such companies difficult to evaluate from a credit perspective. In addition, the balance sheets of these companies often include a disproportionately large amount of intellectual property assets, which can be difficult to value. Finally, the speed of innovation in technology and rapid shifts in consumer demand and market share add to the difficulty in evaluating technology-related companies.

Due to the difficulties described above, we believe traditional lenders generally refrain from entering the Structured Debt financing marketplace, instead preferring the risk-reward profile of asset-based lending. Traditional lenders generally do not have flexible product offerings that meet the needs of technology-related companies. The financing products offered by traditional lenders typically impose on borrowers many restrictive covenants and conditions, including limiting cash outflows and requiring a significant depository relationship to facilitate rapid liquidation.

Unfulfilled Demand for Structured Debt Financing to Technology-Related Companies.

Private debt capital in the form of Structured Debt financing from specialty finance companies continues to be an important source of funding for technology-related companies. We believe that the level of demand for Structured Debt financing is a function of the level of annual venture equity investment activity.

We believe that demand for Structured Debt financing is currently underserved. The venture capital market for the technology-related companies in which we invest has been active. Therefore, to the extent we have capital available, we believe this is an opportune time to be active in the structured lending market for technology-related companies.

Structured Debt Products Complement Equity Financing from Venture Capital and Private Equity Funds.

We believe that technology-related companies and their financial sponsors will continue to view Structured Debt securities as an attractive source of capital because it augments the capital provided by venture capital and private equity funds. We believe that our Structured Debt products provide access to growth capital that otherwise may only be available through incremental investments by existing equity investors. As such, we provide portfolio companies and their financial sponsors with an opportunity to diversify their capital sources. Generally, we believe many technology-related companies at all stages of development target a portion of their capital to be debt in an attempt to achieve a higher valuation through internal growth. In addition, because financial sponsor-backed companies have reached a more mature stage prior to reaching a liquidity event, we believe our investments could provide the debt capital needed to grow or recapitalize during the extended period sometimes required prior to liquidity events.

 

5


OUR BUSINESS STRATEGY

Our strategy to achieve our investment objective includes the following key elements:

Leverage the Experience and Industry Relationships of Our Management Team and Investment Professionals.

We have been investing in venture capital-backed and institutional-backed companies for over 19 years. Our investment professionals are led by individuals with extensive experience as venture capitalists, commercial lenders, and originators of Structured Debt and equity investments in technology-related companies. In addition, our team members have originated Structured Debt, senior debt, and equity investments in over 600 technology-related companies, representing more than $16.0 billion in commitments from inception to December 31, 2022, and have developed a network of industry contacts with investors and other participants within the venture capital and private equity communities. Members of our management team also have operational, research and development and finance experience with technology-related companies. Furthermore, we have established contacts with leading venture capital and private equity fund sponsors, public and private companies, research institutions and other industry participants, which we believe will enable us to identify and attract well-positioned prospective portfolio companies.

We focus our investing activities generally in industries in which our investment professionals have investment experience. We believe that our focus on financing technology-related companies will enable us to leverage our expertise in structuring prospective investments, to assess the value of both tangible and intangible assets, to evaluate the business prospects and operating characteristics of technology-related companies and to identify and originate potentially attractive investments with these types of companies.

Mitigate Risk of Principal Loss and Build a Portfolio of Warrant and Equity Securities.

We expect that our investments have the potential to produce attractive risk-adjusted returns through current income, in the form of interest and fee income, as well as capital appreciation from warrant and equity securities. We believe that we can mitigate the risk of loss on our debt investments through the combination of loan principal amortization after an initial interest only period, cash interest payments, relatively short maturities (typically between 36-48 months), security interests in the assets of our portfolio companies, and on select investment covenants requiring prospective portfolio companies to have certain amounts of available cash at the time of our investment and the continued support from a venture capital or private equity firm at the time we make our investment. Although we do not currently engage in hedging transactions, we may engage in hedging transactions in the future utilizing instruments such as forward contracts, currency options and interest rate swaps, caps, collars, and floors.

Historically our Structured Debt investments to technology-related companies typically include warrants or other equity interests, giving us the potential to realize equity-like returns on a portion of our investment. In addition, in some cases, we receive the right to make additional equity investments in our portfolio companies, including the right to convert some portion of our debt into equity, in connection with future equity financing rounds. We believe these equity interests will create the potential for meaningful long-term capital gains in connection with the future liquidity events of these technology-related companies.

Provide Customized Financing Complementary to Financial Sponsors’ Capital.

We offer a broad range of investment structures and possess expertise and experience to effectively structure and price investments in technology-related companies. Unlike many of our competitors that only invest in companies that fit a specific set of investment parameters, we have the flexibility to structure our investments to suit the particular needs of our portfolio companies. We offer customized financing solutions ranging from senior debt, including below-investment grade debt instruments, also known as “junk bonds”, to equity capital, with a focus on Structured Debt.

We use our relationships in the financial sponsor community to originate investment opportunities. Because venture capital and private equity funds typically invest solely in the equity securities of their portfolio companies, we believe that our debt investments will be viewed as an attractive and complimentary source of capital, both by the portfolio company and by the portfolio company’s financial sponsor. In addition, we believe that many venture capital and private equity fund sponsors encourage their portfolio companies to use debt financing for a portion of their capital needs as a means of potentially enhancing equity returns, minimizing equity dilution and increasing valuations prior to a subsequent equity financing round or a liquidity event.

Invest at Various Stages of Development.

We provide growth capital to technology-related companies at all stages of development, including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancings and established-stage companies. We believe that this provides us with a broader range of potential investment opportunities than those available to many of our competitors, who generally focus their investments on a particular stage in a company’s development. Because of the flexible structure of our investments and the extensive experience of our investment professionals, we believe we are well positioned to take advantage of these investment opportunities at all stages of prospective portfolio companies’ development.

 

6


Benefit from Our Efficient Organizational Structure.

We believe that the perpetual nature of our corporate structure enables us to be a long-term partner for our portfolio companies in contrast to traditional investment funds, which typically have a limited life. In addition, because of our access to the equity markets, we believe that we may benefit from a lower cost of capital than that available to private investment funds. We are not subject to requirements to return invested capital to investors, nor do we have a finite investment horizon. Capital providers that are subject to such limitations are often required to seek a liquidity event more quickly than they otherwise might, which can result in a lower overall return on an investment.

OUR INVESTMENTS AND OPERATIONS

We principally invest in debt securities and, to a lesser extent, equity securities, with a particular emphasis on Structured Debt. We generally seek to invest in companies that have been operating for at least six to twelve months prior to the date of our investment. We anticipate that such entities may, at the time of investment, be generating revenues or will have a business plan that anticipates generation of revenues within 24 to 48 months. Further, we anticipate that on the date of our investment we will generally obtain a lien on available assets, which may or may not include intellectual property, and these companies will have sufficient cash on their balance sheet to operate as well as potentially amortize their debt for at least three to nine months following our investment. We generally require that a prospective portfolio company, in addition to having sufficient capital to support leverage, demonstrate an operating plan capable of generating cash flows or raising the additional capital necessary to cover its operating expenses and service its debt, for an additional six to twelve months subject to market conditions.

We expect that our investments will generally range from $15.0 million to $40.0 million, although we may make investments in amounts above or below this range. We typically structure our debt securities to provide for amortization of principal over the life of the loan, but may include a period of interest-only payments. Our loans will typically be collateralized by a security interest in the borrower’s assets, although we may not have the first claim on these assets and the assets may not include intellectual property. Our debt investments carry fixed or variable contractual interest rates which generally ranged from approximately 6.0% to 15.0% as of December 31, 2022. Approximately 95.3% of our loans were at floating rates or floating rates with a floor and 4.7% of the loans were at fixed rates as of December 31, 2022.

In addition to the cash yields received on our loans, our loans generally include one or more of the following: exit fees, balloon payment fees, commitment fees, success fees, or prepayment fees. In some cases, our loans also include contractual payment-in-kind ("PIK") interest arrangements. The increases in loan balances as a result of contractual PIK arrangements are included in income for the period in which such PIK interest was accrued, which is often in advance of receiving cash payment, and are separately identified on our statements of cash flows. We also may be required to include in income for U.S. federal, state, and local tax purposes certain other amounts prior to receiving the related cash.

Moreover as noted above, our debt investments in venture capital-backed and institutional-backed companies are generally structured with equity enhancement features. These enhancement features typically are received in the form of warrants or other equity securities that are considered original issue discounts ("OID") to our loans and are designed to provide us with an opportunity for potential capital appreciation. Warrants received are typically immediately exercisable upon issuance and generally will remain exercisable for the lesser of five to ten years or three to five years after completion of an initial public offering (“IPO”). The exercise prices for the warrants varies from nominal exercise prices to exercise prices that are at or above the current fair market value of the equity for which we receive warrants. We may structure warrants to provide minority rights provisions or, on a very select basis, put rights upon the occurrence of certain events. We generally target a total annualized return (including interest, fees and value of warrants) of 10% to 20% for our debt investments.

Typically, our debt and equity investments take one of the following forms:

Structured Debt: We seek to invest a majority of our assets in debt structured with warrants, equity, options, or other rights to purchase or convert into common or preferred stock of prospective portfolio companies. Our investments in Structured Debt may be the only debt capital on the balance sheet of our portfolio companies, and in many cases, we have a first priority security interest in all of our portfolio company’s assets, or in certain investments we may have a negative pledge on intellectual property. Our Structured Debt typically has a maturity of between two and five years, and it may provide for full amortization after an interest only period. Our Structured Debt with warrants carries an interest rate referenced to Prime, SOFR, LIBOR, or a similar benchmark rate plus a spread with a floor and may include an additional exit fee payment or contractual PIK interest arrangements. Additionally, our Structured Debt financings may include restrictive affirmative and negative covenants, default penalties, prepayment penalties, lien protection, equity calls, change-in-control provisions or board observation rights.
Senior Debt: We seek to invest a limited portion of our assets in senior debt. Senior debt may be collateralized by accounts receivable and/or inventory financing of prospective portfolio companies. Senior debt has a senior position with respect to a borrower’s scheduled interest and principal payments and holds a first priority security interest in the assets pledged as collateral. Senior debt also may impose covenants on a borrower with regard to cash flows and changes in capital structure, among other items. We generally collateralize our investments by obtaining security interests in our

 

7


portfolio companies’ assets, which may include their intellectual property. In other cases, we may obtain a negative pledge covering a company’s intellectual property. Our senior loans, in certain instances, may be tied to the financing of specific assets. In connection with a senior debt investment, we may also provide the borrower with a working capital line-of-credit that will carry an interest rate generally referenced to Prime, SOFR, LIBOR, or a similar benchmark rate plus a spread with a floor, generally maturing in three to five years, and typically secured by accounts receivable and/or inventory. We also provide “unitranche” loans, which are loans that combine both senior and mezzanine debt, generally in a first lien position with security interest in all the assets of the portfolio company. The loans can either be “first out” or “last out”, whereby the “last-out” loans will be subordinated to the “first-out” portion of the unitranche loan in a liquidation, sale or other disposition.
Equity Securities: The equity securities we hold consist primarily of warrants or other equity interests generally obtained in connection with our Structured Debt investments. In addition to the warrants received as a part of a Structured Debt financing, we typically receive the right to make equity investments in a portfolio company in connection with that company’s next round of equity financing. We may also hold certain debt investments that have the right to convert a portion of the debt investment into equity. These rights will provide us with the opportunity to further enhance our returns over time through opportunistic equity investments in our portfolio companies. These equity investments are typically in the form of preferred or common equity and may be structured with a dividend yield, providing us with a current return, and with customary anti-dilution protection and preemptive rights. We may achieve liquidity through a merger or acquisition of a portfolio company, a public offering of a portfolio company’s stock or by exercising our right, if any, to require a portfolio company to buy back the equity securities we hold. We may also make stand-alone direct equity investments into portfolio companies in which we may not have any debt investment in the company. As of December 31, 2022, we held warrant and equity securities in 168 portfolio companies.

In addition to the characteristics described above, the table below compares the typical features of our investments.

 

Structured Debt

Senior Debt

Equity Securities

Typical Structure

Term debt with warrants

Term or revolving debt

Warrants, preferred stock, or common stock

Investment Horizon

Long-term: 2 to 5 years; Average of 3.5 years

Generally under 4 years

3 to 7 years

Covenants

Less restrictive; mostly financial

Generally borrowing base and financial

None

Investment Criteria

We have identified several criteria, among others, that we believe are important in achieving our investment objective with respect to prospective portfolio companies. These criteria, while not inclusive, provide general guidelines for our investment decisions.

Portfolio Composition - While we generally focus our investments in venture capital-backed and institutional-backed companies in a variety of technology-related industries, we seek to invest across various financial sponsors as well as across various stages of companies’ development and various technology industry sub-sectors and geographies. As of December 31, 2022, approximately 80.5% of the fair value of our portfolio was composed of investments in three industries: 38.8% was composed of investments in the "Drug Discovery & Development" industry, 26.9% was composed of investments in the "Software" industry, and 14.8% was composed of investments in the "Consumer & Business Services" industry.

Continuing Support from One or More Financial Sponsors - We generally invest in companies in which one or more established financial sponsors have previously invested and continue to make a contribution to the management of the business. We believe that having established financial sponsors with meaningful commitments to the business is a key characteristic of a prospective portfolio company. In addition, we look for representatives of one or more financial sponsors to maintain seats on the board of directors of a prospective portfolio company as an indication of such commitment.

Company Stage of Development - While we invest in companies at various stages of development, we generally require that prospective portfolio companies be beyond the seed stage of development and generally have received or anticipate having commitments for their first institutional round of equity financing for early-stage companies. We expect a prospective portfolio company to demonstrate progress in its product development or demonstrate a path towards revenue generation or increase its revenues and operating cash flow over time. The anticipated growth rate of a prospective portfolio company is a key factor in determining the value that we ascribe to any warrants or other equity securities that we may acquire in connection with an investment in debt securities.

 

8


Operating Plan - We generally require that a prospective portfolio company, in addition to having potential access to capital to support leverage, demonstrate an operating plan capable of generating cash flows or the ability to potentially raise the additional capital necessary to cover its operating expenses and service its debt for a specific period. Specifically, we require that a prospective portfolio company demonstrate at the time of our proposed investment that in addition to having sufficient capital to support leverage, it has an operating plan capable of generating cash flows or raising the additional capital necessary to cover its operating expenses and service its debt for an additional six to twelve months subject to market conditions.

Security Interest - In many instances we seek a first priority security interest in all of the portfolio company’s tangible and intangible assets as collateral for our debt investment, subject in some cases to permitted exceptions. In other cases, we may obtain a negative pledge prohibiting a company from pledging or otherwise encumbering their intellectual property. Although we do not intend to operate as an asset-based lender, the estimated liquidation value of the assets, if any, collateralizing the debt securities that we hold is an important factor in our credit analysis and subject to assumptions that may change over the life of the investment especially when attempting to estimate the value of intellectual property. We generally evaluate both tangible assets, such as accounts receivable, inventory and equipment, and intangible assets, such as intellectual property, customer lists, networks and databases.

Covenants - Our investments may include one or more of the following covenants: cross-default; material adverse change provisions; requirements that the portfolio company provide periodic financial reports and operating metrics; and limitations on the portfolio company’s ability to incur additional debt, sell assets, dividend recapture, engage in transactions with affiliates and consummate an extraordinary transaction, such as a merger or recapitalization without our consent. In addition, we may require other performance or financial based covenants, as we deem appropriate.

Exit Strategy - Prior to making a debt investment that is accompanied by a warrant or other equity security in a prospective portfolio company, we analyze the potential for that company to increase the liquidity of its equity through a future event that would enable us to realize appreciation in the value of our equity interest. Liquidity events may include an IPO, a private sale of our equity interest to a third party, a merger or an acquisition of the company or a purchase of our equity position by the company or one of its stockholders.

Investment Process

We have organized our management team around the four key elements of our investment process:

Origination;
Underwriting;
Documentation; and
Loan and Compliance Administration.

Our investment process is summarized in the following chart:

img259755906_0.jpg 

 

9


Origination

The origination process for our investments includes sourcing, screening, preliminary due diligence and deal structuring and negotiation, all leading to an executed non-binding term sheet. As of December 31, 2022, our investment origination team, which consists of approximately 55 investment professionals, is headed by our Chief Investment Officer and Chief Executive Officer. The origination team is responsible for sourcing potential investment opportunities and members of the investment origination team use their extensive relationships with various leading financial sponsors, management contacts within technology-related companies, trade sources, technology conferences and various publications to source prospective portfolio companies. Our investment origination team is divided into life sciences, technology, SaaS finance, sustainable and renewable technology, and special situation sub-teams to better source potential portfolio companies.

In addition, we have developed a comprehensive proprietary database to track various aspects of our investment process including sourcing, originations, transaction monitoring and post-investment performance. Our proprietary database allows our origination team to maintain, cultivate and grow our industry relationships while providing our origination team with comprehensive details on companies in the technology-related industries and their financial sponsors.

If a prospective portfolio company generally meets certain underwriting criteria, we perform preliminary due diligence, which may include high level company and technology assessments, evaluation of its financial sponsors’ support, market analysis, competitive analysis, identifying key management, risk analysis and transaction size, pricing, return analysis and structure analysis. If the preliminary due diligence is satisfactory, and the origination team recommends moving forward, we then structure, negotiate and execute a non-binding term sheet with the potential portfolio company. Upon execution of a term sheet, the investment opportunity moves to the underwriting process to complete formal due diligence review and approval.

Underwriting

The underwriting review includes formal due diligence and approval of the proposed investment in the portfolio company.

Due Diligence - Our due diligence on a prospective investment is typically completed by two or more investment professionals whom we define as the underwriting team. The underwriting team for a proposed investment consists of the deal sponsor who typically possesses general industry knowledge and is responsible for originating and managing the transaction, other investment professionals who perform due diligence, credit and corporate financial analyses and our legal professionals, as needed. To ensure consistent underwriting, we generally use our standardized due diligence methodologies, which include due diligence on financial performance and credit risk as well as an analysis of the operations and the legal and applicable regulatory framework of a prospective portfolio company. The members of the underwriting team work together to conduct due diligence and understand the relationships among the prospective portfolio company’s business plan, operations and financial performance.

As part of our evaluation of a proposed investment, the underwriting team prepares an investment memorandum for presentation to the investment committee. In preparing the investment memorandum, the underwriting team typically interviews select key management of the company and select financial sponsors and assembles information necessary to the investment decision. If and when appropriate, the investment professionals may also contact industry experts and customers, vendors or, in some cases, competitors of the company. The underwriting team collaborates with the credit and legal teams to ensure the final credit underwriting deal structure meets our standards. In addition to the aforementioned members of the investment team, each deal is also assigned to a member of the credit team. The credit team is responsible for making sure that all material risks in the transaction are identified and mitigated to the extent possible in the investment memorandum and that the legal documentation properly reflects the transaction as approved by the investment committee.

Approval Process - The sponsoring managing director or principal presents the investment memorandum to our investment committee for consideration. The approval of a majority of our investment committee is required before we proceed with any investment. The investment committee members include our Chief Executive Officer and Chief Investment Officer, Chief Financial Officer, Chief Credit Officer, and Senior Managing Director of Risk Management. The investment committee meets on an as-needed basis.

Documentation

Our legal department administers the documentation process for our investments. This department is responsible for documenting the transactions approved by our investment committee with a prospective portfolio company. This department negotiates loan documentation and, subject to appropriate approvals, final documents are prepared for execution by all parties. The legal department generally uses the services of external law firms to complete the necessary documentation.

 

10


Loan and Compliance Administration

Our investment committee, supported by our investment team, credit team, and finance department, administers loans and tracks covenant compliance, if applicable, of our investments and oversees periodic reviews of our critical functions to ensure adherence with our internal policies and procedures. After the funding of a loan in accordance with the investment committee’s approval, the loan is recorded in our loan administration software and our proprietary database. The investment team, credit team, and finance department are responsible for ensuring timely interest and principal payments and collateral management as well as advising the investment committee on the financial performance and trends of each portfolio company, including any covenant violations that occur, to aid us in assessing the appropriate course of action for each portfolio company and evaluating overall portfolio quality. In addition, the investment team and credit team advise the investment committee and the Audit Committee of our Board, accordingly, regarding the credit and investment grading for each portfolio company as well as changes in the value of collateral that may occur.

The investment team and credit team monitor our portfolio companies in order to determine whether the companies are meeting our financing criteria and their respective business plans and also monitors the financial trends of each portfolio company from its monthly or quarterly financial statements to assess the appropriate course of action for each company and to evaluate overall portfolio quality. In addition, our management team closely monitors the status and performance of each individual company through our proprietary database and periodic contact with our portfolio companies’ management teams and their respective financial sponsors.

Credit and Investment Grading System. Our investment and credit teams use an investment grading system to characterize and monitor our outstanding loans. They monitor and when appropriate, recommend changes to investment grading. Our investment committee reviews and approves the recommendations and/or changes to the investment grading. These approved investment gradings are provided on a quarterly basis to the Audit Committee and our Board, along with valuations for our investments which are submitted for approval.

From time to time, we will identify investments that require closer monitoring or become workout assets. We develop a workout strategy for workout assets and our investment committee monitors the progress against the strategy. We may incur losses from our investing activities; however, we work with our troubled portfolio companies to recover as much of our investments as is practicable, including possibly taking control of the portfolio company. There can be no assurance that principal will be recovered.

We use the following investment grading system approved by our Board:

Grade 1

Loans involve the least amount of risk in our portfolio. The borrower is performing above expectations, and the trends and risk profile is generally favorable.

Grade 2

The borrower is performing as expected and the risk profile is neutral to favorable. All new loans are initially graded 2.

Grade 3

The borrower may be performing below expectations, and the loan’s risk has increased materially since origination. We typically increase procedures to monitor a borrower when it is determined that credit risk has increased meaningfully since origination, such as, when the borrower is approaching a low liquidity point and an expected capital raise event is not imminent, when an expected milestone has slipped or failed, when performance or new business is materially below our plan, or if the estimated fair value of the enterprise is materially lower than it was when the loan was originated.

Grade 4

The borrower is performing materially below expectations, and the loan risk has substantially increased since origination with the prospect of raising additional capital significantly in question. Loans graded 4 may experience some partial loss or full return of principal but are expected to realize some loss of interest which is not anticipated to be repaid in full, which, to the extent not already reflected, may require the fair value of the loan to be reduced to the amount we anticipate will be recovered. Grade 4 investments are closely monitored.

Grade 5

The borrower is in workout, materially performing below expectations and a significant risk of principal loss is probable. Loans graded 5 will experience some partial principal loss or full loss of remaining principal outstanding is expected. Grade 5 loans will require the fair value of the loans be reduced to the amount, if any, we anticipate will be recovered.

As of December 31, 2022, our investment portfolio had a weighted average investment grading of 2.23.

Managerial Assistance

As a BDC, we are generally required to offer and provide, upon request, significant managerial assistance to our portfolio companies. This assistance could involve monitoring the operations of our portfolio companies, participating in board and management meetings, consulting with and advising officers of portfolio companies and providing other organizational and financial guidance, among other things. We may, from time to time, receive fees for these services. In the event that such fees are received, they are incorporated into our operating income and are passed through to our stockholders, given the nature of our structure as an internally managed BDC. See “—Regulation—Significant Managerial Assistance” for additional information.

 

11


COMPETITION

Our primary competitors provide financing to prospective portfolio companies and include non-bank financial institutions, federally or state-chartered banks, venture debt funds, financial institutions, venture capital funds, private equity funds, investment funds and investment banks. Many of these entities have greater financial and managerial resources than we have, and the 1940 Act imposes certain regulatory restrictions on us as a BDC to which many of our competitors are not subject. However, we believe that few of our competitors possess the expertise to properly structure and price debt investments to venture capital-backed and institutional capital-backed companies in technology-related industries. We believe that our specialization in financing technology-related companies will enable us to determine a range of potential values of intellectual property assets, evaluate the business prospects and operating characteristics of prospective portfolio companies and, as a result, identify investment opportunities that produce attractive risk-adjusted returns. For additional information concerning the competitive risks we face, see “Item 1A. Risk Factors—Risks Related to our Business Structure—We operate in a highly competitive market for investment opportunities”.

HUMAN CAPITAL DISCLOSURES

 

As an internally managed BDC, we believe that one of the strengths and principal reasons for the long-term success of our company is the quality and dedication of our people. As of December 31, 2022, our team comprises over 100 professionals across our 8 offices globally. Our investment team includes approximately 50 investment professionals, whom are led by professionals with extensive experience in venture capital, structured finance, origination of debt and equity investments, commercial lending and acquisition finance with technology and biomedical companies, as well as our executive officers and treasury, finance, risk management, administrative support, IT and human resources professionals. We leverage the experience and relationships of our management team to successfully identify attractive investment opportunities, underwrite prospective portfolio companies and structure customized financing solutions. From inception to December 31, 2022, our team has originated Structured Debt, debt with warrants and equity investments in over 600 companies, representing more than $16.0 billion in commitments. Our investment team leverages established contacts with leading venture capital and private equity fund sponsors, public and private companies, research institutions and other industry participants, to identify and source our investments. We believe that leveraging the relationships that our investment teams have established will enable us to continue to identify and attract well-positioned prospective portfolio companies.

Talent Acquisition and Retention

We are committed to attracting, developing, and retaining the right blend of talent to support our business.

Our recruiting process is strategic and purposeful to ensure our business and culture continue to thrive. We may contract with employment agencies with whom we have developed relationships and who have learned our culture to assist with our recruitment efforts. From time to time, we may also contract with independent contractors on a temporary basis. We also sponsor an internship program that invites quality college students from a diverse pool of applicants to learn our business and contribute to our work for a period of approximately six months. Students who intern in our investment teams are provided visibility into the full investment process from due diligence to closing to ongoing portfolio management activities, and the internship may lead to permanent roles.

Retention of our personnel is important to the management of our business and believe that compensation and benefits and opportunities for professional development are a key driver of retention. We offer a competitive, compensation and benefits structure that we believe attracts current and prospective professionals relative to their local markets and industry. Our compensation strategy includes, for certain professionals, equity incentive plans. Such plans are structured to further align the interests of our professionals with those of our stockholders, and to cultivate a strong sense of ownership and commitment to our Company. To foster professional development, we provide training opportunities for our employees to continue to build their skills and increase their effectiveness as members of our team. Such opportunities include a variety of external and internal classes and training sessions as well as hands-on learning and one-on-one mentorship. Through our goal setting and performance review process, employees are annually evaluated by managers and senior management to ensure employees continue to develop and advance as expected. As we hire and develop individuals, we also plan for succession. We have succession plans in place for each of our named executive officers.

The pandemic has presented new challenges and opportunities to improve with respect to employee engagement and well-being. We continue to provide employees with flexibility to work from home and support our employees through dialogue with managers, colleagues, and leaders. Our Employee Assistance Program continues to provide additional, ongoing support and information for our employees and their families.

 

Our Culture

We are committed to fostering a workplace conducive to the open communication of any concerns regarding unethical, fraudulent or illegal activities. We seek to promote a safe environment that is free of harassment or bullying. We do not tolerate discrimination or harassment of any kind, including, but not limited to, sexual, gender identity, race, religion, ethnicity, age, or disability, among others. We seek feedback from employees on matters related to their employment or our operations including its financial statement disclosures, accounting, internal accounting controls or auditing matters. Under our Whistleblower Policy, each director, officer, regular full-time, part-time and temporary employee of the Company has the ability to confidentially report any: questionable or improper accounting, internal controls, auditing matters, disclosure, or fraudulent business practices or other illegal or

 

12


unethical behavior. We seek to protect the confidentiality of those making reports of possible misconduct and our Whistleblower Policy prohibits retaliation against those who report activities believed in good faith to be a violation of any law, rule, regulation or internal policy.

Our Code of Business Conduct and Ethics establishes applicable policies, guidelines, and procedures that promote ethical practices and conduct by the Company and all its employees, officers, and directors. Upon joining and annually, all employs receive compliance training. Our Whistleblower Policy and Code of Business Conduct and Ethics Policy can be found on our website at investor.htgc.com/corporate-governance/governance-documents.

Diversity, Equity, and Inclusion

At Hercules, we feel strongly that building a diverse and inclusive team is an important priority. We aim to attract, motivate, and retain a diverse group of individuals and to create an inclusive community where all individuals are welcomed, valued, respected, and heard. We are proud that our workforce consists of diverse professionals including approximately 60% that are women or people of diverse ethnic backgrounds. Over 60% of our senior leaders, which includes our managing directors on the investment team and senior executives are women or people of diverse ethnic backgrounds. We strive to continue to create a welcoming and inclusive work environment for our employees.

Philanthropy

Hercules encourages and supports our employees to be active participants in our local communities. As a Company, we support local non-profit organizations by hosting annual fundraising, food, supply, and toy drives. In addition to our Company sponsored philanthropic initiatives, we also provide employees with paid days off to volunteer at organizations of their choice. Hercules supports a variety of non-profit organizations through corporate sponsorship and donations. In addition, we support our employees and the causes that are most important to them through our Charitable Donation Matching program, in which we match donations our employees make to qualified 501(c)(3) non-profits (subject to maximum limits per employee).

For more information on our approach to social, governance, and environmental topics, please refer to our Environmental, Social and Governance Policy (“ESG Policy”), which can be found on our website at investor.htgc.com/esg.

REGULATION

We have elected to be regulated as a BDC under the 1940 Act. The following discussion is a general summary of the material prohibitions and descriptions governing BDCs. It does not purport to be a complete description of all of the laws and regulations affecting BDCs.

Regulation as a Business Development Company

A BDC primarily focuses on investing in or lending to private companies and making significant managerial assistance available to them, while providing its stockholders with the ability to retain the liquidity of a publicly traded stock. The 1940 Act contains prohibitions and restrictions relating to transactions between BDCs and their directors and officers and principal underwriters and certain other related persons and requires that a majority of the directors be persons other than “interested persons,” as that term is defined in the 1940 Act. In addition, the 1940 Act provides that we may not change the nature of our business so as to cease to be, or to withdraw our election as, a BDC unless approved by a majority of our outstanding voting securities as defined in the 1940 Act. A majority of the outstanding voting securities of a company is defined under the 1940 Act as the lesser of: (i) 67% or more of such company’s shares present at a meeting if more than 50% of the outstanding shares of such company are present or represented by proxy, or (ii) more than 50% of the outstanding shares of such company.

Qualifying Assets

Under the 1940 Act, a BDC may not acquire any asset other than assets of the type listed in Section 55(a) of the 1940 Act, which are referred to as qualifying assets, unless, at the time the acquisition is made, qualifying assets represent at least 70% of the company’s total assets. The principal categories of qualifying assets relevant to our business are the following:

(1) Securities purchased in transactions not involving any public offering from the issuer of such securities, which issuer (subject to certain limited exceptions) is an eligible portfolio company, or from any person who is, or has been during the preceding 13 months, an affiliated person of an eligible portfolio company, or from any other person, subject to such rules as may be prescribed by the SEC. An eligible portfolio company is defined in the 1940 Act as any issuer which:

(a) is organized under the laws of, and has its principal place of business in, the United States;

(b) is not an investment company (other than a SBIC wholly owned by the BDC) or a company that would be an investment company but for certain exclusions under the 1940 Act; and

(c) does not have any class of securities listed on a national securities exchange; or if it has securities listed on a national securities exchange such company has a market capitalization of less than $250 million; is controlled by the BDC and has an affiliate of a BDC on its Board; or meets such other criteria as may be established by the SEC.

(2) Securities of any portfolio company which we control.

 

13


(3) Securities purchased in a private transaction from a U.S. issuer that is not an investment company or from an affiliated person of the issuer, or in transactions incident thereto, if the issuer is in bankruptcy and subject to reorganization or if the issuer, immediately prior to the purchase of its securities was unable to meet its obligations as they came due without material assistance other than conventional lending or financing arrangements.

(4) Securities of an eligible portfolio company purchased from any person in a private transaction if there is no ready market for such securities and we already own 60% of the outstanding equity of the eligible portfolio company.

(5) Securities received in exchange for or distributed on or with respect to securities described in (1) through (4) above, or pursuant to the exercise of warrants or rights relating to such securities.

(6) Cash, cash equivalents, U.S. Government securities or high-quality debt securities maturing in one year or less from the time of investment.

Control, as defined by the 1940 Act, is presumed to exist where a BDC beneficially owns more than 25% of the outstanding voting securities of the portfolio company or has greater than 50% representation on its board.

We do not intend to acquire securities issued by any investment company, including other BDCs, that exceed the limits imposed by the 1940 Act. Under these limits, we generally cannot acquire more than 3% of the voting stock of any investment company (as defined in the 1940 Act), invest more than 5% of the value of our total assets in the securities of one such investment company or invest more than 10% of the value of our total assets in the securities of such other investment companies in the aggregate. SEC rules permit us to exceed these limits, subject to certain conditions. With regard to that portion of our portfolio invested in securities issued by investment companies, it should be noted that such investments might subject our stockholders to additional expenses.

Significant Managerial Assistance

BDCs generally must offer to make available to the issuer of the securities significant managerial assistance, except in circumstances where either (i) the BDC controls such issuer of securities or (ii) the BDC purchases such securities in conjunction with one or more other persons acting together and one of the other persons in the group makes available such managerial assistance. Making available significant managerial assistance means, among other things, any arrangement whereby the BDC, through its directors, officers or employees, offers to provide and, if accepted, does so provide, significant guidance and counsel concerning the management, operations or business objectives and policies of a portfolio company through monitoring of portfolio company operations, selective participation in board and management meetings, consulting with and advising a portfolio company’s officers or other organizational or financial guidance.

Temporary Investments

Pending investment in other types of qualifying assets, as described above, our investments may consist of cash, cash equivalents, U.S. government securities or high-quality debt securities maturing in one year or less from the time of investment, which we refer to, collectively, as temporary investments, so that 70% of our assets are qualifying assets. We may invest in U.S. Treasury bills or in repurchase agreements, provided that such agreements are fully collateralized by cash or securities issued by the U.S. government or its agencies. A repurchase agreement involves the purchase by an investor, such as us, of a specified security and the simultaneous agreement by the seller to repurchase it at an agreed upon future date and at a price which is greater than the purchase price by an amount that reflects an agreed-upon interest rate. There is no percentage restriction on the proportion of our assets that may be invested in such repurchase agreements. However, if more than 25% of our total assets constitute repurchase agreements from a single counterparty, we generally would not meet the diversification tests imposed on us by the Code in order to qualify as a RIC for U.S. federal tax purposes. Thus, we do not intend to enter into repurchase agreements with a single counterparty in excess of this limit. We will monitor the creditworthiness of the counterparties with which we enter into repurchase agreement transactions.

Warrants, Options, and Restricted Stock

Under the 1940 Act, a BDC is subject to restrictions on the amount of warrants, options, restricted stock or rights to purchase shares of capital stock that it may have outstanding at any time. In particular, the amount of capital stock that would result from the conversion or exercise of all outstanding warrants, options or other rights to purchase or convert into capital stock cannot exceed 25% of the BDC’s total outstanding shares of capital stock. This amount is reduced to 20% of the BDC’s total outstanding shares of capital stock if the amount of warrants, options or rights issued pursuant to an executive compensation plan would exceed 15% of the BDC’s total outstanding shares of capital stock. We have received exemptive relief from the SEC permitting us to issue stock options and restricted stock to our employees and directors subject to the above conditions, among others. For a discussion regarding the conditions of this exemptive relief, see “—No-action and Exemptive Relief” below and "Note 8 - Equity Incentive Plans" to our consolidated financial statements.

 

14


Reduced Asset Coverage Requirements

In accordance with the Small Business Credit Availability Act ("SBCAA"), our Board and stockholders approved the reduction of our minimum asset coverage ratio applicable under Section 61(a)(2) of the 1940 Act on September 4, 2018 and December 6, 2018, respectively. As a result, effective December 7, 2018, the minimum asset coverage ratio under the 1940 Act applicable to us decreased from 200% to 150%, permitting us to incur additional leverage.

Senior Securities; Coverage Ratio

We will be permitted, under specified conditions, to issue multiple classes of indebtedness and one class of stock senior to our common stock if our asset coverage, as defined in the 1940 Act, is at least equal to 150% immediately after each such issuance. In addition, we may not be permitted to declare any cash dividend distribution on our outstanding common shares, or purchase any such shares, unless, at the time of such declaration or purchase, we have asset coverage of at least 150% after deducting the amount of such distribution or purchase price. On April 5, 2007, we received approval from the SEC on our request for exemptive relief that permits us to exclude the indebtedness of our wholly owned subsidiaries that are SBICs from the 150% asset coverage requirement applicable to us. We may also borrow amounts up to 5% of the value of our total assets for temporary or emergency purposes. For a discussion of the risks associated with the resulting leverage, see “Item 1A. Risk Factors—Risks Related To Leverage—Because we borrow money, the potential for gain or loss on amounts invested in us is magnified and may increase the risk of investing in us.”

Capital Structure

Subject to limited exceptions, we are not generally able to issue and sell our common stock at a price per share below NAV. We may, however, sell our common stock, or warrants, options or other rights to acquire such common stock, at a price below the current NAV if our Board determines that such sale is in the best interests of our stockholders and if stockholders, including a majority of those stockholders that are not affiliated with us, approve of such sale.

In any such case, the price at which our securities are to be issued and sold may not be less than a price that, in the determination of the Board, closely approximates the market value of such securities (less any distribution commission or discount). We do not currently have authorization from our stockholders to issue common stock at a price below its then current NAV per share.

Other 1940 Act Regulations

As a closed-end investment company that has elected to be regulated as a BDC under the 1940 Act, we are periodically examined by, and required to submit information to, the SEC for compliance with the Exchange Act and the 1940 Act. We are also prohibited under the 1940 Act from knowingly participating in certain transactions with our affiliates without the prior approval of our Board who are not interested persons and, in some cases, prior approval by the SEC. We are required by the 1940 Act to provide and maintain a bond issued by a reputable fidelity insurance company to protect us against larceny and embezzlement. Furthermore, as a BDC, we are prohibited from protecting any director or officer against any liability to our stockholders arising from willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of such person’s office. We are also required to adopt and implement written policies and procedures reasonably designed to prevent violation of the federal securities laws, review these policies and procedures annually for their adequacy and the effectiveness of their implementation. Our Chief Compliance Officer is responsible for administering these policies and procedures.

Code of Ethics

We have adopted and will maintain a code of ethics that establishes procedures for personal investments and restricts certain personal securities transactions. Personnel subject to the code may invest in securities for their personal investment accounts, including securities that may be purchased or held by us, so long as such investments are made in accordance with the code’s requirements. We may be prohibited under the 1940 Act from conducting certain transactions with our affiliates without the prior approval of our directors who are not interested persons and, in some cases, the prior approval of the SEC.

Our current code of ethics is posted on our website at investor.htgc.com/corporate-governance/governance-documents. In addition, the code of ethics is available on the EDGAR Database on the SEC’s Internet site at http://www.sec.gov. You may also obtain copies of the code of ethics, after paying a duplicating fee, by electronic request at the following e-mail address: publicinfo@sec.gov.

Privacy Principles

We are committed to maintaining the privacy of our stockholders and safeguarding their non-public personal information. The following information is provided to help you understand what personal information we collect, how we protect that information and why, in certain cases, we may share information with select other parties.

Generally, we do not receive any non-public personal information relating to our stockholders, although certain non-public personal information of our stockholders may become available to us. We do not disclose any non-public personal information about our stockholders or former stockholders, except as permitted by law or as is necessary in order to service stockholder accounts (for example, to a transfer agent).

 

15


We restrict access to non-public personal information about our stockholders to our employees with a legitimate business need for the information. We maintain physical, electronic and procedural safeguards designed to protect the non-public personal information of our stockholders.

Indemnification Agreements

We have entered into indemnification agreements with our directors and executive officers. The indemnification agreements are intended to provide our directors and executive officers the maximum indemnification permitted under Maryland law and the 1940 Act. Each indemnification agreement provides that we shall indemnify the director or executive officer who is a party to the agreement, or an “Indemnitee,” including the advancement of legal expenses, if, by reason of his or her corporate status, the Indemnitee is, or is threatened to be, made a party to or a witness in any threatened, pending, or completed proceeding, to the maximum extent permitted by Maryland law and the 1940 Act. We and our executives and directors are covered by Directors and Officers Insurance, with the directors and officers being indemnified by us to the maximum extent permitted by Maryland law subject to the restrictions in the 1940 Act.

Proxy Voting Policies and Procedures

We vote proxies relating to our portfolio securities in the best interest of our stockholders. Our proxy voting decisions are made by members of the Company's investment team, who review on a case-by-case basis each proposal submitted to a stockholder vote to determine its impact on the portfolio securities held by us. Although we generally vote against proposals that may have a negative impact on our portfolio securities, we may vote for such a proposal if there exists compelling long-term reasons to do so. We generally do not believe it is necessary to engage the services of an independent third party to assist in issue analysis and vote recommendation for proxy proposals.

To ensure that our vote is not the product of a conflict of interest, we require that: (i) anyone involved in the decision making process disclose to our Chief Compliance Officer any potential conflict that he or she is aware of and any contact that he or she has had with any interested party regarding a proxy vote; and (ii) employees involved in the decision making process or vote administration are prohibited from revealing how we intend to vote on a proposal in order to reduce any attempted influence from interested parties.

Small Business Administration Regulations

We make investments in qualifying small businesses through wholly owned SBIC subsidiaries. SBICs are designed to stimulate the flow of private equity capital to eligible small businesses. Under present SBA regulations, eligible small businesses include those businesses that are below small business size standards as published by the North American Industry Classification System (“NASIC”) and adopted by the SBA or any eligible business that has a tangible net worth not exceeding $19.5 million and have average annual fully taxed net income not exceeding $6.5 million for the two most recent fiscal years. In addition, SBICs must devote 25.0% of its investment activity to “smaller” enterprises as defined by the SBA. A smaller enterprise is one that meets the NASIC size standard for its industry or has a tangible net worth not exceeding $6.0 million and has average annual fully taxed net income not exceeding $2.0 million for the two most recent fiscal years. According to SBA regulations, SBICs may make long-term loans to small businesses, invest in the equity securities of such businesses and provide them with consulting and advisory services.

Each SBIC subsidiary is subject to regulation and oversight by the SBA, including requirements with respect to maintaining certain minimum financial ratios and other covenants. As part of the SBA's oversight, each SBIC is periodically examined and audited by the SBA’s staff to determine their compliance with SBA regulations. If any of our SBICs fails to comply with applicable SBA regulations, the SBA could, depending on the severity of the violation, limit or prohibit our SBICs' use of debentures, declare outstanding debentures immediately due and payable, and/or limit our SBICs from making new investments. In addition, our SBICs may also be limited in their ability to make distributions to us if they do not have sufficient capital in accordance with SBA regulations. Such actions by the SBA would, in turn, negatively impact us because our SBICs are wholly owned subsidiaries. Further, the SBA restricts the ability of SBICs to repurchase their capital stock. SBA regulations also include restrictions on a “change of control” or transfer of an SBIC and require that SBICs invest idle funds in accordance with SBA regulations. As of December 31, 2022, as a result of having sufficient capital as defined under the SBA regulations, our SBICs were in compliance with the terms of the SBA’s leverage requirements.

The receipt of an SBIC license does not assure that a SBIC will receive SBA guaranteed debenture funding, which is dependent upon our SBICs continuing to be in compliance with SBA regulations and policies. The SBA, as a creditor, will have a superior claim to our SBICs’ assets over our stockholders in the event we liquidate our SBICs or the SBA exercises its remedies under the SBA-guaranteed debentures issued by our SBICs upon an event of default.

 

16


Compliance with the Securities Exchange Act of 1934 and Sarbanes-Oxley Act

We are subject to the reporting and disclosure requirements of the Exchange Act, including the filing of quarterly, annual and current reports, proxy statements and other required items. In addition, we are subject to the Sarbanes-Oxley Act of 2002, which imposes a wide variety of regulatory requirements on publicly-held companies and their insiders. For example:

pursuant to Rule 13a-14 of the Exchange Act, our Chief Executive Officer and Chief Financial Officer are required to certify the accuracy of the consolidated financial statements contained in our periodic reports;
pursuant to Item 307 of Regulation S-K, our periodic reports are required to disclose our conclusions about the effectiveness of our disclosure controls and procedures;
pursuant to Rule 13a-15 of the Exchange Act, our management is required to prepare a report regarding its assessment of our internal control over financial reporting, which must be audited by our independent registered public accounting firm;
pursuant to Item 308 of Regulation S-K and Rule 13a-15 of the Exchange Act, our periodic reports must disclose whether there were significant changes in our internal control over financial reporting or in other factors that could significantly affect these controls subsequent to the date of their evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

The Sarbanes-Oxley Act requires us to review our policies and procedures to determine whether we comply with the Sarbanes-Oxley Act and the regulations promulgated thereunder. We will continue to monitor our compliance with all future regulations that are adopted under the Sarbanes-Oxley Act and will take actions necessary to ensure that we are in compliance therewith.

Compliance with The New York Stock Exchange (NYSE) Corporate Governance Regulations

Our common stock is listed on the NYSE under the symbol “HTGC”. As a listed company on the NYSE, we are subject to various listing standards including corporate governance listing standards. We believe we are in compliance with such corporate governance listing standards. We intend to monitor our compliance with all future listing standards and to take all necessary actions to ensure that we stay in compliance.

Brokerage Allocations and Other Practices

Because we generally acquire and dispose of our investments in privately negotiated transactions, we typically do not use brokers in the normal course of business. However, from time to time, we may work with brokers to sell positions we have acquired in the securities of publicly listed companies or to acquire positions (principally equity) in companies where we see a market opportunity to acquire such securities at attractive valuations. In cases where we do use a broker, we do not execute transactions through any particular broker or dealer, but will seek to obtain the best net results for the Company, taking into account such factors as price (including the applicable brokerage commission or dealer spread), size of order, difficulty of execution, and operational facilities of the firm and the firm’s risk and skill in positioning blocks of securities. While we generally seek reasonably competitive execution costs, we may not necessarily pay the lowest spread or commission available. Subject to applicable legal requirements, we may select a broker based partly upon brokerage or research services provided to us. In return for such services, we may pay a higher commission than other brokers would charge if we determine in good faith that such commission is reasonable in relation to the services provided.

No-action and Exemptive Relief Obtained

On May 11, 2020, we received no-action relief from the SEC staff that allowed us to form the Adviser Subsidiary as a registered investment adviser under the Advisers Act. Separately, for information regarding our SEC exemptive relief obtained, please see the section entitled “Regulation – Exemptive Relief Obtained” in our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 20, 2020 (the “2019 10-K”), which is incorporated by reference.

Investment Adviser Regulation

The Adviser Subsidiary, which is wholly owned by us, is subject to regulation under the Advisers Act. The Advisers Act establishes, among other things, recordkeeping and reporting requirements, disclosure requirements, limitations on transactions between the adviser's account and an advisory client's account, limitations on transactions between the accounts of advisory clients, and general anti-fraud prohibitions. The Adviser Subsidiary may be examined by the SEC from time to time for compliance with the Advisers Act.

 

17


CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS

The following discussion is a general summary of certain material U.S. federal income tax considerations relating to our qualification and taxation as a RIC and the acquisition, ownership and disposition of our preferred stock or common stock, but does not purport to be a complete description of the income tax considerations relating thereto. Except as otherwise noted, this discussion assumes you are a taxable U.S. person (as defined for U.S. federal income tax purposes) and that you hold your shares of our stock as capital assets for U.S. federal income tax purposes (generally, assets held for investment). This discussion is based upon current provisions of the Code, the regulations promulgated thereunder and judicial and administrative authorities, all of which are subject to change or differing interpretations by the courts or the Internal Revenue Service (the “IRS”), possibly with retroactive effect. No attempt is made to present a detailed explanation of all U.S. federal income tax concerns affecting us and our stockholders (including stockholders subject to special rules under U.S. federal income tax law).

The discussions set forth herein do not constitute tax advice. We have not sought and will not seek any ruling from the IRS regarding any matters discussed herein. No assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to those set forth below. This summary does not discuss any aspects of foreign, state or local tax. Prospective investors must consult their own tax advisers as to the U.S. federal income tax consequences (including the alternative minimum tax consequences) of acquiring, holding and disposing of shares of our stock, as well as the effects of state, local, and foreign tax laws.

Election to be Subject to Tax as a RIC

Through December 31, 2005, we were subject to U.S. federal income tax as an ordinary corporation under Subchapter C of the Code. Effective for the tax year beginning on January 1, 2006, we met the criteria specified below to qualify as a RIC and elected to be treated as a RIC under Subchapter M Part I of the Code. To qualify for treatment as a RIC we must, among other requirements, meet certain source of income and asset diversification requirements (as described below). In addition, we must distribute to our stockholders, in respect of each taxable year, dividends for U.S. federal income tax purposes of an amount generally at least equal to 90% of our “investment company taxable income,” which is generally equal to the sum of our net ordinary income plus the excess of our realized net short-term capital gains over our realized net long-term capital losses, determined without regard to any deduction for distributions paid (the “Annual Distribution Requirement”). Upon satisfying the Annual Distribution Requirement in respect of a taxable year, we generally will not be subject to U.S. federal income taxes on any income we distribute to our stockholders as dividend distributions.

Taxation as a Regulated Investment Company

For any taxable year in which we:

qualify as a RIC; and
distribute dividends for U.S. federal income tax purposes to our stockholders of an amount at least equal to the Annual Distribution Requirement;

We generally will not be subject to U.S. federal income tax on the portion of our investment company taxable income and net capital gains we distribute (or are deemed to distribute) as dividends for U.S. federal income tax purposes to stockholders with respect to that taxable year.

We made the election to recognize built-in gains as of the effective date of our election to be treated as a RIC and therefore were not subject to any built-in gains tax when we sold those assets. However, if we subsequently acquire built-in gain assets from a C corporation in a carryover basis transaction, then we may be subject to taxes on the gains recognized by us on dispositions of such assets unless we make a special election to pay corporate-level taxes on such built-in gain at the time the assets are acquired. We will be subject to U.S. federal income taxes at regular corporate rates on any income or capital gains not distributed (or deemed distributed) as dividends for U.S. federal income tax purposes to our stockholders.

In order to qualify as a RIC for U.S. federal income tax purposes and obtain the tax benefits of RIC status, in addition to satisfying the Annual Distribution Requirement, we must, among other requirements:

have in effect at all times during each taxable year an election to be regulated as a BDC under the 1940 Act;
derive in each taxable year at least 90% of our gross income from (a) dividends, interest, payments with respect to certain securities loans, gains from the sale of stock or other securities, foreign currencies, or other income derived with respect to our business of investing in such stock or securities and (b) net income derived from an interest in a “qualified publicly traded partnership” (the “90% Income Test”);

 

18


diversify our holdings so that at the end of each quarter of the taxable year:
o
at least 50% of the value of our assets consists of cash, cash equivalents, U.S. government securities, securities of other RICs, and other securities if such other securities of any one issuer do not represent more than 5% of the value of our assets or more than 10% of the outstanding voting securities of such issuer; and
o
no more than 25% of the value of our assets is invested in (i) securities (other than U.S. government securities or securities of other RICs) of any one issuer, (ii) securities (other than U.S. government securities or securities of other RICs) of two or more issuers that are controlled, as determined under applicable tax rules, by us and that are engaged in the same or similar or related trades or businesses or (iii) securities of one or more “qualified publicly traded partnerships” (the “Diversification Tests”).

We may invest in partnerships which may result in our being subject to state, local, or foreign income, franchise or other tax liabilities. In addition, some of the income and fees that we may recognize will not be qualifying income under the 90% Income Test. In order to mitigate the risk that such income and fees would disqualify us as a RIC as a result of a failure to satisfy the 90% Income Test, we may be required to recognize such income and fees indirectly through one or more entities classified as corporations for U.S. federal income tax purposes. Such corporations generally will be subject to U.S. federal, state, and potentially local taxes, which ultimately will reduce our return on such income and fees.

As a RIC, we will be subject to a 4% non-deductible U.S. federal excise tax on certain undistributed income and gains unless we make distributions treated as dividends for U.S. federal income tax purposes in a timely manner to our stockholders in respect of each calendar year of an amount at least equal to the sum of (1) 98% of our ordinary income (taking into account certain deferrals and elections) for each calendar year, (2) 98.2% of our capital gain net income (adjusted for certain ordinary losses) for the 1-year period ending October 31 of each such calendar year and (3) any ordinary income and capital gain net income realized, but not distributed, in preceding calendar years (“Excise Tax Avoidance Requirement”). We are not subject to this excise tax on any amount on which we incurred U.S. federal income taxes.

Depending on the level of taxable income earned in a taxable year, we may choose to carry over taxable income in excess of current taxable year distributions treated as dividends for U.S. federal income tax purposes from such taxable income into the next taxable year and incur a 4% U.S. federal excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions treated as dividends for U.S. federal income tax purposes paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent we choose to carry over taxable income into the next tax year, distributions declared and paid by us in a tax year may differ from our taxable income for that tax year. As such, distributions may include the distribution of the current tax year taxable income, the distribution of the prior tax year taxable income that has been carried over and distributed in the current tax year, or may include a return of capital.

Under applicable Treasury regulations and other administrative guidance issued by the IRS, we are permitted to treat certain distributions payable in our stock as taxable distributions that will satisfy the Annual Distribution Requirement as well as the Excise Tax Avoidance Requirement provided that stockholders have the opportunity to elect to receive the distribution in cash. Taxable stockholders receiving such distributions will be required to include the full amount of such distributions as ordinary income (or as long-term capital gains to the extent such distribution is properly reported as a capital gain dividend) to the extent of our current and accumulated earnings and profits for U.S. federal income tax purposes. As a result, a U.S. stockholder may be subject to tax with respect to such distributions in excess of any cash received. If a U.S. stockholder sells the stock it receives as a distribution in order to pay this tax, the sales proceeds may be less than the amount included in income with respect to the distribution, depending on the market price of our stock at the time of the sale. Furthermore, with respect to non-U.S. stockholders, we may be required to withhold certain U.S. taxes with respect to such distributions, including in respect of all or a portion of such distribution that is payable in stock. In addition, if a significant number of our stockholders determine to sell shares of our stock in order to pay taxes owed on distributions, then such sales may put downward pressure on the trading price of our stock. We may in the future determine to make taxable distributions that are payable in part in our common stock.

We may be required to recognize taxable income in circumstances in which we do not receive a corresponding payments in cash. For example, certain of our debt investments may earn OID or PIK income, which we must include in taxable income regardless of whether cash representing such income is received by us in the same tax year. Because OID or PIK income recognized is generally required to be included in our taxable income in the tax year it is recognized, we may be required to make a distribution to our stockholders in order to satisfy the Annual Distribution Requirement and the Excise Tax Avoidance Requirement, even though we will not have received any corresponding cash amount.

Gains or losses realized by us from the sale or exchange of equity or warrants acquired by us, as well as any losses attributable to the lapse of such warrants, generally will be treated as capital gains or losses. Such capital gains or losses will be long-term or short-term, depending on how long we held related equity or warrant instrument.

We are authorized to borrow funds and to sell assets in order to satisfy the Annual Distribution Requirement and the Excise Tax Avoidance Requirement (collectively the “Distribution Requirements”). However, under the 1940 Act, we are not permitted to make distributions to our stockholders while our debt obligations and other senior securities are outstanding unless certain “asset

 

19


coverage” tests are met. See “Regulation—Senior Securities; Coverage Ratio”. Additionally, we may also be restricted from making distributions under the terms of our debt obligations themselves unless certain conditions are satisfied. Moreover, our ability to dispose of assets to meet the Distribution Requirements may be limited by (1) the illiquid nature of our portfolio, or (2) other requirements relating to our status as a RIC, including the Diversification Tests. If we dispose of assets in order to meet the Distribution Requirements, we may make such dispositions at times that, from an investment standpoint, are not advantageous. If we are prohibited from making distributions or are unable to obtain cash from other sources to make the distributions, we may lose our RIC status, which would result in us becoming subject to U.S. federal income taxes.

In addition, we may have to request a waiver of the SBA’s restrictions applicable to our SBICs to enable us to meet the RIC Distribution Requirement. Our SBIC subsidiaries are subject to regulation by the Small Business Investment Act of 1958, as amended, and SBA regulations governing SBICs. Certain SBA regulations may restrict us from making distributions to us that may be necessary to maintain our status as a RIC. While we may request a waiver of the SBA's restrictions, we cannot assure you that the SBA will grant such waiver. If our SBICs are unable to obtain a waiver, compliance with the SBA regulations may cause us to lose our RIC status, which would result in us becoming subject to U.S. federal income taxes.

Certain of our investment practices are subject to special and complex U.S. federal income tax provisions that may, among other things, (i) convert distributions that would otherwise constitute qualified dividend income into ordinary income, (ii) treat distributions that would otherwise be eligible for deductions available to certain U.S. corporations under the Code as ineligible for such treatment, (iii) disallow, suspend or otherwise limit the allowance of certain losses or deductions, (iv) convert long-term capital gains into short-term capital gains or ordinary income, (v) convert short-term capital losses into long-term capital losses, (vi) convert an ordinary loss or deduction into a capital loss (the deductibility of which is more limited), (vii) cause us to recognize income or gain without a corresponding receipt of cash, (viii) adversely alter the characterization of certain complex financial transactions, and (ix) produce gross income that will not constitute qualifying gross income for purposes of the 90% Income Test. These rules also could affect the amount, timing and character of distributions to stockholders.

A RIC is limited in its ability to deduct expenses in excess of its taxable income. If our otherwise deductible expenses in a given tax year exceed our ordinary taxable gross income, we would incur a net operating loss for that tax year. However, a RIC is not permitted to carry back or carry forward net operating losses, respectively, to prior and subsequent tax years, and such net operating losses would not pass through to the RIC’s stockholders. In addition, deductible expenses can only be used to offset investment company taxable income, and not any net capital gains recognized. Furthermore, RICs cannot use net capital losses to offset the RIC’s investment company taxable income. However, a RIC generally may carry forward such net capital losses in order to use them as an offset to future capital gains indefinitely. Due to these limitations on the deductibility of expenses and net capital losses, we may for U.S. federal tax purposes have aggregate taxable income for several tax years that we are required to distribute and that is taxable to our stockholders even if such taxable income is greater than the aggregate net income we actually earned during those tax years. Such required distributions may be made from our cash assets or by liquidation of investments, if necessary. We may realize capital gains or losses from such liquidations. In the event we realize net capital gains from such transactions, you may receive a larger capital gain distribution than you would have received in the absence of such transactions.

Investment income received from sources located within foreign countries, or capital gains earned by investing in securities of foreign issuers, may be subject to foreign income taxes and withheld at the source. In this regard, countries with which the United States does not have a tax treaty can result in high withholding tax rates, dependent on each taxpayer's circumstances. The United States has entered into tax treaties with many foreign countries that may entitle us to a reduced rate of tax or exemption from tax on this related income and capital gains. The effective rate of foreign taxes may vary depending on the location, status of tax treaties, changes in international tax laws, and types of investment held, among other reasons. Further, we do not anticipate being eligible for the special election that allows a RIC to treat foreign income taxes paid by us as having been paid by its stockholders.

If we acquire the equity securities of passive foreign investment companies (“PFICs”), which are foreign corporations that earn at least 75% of their annual gross income from passive sources (such as interest, dividends, rents, royalties or capital gain) or hold at least 50% of their total assets in investments producing such passive income, we could be subject to federal income tax and additional interest charges on “excess distributions” received from such companies or gain from the sale of stock in such companies, even if all income or gain actually received by us is timely distributed to our stockholders to the extent that such income or gain is attributable to our ownership of PFIC stock in a prior taxable year. We would not be able to pass through to our stockholders any credit or deduction for such a tax. Certain elections may, if available, ameliorate these adverse tax consequences, but any such election could require us to recognize taxable income or gain without the concurrent receipt of cash. We intend to limit and/or manage our holdings in PFICs to minimize our liability for any such taxes and related interest charges.

If we acquire the equity securities of a controlled foreign corporation (a “CFC”), which is a foreign corporation in which more than 50% of the stock, by vote or value, is owned by U.S. persons each of whom either directly or constructively own 10% or more of the stock of a foreign corporation by vote or by value, we would generally be required to include as ordinary income our allocable share of the CFC's income derived from certain specified sources with our investment company taxable income for such tax year, regardless of when the CFC makes distributions to us. We intend to limit and/or manage our holdings in issuers that could be treated as CFCs in order to limit our tax liability or maximize our after-tax return from these investments.

 

20


Our functional currency, for U.S. federal income tax purposes, is the U.S. dollar. Under the Code, foreign exchange gains and losses realized by us in connection with certain transactions involving foreign currencies, or payables or receivables denominated in a foreign currency, as well as certain non-U.S. dollar denominated debt securities, certain foreign currency futures contracts, foreign currency option contracts, foreign currency forward contracts, and similar financial instruments are subject to Code provisions that generally treat such gains and losses as ordinary income and losses and may affect the amount, timing and character of distributions to our stockholders. Any such transactions that are not directly related to our investment in securities (possibly including speculative currency positions or currency derivatives not used for hedging purposes) also could, under future Treasury regulations, produce income not among the types of qualifying income from which a RIC must derive at least 90% of its annual gross income.

Failure to Qualify as a Regulated Investment Company

If we were unable to qualify for treatment as a RIC and are unable to cure the failure, for example, by disposing of certain investments timely or raising additional capital to prevent the loss of RIC status, we generally would be subject to tax on all of our taxable income at regular corporate rates. The Code provides some relief from RIC disqualification due to failures to comply with the 90% Income Test and the Diversification Tests, although there could be additional taxes due in such cases. We cannot assure you that we would qualify for any such relief should we fail the 90% Income Test or the Diversification Tests.

Should failure occur, not only would all our taxable income be subject to tax at regular corporate rates, we would not be able to deduct dividend distributions to stockholders, nor would they be required to be made. Distributions, including distributions of net long-term capital gain, would generally be treated as ordinary dividend income to the extent of our current and accumulated earnings and profits. Subject to certain limitations under the Code, certain corporate stockholders would be eligible to claim dividends received deduction with respect to such dividends and non-corporate stockholders would generally be able to treat such dividends as “qualified dividend income,” which is subject to reduced rates of U.S. federal income tax. Distributions in excess of our current and accumulated earnings and profits would be treated first as a return of capital to the extent of the stockholder’s tax basis, and any remaining distributions would be treated as a capital gain. Further, we would also be subject to regular corporate tax on any net built-in gains with respect to certain of our assets (i.e., the excess of the aggregate gains, including items of income, over aggregate losses that would have been realized with respect to such assets if we had been liquidated) that we elect to recognize on requalification or when recognized over the next five taxable years. The remainder of this discussion assumes that we qualify as a RIC and have satisfied the Annual Distribution Requirement.

 

21


DETERMINATION OF NET ASSET VALUE

We determine the NAV per share of our common stock quarterly. The NAV per share is equal to the value of our total assets minus liabilities and any preferred stock outstanding divided by the total number of shares of common stock outstanding. As of the date of this report, we do not have any preferred stock outstanding.

As of December 31, 2022, approximately 97.9% of our total assets represented investments in portfolio companies whose fair value is determined in good faith by the Board. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the Board. Our investments are carried at fair value in accordance with the 1940 Act and ASC Topic 946 and measured in accordance with ASC Topic 820, Fair Value Measurements and Disclosures. Our debt securities are primarily invested in venture capital-backed and institutional-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of our investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, we value substantially all of our investments at fair value as determined in good faith pursuant to a consistent valuation policy by our Board in accordance with the provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of our investments determined in good faith by our Board may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.

We intend to continue to engage one or more independent valuation firm(s) to provide us with assistance regarding our determination of the fair value of selected portfolio investments each quarter unless directed by the Board to cancel such valuation services. Specifically, on a quarterly basis, we will identify portfolio investments with respect to which an independent valuation firm will assist in valuing. We select these portfolio investments based on a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, credit quality and the time lapse since the last valuation of the portfolio investment by an independent valuation firm. The scope of the services rendered by an independent valuation firm is at the discretion of the Board. Our Board is ultimately, and solely, responsible for determining the fair value of our investments in good faith.

See “Note 2 – Summary of Significant Accounting Policies” in the notes to the consolidated financial statements for a detailed discussion of our investment portfolio valuation process and procedures.

Determinations in Connection with Offerings

In connection with each offering of shares of our common stock, the Board or a committee thereof is required to make the determination that we are not selling shares of our common stock at a price below our then current NAV at the time at which the sale is made, unless it is determined by the Board that such sale is in the best interests of our stockholders. The Board considers the following factors, among others, in making such determination:

the NAV of our common stock disclosed in the most recent periodic report we filed with the SEC;
our management’s assessment of whether any material change in the NAV has occurred (including through the realization of net gains on the sale of our portfolio investments) from the period beginning on the date of the most recently disclosed NAV to the period ending two days prior to the date of the sale of our common stock; and
the magnitude of the difference between (i) a value that our Board or an authorized committee thereof has determined reflects the current NAV of our common stock, which is generally based upon the NAV of our common stock disclosed in the most recent periodic report that we filed with the SEC, as adjusted to reflect our management’s assessment of any material change in the NAV of our common stock since the date of the most recently disclosed NAV of our common stock, and (ii) the offering price of the shares of our common stock in the proposed offering.

Importantly, this determination does not require that we calculate NAV in connection with each offering of shares of our common stock, but instead it involves the determination by the Board or a committee thereof that we are not selling shares of our common stock at a price below the then current NAV at the time at which the sale is made.

Moreover, to the extent that there is a possibility that we may (i) issue shares of our common stock at a price below the then current NAV of our common stock at the time at which the sale is made or (ii) trigger the undertaking (which we will provide to the SEC in a registration statement to which a prospectus will be a part) to suspend the offering of shares of our common stock pursuant to a prospectus if the NAV fluctuates by certain amounts in certain circumstances until such prospectus is amended, the Board or a committee thereof will elect, in the case of clause (i) above, either to postpone the offering until such time that there is no longer the possibility of the occurrence of such, events or to undertake to determine NAV within two days prior to any such sale to ensure that such sale will not be below our then current NAV, and, in the case of clause (ii) above, to comply with such undertaking or to undertake to determine NAV to ensure that such undertaking has not been triggered.

These processes and procedures are part of our compliance policies and procedures. Records will be made contemporaneously with all determinations described in this section and these records will be maintained with other records we are required to maintain under the 1940 Act.

 

22


SUMMARY OF RISK FACTORS

The risk factors described below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should carefully consider these risk factors, together with the risk factors set forth in Item 1A. of this Annual Report on Form 10-K and the other reports and documents filed by us with the SEC.

Risks Related To Our Business And Structure

We operate in a highly competitive market for investment opportunities.
We are dependent upon senior management personnel for our future success, particularly our CEO, Scott Bluestein.
Our success depends on attracting and retaining qualified personnel in a competitive environment.
Our business model depends to a significant extent upon strong referral relationships.
Our Board may change our operating policies and strategies without prior notice or stockholder approval, the effects of which may be adverse.
We may not be able to pay distributions to our stockholders, our distributions may not grow over time, and a portion of distributions paid to our stockholders may be a return of capital, which is a distribution of the stockholders’ invested capital.
We are subject to risks related to corporate social responsibility.

Risks Related To Our Investments

Our investments in portfolio companies involve higher levels of risk, and we could lose all or part of our investment.
Our investments are concentrated in certain technology-related industries, which subjects us to the risk of significant loss if any one or more of such industries experiences a downturn.
Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected.
We may be exposed to higher risks with respect to our investments that include PIK interest or Exit fees.
The lack of liquidity in our investments may adversely affect our business.
We may not have the funds or ability to make additional investments in our portfolio companies.
There may be circumstances where our debt investments could be subordinated to claims of other creditors or we could be subject to lender liability claims.
We are a non-diversified investment company within the meaning of the 1940 Act, and therefore we are not limited with respect to the proportion of our assets that may be invested in securities of a single issuer, which may subject us to a risk of significant loss if any such issuer experiences a downturn.
We generally will not control our portfolio companies, which may result in the portfolio company making decisions which could adversely impact the value of our investments in the portfolio company's securities.
Defaults by our portfolio companies will harm our operating results.
Substantially all of our portfolio investments are recorded at fair value as determined in accordance with our Valuation Guidelines and, as a result, there may be uncertainty as to the value of our portfolio investments.
Any unrealized depreciation we experience on our investment portfolio may be an indication of future realized losses, which could reduce our income available for distribution and could impair our ability to service our borrowings.
We are subject to risks associated with the current interest rate environment and changes in interest rates will affect our cost of capital, net investment income and the value of our investments.
We may not realize gains from our equity or warrant investments.
Our investments in foreign securities or investments denominated in foreign currencies may involve significant risks in addition to the risks inherent in U.S. and U.S.-denominated investments.

Risks Related To Leverage

Because we borrow money, the potential for gain or loss on amounts invested in us is magnified and may increase the risk of investing in us.
Substantially all of our assets are subject to security interests under our senior securities and if we default on our obligations under our senior securities, we may suffer adverse consequences, including foreclosure on our assets.

Risks Related To Our Investment Management Activities

Our executive officers and employees, through the Adviser Subsidiary, are expected to manage the Adviser Funds or separately managed accounts, which includes funds from External Parties, that operate in the same or a related line of business as we do, which may result in significant conflicts of interest.
Investments in the Adviser Funds managed by our Adviser Subsidiary may create conflicts of interests.
We, through the Adviser Subsidiary, derive revenues from managing third-party funds pursuant to management agreements that may be terminated, which could negatively impact our operating results.

 

23


Risks Related To BDCs

Failure to comply with applicable laws or regulations and changes in laws or regulations governing our operations may adversely affect our business or cause us to alter our business strategy.
Failure to maintain our status as a BDC would reduce our operating flexibility.
Operating under the constraints imposed on us as a BDC and RIC may hinder the achievement of our investment objectives.
Regulations governing our operation as a BDC will affect our ability to, and the way in which we, raise additional capital.

Risks Related To Our Securities

Investing in our securities may involve a high degree of risk.
Shares of closed-end investment companies, including BDCs, may trade at a discount to their NAV.
The market price of our securities may be volatile and fluctuate significantly.
Stockholders may incur dilution if we sell shares of our common stock in one or more offerings at prices below the then current NAV per share of our common stock or issue securities to subscribe to, convert to or purchase shares of our common stock.
Certain Debt securities are unsecured and therefore effectively subordinated to any current or future secured indebtedness or may be structurally subordinated to the indebtedness and other liabilities of our subsidiaries.
Our debt securities may or may not have an established trading market. If a trading market in our debt securities is developed, it may not be maintained.
A downgrade, suspension, or withdrawal of the credit rating assigned by a rating agency to us or our debt securities, if any, or change in the debt markets could cause the liquidity or market value of our debt securities to decline significantly.
The indentures under which our debt securities were issued contain limited protections for the holders of the debt securities.
If we default on our obligations to pay our other indebtedness, we may not be able to make payments on our outstanding Notes and Credit Facilities.
We may not be able to prepay the Notes or Credit Facilities upon a change in control.

Risks Related To Our SBIC Subsidiaries

We, through our wholly owned subsidiary, issue debt securities guaranteed by the SBA and sold in the capital markets. As a result of its guarantee of the debt securities, the SBA has fixed dollar claims on the assets of our subsidiary that are superior to the claims of our securities holders.
Our wholly owned subsidiary is licensed by the SBA, and therefore subject to SBIC regulations.
Our SBIC subsidiary may be unable to make distributions to us that will enable us to meet or maintain RIC status, which could result in the imposition of an entity-level tax.

Risks Related To Operating As A RIC And U.S. Federal Income Taxes

We will be subject to U.S. federal income taxes if we are unable to qualify as a RIC under Subchapter M of the Code.
We may have difficulty paying the distributions required to maintain our RIC status under the Code if we recognize income before or without receiving cash representing such income.
Legislative or regulatory tax changes could adversely affect our stockholders.

General Risk Factors

We are currently operating in a period of capital markets disruption and economic uncertainty, and capital markets may experience periods of disruption and instability in the future. These market conditions may materially and adversely affect debt and equity capital markets in the United States and abroad, which may have a negative impact on our business and operations.
Terrorist attacks, acts of war, public health crises or natural disasters may affect any market for our securities, impact the businesses in which we invest and harm our business, operating results and financial condition.
We are highly dependent on information systems and systems failures could significantly disrupt our business, which may, in turn, negatively affect the market price of our common stock and our ability to pay dividends.
The failure in cyber security systems, as well as the occurrence of events unanticipated in our disaster recovery systems and management continuity planning could impair our ability to conduct business effectively.
We may be the target of litigation.

 

24


Item 1A. Risk Factors

Investing in our securities involves a number of significant risks. In addition to the other information contained in this Annual Report on Form 10-K, you should carefully consider the following information before making an investment in our securities. The risks set forth below are not the only risks we face. Additional risks and uncertainties not presently known to us or not presently deemed material by us may also impair our operations and performance. If any of the following events occur, our business, financial condition, and results of operations could be materially adversely affected. In such case, our NAV and the trading price of our common stock or the value of our other securities could decline, and you may lose all or part of your investment.

Risks Related To Our Business Structure

We operate in a highly competitive market for investment opportunities.

We compete for investments with a number of other investment funds (including venture capital and private equity funds, debt funds, BDCs and SBICs), as well as traditional financial services companies such as commercial and investment banks and other sources of funding. Many of our competitors are substantially larger and have considerably greater financial, technical, marketing and other resources than we do. For example, some competitors may have a lower cost of funds and/or access to funding sources that are not available to us. In addition, some of our competitors may have higher risk tolerances or different risk assessments than we have. These characteristics could allow our competitors to consider a wider variety of investments, establish more relationships and offer better pricing and more flexible structuring than we are able to do. We may lose investment opportunities if we do not match our competitors’ pricing, terms and structure. If we do match our competitors’ pricing, terms or structure, we may not be able to achieve acceptable returns on our investments or may bear substantial risk of capital loss. A significant increase in the number and/or the size of our competitors in this target market could force us to accept less attractive investment terms. Furthermore, many of our competitors are not subject to the regulatory restrictions that the 1940 Act imposes on us as a BDC or that the Code imposes on us as a RIC.

We are dependent upon senior management personnel for our future success, particularly our CEO, Scott Bluestein.

We depend upon the members of our senior management, particularly Mr. Bluestein, and other key personnel for the identification, final selection, structuring, closing and monitoring of our investments. These employees have critical industry experience and relationships on which we rely to implement our business plan. Our future success depends on the continued service of our senior management team. The departure of Mr. Bluestein or any member of our senior management team or a significant number of the members of our investment team could have a material adverse effect on our ability to achieve our investment objective as well as our business, financial condition or results of operation. As a result, we may not be able to operate our business as we expect, and our ability to compete could be harmed, which could cause our operating results to suffer.

Our success depends on attracting and retaining qualified personnel in a competitive environment.

Our growth will require that we retain new investment and administrative personnel in a competitive market. Our ability to attract and retain personnel with the requisite credentials, experience and skills depends on several factors including, but not limited to, our ability to offer competitive wages, benefits and professional growth opportunities. Many of the entities, including investment funds (such as venture capital funds, private equity funds, debt funds and mezzanine funds) and traditional financial services companies, with which we compete for experienced personnel have greater resources than we have.

The competitive environment for qualified personnel may require us to take certain measures to ensure that we are able to attract and retain experienced personnel. Such measures may include increasing the attractiveness of our overall compensation packages, altering the structure of our compensation packages through the use of additional forms of compensation, or other steps. The inability to attract and retain experienced personnel would have a material adverse effect on our business.

As an internally managed BDC, we are subject to certain restrictions that may adversely affect our business.

As an internally managed BDC, the size and categories of our assets under management is limited, and we are unable to offer as wide a variety of financial products to prospective portfolio companies and sponsors (potentially limiting the size and diversification of our asset base). We therefore may not achieve efficiencies of scale and greater management resources available to externally managed business development companies. In addition, if we fail to comply with restrictions applicable to an internally managed BDC, for example with respect to the portion of our assets representing qualifying assets, we may be subject to further restrictions that could have a negative impact on our business. See “Item 1. Business — Regulation.”

Additionally, as an internally managed BDC, our ability to offer more competitive and flexible compensation structures, such as offering both a profit-sharing plan and an equity incentive plan, is subject to the limitations imposed by the 1940 Act, which limits our ability to attract and retain talented investment management professionals. As such, these limitations could inhibit our ability to grow, pursue our business plan and attract and retain professional talent, any or all of which may have a negative impact on our business, financial condition and results of operations.

 

25


Our business model depends to a significant extent upon strong referral relationships.

We expect that members of our management team will maintain their relationships with venture capital and private equity firms, other financial institutions and intermediaries, investment bankers, commercial bankers, financial advisers, attorneys, accountants, consultants and other individuals within our network, and we will rely to a significant extent upon these relationships to provide us with potential investment opportunities. If we fail to maintain our existing relationships or develop new relationships with sources of investment opportunities, we will not be able to grow our investment portfolio. In addition, individuals with whom members of our management team have relationships are not obligated to provide us with investment opportunities and, therefore, there is no assurance that such relationships will general investment opportunities for us.

Our Board may change our operating policies and strategies without prior notice or stockholder approval, the effects of which may be adverse.

Our Board has the authority to modify or waive certain of our current operating policies and strategies without prior notice and without stockholder approval. We cannot predict the effect any changes to our current operating policies and strategies would have on our business, NAV, operating results and value of our stock. However, the effect might be adverse, which could negatively impact our ability to pay interest and principal payments to holders of our debt instruments and dividends to our stockholders and cause our investors to lose all or part of their investment in us.

We may not be able to pay distributions to our stockholders, our distributions may not grow over time, and a portion of distributions paid to our stockholders may be a return of capital, which is a distribution of the stockholders’ invested capital.

We intend to pay distributions to our stockholders out of assets legally available for distribution. We cannot assure you that we will achieve investment results that will allow us to pay a specified level of cash distributions, previously projected distributions for future periods, or year-to-year increases in cash distributions. Our ability to pay distributions might be adversely affected by, among other things, the impact of one or more of the risk factors described herein. In addition, the inability to satisfy the asset coverage test applicable to us as a BDC could limit our ability to pay distributions. All distributions will be paid at the discretion of our Board and will depend on our earnings, our financial condition, maintenance of our RIC status, compliance with applicable BDC regulations, compliance with our debt covenants and such other factors as our Board may deem relevant from time to time. We cannot assure you that we will pay distributions to our stockholders in the future.

When we make distributions, we will be required to determine the extent to which such distributions are paid out of current or accumulated taxable earnings, recognized capital gains or capital. To the extent there is a return of capital, investors will be required to reduce their basis in our stock for U.S. federal income tax purposes, which may result in higher tax liability when the shares are sold, even if they have not increased in value or have lost value. In addition, any return of capital will be net of any sales load and offering expenses associated with sales of shares of our common stock. In the future, our distributions may include a return of capital.

We are subject to risks related to corporate social responsibility.

Our business faces increasing public scrutiny related to environmental, social and governance (“ESG”) activities. We risk damage to our brand and reputation if we fail to act responsibly in a number of areas, such as diversity and inclusion, environmental stewardship, support for local communities, corporate governance and transparency and considering ESG factors in our investment processes. Adverse incidents with respect to ESG activities could impact the value of our brand, the cost of our operations and relationships with investors, all of which could adversely affect our business and results of operations. Additionally, new regulatory initiatives related to ESG could adversely affect our business.

Risks Related To Our Investments

Our investments in portfolio companies involve higher levels of risk, and we could lose all or part of our investment.

Investing in our portfolio companies exposes us indirectly to a number of significant risks. Among other things, these companies:

may have limited financial resources (including the inability to obtain additional equity or debt financing as needed) and may be unable to meet their obligations under their debt instruments that we hold, which may be accompanied by a deterioration in the value of any collateral and a reduction in the likelihood of us realizing any guarantees from subsidiaries or affiliates of our portfolio companies that we may have obtained in connection with our investment, as well as a corresponding decrease in the value of the equity components of our investments;
may require substantial additional financing to satisfy their continuing working capital and other cash requirements;
may have shorter operating histories, narrower product lines, smaller market shares and/or significant customer concentrations than larger businesses, which tend to render them more vulnerable to competitors’ actions and market conditions, as well as general economic downturns;
are more likely to depend on the management talents and efforts of a small group of persons; therefore, the death, disability, resignation, termination or significant under-performance of one or more of these persons could have a material adverse impact on our portfolio company and, in turn, on us;

 

26


generally have less predictable operating results which may fluctuate suddenly and dramatically, may from time-to-time be parties to litigation, may be engaged in rapidly changing businesses with products subject to a substantial risk of obsolescence, may require substantial additional capital to support their operations, finance expansion or maintain their competitive position, and may have more limited access to capital and higher funding costs;
may be adversely affected by a lack of IPO or merger and acquisition opportunities; and
generally have less publicly available information about their businesses, operations and financial condition. We are required to rely on the ability of our management team and investment professionals to obtain adequate information to evaluate the potential returns from investing in these companies. If we are unable to uncover all material information about these companies, we may not make a fully informed investment decision, and may lose all or part of our investment.

In addition, in the course of providing significant managerial assistance to certain of our portfolio companies, certain of our officers and directors may serve as directors on the boards of such companies. To the extent that litigation arises out of our investments in these companies, our officers and directors may be named as defendants in such litigation, which could result in an expenditure of funds (through our indemnification of such officers and directors) and the diversion of management time and resources.

A lack of IPO or merger and acquisition opportunities may cause companies to stay in our portfolio longer, leading to lower returns, unrealized depreciation, or realized losses.

A lack of IPO or merger and acquisition, or M&A, opportunities for private companies, including venture capital-backed and institutional-backed companies could lead to portfolio companies staying longer in our portfolio as private entities still requiring funding. IPO activity in particular has slowed significantly during 2022 and this trend may remain for the foreseeable future. This situation may adversely affect the amount of available funding for early-stage companies in particular as, in general, venture capital, institutional, and other sponsor firms are being forced to provide additional financing to late-stage companies that cannot complete an IPO or M&A transaction. In the best case, such stagnation would dampen returns, and in the worst case, could lead to unrealized depreciation and realized losses as some portfolio companies run short of cash and have to accept lower valuations in private fundings or are not able to access additional capital at all. A lack of IPO or M&A opportunities for private companies can also cause some venture capital, institutional, and other sponsor firms to change their strategies, leading some of them to reduce funding to their portfolio companies and making it more difficult for such companies to access capital and to fulfill their potential, which can result in unrealized depreciation and realized losses in such portfolio companies by other companies, such as ourselves, who are co-investors in such portfolio companies.

Investing in publicly traded companies can involve a high degree of risk and can be speculative.

A portion of our portfolio is invested in publicly traded companies or companies that are in the process of completing their IPO. As publicly traded companies, the securities of these companies may not trade at high volumes, and prices can be volatile, particularly during times of general market volatility, which may restrict our ability to sell our positions and may have a material adverse impact on us.

In addition, our ability to invest in public companies may be limited in certain circumstances. To maintain our status as a BDC, we are not permitted to acquire any assets other than “qualifying assets” specified in the 1940 Act unless, at the time the acquisition is made and giving effect to it, at least 70% of our total assets are qualifying assets (with certain limited exceptions). Subject to certain exceptions for follow-on investments and distressed companies, an investment in an issuer that has outstanding securities listed on a national securities exchange may be treated as a qualifying asset only if such issuer has a market capitalization that is less than $250.0 million at any point in the 60 days prior to the time of such investment and meets the other specified requirements.

Our investments are concentrated in certain technology-related industries, which subjects us to the risk of significant loss if any one or more of such industries experiences a downturn.

We have invested and intend to continue investing in a limited number of companies that operate in technology-related industries. A downturn in one or more technology-related industry sectors and particularly those in which we are heavily concentrated could materially adversely affect our financial condition more than if we invested in a wider range of industries. As of December 31, 2022, approximately 80.5% of the fair value of our portfolio comprised investments in three industries: 38.8% comprised investments in the “Drug Discovery and Development” industry, 26.9% comprised investments in the “Software” industry and 14.8% comprised investments in the “Consumer & Business Services” industry. Companies in technology-related industries are subject to numerous risks, including:

Technology Industry (including Software and Consumer & Business Services Industries) Risk. The market prices and values of companies operating in the technology industry – including software and consumer and business services companies – tend to exhibit a greater degree of risk and volatility than other types of investments. These companies may fall in and out of favor with the public and investors rapidly, which may cause sudden selling and dramatically lower market prices. These companies also may be affected adversely by changes in technology, consumer and business purchasing patterns, short product cycles, falling prices and profits, government regulation, lack of standardization or compatibility with existing technologies, intense competition, aggressive pricing, dependence on copyright and/or patent protection and/or obsolete products or services. Certain technology-related companies may face special risks that their

 

27


products or services may not prove to be commercially successful. Technology-related companies are also strongly affected by worldwide scientific or technological developments. As a result, their products may rapidly become obsolete.

Companies in the application software industry, in particular, may also be negatively affected by the decline or fluctuation of subscription renewal rates for their products and services, which may have an adverse effect on profit margins. Companies in the systems software industry may be adversely affected by, among other things, actual or perceived security vulnerabilities in their products and services, which may result in individual or class action lawsuits, state or federal enforcement actions and other remediation costs.

Such companies are also often subject to governmental regulation and may, therefore, be adversely affected by governmental policies. In addition, a rising interest rate environment tends to negatively affect technology and technology-related companies. Those technology or technology-related companies seeking to finance their expansion would have increased borrowing costs, which may negatively impact their earnings. Technology-related companies are often smaller and less experienced companies and may be subject to greater risks than larger companies, such as limited product lines, markets and financial and managerial resources. These risks may be heightened for technology companies in foreign markets.

Drug Discovery & Development Industry Risk. The success of pharmaceutical companies operating in the drug discovery and development industry is highly dependent on the development, procurement and marketing of drugs. The values of pharmaceutical companies are also dependent on the development, protection and exploitation of intellectual property rights and other proprietary information, and the profitability of pharmaceutical companies may be significantly affected by such things as the expiration of patents or the loss of, or the inability to enforce, intellectual property rights. The research and other costs associated with developing or procuring new drugs and the related intellectual property rights can be significant, and the results of such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result in the development of a profitable drug. Pharmaceutical companies may be susceptible to product obsolescence. Many pharmaceutical companies face intense competition from new products and less costly generic products. Moreover, the process for obtaining regulatory approval by the FDA or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained or maintained.

Pharmaceutical companies are also subject to rapid and significant technological change and competitive forces that may make drugs obsolete or make it difficult to raise prices and, in fact, may result in price discounting. Pharmaceutical companies may also be subject to expenses and losses from extensive litigation based on intellectual property, product liability and similar claims. Failure of pharmaceutical companies to comply with applicable laws and regulations can result in the imposition of civil and criminal fines, penalties and, in some instances, exclusion of participation in government sponsored programs such as Medicare and Medicaid. Pharmaceutical companies may be adversely affected by government regulation and changes in reimbursement rates. The ability of many pharmaceutical companies to commercialize current and any future products depends in part on the extent to which reimbursement for the cost of such products and related treatments are available from third party payors, such as Medicare, Medicaid, private health insurance plans and health maintenance organizations. Third-party payors are increasingly challenging the price and cost-effectiveness of medical products. Significant uncertainty exists as to the reimbursement status of health care products, and there can be no assurance that adequate third-party coverage will be available for pharmaceutical companies to obtain satisfactory price levels for their products.

The international operations of many pharmaceutical companies expose them to risks associated with instability and changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations and other risks inherent to international business. Additionally, a pharmaceutical company’s valuation can often be based largely on the potential or actual performance of a limited number of products. A pharmaceutical company’s valuation can also be greatly affected if one of its products proves unsafe, ineffective or unprofitable. Such companies also may be characterized by thin capitalization and limited markets, financial resources or personnel, as well as dependence on wholesale distributors. The values of companies in the pharmaceutical industry have been and will likely continue to be extremely volatile.

Biotechnology Industry Risk. The success of biotechnology companies is highly dependent on the development, procurement and/or marketing of drugs. The values of biotechnology companies are also dependent on the development, protection and exploitation of intellectual property rights and other proprietary information, and the profitability of biotechnology companies may be significantly affected by such things as the expiration of patents or the loss of, or the inability to enforce, intellectual property rights. The research and other costs associated with developing or procuring new drugs, products or technologies and the related intellectual property rights can be significant, and the results of such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result in the development of a profitable drug, product or technology. Moreover, the process for obtaining regulatory approval by the FDA or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained or maintained. Biotechnology companies are also subject to rapid and significant technological change and competitive forces that may make drugs, products or technologies obsolete or make it difficult to raise prices and, in fact, may result in price discounting. Biotechnology companies may also be subject to expenses and losses from extensive litigation based on intellectual property, product liability and similar claims.

 

28


Failure of biotechnology companies to comply with applicable laws and regulations can result in the imposition of civil and/or criminal fines, penalties and, in some instances, exclusion of participation in government sponsored programs such as Medicare and Medicaid. Biotechnology companies may be adversely affected by government regulation and changes in reimbursement rates. Healthcare providers, principally hospitals, that transact with biotechnology companies, often rely on third party payors, such as Medicare, Medicaid, private health insurance plans and health maintenance organizations to reimburse all or a portion of the cost of healthcare related products or services. Biotechnology companies will continue to be affected by the efforts of governments and third-party payors to contain or reduce health care costs. For example, certain foreign markets control pricing or profitability of biotechnology products and technologies. In the United States, there has been, and there will likely continue to be, a number of federal and state proposals to implement similar controls. A biotechnology company’s valuation could be based on the potential or actual performance of a limited number of products. A biotechnology company’s valuation could be affected if one of its products proves unsafe, ineffective or unprofitable. Such companies may also be characterized by thin capitalization and limited markets, financial resources or personnel. The stock prices of companies involved in the biotechnology sector have been and will likely continue to be extremely volatile.

Life Sciences Industry Risk. Life sciences industries are characterized by limited product focus, rapidly changing technology and extensive government regulation. In particular, technological advances can render an existing product, which may account for a disproportionate share of a company’s revenue, obsolete. Obtaining governmental approval from agencies such as the FDA, the U.S. Department of Agriculture and other governmental agencies for new products can be lengthy, expensive and uncertain as to outcome. Any delays in product development may result in the need to seek additional capital, potentially diluting the interests of existing investors such as the Company. In addition, governmental agencies may, for a variety of reasons, restrict the release of certain innovative technologies of commercial significance, such as genetically altered material. These various factors may result in abrupt advances and declines in the securities prices of particular companies and, in some cases, may have a broad effect on the prices of securities of companies in particular life sciences industries.

Intense competition exists within and among certain life sciences industries, including competition to obtain and sustain proprietary technology protection. Life sciences companies can be highly dependent on the strength of patents, trademarks and other intellectual property rights for maintenance of profit margins and market share. The complex nature of the technologies involved can lead to patent disputes, including litigation that may be costly and that could result in a company losing an exclusive right to a patent. Competitors of life sciences companies may have invested substantially in developing technologies and products that are more effective or less costly than any that may be developed by life sciences companies in which the Company invests and may also prove to be more successful in production and marketing. Competition may increase further as a result of potential advances in health services and medical technology and greater availability of capital for investment in these fields.

With respect to healthcare, cost containment measures already implemented by the federal government, state governments and the private sector have adversely affected certain sectors of these industries. Increased emphasis on managed care in the United States may put pressure on the price and usage of products sold by life sciences companies in which the Company may invest in and may adversely affect the sales and revenues of life sciences companies.

Product development efforts by life sciences companies may not result in commercial products for many reasons, including, but not limited to, failure to achieve acceptable clinical trial results, limited effectiveness in treating the specified condition or illness, harmful side effects, failure to obtain regulatory approval, and high manufacturing costs. Even after a product is commercially released, governmental agencies may require additional clinical trials or change the labeling requirements for products if additional product side effects are identified, which could have a material adverse effect on the market price of the securities of those life sciences companies.

Certain life sciences companies in which the Company may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing and sale of pharmaceuticals, medical devices or other products. There can be no assurances that a product liability claim would not have a material adverse effect on the business, financial condition or securities prices of a company in which the Company has invested.

Healthcare Services Industry Risk. The operations of healthcare services companies are subject to extensive federal, state and local government regulations, including Medicare and Medicaid payment rules and regulations, federal and state anti-kickback laws, the physician self-referral law and analogous state self-referral prohibition statutes, Federal Acquisition Regulations, the False Claims Act and federal and state laws regarding the collection, use and disclosure of patient health information and the storage, handling and administration of pharmaceuticals. The Medicare and Medicaid reimbursement rules related to claims submission, enrollment and licensing requirements, cost reporting, and payment processes impose complex and extensive requirements upon dialysis providers as well. A violation or departure from any of these legal requirements may result in government audits, lower reimbursements, significant fines and penalties, the potential loss of certification, recoupment efforts or voluntary repayments. If healthcare services companies fail to adhere to all of the complex government regulations that apply to their businesses, such companies could suffer severe consequences that would substantially reduce revenues, earnings, cash flows and stock prices. If healthcare companies are unable to successfully expand their product lines through internal research and development and acquisitions, their business may be

 

29


materially and adversely affected. In addition, if these companies are unable to successfully grow their businesses through marketing partnerships and acquisitions, their business may be materially and adversely affected.
Sustainable and Renewable Technology Industry Risk. Companies in sustainable and renewable technology sectors may be subject to extensive regulation by foreign, U.S. federal, state and/or local agencies. Changes in existing laws, rules or regulations, or judicial or administrative interpretations thereof, new laws, rules or regulations, or changes in government priorities or limitations on government resources could all have an adverse impact on the business and industries of these companies. We are unable to predict whether any such changes in laws, rules or regulations will occur and, if they do occur, the impact of these changes on our portfolio companies and our investment returns. Furthermore, if any of our portfolio companies fail to comply with applicable regulations, they could be subject to significant penalties and claims that could materially and adversely affect their operations, which would also impact our ability to realize value since our exit from the investment may be subject to the portfolio company obtaining the necessary regulatory approvals. Our portfolio companies may be subject to the expense, delay and uncertainty of the regulatory approval process for their products and, even if approved, these products may not be accepted in the marketplace. In addition, there is considerable uncertainty about whether foreign, U.S., state and/or local governmental entities will enact or maintain legislation or regulatory programs that mandate reductions in greenhouse gas emissions or provide incentives for sustainable and renewable technology companies. Without such regulatory policies, investments in sustainable and renewable technology companies may not be economical and financing for sustainable and renewable technology companies may become unavailable.

Further, industries within the energy sector are cyclical with fluctuations in commodity prices and demand for, and production of commodities driven by a variety of factors. The highly cyclical nature of the industries within the energy sector may lead to volatile changes in commodity prices. Commodity price fluctuation may adversely affect the earnings of companies in which we may invest.

Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected.

Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform as expected, our financial results could be more negatively affected, and the magnitude of the loss could be more significant than if we had made smaller investments in more companies.

The following table shows the fair value of the investments held in portfolio companies as of December 31, 2022, that represent greater than 5% of our net assets:

(in thousands)

December 31, 2022

 

 

Fair Value

 

 

Percentage of Net Assets

 

Corium, Inc.

$

135,619

 

 

 

9.7

%

Worldremit Group Limited

 

94,031

 

 

 

6.7

%

Phathom Pharmaceuticals, Inc.

 

94,017

 

 

 

6.7

%

Axsome Therapeutics, Inc.

 

89,461

 

 

 

6.4

%

Rocket Lab Global Services, LLC

 

87,933

 

 

 

6.3

%

SeatGeek, Inc.

 

87,876

 

 

 

6.3

%

Convoy, Inc.

 

73,862

 

 

 

5.3

%

uniQure B.V.

 

73,408

 

 

 

5.2

%

 

Corium, Inc. develops, engineers, and manufactures drug delivery products and devices that utilize the skin and mucosa as a primary means of transport.
Worldremit Group Limited is a global online money transfer business.
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system disorders for which there are limited treatment options.
Rocket Lab Global Services, LLC is a commercial space provider of high-frequency, low-cost launches.
SeatGeek, Inc. is a mobile-focused ticket platform that enables users to buy and sell tickets for live sports, concerts and theater events.
Convoy, Inc. is a developer for on-demand shipment services.
uniQure B.V. is a leader in the field of gene therapy, developing proprietary therapies to treat patients with severe genetic diseases of the central nervous system and liver.

Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial difficulty and fail to repay their obligations or to perform as expected.

We may be exposed to higher risks with respect to our investments that include PIK interest or exit fees.

Our investments may include contractual PIK interest and exit fees. PIK interest represents contractual interest added to a loan's principal balance and is due in accordance with the loan's amortization terms. Exit fees represent a contractual fee accrued over the life

 

30


of the loan and is typically due at loan payoff. To the extent PIK interest and exit fees constitute a portion of our income, we are exposed to typical risks associated with such income being required to be included in taxable and accounting income prior to receipt of cash, including the following:

PIK interest and exit fee instruments may have higher yields, which reflect the payment deferral and credit risk associated with these instruments;
PIK interest and exit fee instruments may have unreliable valuations because their continuing accruals require continuing judgments about the collectability of the deferred payments and the value of the collateral; and
PIK interest and exit fee instruments may represent a higher credit risk than coupon loans; even if the conditions for income accrual under generally accepted accounting principles in the United States of America are satisfied, a borrower could still default when actual payment is due upon the maturity of such loan.

The lack of liquidity in our investments may adversely affect our business.

We generally invest in companies whose securities are not publicly traded and/or whose securities will be subject to legal and other restrictions on resale or will otherwise be less liquid than publicly traded securities. The illiquidity of these investments may make it difficult for us to sell these investments when desired. In addition, if we are required to liquidate all or a portion of our portfolio quickly, we may realize significantly less than the value at which we had previously recorded these investments. As a result, we do not expect to achieve liquidity in our investments in the near-term. Our investments are usually subject to contractual or legal restrictions on resale or are otherwise illiquid because there is usually no established trading market for such investments. Even if an established trading market for such securities were established, we may be limited in our ability to divest ourselves from a debt or equity instrument for a variety of reasons, such as limited trading volume in a public company’s securities, or regulatory factors such as the receipt of material non-public information or insider blackout periods when we are legally prohibited from selling. The illiquidity of most of our investments may make it difficult for us to dispose of them at a favorable price or at all and, as a result, we may suffer losses.

We may not have the funds or ability to make additional investments in our portfolio companies.

We may not have the funds or ability to make additional investments in our portfolio companies. After our initial investment in a portfolio company, we may be called upon from time to time to provide additional funds to such company or have the opportunity to increase our investment through the extension of additional loans, the exercise of a warrant to purchase equity securities, or the funding of additional equity investments. There is no assurance that we will make, or will have sufficient funds to make, follow-on investments. Any decisions not to make a follow-on investment or any inability on our part to make such an investment may have a negative impact on a portfolio company in need of such an investment, may result in a missed opportunity for us to increase our participation in a successful operation, may reduce our ability to protect an existing investment or may dilute our equity interest or otherwise reduce the expected yield on the investment.

There may be circumstances where our debt investments could be subordinated to claims of other creditors or we could be subject to lender liability claims.

Our portfolio companies may have, or may be permitted to incur, other debt that ranks equally with, or senior to, the debt in which we invest. By their terms, such debt instruments may entitle the holders to receive payment of interest or principal on or before the dates on which we are entitled to receive payments with respect to the debt instruments in which we invest. Also, in the event of insolvency, liquidation, dissolution, reorganization or bankruptcy of a portfolio company, holders of debt instruments ranking senior to our investment in that portfolio company would typically be entitled to receive payment in full before we receive any distribution. After repaying such senior creditors, such portfolio company may not have any remaining assets to use for repaying its obligation to us. In the case of debt ranking equally with debt instruments in which we invest, we would have to share on an equal basis any distributions with other creditors holding such debt in the event of an insolvency, liquidation, dissolution, reorganization or bankruptcy of the relevant portfolio company.

Even if our investment is structured as a senior-secured loan, principles of equitable subordination, as defined by existing case law, could lead a bankruptcy court to subordinate all or a portion of our claim to that of other creditors and transfer any lien securing such subordinated claim to the bankruptcy estate. The principles of equitable subordination defined by case law have generally indicated that a claim may be subordinated only if its holder is guilty of misconduct or where the senior loan is re-characterized as an equity investment and the senior lender has actually provided significant managerial assistance to the bankrupt debtor. We may also be subject to lender liability claims for actions taken by us with respect to a borrower’s business or instances where we exercise control over the borrower. It is possible that we could become subject to a lender liability claim, including as a result of actions taken in rendering significant managerial assistance or actions to compel and collect payments from the borrower outside the ordinary course of business.

We are a non-diversified investment company within the meaning of the 1940 Act, and therefore we are not limited with respect to the proportion of our assets that may be invested in securities of a single issuer, which may subject us to a risk of significant loss if any such issuer experiences a downturn.

 

31


We are classified as a non-diversified investment company within the meaning of the 1940 Act, which means that we are not limited by the 1940 Act with respect to the proportion of our assets that we may invest in securities of a single issuer. Under the 1940 Act, a “diversified” investment company is required to invest at least 75% of the value of its total assets in cash and cash items, government securities, securities of other investment companies and other securities limited in respect of any one issuer to an amount not greater than 5% of the value of the total assets of such company and no more than 10% of the outstanding voting securities of such issuer. As a non-diversified investment company, we are not subject to this requirement. To the extent that we assume large positions in the securities of a small number of issuers, our NAV may fluctuate to a greater extent than that of a diversified investment company as a result of changes in the financial condition or the market’s assessment of the issuer. We may also be more susceptible to any single economic or regulatory occurrence than a diversified investment company might be. Beyond our RIC asset diversification requirements, we do not have fixed guidelines for portfolio diversification, and our investments could be concentrated in relatively few portfolio companies. See “Risk Factors – Federal Income Tax Risks – We will be subject to corporate-level U.S. federal income tax if we are unable to qualify as a RIC under Subchapter M of the Code.”

We generally will not control our portfolio companies, which may result in the portfolio company making decisions which could adversely impact the value of our investments in the portfolio company's securities.

In some instances, we may control our portfolio companies or provide our portfolio companies with significant managerial assistance. However, we do not, and do not expect to, control the ultimate decision making in most of our portfolio companies, even though we may have board representation or board observation rights, and our debt agreements may contain certain restrictive covenants. As a result, we are subject to the risk that a portfolio company in which we invest will make business decisions with which we disagree, and the management of such company will take risks or otherwise act in ways that do not serve our interests as debt investors or minority equity holders. Due to the lack of liquidity for our investments in non-traded companies, we may not be able to dispose of our interests in our portfolio companies as readily as we would like or at an appropriate valuation. As a result, a portfolio company may make decisions that would decrease the value of our portfolio holdings.

Defaults by our portfolio companies will harm our operating results.

A portfolio company’s failure to satisfy financial or operating covenants imposed by us or other lenders could lead to non-payment of interest and other defaults and, potentially, termination of its loans and foreclosure on its secured assets, which could trigger cross-defaults under other agreements and jeopardize a portfolio company’s ability to meet its obligations under the debt or equity securities that we hold. In addition, in the event of a default by a portfolio company on a secured loan, we will only have recourse to the assets collateralizing the loan, which in some cases excludes the IP on which we have only a negative pledge. In any case, the assets collateralizing our loan may not be sufficient to fully cover our indebtedness. Further, some of our secured loans are secured by a negative pledge on a portfolio company’s intellectual property. In the event of a default on a loan, there can be no assurance that our security interest will be enforceable in a court of law or bankruptcy court or that there will not be others with senior or pari passu credit interests. We may incur expenses to the extent necessary to seek recovery upon default or to negotiate new terms, which may include the waiver of certain financial covenants, with a defaulting portfolio company.

Substantially all of our portfolio investments are recorded at fair value as determined in accordance with our Valuation Guidelines and, as a result, there may be uncertainty as to the value of our portfolio investments.

As a BDC, we are required to carry our investments at market value or, if no market value is ascertainable, at the fair value as determined in accordance with our Valuation Guidelines adopted pursuant to Rule 2a-5 under the 1940 Act. As of December 31, 2022, portfolio investments, whose fair value is determined in good faith by our Valuation Committee and approved by the Board were approximately 97.9% of our total assets. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of our investments may differ significantly from the values that would have been used had a readily available market value existed for such investments, and the differences could be material. Our NAV could be adversely affected if determinations regarding the fair value of these investments were materially higher than the values ultimately realized upon the disposal of such investments.

Any unrealized depreciation we experience on our investment portfolio may be an indication of future realized losses, which could reduce our income available for distribution and could impair our ability to service our borrowings.

Decreases in the market values or fair values of our investments will be recorded as unrealized depreciation. Any unrealized depreciation in our portfolio could be an indication of a portfolio company’s inability to meet its repayment obligations to us with respect to the affected loans or potential impairment of the value of affected equity investments. This could result in realized losses in the future and ultimately in reductions of our income and gains available for distribution in future periods.

Prepayments of our debt investments by our portfolio companies could adversely impact our results of operations and reduce our return on equity.

During the year ended December 31, 2022, we received early principal payments and early payoffs on our debt investments of approximately $373.3 million. We are subject to the risk that the debt investments we make in our portfolio companies may be repaid prior to maturity. When this occurs, we will generally reinvest these proceeds in temporary investments, pending their future investment in new portfolio companies. These temporary investments will typically have substantially lower yields than the debt being

 

32


prepaid, and we could experience significant delays in reinvesting these amounts. Any future investment in a new portfolio company may also be at lower yields than the debt that was repaid. As a result, our results of operations could be materially adversely affected if one or more of our portfolio companies elect to prepay amounts owed to us. Additionally, prepayments could negatively impact our return on equity, which could result in a decline in the market price of our securities.

The phase-out of LIBOR and the use of replacement rates for LIBOR may adversely affect the value of our portfolio securities.

On March 5, 2021, the U.K.’s Financial Conduct Authority publicly announced that all U.S. Dollar LIBOR settings will either cease to be provided by any administrator or no longer be representative (i) immediately after December 31, 2021 for one-week and two-month U.S. Dollar LIBOR settings and (ii) immediately after June 30, 2023 for the remaining U.S. Dollar LIBOR settings. The U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised of large U.S. financial institutions, supports replacing U.S. Dollar LIBOR with the Secured Overnight Financing Rate, or SOFR, a new index calculated by short-term repurchase agreements, backed by Treasury securities. Although there are an increasing number of issuances utilizing SOFR or the Sterling Over Night Index Average, or SONIA, an alternative reference rate that is based on transactions, these alternative reference rates may not attain market acceptance as replacements for LIBOR. The transition away from LIBOR to alternative reference rates is complex and could have a material adverse effect on our business, financial condition and results of operations, including as a result of any changes in the pricing of our investments, changes to the documentation for certain of our investments and the pace of such changes, disputes and other actions regarding the interpretation of current and prospective loan documentation or modifications to processes and systems.

In anticipation of the cessation of LIBOR, we may need to renegotiate any credit agreements extending beyond June 30, 2023 with our portfolio companies that utilize LIBOR as a factor in determining the interest rate or rely on certain fallback provisions that could cause interest rates to shift to a base rate plus a margin. Any such renegotiations may have a material adverse effect on our business, financial condition and results of operations, including as a result of changes in interest rates payable to us by our portfolio companies. In addition, if a replacement rate is not widely agreed upon, the mismatch on the interest rates payable by any leverage incurred by us and the interest rate payable to us on our portfolio company investments could result in a decrease in our net investment income and distributions we are able to pay to our stockholders.

We are subject to risks associated with the current interest rate environment and changes in interest rates will affect our cost of capital, net investment income and the value of our investments.

To the extent we borrow money or issue debt securities or preferred stock to make investments, our net investment income will depend, in part, upon the difference between the rate at which we borrow funds or pay interest or dividends on such debt securities or preferred stock and the rate at which we invest these funds. In addition, many of our debt investments and borrowings have floating interest rates that reset on a periodic basis, and many of our investments are subject to interest rate floors and caps. As of December 31, 2022, approximately 95.3% of our debt investments were at floating rates or floating rates with a floor, and 4.7% of our debt investments were at fixed rates. As a result, a change in market interest rates could have a material adverse effect on our net investment income, in particular with respect to increases from current levels to the level of the interest rate caps on certain investments. In periods of rising interest rates, our cost of funds will increase because the interest rates on the amounts borrowed under our Credit Facilities are floating and are not subject to interest rate caps, which could reduce our net investment income to the extent any debt investments have either fixed interest rates, or floating interest rates subject to an interest rate cap below the then current levels, and as a result such interest rates on these debt investments will not increase.

Some of our portfolio companies have debt investments which bear interest at variable rates and may be negatively affected by changes in market interest rates. An increase in market interest rates would increase the interest costs and reduce the cash flows of our portfolio companies that have variable rate debt instruments, a situation which could reduce the value of our investments in these portfolio companies. The value of our securities could also be reduced from an increase in market interest rates as rates available to investors could make an investment in our securities less attractive than alternative investments. Conversely, decreases in market interest rates could negatively impact the interest income from our variable rate debt investments. A decrease in market interest rates may also have an adverse impact on our returns by requiring us to accept lower yields on our debt investments and by increasing the risk that our portfolio companies will prepay our debt investments, resulting in the need to redeploy capital at potentially lower rates. See further discussion and analysis at “Item 7A. Quantitative and Qualitative Disclosures about Market Risk.”

We may not realize gains from our equity or warrant investments.

Certain investments that we have made in the past and may make in the future include warrants or other equity securities. Investments in equity securities involve a number of significant risks, including the risk of further dilution as a result of additional issuances, inability to access additional capital and failure to pay current distributions. We may from time to time make non-control, equity investments in portfolio companies. Our goal is ultimately to realize gains upon our disposition of such equity interests. However, the equity interests we receive may not appreciate in value and, in fact, may decline in value. Accordingly, we may not be able to realize gains from our equity interests, and any gains that we do realize on the disposition of any equity interests may not be sufficient to offset any other losses we experience. We also may be unable to realize any value if a portfolio company does not have a liquidity event, such as a sale of the business, recapitalization or public offering, which would allow us to sell the underlying equity interests. We may seek puts or similar rights to give us the right to sell our equity securities back to the portfolio company issuer;

 

33


however, we may be unable to exercise these put rights for the consideration provided in our investment documents if the issuer is in financial distress. In addition, we anticipate that approximately 50% of our warrants may not realize any exit or generate any returns. Furthermore, because of the financial reporting requirements under U.S. generally accepted accounting principles ("U.S. GAAP"), of those approximately 50% of warrants that we do not realize any exit, the assigned costs to the initial warrants may lead to realized losses when the warrants either expire or are not exercised.

We may expose ourselves to risks if we engage in hedging transactions.

If we engage in hedging transactions, we may expose ourselves to risks associated with such transactions. We may utilize instruments such as forward contracts, currency options and interest rate swaps, caps, collars and floors to seek to hedge against fluctuations in the relative values of our portfolio positions from changes in currency exchange rates and market interest rates. Hedging against a decline in the values of our portfolio positions does not eliminate the possibility of fluctuations in the values of such positions or prevent losses if the values of such positions decline. However, such hedging can establish other positions designed to gain from those same developments, thereby offsetting the decline in the value of such portfolio positions. Such hedging transactions may also limit the opportunity for gain if the values of the underlying portfolio positions should increase. It may not be possible to hedge against an exchange rate or interest rate fluctuation that is so generally anticipated that we are not able to enter into a hedging transaction at an acceptable price. Moreover, for a variety of reasons, we may not seek to establish a perfect correlation between such hedging instruments and there can be no assurance that any such hedging arrangements will achieve the desired effect. During the year ended December 31, 2022, we did not engage in any hedging activities.

Our investments in foreign securities or investments denominated in foreign currencies may involve significant risks in addition to the risks inherent in U.S. and U.S.-denominated investments.

Our investment strategy contemplates potential investments in securities of foreign companies. Our total investments at value in foreign companies were approximately $293.4 million or 9.9% of total investments as of December 31, 2022. Investing in foreign companies may expose us to additional risks not typically associated with investing in securities of U.S. companies. These risks include changes in exchange control regulations, political and social instability, expropriation, imposition of foreign taxes, less liquid markets and less available information than is generally the case in the U.S., higher transaction costs, less government supervision of exchanges, brokers and issuers, less developed bankruptcy laws, difficulty in enforcing contractual obligations, lack of uniform accounting and auditing standards and greater price volatility.

Although most of our investments will be U.S. dollar denominated, any investments denominated in a foreign currency will be subject to the risk that the value of a particular currency will change in relation to one or more other currencies. Among the factors that may affect currency values are trade balances, the level of short-term interest rates, differences in relative values of similar assets in different currencies, long-term opportunities for investment and capital appreciation, and political developments.

The disposition of our investments may result in contingent liabilities.

Many of our investments involve private securities. In connection with the disposition of an investment in private securities, we may be required to make representations about the business and financial affairs of the portfolio company typical of those made in connection with the sale of a business. We may also be required to indemnify the purchasers of such investment to the extent that any such representations turn out to be inaccurate or with respect to certain potential liabilities. These arrangements may result in contingent liabilities that ultimately yield funding obligations that must be satisfied through our return of certain distributions previously made to us.

Depending on funding requirements, we may need to raise additional capital to meet our unfunded commitments through additional borrowings.

As of December 31, 2022, we had approximately $628.9 million of available unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by milestones.

Our unfunded contractual commitments may be significant from time-to-time. A portion of these unfunded contractual commitments are dependent upon the portfolio company achieving certain milestones before the debt commitment becomes available. Furthermore, our credit agreements contain customary lending provisions which allow us relief from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as are the on-balance sheet financial instruments that we hold. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash requirements. Closed commitments generally fund 50-80% of the committed amount in aggregate over the life of the commitment. We believe that our assets provide adequate cover to satisfy all of our unfunded commitments and we intend to use cash flow from operations and early principal repayments and proceeds from borrowings and notes to fund these commitments. However, there can be no assurance that we will have sufficient capital available to fund these commitments as they come due, which could have a material adverse effect on our reputation in the market and our ability to generate incremental lending activity and subject us to lender liability claims.

 

34


Our ability to secure additional financing and satisfy our financial obligations under indebtedness outstanding from time to time will depend upon our future operating performance, which is subject to the prevailing general economic and credit market conditions, including interest rate levels and the availability of credit generally, and financial, business and other factors, many of which are beyond our control. The prolonged continuation or worsening of current economic and capital market conditions could have a material adverse effect on our ability to secure financing on favorable terms, if at all.

Risks Related To Leverage

Because we have substantial borrowings, the potential for gain or loss on amounts invested in us is magnified and may increase the risk of investing in us.

Borrowings, also known as leverage, magnify the potential for loss on investments in our indebtedness and gain or loss on investments in our equity capital. As we use leverage to partially finance our investments, you will experience increased risks of investing in our securities. Accordingly, any event that adversely affects the value of an investment would be magnified to the extent we use leverage. Such events could result in a substantial loss to us, which would be greater than if leverage had not been used. In addition, our investment objectives are dependent on the continued availability of leverage at attractive relative interest rates.

We may also borrow from banks and other lenders and may issue debt securities or enter into other types of borrowing arrangements in the future. Lenders of these senior securities will have fixed dollar claims on our assets that are superior to the claims of our common stockholders, and we would expect such lenders to seek recovery against our assets in the event of a default. We generally may grant security interests in our assets, subject to our requirement to maintain a 150% minimum asset coverage ratio and any restrictions on encumbered assets imposed by the terms of our existing indebtedness.

The terms of our existing indebtedness require us to comply with certain financial and operational covenants, and we expect similar covenants in future debt instruments. Failure to comply with such covenants could result in a default under the applicable credit facility or debt instrument if we are unable to obtain a waiver from the applicable lender or holder, and such lender or holder could accelerate repayment under such indebtedness and negatively affect our business, financial condition, results of operations and cash flows. In addition, under the terms of any credit facility or other debt instrument we enter into, in the event of a default, we are likely to be required by its terms to use the net proceeds of any investments that we sell to repay a portion of the amount borrowed under such facility or instrument before applying such net proceeds to any other uses. See “Note 5 – Debt” and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations — Financial Condition, Liquidity, Capital Resources and Obligations” for a discussion regarding our outstanding indebtedness.

If the value of our assets decreases, leveraging would cause NAV to decline more sharply than it otherwise would have had we not leveraged our business. Similarly, any decrease in our income would cause net investment income to decline more sharply than it would have had we not leveraged our business. Such a decline could negatively affect our ability to pay common stock dividends, scheduled debt payments or other payments related to our securities.

Our ability to service our debt depends largely on our financial performance and will be subject to prevailing economic conditions and competitive pressures. Our secured credit facilities with Sumitomo Mitsui Banking Corporation (the “SMBC Facility”) and MUFG Union Bank, N.A., (the “MUFG Bank Facility”) and our letter of credit facility with Sumitomo Mitsui Banking Corporation entered into in January 2023 (the “SMBC LC Facility” and together with the SMBC Facility and MUFG Bank Facility, our “Credit Facilities”), as well as the July 2024 Notes, February 2025 Notes, June 2025 Notes, June 2025 3-Year Notes, March 2026 A Notes, March 2026 B Notes, September 2026 Notes, January 2027 Notes, 2031 Asset-Backed Notes and 2033 Notes (each term as is individually defined herein and collectively, the “Notes”) contain financial and operating covenants that could restrict our business activities, including our ability to declare dividend distributions if we default under certain provisions. As of December 31, 2022, we had $72.0 million and $107.0 million in borrowings under the SMBC Facility and MUFG Bank Facility. As of December 31, 2022, we had approximately $175.0 million of indebtedness outstanding incurred by our SBIC subsidiary, and approximately $1.24 billion in aggregate principal outstanding Notes.

Illustration. The following table illustrates the effect of leverage on returns from an investment in our common stock assuming that we employ (1) our actual asset coverage ratio as of December 31, 2022, (2) a hypothetical asset coverage ratio of 200%, and (3) a hypothetical asset coverage ratio of 150% (each excluding our SBA debentures as permitted by our exemptive relief) each at various annual returns on our portfolio as of December 31, 2022, net of expenses. The calculations in the table below are hypothetical, and actual returns may be higher or lower than those appearing in the table below.

 

Annual Return on Our Portfolio

 

 

(Net of Expenses)

 

 

-10%

 

 

-5%

 

 

0%

 

 

5%

 

 

10%

 

Corresponding return to common stockholder assuming our actual asset coverage of 198.5% as of December 31, 2022(1)

 

(26.44

)%

 

 

(15.64

)%

 

 

(4.83

)%

 

 

5.98

%

 

 

16.78

%

Corresponding return to common stockholder assuming 200% asset coverage(2)

 

(26.23

)%

 

 

(15.50

)%

 

 

(4.77

)%

 

 

5.97

%

 

 

16.70

%

Corresponding return to common stockholder assuming 150% asset coverage(3)

 

(40.44

)%

 

 

(24.72

)%

 

 

(9.00

)%

 

 

6.72

%

 

 

22.44

%

(1)
Assumes $3.0 billion in total assets, $1.6 billion in debt outstanding, $1.4 billion in stockholders’ equity, and an average cost of funds of 4.2%, which is the approximate average cost of our Notes and Credit Facilities for the period ended December 31, 2022. Actual interest payments may be different.

 

35


(2)
Assumes $3.0 billion in total assets including debt issuance costs on a pro forma basis, $1.6 billion in debt outstanding, $1.4 billion in stockholders’ equity, and an average cost of funds of 4.2%, which is the approximate average cost of our Notes and Credit Facilities for the period ended December 31, 2022, along with the hypothetical estimated incremental cost of debt that would be incurred on offering the maximum permissible debt under the 200% asset coverage. Actual interest payments may be different.
(3)
Assumes $4.4 billion in total assets including debt issuance costs on a pro forma basis, $3.0 billion in debt outstanding, $1.4 billion in stockholders’ equity, and an average cost of funds of 4.2%, which is the approximate average cost of our Notes and Credit Facilities for the period ended December 31, 2022, along with the hypothetical estimated incremental cost of debt that would be incurred on offering the maximum permissible debt under the 150% asset coverage. Actual interest payments may be different.

Our ability to achieve our investment objective may depend in part on our ability to access additional leverage on favorable terms and there can be no assurance that such additional leverage can in fact be achieved. If we are unable to obtain leverage or renew, extend or replace our current leverage facilities, or if the interest rates of such leverage are not attractive, we could experience diminished returns. The number of leverage providers and the total amount of financing available could decrease or remain static.

Certain of our assets are subject to security interests under our senior securities and if we default on our obligations under our senior securities, we may suffer adverse consequences, including foreclosure on those assets.

Certain of our assets are currently pledged as collateral under our senior securities, including any credit facilities or notes. If we default on our obligations under our senior securities, our lenders may have the right to foreclose upon and sell, or otherwise transfer, the collateral subject to their security interests or their superior claim. In such event, we may be forced to sell our investments to raise funds to repay our outstanding borrowings in order to avoid foreclosure and these forced sales may be at times and at prices we would not consider advantageous. Moreover, such deleveraging of our company could significantly impair our ability to effectively operate our business in the manner in which we have historically operated. As a result, we could be forced to curtail or cease new investment activities and lower or eliminate the dividends that we have historically paid to our stockholders. In addition, if the lenders exercise their right to sell the assets pledged under our senior securities, such sales may be completed at distressed sale prices, thereby diminishing or potentially eliminating the amount of cash available to us after repayment of the amounts outstanding under the senior securities.

If our operating performance declines and we are not able to generate sufficient cash flow to service our debt obligations, we may in the future need to refinance or restructure our debt, sell assets, reduce or delay capital investments, seek to raise additional capital or seek to obtain waivers from the required lenders under our senior securities to avoid being in default. If we are unable to implement one or more of these alternatives, we may not be able to meet our payment obligations under our senior securities. If we breach our covenants under our senior securities and seek a waiver, we may not be able to obtain a waiver from the required lenders or debt holders. If this occurs, we would be in default under our senior securities, the lenders or debt holders could exercise their rights as described above, and we could be forced into bankruptcy or liquidation. If we are unable to repay debt, lenders having secured obligations could proceed against the collateral securing the debt. Because certain of our senior securities have customary cross-default and cross-acceleration provisions, if the indebtedness under our senior securities is accelerated, we may be unable to repay or finance the amounts due.

Risks Related To Our Investment Management Activities

Our executive officers and employees, through the Adviser Subsidiary, are expected to manage the Adviser Funds or separately managed accounts, which includes funds from External Parties, that operate in the same or a related line of business as we do, which may result in significant conflicts of interest.

Our executive officers and employees, through the Adviser Subsidiary, are expected to manage the Adviser Funds that operate in the same or a related line of business as we do, and which funds may be invested in by us and/or our executive officers and employees. Accordingly, they may have obligations to such other entities, the fulfillment of which obligations may not be in the interests of us or our stockholders. Our relationship with the Adviser Subsidiary may require us to commit resources to achieving the Adviser Funds or External Parties’ investment objectives, while such resources were previously solely devoted to achieving our investment objective. Our investment objective and investment strategies may be very similar to those of the Adviser Funds and External Parties, and it is likely that an investment appropriate for us, the Adviser Funds, or External Parties would be appropriate for the other entity. Because the Adviser Subsidiary may receive performance-based fee compensation from the Adviser Funds or External Parties, this may provide an incentive to allocate opportunities to the Adviser Funds or External Parties instead of us. Accordingly, we and the Adviser Subsidiary have established policies and procedures governing the allocation investment opportunities between us, the Adviser Funds, and External Parties. We may be limited in or unable to participate in certain investments based upon such allocation policy. Although we will endeavor to allocate investment opportunities in a fair and equitable manner, we may face conflicts in allocating investment opportunities between us, the Adviser Funds and External Parties managed by the Adviser Subsidiary.

Investments in the Adviser Funds managed by our Adviser Subsidiary may create conflicts of interests.

Our Adviser Subsidiary is committed to make contributions as a limited partner to certain Adviser Funds, it is also entitled to receive distributions on such interest. Our officers and employees may dedicate more time or resources to the Adviser Funds or allocate more favorable investment opportunities to the Adviser Funds instead of us. The Adviser Funds will, at times, acquire, hold,

 

36


or sell investments that are also suitable for us. Investments allocated to the Adviser Funds may reduce the amount of investments available to us. Our officers and employees may make investment decisions or recommendations for the Adviser Funds that differ from the investment decisions that are made for us. The Adviser Subsidiary could determine to sell a loan for one or more Adviser Funds while all or a portion of such loan is retained by us, or vice-versa. The Adviser Subsidiary makes its decisions as to whether the Adviser Funds should invest pursuant to, among other things, its duties under the applicable governing documents for the Adviser Funds. Conflicts of interest can arise if the Adviser Subsidiary seeks to acquire or sell portions of one or more loans for one or more of the Adviser Funds while we also seek to acquire or sell portions of such loans. We and the Adviser Subsidiary have implemented an investment allocation policy and procedures designed to ensure that investment opportunities are allocated among us and the Adviser Funds fairly and equitably over time; however, there can be no assurance that the application of our allocation policy will result in our desired participation in every investment opportunity that may be suitable for both us and the Adviser Funds.

In addition, we may make investments in the Adviser Funds in the form of loans. For example, prior to the receipt by the Adviser Funds of capital contributions from investors for which a capital call notice has or will be given, we expect to provide loan financing to such Adviser Funds to fund such amounts on a temporary basis in order to permit the Adviser Funds to invest in a target portfolio company within the applicable time constraints prior to the receipt by the Adviser Funds of a capital call in respect of such investment. In addition, we may provide loan financing to the Adviser Funds to cover start-up and initial operating costs prior to the receipt by the Adviser Funds of a capital call in respect of such expenses. The provision of debt financing to the Adviser Funds may cause conflicts of interest, including in situations where our interest as a lender to the Adviser Funds conflicts with the interest of holders of third-party equity interests.

We, through the Adviser Subsidiary, derive revenues from managing third-party funds pursuant to management agreements that may be terminated, which could negatively impact our operating results.

We will derive our revenues related to the Adviser Subsidiary primarily from dividend income, which the Adviser Subsidiary will pay from net profits generated from advisory fees charged to the Adviser Funds. The Adviser Funds may be established with different fee structures, including management fees payable at varying rates and carried interest or performance fees that are payable at varying hurdle rates. Investment advisory, carried interest, and performance fee revenues can be adversely affected by several factors, including market factors, third-party investor preferences, and our Adviser Subsidiary’s performance and track record. A reduction in revenues of our Adviser Subsidiary, without a commensurate reduction in expenses, would adversely affect our Adviser Subsidiary’s business and our revenues and results of operations derived from the Adviser Subsidiary. In addition, the terms of the investment management agreements with the Adviser Funds generally provide for the right to terminate the management agreement in certain circumstances. Termination of any such management agreements would reduce the fees we earn from the Adviser Funds, which could have a material adverse effect on our results of operations.

Risk Related To BDCs

Failure to comply with applicable laws or regulations and changes in laws or regulations governing our operations may adversely affect our business or cause us to alter our business strategy.

We, the Adviser Funds and our portfolio companies are subject to applicable local, state and federal laws and regulations, including those promulgated by the SEC, the NYSE, and the Public Company Accounting Oversight Board. Failure to comply with any applicable local, state or federal law or regulation could negatively impact our reputation and our business results. New legislation may also be enacted or new interpretations, rulings or regulations could be adopted, including those governing the types of investments we are permitted to make, any of which could harm us and our stockholders, potentially with retroactive effect. Additionally, any changes to the laws and regulations governing our operations relating to permitted investments may cause us to alter our investment strategy in order to avail ourselves of new or different opportunities. Such changes could result in material differences to the strategies and plans set forth herein and may result in our investment focus shifting from the areas of expertise of our investment team to other types of investments in which our investment team may have less expertise or little or no experience. Thus, any such changes, if they occur, could have a material adverse effect on our results of operations and the value of your investment.

Failure to maintain our status as a BDC would reduce our operating flexibility.

If we do not remain a BDC, we might be regulated as a closed-end investment company under the 1940 Act, which would subject us to substantially more regulatory restrictions under the 1940 Act and correspondingly decrease our operating flexibility.

Operating under the constraints imposed on us as a BDC and RIC may hinder the achievement of our investment objectives.

The 1940 Act and the Code impose numerous constraints on the operations of BDCs and RICs that do not apply to certain of the other investment vehicles that we may compete with. BDCs are required, for example, to invest at least 70% of their total assets in certain qualifying assets, including U.S. private or smaller U.S. public companies, cash, cash equivalents, U.S. government securities and other high-quality debt instruments that mature in one year or less from the date of investment. See “Item 1. Business – Regulation.” Moreover, qualification for taxation as a RIC requires satisfaction of source-of-income, asset diversification and distribution requirements. Operating under these constraints may hinder our ability to take advantage of attractive investment opportunities and to achieve our investment objective. Any failure to do so could subject us to enforcement action by the SEC, cause us to fail to satisfy the requirements associated with RIC status and subject us to entity-level corporate income taxation, cause us to

 

37


fail the 70% test described above or otherwise have a material adverse effect on our business, financial condition or results of operations.

Regulations governing our operation as a BDC will affect our ability to, and the way in which we, raise additional capital.

Our business will require capital to operate and grow. In addition to funding new and existing investments, we may pursue growth through acquisitions or strategic investments in new businesses. Completion and timing of any such acquisitions or strategic investments may be subject to a number of contingencies and risks. There can be no assurance that the integration of an acquired business will be successful or that an acquired business will prove to be profitable or sustainable. We may acquire additional capital from the following sources:

Senior Securities. We may issue debt securities or preferred stock and/or borrow money from banks or other financial institutions, which we refer to collectively as senior securities. As a result of issuing senior securities, we will be exposed to additional risks, including the following:

Under the provisions of the 1940 Act, we are permitted, as a BDC, to issue senior securities only in amounts such that our asset coverage, as defined in the 1940 Act, equals at least 150% immediately after each issuance of senior securities. If the value of our assets declines, we may be unable to satisfy this test. If that happens, we will be prohibited from issuing debt securities or preferred stock and/or borrowing money from banks or other financial institutions and may not be permitted to declare a dividend or make any distribution to stockholders or repurchase shares until such time as we satisfy this test.
Any amounts that we use to service our debt or make payments on preferred stock will not be available for dividends to our common stockholders.
It is likely that any senior securities or other indebtedness we issue will be governed by an indenture or other instrument containing covenants restricting our operating flexibility. Additionally, some of these securities or other indebtedness may be rated by rating agencies, and in obtaining a rating for such securities and other indebtedness, we may be required to abide by operating and investment guidelines that further restrict operating and financial flexibility.
We and, indirectly, our stockholders will bear the cost of issuing and servicing such securities and other indebtedness.
Preferred stock or any convertible or exchangeable securities that we issue in the future may have rights, preferences and privileges more favorable than those of our common stock, including separate voting rights and could delay or prevent a transaction or a change in control to the detriment of the holders of our common stock.
Any unsecured debt issued by us would generally rank (i) pari passu with our current and future unsecured indebtedness and effectively subordinated to all of our existing and future secured indebtedness, to the extent of the value of the assets securing such indebtedness, and (ii) structurally subordinated to all existing and future indebtedness and other obligations of any of our subsidiaries.

Additional Common Stock. We are not generally able to issue and sell our common stock at a price below NAV per share. We may, however, sell our common stock, warrants, options or rights to acquire our common stock, at a price below the current NAV of the common stock if our Board of Directors determines that such sale is in the best interests of our stockholders, and our stockholders approve such sale. See “Risk Factors – Risks Related to our Securities — Stockholders may incur dilution if we sell shares of our common stock in one or more offerings at prices below the then current NAV per share of our common stock or issue securities to subscribe to, convert to or purchase shares of our common stock” for a discussion of the risks related to us issuing shares of our common stock below NAV. Our stockholders have authorized us to issue warrants, options or rights to subscribe for, convert to, or purchase shares of our common stock at a price per share below the NAV per share, subject to the applicable requirements of the 1940 Act. There is no expiration date on our ability to issue such warrants, options, rights or convertible securities based on this stockholder approval. If we raise additional funds by issuing more common stock or senior securities convertible into, or exchangeable for, our common stock, the percentage ownership of our stockholders at that time would decrease, and they may experience dilution. Moreover, we can offer no assurance that we will be able to issue and sell additional equity securities in the future, on favorable terms or at all.

Risks Related To Our Securities

Investing in our securities may involve a high degree of risk.

The investments we make in accordance with our investment objective may be highly speculative and result in a higher amount of risk than alternative investment options and a higher risk of volatility or loss of principal. Our investments in portfolio companies involve higher levels of risk, and therefore, an investment in our securities may not be suitable for someone with lower risk tolerance.

Shares of closed-end investment companies, including BDCs, may trade at a discount to their NAV.

Shares of closed-end investment companies, including BDCs, may trade at a discount to NAV. This characteristic of closed-end investment companies and BDCs is separate and distinct from the risk that our NAV per share may decline. We cannot predict whether our common stock will trade at, above or below NAV. In addition, if our common stock trades below our NAV per share, we will generally not be able to issue additional common stock at the market price unless our stockholders approve such a sale and our Board makes certain determinations. See “Risk Factors — Risks Related to our Securities — Stockholders may incur dilution if we

 

38


sell shares of our common stock in one or more offerings at prices below the then current NAV per share of our common stock or issue securities to subscribe to, convert to or purchase shares of our common stock” for a discussion related to us issuing shares of our common stock below NAV.

The market price of our securities may be volatile and fluctuate significantly.

Fluctuations in the trading prices of our securities may adversely affect the liquidity of the trading market for our securities and, if we seek to raise capital through future securities offerings, our ability to raise such capital. The market price and liquidity of the market for our securities may be significantly affected by numerous factors, some of which are beyond our control and may not be directly related to our operating performance. These factors include:

significant volatility in the market price and trading volume of securities of BDCs or other companies in our sector, which are not necessarily related to the operating performance of these companies;
changes in regulatory policies, accounting pronouncements or tax guidelines;
the exclusion of BDC common stock from certain market indices, such as what happened with respect to the Russell indices and the Standard and Poor’s indices, could reduce the ability of certain investment funds to own our common stock and limit the number of owners of our common stock and otherwise negatively impact the market price of our common stock;
inability to obtain any exemptive relief that may be required by us in the future from the SEC;
loss of our BDC or RIC status or our wholly owned subsidiary’s status as an SBIC;
changes in our earnings or variations in our operating results;
changes in the value of our portfolio of investments;
any shortfall in our investment income or net investment income or any increase in losses from levels expected by investors or securities analysts;
loss of a major funding source;
fluctuations in interest rates;
the operating performance of companies comparable to us;
departure of our key personnel;
proposed, or completed, offerings of our securities, including classes other than our common stock;
global or national credit market changes; and
general economic trends and other external factors.

Stockholders may incur dilution if we sell shares of our common stock in one or more offerings at prices below the then current NAV per share of our common stock or issue securities to subscribe to, convert to or purchase shares of our common stock.

The 1940 Act prohibits us from selling shares of our common stock at a price below the current NAV per share of such stock, with certain exceptions. One such exception is prior stockholder approval of issuances below NAV provided that our Board of Directors makes certain determinations. We did not seek stockholder authorization to sell shares of our common stock below the then current NAV per share of our common stock at our 2022 Annual Meeting of Stockholders. We may, however, seek such authorization at future annual or special meetings of stockholders. Our stockholders have previously approved a proposal to authorize us to issue securities to subscribe to, convert to, or purchase shares of our common stock in one or more offerings. Any decision to sell shares of our common stock below the then current NAV per share of our common stock or securities to subscribe to, convert to, or purchase shares of our common stock would be subject to the determination by our Board that such issuance is in our and our stockholders’ best interests.

If we were to sell shares of our common stock below NAV per share, such sales would result in an immediate dilution to the NAV per share. This dilution would occur as a result of the sale of shares at a price below the then current NAV per share of our common stock and a proportionately greater decrease in a stockholder’s interest in our earnings and assets and voting interest in us than the increase in our assets resulting from such issuance. In addition, if we issue securities to subscribe to, convert to or purchase shares of common stock, the exercise or conversion of such securities would increase the number of outstanding shares of our common stock. Any such exercise would be dilutive on the voting power of existing stockholders and could be dilutive with regard to dividends and our NAV, and other economic aspects of the common stock.

Because the number of shares of common stock that could be so issued and the timing of any issuance is not currently known, the actual dilutive effect cannot be predicted; however, the example below illustrates the effect of dilution to existing stockholders resulting from the sale of common stock at prices below the NAV of such shares.

Illustration: Example of Dilutive Effect of the Issuance of Shares Below NAV. Assume that Company XYZ has 1,000,000 total shares outstanding, $15,000,000 in total assets and $5,000,000 in total liabilities. The NAV per share of the common stock of

 

39


Company XYZ is $10.00. The following table illustrates the reduction to NAV, or NAV, and the dilution experienced by Stockholder A following the sale of 40,000 shares of the common stock of Company XYZ at $9.50 per share, a price below its NAV per share.

 

Prior to Sale

 

 

Following Sale

 

 

Percentage

 

 

Below NAV

 

 

Below NAV

 

 

Change

 

Reduction to NAV

 

 

 

 

 

 

 

 

Total Shares Outstanding

 

1,000,000

 

 

 

1,040,000

 

 

 

4.0

%

NAV per share

$

10.00

 

 

$

9.98

 

 

 

(0.2

)%

Dilution to Existing Stockholder

 

 

 

 

 

 

 

 

Shares Held by Stockholder A

 

10,000

 

 

10,000(1)

 

 

 

0.0

%

Percentage Held by Stockholder A

 

1.00

%

 

 

0.96

%

 

 

(4.0

)%

Total Interest of Stockholder A in NAV

$

100,000

 

 

$

99,808

 

 

 

(0.2

)%

(1)
Assumes that Stockholder A does not purchase additional shares in the sale of shares below NAV.

In addition, all distributions in cash payable to stockholders who participate in our dividend reinvestment plan are automatically reinvested in shares of our common stock. As a result, stockholders who opt out of our dividend reinvestment plan will experience dilution of their ownership percentage of our common stock over time.

Provisions of the Maryland General Corporation Law and of our charter and bylaws could deter takeover attempts and have an adverse impact on the price of our common stock.

The Maryland General Corporation Law and our charter and bylaws contain provisions that may have the effect of discouraging, delaying, or making difficult a change in control of our company or the removal of our incumbent directors. For example, our governing documents provide for a staggered board and authorize the issuance of “blank check” preferred stock. The existence of these provisions, among others, may have a negative impact on the price of our common stock and may discourage third party bids for ownership of our company. These provisions may prevent any premiums being offered to you for our common stock.

We may in the future determine to issue preferred stock, which could adversely affect the market value of our common stock.

The issuance of shares of preferred stock with dividend or conversion rights, liquidation preferences or other economic terms favorable to the holders of preferred stock could adversely affect the market price for our common stock by making an investment in the common stock less attractive. In addition, the dividends on any preferred stock we issue must be cumulative. Payment of dividends and repayment of the liquidation preference of preferred stock must take preference over any dividends or other payments to our common stockholders, and holders of preferred stock are not subject to any of our expenses or losses and are not entitled to participate in any income or appreciation in excess of their stated preference (other than convertible preferred stock that converts into common stock). In addition, under the 1940 Act, preferred stock constitutes a “senior security” for purposes of the asset coverage test.

The Notes are unsecured and therefore effectively subordinated to any current or future secured indebtedness.

The Notes are not secured by any of our assets or any of the assets of our subsidiaries and rank equally in right of payment with all of our existing and future unsubordinated, unsecured indebtedness. As a result, the Notes are effectively subordinated to any secured indebtedness we or our subsidiaries have currently incurred and may incur in the future (or any indebtedness that is initially unsecured to which we subsequently grant security) to the extent of the value of the assets securing such indebtedness. In any liquidation, dissolution, bankruptcy or other similar proceeding, the holders of any of our existing or future secured indebtedness and the secured indebtedness of our subsidiaries may assert rights against the assets pledged to secure that indebtedness in order to receive full payment of their indebtedness before the assets may be used to pay other creditors, including the holders of the Notes.

The Notes are structurally subordinated to the indebtedness and other liabilities of our subsidiaries.

The Notes are obligations exclusively of Hercules Capital, Inc. and not of any of our subsidiaries. None of our subsidiaries are or act as guarantors of the Notes. Furthermore, the Notes are not required to be guaranteed by any subsidiaries we may acquire or create in the future. Our secured indebtedness with respect to the SBA debentures is held through our SBIC subsidiary. The assets of any such subsidiary are not directly available to satisfy the claims of our creditors, including holders of the Notes. Except to the extent we are a creditor with recognized claims against our subsidiaries, all claims of creditors (including holders of preferred stock, if any, of our subsidiaries) will have priority over our equity interests in such subsidiaries (and therefore the claims of our creditors, including holders of the Notes) with respect to the assets of such subsidiaries. Even if we are recognized as a creditor of one or more of our subsidiaries, our claims would still be subordinated to any security interests in the assets of any such subsidiary and to any indebtedness or other liabilities of any such subsidiary senior to our claims. As a result of not having a direct claim against any of our subsidiaries, the Notes are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our subsidiaries and any subsidiaries that we may in the future acquire or establish as financing vehicles or otherwise. In addition, our subsidiaries may incur substantial additional indebtedness in the future, all of which would be structurally senior to the Notes.

The Notes may or may not have an established trading market. If a trading market in the Notes is developed, it may not be maintained.

The Notes may or may not have an established trading market. If a trading market in the Notes is developed, it may not be maintained. If the Notes are traded, they may trade at a discount to their initial offering price depending on prevailing interest rates, the market for similar securities, our credit ratings, our financial condition or other relevant factors. Accordingly, we cannot assure

 

40


you that a liquid trading market has been or will develop for the Notes, that you will be able to sell your Notes at a particular time or that the price you receive when you sell will be favorable. To the extent an active trading market does not develop or is not maintained, the liquidity and trading price for the Notes may be harmed. Accordingly, you may be required to bear the financial risk of an investment in the Notes for an indefinite period of time.

A downgrade, suspension, or withdrawal of the credit rating assigned by a rating agency to us or our debt securities, if any, or change in the debt markets could cause the liquidity or market value of our debt securities to decline significantly.

Our credit ratings are an assessment by rating agencies of our ability to pay our debts when due. Consequently, real or anticipated changes in our credit ratings will generally affect the market value of our outstanding debt and equity securities and our ability to raise capital. These credit ratings may not reflect the potential impact of risks relating to the structure or marketing of such debt and equity securities. Credit ratings are not a recommendation to buy, sell or hold any security, and may be revised or withdrawn at any time by the issuing organization in its sole discretion. Neither we nor any underwriter undertakes any obligation to maintain our credit ratings or to advise holders of our debt and equity securities of any changes in our credit ratings. There can be no assurance that a credit rating will remain for any given period of time or that such credit ratings will not be lowered or withdrawn entirely if future circumstances relating to the basis of the credit rating, such as adverse changes in our company, so warrant. An increase in the competitive environment, inability to cover distributions, or increase in leverage could lead to a downgrade in our credit ratings and limit our access to the debt and equity markets capability impairing our ability to grow the business. The conditions of the financial markets and prevailing interest rates have fluctuated in the past and are likely to fluctuate in the future.

The indentures under which the Notes were issued contain limited protections for the holders of the Notes.

The indentures under which the Notes were issued offers limited protections to the holders of the Notes. The terms of the respective Notes indentures do not restrict our or any of our subsidiaries’ ability to engage in, or otherwise be a party to, a variety of corporate transactions, circumstances or events that could have an adverse impact on an investment in the Notes. In particular, the terms of the respective Notes indentures do not place any restrictions on our or our subsidiaries’ ability to:

issue securities or otherwise incur additional indebtedness or other obligations, including (1) any indebtedness or other obligations that would be equal in right of payment to the Notes, (2) any indebtedness or other obligations that would be secured and therefore rank effectively senior in right of payment to the Notes to the extent of the values of the assets securing such debt, (3) indebtedness of ours that is guaranteed by one or more of our subsidiaries and which therefore would rank structurally senior to the Notes and (4) securities, indebtedness or other obligations issued or incurred by our subsidiaries that would be senior in right of payment to our equity interests in our subsidiaries and therefore would rank structurally senior in right of payment to the Notes with respect to the assets of our subsidiaries, in each case other than an incurrence of indebtedness or other obligation that would cause a violation of Section 18(a)(1)(A) as modified by Section 61(a)(1) of the 1940 Act or any successor provisions, whether or not we continue to be subject to such provisions of the 1940 Act, but giving effect to any exemptive relief granted to us by the SEC (currently, these provisions generally prohibit us from making additional borrowings, including through the issuance of additional debt or the sale of additional debt securities, unless our asset coverage, as defined in the 1940 Act, equals at least 150% thereafter after such borrowings);
pay dividends on, or purchase or redeem or make any payments in respect of, capital stock or other securities ranking junior in right of payment to the Notes, including subordinated indebtedness;
sell assets (other than certain limited restrictions on our ability to consolidate, merge or sell all or substantially all of our assets);
enter into transactions with affiliates;
create liens (including liens on the shares of our subsidiaries) or enter into sale and leaseback transactions;
make investments; or
create restrictions on the payment of distributions or other amounts to us from our subsidiaries.

Furthermore, the terms of the respective Notes indentures do not protect their respective holders in the event that we experience changes (including significant adverse changes) in our financial condition, results of operations or credit ratings, as they do not require that we or our subsidiaries adhere to any financial tests or ratios or specified levels of net worth, revenues, income, cash flow or liquidity.

Our ability to recapitalize, incur additional debt and take a number of other actions that are not limited by the terms of the Notes may have important consequences for their holders, including making it more difficult for us to satisfy our obligations with respect to the Notes or negatively affecting their trading value.

Certain of our debt instruments include more protections for their respective lenders than the Notes, and we may issue or incur additional debt in the future which could contain more protections for its holders, including additional covenants and events of default. The issuance or incurrence of any such debt with incremental protections could affect the market for and trading levels and prices of the Notes.

 

41


Terms relating to redemption may materially adversely affect your return on any debt securities that we may issue.

If you are holding debt securities issued by us and such securities are redeemable at our option, we may choose to redeem your debt securities at times when prevailing interest rates are lower than the interest rate paid on your debt securities. In addition, if you are holding debt securities issued by us and such securities are subject to mandatory redemption, we may be required to redeem your debt securities at times when prevailing interest rates are lower than the interest rate paid on your debt securities. In this circumstance, you may not be able to reinvest the redemption proceeds in a comparable security at an effective interest rate as high as your debt securities being redeemed. We may redeem our Notes at a redemption price set forth under the terms of the individual indentures. See "Note 5 – Debt." If we choose to redeem our Notes when the fair market value is above par value, you would experience a loss of any potential premium.

If we default on our obligations imposed upon us by our indebtedness, we may not be able to make payments on our outstanding Notes and Credit Facilities.

The agreements governing our indebtedness, including our Notes and Credit Facilities, require us to comply with certain financial, operational and payment covenants. These covenants require us to, among other things, maintain certain financial ratios, including asset coverage, debt to equity and interest coverage. Our ability to continue to comply with these covenants in the future depends on many factors, some of which are beyond our control. Any default under such agreements, or other indebtedness to which we may be a party, that is not waived by the required lenders or holders, and the remedies sought by the holders of such indebtedness, could make us unable to pay principal, premium, if any, and interest on any of our indebtedness, including our Notes and Credit Facilities, or other indebtedness and substantially decrease the market value of our outstanding Notes and Credit Facilities debt. If we are unable to generate sufficient cash flow and are otherwise unable to obtain funds necessary to meet required payments of principal, premium, if any, and interest on our indebtedness, or if we otherwise fail to comply with the various covenants, including financial and operating covenants, in the instruments governing our indebtedness, we could be in default under the terms of the agreements governing such indebtedness. In the event of such default, (i) the holders of such indebtedness could elect to declare all the funds borrowed thereunder to be due and payable, together with accrued and unpaid interest, (ii) the lenders under our Credit Facilities or other debt we may incur in the future could elect to terminate their commitments, cease making further loans and institute foreclosure proceedings against our assets, and (iii) we could be forced into bankruptcy or liquidation. If our operating performance declines, we may in the future need to seek to obtain waivers from the required lenders under our Credit Facilities or the required holders of our outstanding Notes or other debt that we may incur in the future to avoid being in default. If we breach our debt covenants and seek a waiver, we may not be able to obtain a waiver from the required lenders or holders. If this occurs, we would be in default under the related Credit Facility or Notes and the lenders or holders could exercise their rights as described above, and we could be forced into bankruptcy or liquidation. If we are unable to repay debt, lenders having secured obligations, including the lenders under our Credit Facilities, could proceed against the collateral securing the debt. Because our Credit Facilities have, and any future credit facilities will likely have, customary cross-default and cross-acceleration provisions, if our outstanding Notes are accelerated, we may be unable to repay or finance the amounts due.

We may not be able to prepay the Notes or Credit Facilities upon a change in control.

The indentures governing the July 2024 Notes, February 2025 Notes, June 2025 Notes, June 2025 3-Year Notes, March 2026 A Notes, March 2026 B Notes, September 2026 Notes and January 2027 Notes require us to offer to prepay all of the issued and outstanding notes upon a change in control and election by the holders, which could have a material adverse effect on our business, financial condition and results of operations. A change in control under the indentures occurs upon the consummation of a transaction which results in a “person” or “group” (as those terms are used in the Exchange Act and the rules promulgated thereunder) becoming the beneficial owner of more than 50% of our outstanding voting stock.

Upon a change in control event, holders of the notes may require us to prepay for cash some or all of the notes at a prepayment price equal to 100% of the aggregate principal amount of the notes being prepaid, plus accrued and unpaid interest to, but not including, the date of prepayment. If a change in control were to occur, we may not have sufficient funds to prepay any such accelerated indebtedness. The 2033 Notes do not require us to purchase the 2033 Notes in connection with a change of control or any other event.

Any inability to renew, extend or replace our Credit Facilities could adversely impact our liquidity and ability to find new investments or maintain distributions to our stockholders.

As of December 31, 2022, we had two available secured credit facilities, the MUFG Bank Facility and the SMBC Facility, which mature in February 2024 and November 2026, respectively. The MUFG Bank Facility was amended on January 13, 2023 and extended its maturity to January 2027. The SMBC LC Facility has a final maturity date ending January 2026. There can be no assurance that we will be able to renew, extend or replace our Credit Facilities upon maturity on terms that are favorable to us, if at all. Our ability to renew, extend or replace the Credit Facilities will be constrained by then-current economic conditions affecting the credit markets. In the event that we are not able to renew, extend or replace our Credit Facilities at the time of their respective maturities, this could have a material adverse effect on our liquidity and ability to fund new investments, our ability to make distributions to our stockholders and our ability to qualify as a RIC.

 

42


Risks Related To Our SBIC Subsidiaries

We, through our wholly owned subsidiary, issue debt securities guaranteed by the SBA and sold in the capital markets. As a result of its guarantee of the debt securities, the SBA has fixed dollar claims on the assets of our subsidiary that are superior to the claims of our securities holders.

We, through our wholly owned subsidiary Hercules Capital IV, LP ("HC IV"), have outstanding SBIC debentures guaranteed by the SBA. The debentures guaranteed by the SBA have a maturity of ten years from the date of issuance and require semiannual payments of interest. We will need to generate sufficient cash flow to make required interest payments on the debentures. If we are unable to meet the financial obligations under the debentures, the SBA, as a creditor, will have a superior claim to the assets of HC IV over our securities holders in the event we liquidate or the SBA exercises its remedies under such debentures as the result of a default by us. See “Item 1. Business — Regulation—Small Business Administration Regulations.”

Our wholly owned subsidiary is licensed by the SBA, and therefore subject to SBIC regulations.

HC IV is licensed to act as SBICs and is regulated by the SBA. The SBA also places certain limitations on the financing terms of investments by SBICs in portfolio companies and prohibits SBICs from providing funds for certain purposes or to businesses in a few prohibited industries. Compliance with SBA requirements may cause us to forego attractive investment opportunities that are not permitted under SBIC regulations. Further, the SBIC regulations require, among other things, that a licensed SBIC be periodically examined by the SBA and audited by an independent auditor, in each case to determine the SBIC’s compliance with the relevant SBIC regulations. The SBA prohibits, without prior SBA approval, a “change of control” of an SBIC or transfers that would result in any person (or a group of persons acting in concert) owning 10% or more of a class of capital stock of a licensed SBIC. If HC IV fails to comply with applicable SBIC regulations, the SBA could, depending on the severity of the violation, limit or prohibit our use of SBIC debentures, declare outstanding SBIC debentures immediately due and payable, and/or limit HC IV from making new investments. In addition, the SBA can revoke or suspend a license for willful or repeated violation of, or willful or repeated failure to observe, any provision of the Small Business Investment Act of 1958 or any rule or regulation promulgated thereunder. Such actions by the SBA would, in turn, negatively affect us.

Our SBIC subsidiary may be unable to make distributions to us that will enable us to meet or maintain RIC status, which could result in the imposition of an entity-level tax.

In order for us to continue to qualify for RIC tax treatment and to minimize corporate-level U.S. federal taxes, we will be required to distribute substantially all of our net ordinary taxable income and net capital gain income, including taxable income from certain of our subsidiaries, which includes the income from HC IV. We will be partially dependent on HC IV for cash distributions to enable us to meet the RIC distribution requirements. HC IV may be limited by SBIC regulations from making certain distributions to us that may be necessary to enable us to maintain our status as a RIC. We may have to request a waiver of the SBA’s restrictions for HC IV to make certain distributions to maintain our eligibility for RIC status. We cannot assure you that the SBA will grant such waiver and if HC IV is unable to obtain a waiver, compliance with the SBIC regulations may result in loss of RIC status and a consequent imposition of an entity-level tax on us.

Risks Related To Operating As A RIC And U.S. Federal Income Taxes

We will be subject to U.S. federal income tax if we are unable to qualify as a RIC under Subchapter M of the Code.

To maintain RIC status under Subchapter M Part I of the Code, we must meet the following annual distribution, income source and asset diversification requirements:

The Annual Distribution Requirement for a RIC will be satisfied if we distribute to our stockholders on an annual basis at least 90% of our net ordinary taxable income and realized net short-term capital gains in excess of realized net long-term capital losses, if any. Depending on the level of taxable income earned in a tax year, we may choose to carry forward taxable income in excess of current year distributions into the next tax year and pay a 4% U.S. federal excise tax on such income. Any such carryover taxable income must be distributed through a dividend declared prior to filing the final tax return related to the year which generated such taxable income. For more information regarding tax treatment, see “Item 1. Business — Certain United States Federal Income Tax Considerations — Taxation as a Regulated Investment Company.” Because we use debt financing, we are subject to certain asset coverage ratio requirements under the 1940 Act and are (and may in the future become) subject to certain financial covenants under loan and credit agreements that could, under certain circumstances, restrict us from making distributions necessary to satisfy the distribution requirement. In addition, because we receive non-cash sources of income such as PIK interest which involves us recognizing taxable income without receiving the cash representing such income, we may have difficulty meeting the distribution requirement. If we are unable to obtain cash from other sources, we could fail to qualify as a RIC and thus become subject to U.S. federal income tax.
The source-of-income requirement will be satisfied if we obtain at least 90% of our gross income for each year from distributions, interest, gains from the sale of stock or securities or similar sources.
The asset diversification requirement will be satisfied if we meet certain asset diversification requirements at the end of each quarter of our taxable year. To satisfy this requirement, at least 50% of the value of our assets must consist of cash,

 

43


cash equivalents, U.S. government securities, securities of other RICs, and other acceptable securities; and no more than 25% of the value of our assets can be invested in the securities, other than U.S. government securities or securities of other RICs, (i) of one issuer, (ii) of two or more issuers that are controlled, as determined under applicable Code rules, by us and that are engaged in the same or similar or related trades or businesses or (iii) of certain “qualified publicly traded partnerships.”

Failure to meet these requirements may result in our having to dispose of certain investments quickly in order to prevent the loss of RIC status. Because most of our investments are in privately held companies, and therefore illiquid, any such dispositions could be made at disadvantageous prices and could result in substantial losses. Moreover, if we fail to maintain our RIC status for any reason and are subject to U.S. federal income taxes, the resulting taxes could substantially reduce our net assets, the amount of income available for distribution and the amount of our distributions.

We may have difficulty paying the distributions required to maintain RIC status under the Code if we recognize income before or without receiving cash representing such income.

We will include in income certain amounts that we have not yet received in cash. Among other circumstances, these amounts generally relate to: (i) amortization of OID, which may arise if (a) we receive equity, warrants, or another asset in connection with the origination of a loan; (b) we invest or acquire a debt investment at a discount to its par value; (ii) contractual payment-in-kind, or PIK, interest, which represents contractual interest added to the loan balance and due at the end of the loan term; (iii) contractual exit fees, which is a contractual fee accrued over the life of a loan and its typically due at loan payoff; or (iv) contractual preferred dividends, which represents contractual dividends added to the preferred stock and due at the end of the preferred stock term, subject to adequate profitability at the portfolio company. Such amortization of OID, accrual to par of any debt bought below par, accrual of PIK, exit fees, and cumulative preferred dividends will be included in income before we receive the corresponding cash payments.

Since, in certain cases, we may recognize taxable income before or without receiving cash representing such income, we may have difficulty meeting the Annual Distribution Requirement necessary to maintain RIC status under the Code. Accordingly, we may have to sell some of our investments at times and/or at prices we would not consider advantageous, raise additional debt or equity capital or forgo new investment opportunities for this purpose. If we are not able to obtain cash from other sources, we may fail to qualify as a RIC and thus become subject to U.S. federal income tax. For additional discussion regarding the tax implications of a RIC, please see “Item 1. Business — Certain United States Federal Income Tax Considerations – Taxation as a Regulated Investment Company.”

We may in the future choose to pay distributions in our own stock, in which case you may be required to pay tax in excess of the cash you receive.

We may distribute taxable dividends that are payable in part in our stock. Under certain applicable provisions of the Code and the Treasury regulations, distributions payable by us in cash or in shares of stock (at the stockholders’ election) would satisfy the Annual Distribution Requirement. The IRS has issued guidance providing that a dividend payable in stock or in cash at the election of the stockholders will be treated as a taxable dividend eligible for the dividends paid deduction provided that at least 20% of the total dividend is payable in cash and certain other requirements are satisfied. Taxable stockholders receiving such dividends will be required to include the full amount of the dividend as ordinary income (or as long-term capital gain to the extent such dividend is properly reported as a capital gain dividend) to the extent of our current and accumulated earnings and profits for U.S. federal income tax purposes. As a result, a U.S. stockholder may be required to pay tax with respect to such dividends in excess of any cash received. If a U.S. stockholder sells the stock it receives as a dividend in order to pay this tax, the sales proceeds may be less than the amount included in income with respect to the dividend, depending on the market price of our stock at the time of the sale. Furthermore, with respect to non-U.S. stockholders, we may be required to withhold U.S. tax with respect to such dividends, including in respect of all or a portion of such dividend that is payable in stock. In addition, if a significant number of our stockholders determine to sell shares of our stock in order to pay taxes owed on dividends, it may put downward pressure on the trading price of our stock.

Stockholders may have current tax liability on dividends they elect to reinvest in our common stock but would not receive cash from such dividends to pay such tax liability.

If stockholders participate in our dividend reinvestment plan, they will be deemed to have received, and for federal income tax purposes will be taxed on, the amount reinvested in our common stock to the extent the amount reinvested was not a tax-free return of capital. As a result, unless a stockholder is a tax-exempt entity, it may have to use funds from other sources to pay its tax liability on the value of the dividend that they have elected to have reinvested in our common stock.

Legislative or regulatory tax changes could adversely affect our stockholders.

At any time, the U.S. federal income tax laws governing RICs or the administrative interpretations of those laws or regulations may be amended. Significant changes to the existing U.S. tax regulations have been enacted under the Biden Administration that include, among others, a minimum tax on book income and profits of certain multinational corporations, and there are a number of proposals in the U.S. Congress that would similarly modify the existing U.S. tax rules. The likelihood of any new legislation being enacted is uncertain. Any of those new laws, regulations or interpretations may take effect retroactively and could adversely affect the taxation of us or our stockholders. Therefore, changes in tax laws, regulations or administrative interpretations or any amendments

 

44


thereto could diminish the value of an investment in our shares or the value or the resale potential of our investments. If we do not comply with applicable laws and regulations, we could lose any licenses that we then hold for the conduct of our business and may be subject to civil fines and criminal penalties.

FATCA withholding may apply to payments made to certain foreign entities.

The Foreign Account Tax Compliance Act provisions of the Code and the related Treasury Regulations and other administrative guidance promulgated thereunder, or collectively, FATCA, generally requires us to withhold U.S. tax (at a 30% rate) on payments of interest and taxable dividends made to a foreign financial institution or non-financial foreign entity (including such an institution or entity acting as an intermediary) unless the foreign financial institution or non-financial foreign entity complies with certain information reporting, withholding, identification, certification and related requirements imposed by FATCA. Persons located in jurisdictions that have entered into an intergovernmental agreement with the United States to implement FATCA may be subject to different rules. Stockholders may be requested to provide additional information to enable us to determine whether such withholding is required.

General Risk Factors

We are currently operating in a period of capital markets disruption and economic uncertainty, and capital markets may experience periods of disruption and instability in the future. These market conditions may materially and adversely affect debt and equity capital markets in the United States and abroad, which may have a negative impact on our business and operations.

U.S. capital markets have experienced extreme volatility and disruption following the global outbreak of COVID-19 that began in December 2019, as evidenced by the volatility in global stock markets as a result of, among other things, uncertainty surrounding the COVID-19 pandemic and the impact of supply chain disruptions. Despite actions of the U.S. federal government and foreign governments, these events have contributed to unpredictable general economic conditions that are materially and adversely impacting the broader financial and credit markets. These and future market disruptions and/or illiquidity would be expected to have an adverse effect on our business, financial condition, results of operations and cash flows, as well as the businesses of our portfolio companies, and the broader financial and credit markets.

At various times, such disruptions have resulted in, and may in the future result in, a lack of liquidity in parts of the debt capital markets, significant write-offs in the financial services sector and the repricing of credit risk. Such conditions may occur for a prolonged period of time again, and may materially worsen in the future, including as a result of U.S. government shutdowns, or future downgrades to the U.S. government's sovereign credit rating or the perceived credit worthiness of the U.S. or other large global economies. In addition, the current U.S. political environment and the resulting uncertainties regarding actual and potential shifts in U.S. foreign investment, trade, taxation, economic, environmental and other policies under the current Administration, as well as the impact of geopolitical tension, such as a deterioration in the bilateral relationship between the U.S. and China or an escalation in conflict between Russia and Ukraine, could lead to disruption, instability and volatility in the global markets. Unfavorable economic conditions also would be expected to increase our funding costs, limit our access to the capital markets or result in a decision by lenders not to extend credit to us. These events have limited and could continue to limit our investment originations, and limit our ability to grow and could have a material negative impact on our operating results, financial condition, results of operations and cash flows and the fair values of our debt and equity investments.

In addition, the U.S. and global capital markets have in the past, and may in the future, experience periods of extreme volatility and disruption during economic downturns and recessions. Trade wars and volatility in the U.S. repo market, the U.S. high yield bond markets, the Chinese stock markets and global markets for commodities may affect other financial markets worldwide. In addition, while recent government stimulus measures worldwide have reduced volatility in the financial markets, volatility may return as such measures are phased out, and the long-term impacts of such stimulus on fiscal policy and inflation remain unknown. Increases to budget deficits, which have been exacerbated by the COVID-19 pandemic, or direct and contingent sovereign debt may create concerns about the ability of certain nations to service their sovereign debt obligations and any risks resulting from any such debt crisis in Europe, the U.S. or elsewhere could have a detrimental impact on the global economy, sovereign and non-sovereign debt in certain countries and the financial condition of financial institutions generally. Government shutdowns or austerity measures that certain countries may agree to as part of any debt crisis or disruptions to major financial trading markets may adversely affect world economic conditions, our business and the businesses of our portfolio companies.

Additionally, the Federal Reserve may raise the Federal Funds Rate in 2023. These developments, along with the United States government’s debt ceiling, budget, credit, and deficit concerns, global economic uncertainties and market volatility and the impacts of COVID-19, could cause interest rates to be volatile, which may negatively impact our ability to access the capital markets on favorable terms.

Deterioration in the economy and financial markets could impair our portfolio companies’ financial positions and operating results and affect the industries in which we invest, which could, in turn, harm our operating results.

The broader fundamentals of the United States economy remain mixed. In the event that the United States economy contracts, it is likely that the financial results of small to mid-sized companies, like those in which we invest, could experience deterioration or limited growth from current levels, which could ultimately lead to difficulty in meeting their debt service requirements and an increase

 

45


in defaults. In addition, a decline in oil and natural gas prices would adversely affect the credit quality of our debt investments and the underlying operating performance of our equity investments in energy-related businesses. Consequently, we can provide no assurance that the performance of certain portfolio companies will not be negatively impacted by economic cycles, industry cycles or other conditions, which could also have a negative impact on our future results.

Although we have been able to secure access to additional liquidity, the potential for volatility in the debt and equity capital markets provides no assurance that debt or equity capital will be available to us in the future on favorable terms, or at all.

We may experience fluctuations in our operating results.

We could experience fluctuations in our operating results due to a number of factors, including our ability or inability to make investments in companies that meet our investment criteria, the interest rate payable on the debt securities we acquire, the level of portfolio dividend and fee income, the level of our expenses, variations in and the timing of the recognition of realized and unrealized gains or losses, the degree to which we encounter competition in our markets and general economic conditions. As a result of these factors, operating results for any period should not be relied upon as being indicative of performance in future periods.

Terrorist attacks, acts of war, public health crises or natural disasters may affect any market for our securities, impact the businesses in which we invest and harm our business, operating results and financial condition.

Terrorist acts, acts of war, public health crises (including the COVID-19 outbreak) or natural disasters may disrupt our operations, as well as the operations of the businesses in which we invest. Such acts have created, and continue to create, economic and political uncertainties and have contributed to global economic instability. Future terrorist activities, military or security operations, public health crises, or natural disasters could further weaken the domestic/global economies and create additional uncertainties, which may negatively impact the businesses in which we invest directly or indirectly and, in turn, could have a material adverse impact on our business, operating results and financial condition. Losses from terrorist attacks, public health crises and natural disasters are generally uninsurable.

Technological innovations and industry disruptions may negatively impact us.

Technological innovations have disrupted traditional approaches in multiple industries and can permit younger companies to achieve success and in the process disrupt markets and market practices. We can provide no assurance that new businesses and approaches will not be created that would compete with us and/or our portfolio companies or alter the market practices in which we have been designed to function within and on which we depend on for our investment return. New approaches could damage our investments, disrupt the market in which we operate and subject us to increased competition, which could materially and adversely affect our business, financial condition and results of investments.

We are highly dependent on information systems and systems failures could significantly disrupt our business, which may, in turn, negatively affect the market price of our common stock and our ability to pay dividends.

Our business is highly dependent on our and third parties’ communications and information systems. Any failure or interruption of those systems, including as a result of the termination of an agreement with any third-party service providers, could cause delays or other problems in our activities. Our financial, accounting, data processing, backup or other operating systems and facilities may fail to operate properly or become disabled or damaged as a result of a number of factors including events that are wholly or partially beyond our control and adversely affect our business. There could be:

sudden electrical or telecommunications outages;
natural disasters such as earthquakes, tornadoes and hurricanes;
disease pandemics;
events arising from local or larger scale political or social matters, including terrorist acts and social unrest; and
cyber-attacks, including software viruses, ransomware, malware and phishing and vishing schemes.

The failure in cyber security systems, as well as the occurrence of events unanticipated in our disaster recovery systems and management continuity planning could impair our ability to conduct business effectively.

Our business operations rely upon secure information technology systems for data processing, storage and reporting. Despite careful security and controls design, implementation and updating, our information technology systems could become subject to cyber-attacks. Network, system, application and data breaches could result in operational disruptions or information misappropriation, which could have a material adverse effect on our business, results of operations and financial condition.

The occurrence of a disaster such as a cyber-attack, a natural catastrophe, an industrial accident, a terrorist attack or war, events unanticipated in our disaster recovery systems, or a support failure from external providers, could have an adverse effect on our ability to conduct business and on our results of operations and financial condition, particularly if those events affect our computer-based data processing, transmission, storage, and retrieval systems or destroy data. If a significant number of our managers were unavailable in the event of a disaster, our ability to effectively conduct our business could be severely compromised.

 

46


We depend heavily upon computer systems to perform necessary business functions. Despite our implementation of a variety of security measures, our computer systems could be subject to cyber-attacks and unauthorized access, such as physical and electronic break-ins or unauthorized tampering. Like other companies, we may experience threats to our data and systems, including malware and computer virus attacks, unauthorized access, system failures and disruptions. If one or more of these events occurs, it could potentially jeopardize the confidential, proprietary and other information processed and stored in, and transmitted through, our computer systems and networks, or otherwise cause interruptions or malfunctions in our operations, which could result in damage to our reputation, financial losses, litigation, increased costs, regulatory penalties and/or customer dissatisfaction or loss.

Third parties with which we do business (including, but not limited to, service providers, such as accountants, custodians, transfer agents and administrators, and the issuers of securities in which we invest) may also be sources or targets of cyber security or other technological risks. While we engage in actions to reduce our exposure to third-party risks, we cannot control the cyber security plans and systems put in place by these third parties and ongoing threats may result in unauthorized access, loss, exposure or destruction of data, or other cybersecurity incidents, with increased costs and other consequences, including those described above. Privacy and information security laws and regulation changes, and compliance with those changes, may also result in cost increases due to system changes and the development of new administrative processes and may divert management's attention.

We may experience fluctuations in our quarterly operating results.

We could experience fluctuations in our quarterly operating results due to a number of factors, including the interest rate payable on the loans and debt securities we acquire, the default rate on such loans and securities, the level of our expenses, variations in and the timing of the recognition of realized and unrealized gains or losses, the degree to which we encounter competition in our markets and general economic conditions. In light of these factors, results for any period should not be relied upon as being indicative of performance in future periods.

We may be the target of litigation.

We may be the target of securities litigation in the future, particularly if the value of shares of our common stock fluctuates significantly. We could also generally be subject to litigation, including derivative actions by our stockholders or in connection with shareholder activism. In addition, our investment activities subject us to litigation relating to the bankruptcy process and the normal risks of becoming involved in litigation by third parties. This risk is somewhat greater where we exercise control or significant influence over a portfolio company’s direction. Any litigation could result in substantial costs and divert management’s attention and resources from our business and cause a material adverse effect on our business, financial condition and results of operations.

Item 1B. Unresolved Staff Comments

None.

Item 2. Properties

Neither we nor any of our subsidiaries own any real estate or other physical properties materially important to our operation or any of our subsidiaries. Currently, we lease approximately 14,500 square feet of office space in Palo Alto, CA for our corporate headquarters. We also lease office space in Boston, MA, New York, NY, Bethesda, MD, Westport, CT, Chicago, IL, San Diego, CA, and London, United Kingdom.

We may, from time to time, be involved in litigation arising out of our operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on us in connection with the activities of our portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, we do not expect any current matters will materially affect our financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on our financial condition or results of operations in any future reporting period.

Item 4. Mine Safety Disclosures

Not applicable.

 

47


 

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

PRICE RANGE OF COMMON STOCK

Our common stock is traded on the NYSE under the symbol “HTGC.” As of February 3, 2023, we had approximately 117,950 stockholders of record. Most of the shares of our common stock are held by brokers and other institutions on behalf of stockholders. There are currently approximately 154 additional beneficial holders of our common stock.

Shares of BDCs may trade at a market price that is less than the NAV per share. The possibilities that our shares of common stock will trade at a discount from NAV or at premiums that are unsustainable over the long term are separate and distinct from the risk that our NAV will decrease. At times, our shares of common stock have traded at a premium to NAV or at a significant discount to the NAV per share.

Price Range of Common Stock and Distributions

The following table sets forth the range of high and low closing sales prices of our common stock, the sales price as a percentage of NAV and the distributions declared by us for each fiscal quarter. The stock quotations are interdealer quotations and do not include markups, markdowns or commissions.

 

 

 

 

 

 

 

 

 

 

Premium/

 

 

Premium/

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Discount of

 

 

Discount of

 

 

Cash

 

 

 

 

 

Price Range

 

 

High Sales

 

 

Low Sales

 

 

Distribution

 

 

NAV(1)

 

 

High

 

 

Low

 

 

Price to NAV

 

 

Price to NAV

 

 

per Share(2)

 

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

First quarter

$

9.92

 

 

$

15.99

 

 

$

6.81

 

 

 

61.2

%

 

 

(31.40

)%

 

$

0.40

 

Second quarter

$

10.19

 

 

$

11.83

 

 

$

6.64

 

 

 

16.1

%

 

 

(34.80

)%

 

$

0.32

 

Third quarter

$

10.26

 

 

$

11.97

 

 

$

10.02

 

 

 

16.7

%

 

 

(2.30

)%

 

$

0.32

 

Fourth quarter

$

11.26

 

 

$

14.42

 

 

$

11.13

 

 

 

28.1

%

 

 

(1.20

)%

 

$

0.34

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

First quarter

$

11.36

 

 

$

16.60

 

 

$

14.21

 

 

 

46.1

%

 

 

25.1

%

 

$

0.37

 

Second quarter

$

11.71

 

 

$

17.66

 

 

$

15.98

 

 

 

50.8

%

 

 

36.5

%

 

$

0.39

 

Third quarter

$

11.54

 

 

$

17.56

 

 

$

16.50

 

 

 

52.2

%

 

 

43.0

%

 

$

0.39

 

Fourth quarter

$

11.22

 

 

$

18.07

 

 

$

16.14

 

 

 

61.1

%

 

 

43.9

%

 

$

0.40

 

2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

First quarter

$

10.82

 

 

$

18.23

 

 

$

16.56

 

 

 

68.5

%

 

 

53.0

%

 

$

0.48

 

Second quarter

$

10.43

 

 

$

18.91

 

 

$

12.82

 

 

 

81.3

%

 

 

22.9

%

 

$

0.48

 

Third quarter

$

10.47

 

 

$

16.13

 

 

$

11.45

 

 

 

54.1

%

 

 

9.4

%

 

$

0.50

 

Fourth quarter

$

10.53

 

 

$

14.92

 

 

$

11.59

 

 

 

41.7

%

 

 

10.1

%

 

$

0.51

 

 

(1)
NAV per share is generally determined as of the last day in the relevant quarter and therefore may not reflect the NAV per share on the date of the high and low sales prices. The NAVs shown are based on outstanding shares at the end of each period.
(2)
Represents the dividend or distribution declared in the relevant quarter.

SALES OF UNREGISTERED SECURITIES

During 2022, 2021, and 2020, we issued 259,466, 248,041, and 280,690 shares, respectively, of common stock to stockholders in connection with the dividend reinvestment plan. These issuances were not subject to the registration requirements of the Securities Act of 1933, as amended ("the Securities Act"). The aggregate value of the shares of our common stock issued under our dividend reinvestment plan during the years ended December 31, 2022, 2021, and 2020 were approximately $4.0 million, $4.1 million, and $3.3 million, respectively.

EQUITY COMPENSATION PLAN INFORMATION

See “Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.”

ISSUER PURCHASES OF EQUITY SECURITIES

The Company did not repurchase common stock on the open market during the years ended 2022, 2021, and 2020. Upon vesting of restricted stock awarded pursuant to our equity compensation plans, shares may be withheld to meet applicable tax withholding requirements. Any shares withheld are treated as common stock purchases by the Company in our consolidated financial statements as they reduce the number of shares received by employees upon vesting. Please refer to "Retired shares for restricted stock vesting" and "Retired shares from net issuance" in the consolidated statements of changes in net assets for share amounts withheld.

 

48


 

DISTRIBUTION POLICY

Our Board maintains a variable distribution policy with the objective of distributing four quarterly distributions in an amount that approximates 90-100% of our taxable quarterly income or potential annual income for a particular tax year. In addition, periodically our Board may choose to pay additional special distributions, so that we may distribute approximately all of our annual taxable income in the taxable year in which it was earned, or may elect to maintain the option to spill over our excess taxable income into the following taxable year as part of any future distribution payments.

Distributions from our taxable income to a stockholder generally will be treated as a dividend for U.S. federal income tax purposes to the extent of such stockholder’s allocable share of our current or accumulated earnings and profits. Distributions in excess of our current and accumulated earnings and profits would generally be treated first as a return of capital to the extent of a stockholder’s tax basis in our shares, and any remaining distributions would be treated as a capital gain. The determination of the tax attributes of our distributions is made annually as of the end of our taxable year based upon our taxable income for the full taxable year and distributions paid for the full taxable year. Of the distributions declared during the years ended December 31, 2022, 2021, and 2020, 100% were distributions derived from our current and accumulated earnings and profits. There can be no certainty to stockholders that this determination is representative of what the tax attributes of our 2023 distributions to stockholders will actually be and we cannot assure you that we will achieve results that will permit the payment of any cash distributions.

We maintain an “opt-out” distribution reinvestment plan that provides for reinvestment of our distribution on behalf of our stockholders, unless a stockholder elects to receive cash. As a result, if our Board authorizes, and we declare a cash distribution, then our stockholders who have not “opted out” of our distribution reinvestment plan will have their cash distribution automatically reinvested in additional shares of our common stock, rather than receiving the cash distributions. During 2022, 2021, and 2020, we issued 259,466, 248,041 and 280,690 shares, respectively, of common stock to stockholders in connection with the distribution reinvestment plan.

To maintain our RIC status under the Code, we must distribute to our stockholders dividend distributions of an amount generally at least equal to the Annual Distribution Requirement, in order to maintain our RIC status. In addition, we generally will be required to pay an U.S. federal excise tax equal to 4% on certain undistributed U.S. federal taxable income unless we distribute in a timely manner as defined under the Code. Depending on the level of taxable income earned in a tax year, we may choose to carry forward such taxable income for distribution in the following year, and pay any applicable excise tax. See “Item 1. Business— Certain United States Income Tax Considerations.”

 

49


 

PERFORMANCE GRAPH

The following stock performance graph compares the cumulative stockholder return assuming that, on December 31, 2017, a person invested $100 in each of our common stock, the S&P 500 Index, the NASDAQ Financial 100 Index, the S&P BDC Index, and the KBW Regional Bank Index. The graph measures total stockholder return, which takes into account both changes in stock price and distributions, prior to any tax effect. It assumes that distributions paid are reinvested in like securities.

img259755906_1.jpgCopyright© 2023 Standard & Poor's, a division of S&P Global. All rights reserved.

* Assumes $100 invested on December 31, 2017 in Hercules Capital, Inc. or the applicable index, and that all dividends are reinvested.

^ The NYSE Composite Index, which was included in our Form 10-K for the year ended December 31, 2021, has been replaced with the S&P BDC Index, which we believe is more directly comparable to Hercules' performance. The S&P BDC Index measures the performance of business development companies that trade on major U.S. exchanges, whereas the NYSE Composite Index measures performance of any company listed on the New York Stock Exchange irrespective of whether the company is a business development company or not.

This graph and other information furnished under Part II. Item 5 of the Form 10-K shall not be deemed to be “soliciting material” or to be “filed” with the SEC or subject to Regulation 14A or 14C, or to the liabilities of Section 18 of the Exchange Act. The stock price performance included in the above graph is not necessarily indicative of, or intended to forecast, future stock price performance.

Item 6. [Reserved]

 

50


 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD-LOOKING STATEMENTS

The matters discussed in this report, as well as in future oral and written statements by management of Hercules Capital, Inc. that are forward-looking statements are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Important assumptions include our ability to originate new investments, achieve certain margins and levels of profitability, the availability of additional capital, and the ability to maintain certain debt to asset ratios. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this report should not be regarded as a representation by us that our plans or objectives will be achieved. The forward-looking statements contained in this report include statements as to:

our current and future management structure;
our future operating results;
our business prospects and the prospects of our prospective portfolio companies;
the impact of investments that we expect to make;
our informal relationships with third parties including in the venture capital industry;
the expected market for venture capital investments and our addressable market;
the dependence of our future success on the general economy and its impact on the industries in which we invest;
our ability to access debt markets and equity markets;
the occurrence and impact of macro-economic developments (for example, global pandemics, natural disasters, terrorism, international conflicts and war) on us and our portfolio companies;
the ability of our portfolio companies to achieve their objectives;
our expected financings and investments;
our regulatory structure and tax status as a RIC;
our ability to operate as a BDC and a SBIC;
the adequacy of our cash resources and working capital;
the timing of cash flows, if any, from the operations of our portfolio companies;
the timing, form and amount of any distributions;
the impact of fluctuations in interest rates on our business;
the valuation of any investments in portfolio companies, particularly those having no liquid trading market; and
our ability to recover unrealized depreciation on investments.

For a discussion of factors that could cause our actual results to differ from forward-looking statements contained in this report, please see the discussion under “Item 1A. Risk Factors.” You should not place undue reliance on these forward-looking statements. The forward-looking statements made in this report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this report.

The following discussion should be read in conjunction with our consolidated financial statements and related notes and other financial information appearing elsewhere in this report. In addition to historical information, the following discussion and other parts of this report contain forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those anticipated by such forward-looking information due to the factors discussed under “Item 1A—Risk Factors” and “Forward-Looking Statements” of this Item 7.

Use of Non-GAAP Measures

In Item 1. Business and throughout this MD&A, we present our financial condition and results of operations in the way we believe will be most meaningful and representative of our business results. Some of the measurements we use are “Non-GAAP financial measures” under SEC rules and regulations. GAAP is the acronym for “generally accepted accounting principles” in the United States. The Non-GAAP financial measures we present may not be comparable to similarly-named measures reported by other companies.

 

51


 

Overview

We are a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed and institutional-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. Our goal is to be the leading Structured Debt financing provider for venture capital-backed and institutional-backed companies in a variety of technology-related industries requiring sophisticated and customized financing solutions. Our strategy is to evaluate and invest in a broad range of technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology and to offer a full suite of growth capital products. We invest primarily in Structured Debt and, to a lesser extent, in senior debt and equity investments. Our portfolio is comprised of, and we anticipate that our portfolio will continue to be comprised of, investments primarily in technology related companies at various stages of their development.

We are structured as an internally managed, non-diversified, closed-end investment company that has elected to be regulated as a BDC under the 1940 Act. As a BDC, we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in “qualifying assets,” which includes securities of private U.S. companies, cash, cash equivalents, and high-quality debt investments that mature in one year or less. Consistent with requirements under the 1940 Act, we invest primarily in United-States based companies and to a lesser extent in foreign companies. We source our investments through our principal office located in Palo Alto, CA, as well as through our additional offices in Boston, MA, New York, NY, Bethesda, MD, San Diego, CA, and London, United Kingdom.

We have elected to be treated for tax purposes as a RIC under Code and operate in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC, among other requirements, we must maintain certain source-of-income and asset diversification requirements. In addition, we must make timely distributions of at least 90% of annual taxable income to our stockholders. As a RIC, we generally will not be subject to U.S. federal income tax on the income that we distribute (or are deemed to distribute) to our stockholders provided that we maintain our RIC status for a given tax year.

Our primary business objectives are to increase our net income, net investment income, and NAV by investing in Structured Debt and senior secured debt instruments, which are typically senior or subordinated debt structured with warrants, options, equity, or other rights to invest in venture capital-backed and institutional-backed companies in a variety of technology-related industries at attractive current yields and the potential for equity appreciation and realized gains. Our Structured Debt and senior secured debt investments are typically secured by some or all of the assets of the applicable portfolio company. We also invest in “unitranche” loans, which are loans that combine both senior and mezzanine debt, generally in a first lien position. In addition to our debt investments, we regularly engage in discussions with third parties with respect to various potential transactions to explore alternative investment structures. Through such alternative structures we may acquire an investment, a portfolio of investments, an entire company, or sell portions of our portfolio on an opportunistic basis. Through our investment strategy, we aim to achieve our business objectives by maximizing our portfolio total return from generation of investment income from our debt investments and capital appreciation from our warrant and equity investments.

Our equity ownership in our portfolio companies may exceed 25% of the voting securities of such companies, which represents a controlling interest under the 1940 Act. In some cases, we receive the right to make additional equity investments in our portfolio companies in connection with future equity financing rounds. Capital that we provide is generally used for growth and general working capital purposes as well as in select cases for acquisitions or recapitalizations. We invest primarily in private companies but also have investments in public companies.

We, our subsidiaries or our affiliates, may also agree to manage certain other funds that invest in debt, equity or provide other financing or services to companies in a variety of industries for which we may earn management or other fees for our services. We may also invest in the equity of these funds, along with other third parties, from which we would seek to earn a return and/or future incentive allocations. Some of these transactions could be material to our business. Consummation of any such transaction will be subject to completion of due diligence, finalization of key business and financial terms (including price) and negotiation of final definitive documentation as well as a number of other factors and conditions which may include, depending on the transaction and without limitation, the approval of our Board of Directors (the "Board"), required regulatory or third-party consents, and/or the approval of our stockholders. Accordingly, there can be no assurance that any such transaction would be consummated. Any of these transactions or funds may require significant management resources either during the transaction phase or on an ongoing basis depending on the terms of the transaction.

Hercules Adviser LLC (the “Adviser Subsidiary”), is our wholly owned registered investment adviser subsidiary, which began providing investment advisory and related services to investment vehicles (the “Adviser Funds”) in 2021. The Adviser Subsidiary is not consolidated for reporting purposes as noted in “Note 1- Description of Business”. In addition to the Adviser Subsidiary, we have established other wholly owned subsidiaries which are consolidated for reporting. However, certain of these subsidiaries are not consolidated for federal tax purposes and may generate income tax expense or benefit, as well as tax assets and liabilities as a result of their ownership of certain portfolio investments.

 

52


 

Macroeconomic Market Developments

Our investment portfolio continues to be focused on industries and sectors that are generally expected to be more resilient to economic cycles. However, the U.S and global capital markets continue to evolve as a result of the market volatility caused by the ongoing rise of inflation, geopolitical events, the continuing impacts of COVID-19 pandemic, and the supply chain issues. We are continuing to closely monitor the impact of these macroeconomic market developments on all aspects of our business, including impacts to our portfolio companies, employees, due diligence and underwriting processes, and financial markets. As a result, pressure on liquidity and financial results of certain of our portfolio companies have persisted, and our portfolio companies may draw on most, if not all, of the unfunded portion of any revolving or delayed draw term loans made by us, subject to availability under the terms of such loans. The extent to which the ongoing macroeconomic market events will continue to affect the financial condition and liquidity of our portfolio companies’ results of operations are highly uncertain and cannot be predicted.

The extent of the impact that macroeconomic developments will have on our own operational and financial performance, including our ability to execute our business strategies and initiatives in the expected time frame is uncertain. Inflation historically has not had a significant effect on our results of operations in any of the reporting periods presented herein. However, the impact that these macroeconomic events have on our portfolio companies could have a negative impact on the fair value of our investments in these portfolio companies. Further, an extended period of global supply chain and economic disruption, including inflation, could materially affect our business, results of operations, access to sources of liquidity and financial condition. Given the fluidity of these market events, neither our management nor our Board is able to predict the full impact of the current macroeconomic events on our business, future results of operations, financial position, or cash flows at this time.

Portfolio and Investment Activity

As of December 31, 2022, the total fair value of our investment portfolio was approximately $3.0 billion, as compared to approximately $2.4 billion as of December 31, 2021. The fair value of our debt investment portfolio as of December 31, 2022 was approximately $2.8 billion, compared to a fair value of approximately $2.2 billion as of December 31, 2021. The fair value of the equity portfolio as of December 31, 2022, was approximately $134.0 million, compared to a fair value of approximately $184.7 million as of December 31, 2021. The fair value of the warrant portfolio as of December 31, 2022, was approximately $30.6 million, compared to a fair value of approximately $38.4 million as of December 31, 2021.

Portfolio Activity

Our investments in portfolio companies take a variety of forms, including unfunded contractual commitments and funded investments. Not all debt commitments represent future cash requirements. Unfunded contractual commitments depend upon a portfolio company reaching certain milestones before the debt commitment is available to the portfolio company, which is expected to affect our funding levels. These commitments are subject to the same underwriting and ongoing portfolio maintenance as the on-balance sheet financial instruments that we hold. Debt commitments generally fund over the two succeeding quarters from close. From time to time, unfunded contractual commitments may expire without being drawn and thus do not represent future cash requirements.

Prior to entering into a contractual commitment, we generally issue a non-binding term sheet to a prospective portfolio company. Non-binding term sheets are subject to completion of our due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. These non-binding term sheets generally convert to contractual commitments in approximately 90 days from signing and some portion may be assigned or allocated to or directly originated by the Adviser Funds prior to or after closing. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

During the year ended December 31, 2022, Hercules and the Adviser Funds directly committed or originated an aggregate total $3,121.4 million of investment commitments. Of the aggregated total directly committed or originated by Hercules and the Adviser Funds, $747.1 million of investment commitments were directly committed or originated by the Adviser Funds. Of the aggregate total direct fundings or originations, $330.2 million of debt, equity, and warrant fundings during the period, were assigned to, directly funded or originated by the Adviser Funds.

During the year ended December 31, 2021, Hercules and the Adviser Funds directly committed or originated an aggregate total $2,639.2 million of investment commitments. Of the aggregated total directly committed or originated by Hercules and the Adviser Funds, $374.5 million of investment commitments were directly committed or originated by the Adviser Funds. Of the aggregate total direct fundings or originations, $226.4 million of debt, equity, and warrant fundings during the period, were assigned to, directly funded or originated by the Adviser Funds.

 

53


 

Our portfolio activity for the years ended December 31, 2022, and 2021 was comprised of the following:

(in millions)

 

December 31, 2022

 

 

December 31, 2021

 

Gross Debt Commitments Originated by Hercules Capital and the Adviser Funds (1)

 

 

 

 

 

 

New portfolio company

 

$

2,612.0

 

 

$

1,810.4

 

Existing portfolio company

 

 

482.3

 

 

 

801.3

 

Sub-total

 

 

3,094.3

 

 

 

2,611.7

 

Less: Debt commitments assigned to or directly committed by the Adviser Funds (3)

 

 

(742.4

)

 

$

(371.7

)

Net Total Debt Commitments

 

$

2,351.9

 

 

$

2,240.0

 

Gross Debt Fundings by Hercules Capital and the Adviser Funds (2)

 

 

 

 

 

 

New portfolio company

 

$

1,068.1

 

 

$

1,056.7

 

Existing portfolio company

 

 

371.5

 

 

 

482.6

 

Sub-total

 

 

1,439.6

 

 

 

1,539.3

 

Less: Debt fundings assigned to or directly funded by the Adviser Funds (3)

 

 

(325.5

)

 

 

(223.6

)

Net Total Debt Fundings

 

$

1,114.1

 

 

$

1,315.7

 

Equity Investments and Investment Funds and Vehicles Fundings by Hercules Capital and the Adviser Funds

 

 

 

 

 

 

New portfolio company

 

$

5.0

 

 

$

18.6

 

Existing portfolio company

 

 

20.4

 

 

 

10.5

 

Sub-total

 

$

25.4

 

 

$

29.1

 

Less: Equity fundings assigned to or directly funded by the Adviser Funds (3)

 

 

(4.7

)

 

 

(2.8

)

Net Total Equity and Investment Funds and Vehicle Fundings

 

$

20.7

 

 

$

26.3

 

 

 

 

 

 

 

 

Total Unfunded Contractual Commitments (4)

 

$

628.9

 

 

$

286.8

 

 

 

 

 

 

 

 

Non-Binding Term Sheets

 

 

 

 

 

 

New portfolio company

 

$

96.7

 

 

$

275.0

 

Existing portfolio company

 

 

39.4

 

 

 

 

Total

 

$

136.1

 

 

$

275.0

 

(1)
Includes restructured loans and renewals in addition to new commitments.
(2)
Funded amounts include borrowings on revolving facilities.
(3)
Commitments and fundings include amounts assigned to, directly committed or originated, or funded by the Adviser Funds, as applicable.
(4)
Amount represents unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. This excludes $173.5 million and $34.9 million of unfunded commitments as of December 31, 2022 and December 31, 2021, respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds.

We receive principal payments on our debt investment portfolio based on scheduled amortization of the outstanding balances. In addition, we receive principal repayments for some of our loans prior to their scheduled maturity date. The frequency or volume of these early principal repayments may fluctuate significantly from period to period. During the year ended December 31, 2022, we received approximately $443.4 million in aggregate principal repayments. Of the aggregate principal repayments, approximately $70.1 million were scheduled principal payments, and approximately $373.3 million were early principal repayments related to 29 portfolio companies. Of the approximately $373.3 million early principal repayments, approximately $53.4 million were early repayments due to merger and acquisition transactions related to four portfolio companies.

Total portfolio investment activity (inclusive of unearned income and excluding activity related to taxes payable, and escrow receivables) as of and for each of the years ended December 31, 2022, and 2021 was as follows:

(in millions)

 

December 31, 2022

 

 

December 31, 2021

 

Beginning portfolio

 

$

2,434.5

 

 

$

2,354.1

 

New fundings and restructures

 

 

1,465.0

 

 

 

1,568.4

 

Fundings assigned to or directly funded by the Adviser Funds(1)

 

 

(330.2

)

 

 

(226.4

)

Warrants not related to current period fundings

 

 

2.0

 

 

 

1.1

 

Principal payments received on investments

 

 

(70.1

)

 

 

(80.9

)

Early payoffs

 

 

(373.3

)

 

 

(1,104.1

)

Proceeds from sale of debt investments

 

 

(84.0

)

 

 

 

Proceeds from sale of equity investments

 

 

(17.6

)

 

 

(111.2

)

Accretion of loan discounts and paid-in-kind principal

 

 

54.8

 

 

 

44.5

 

Net acceleration of loan discounts and loan fees due to early payoffs or restructures

 

 

(17.7

)

 

 

(23.4

)

New loan fees

 

 

(13.8

)

 

 

(17.2

)

Gain (loss) on investments due to sales or write offs

 

 

(0.3

)

 

 

24.7

 

Net change in unrealized appreciation (depreciation)

 

 

(85.4

)

 

 

4.9

 

Ending portfolio

 

$

2,963.9

 

 

$

2,434.5

 

(1)
Funded amounts include $193.2 million and $101.2 million of direct fundings of investments made by the Adviser Funds for the years ended December 31, 2022 and 2021, respectively.

Periodically, we may hold investments in debt, warrant, or equity positions of portfolio companies that have filed a registration statement with the SEC in contemplation of a potential initial public offering. There can be no assurance that companies that have yet to complete their initial public offerings will do so in a timely manner or at all.

 

54


 

The following table presents certain selected information regarding our debt investment portfolio:

 

 

December 31, 2022

 

 

December 31, 2021

 

Number of portfolio companies with debt outstanding

 

 

120

 

 

 

92

 

Percentage of debt bearing a floating rate

 

 

95.3

%

 

 

94.0

%

Percentage of debt bearing a fixed rate

 

 

4.7

%

 

 

6.0

%

Weighted average core yield (1)

 

 

12.3

%

 

 

11.4

%

Weighted average effective yield (2)

 

 

12.7

%

 

 

12.9

%

Prime rate at the end of the period

 

 

7.5

%

 

 

3.3

%

(1)
The core yield is a Non-GAAP financial measure. The core yield on our debt investments excludes the effects of fee and income accelerations attributed to early payoffs, restructuring, loan modifications, other one-time events, and includes income from expired commitments. Please refer to the "Portfolio Yield" section below for further discussion of this measure.
(2)
The effective yield on our debt investments includes the effects of fee and income accelerations attributed to early payoffs, restructuring, loan modifications, and other one-time events. The effective yield is derived by dividing total investment income by the weighted average earning investment portfolio assets outstanding during the year, excluding non-interest earning assets such as warrants and equity investments.

Income from Portfolio

We generate revenue in the form of interest income, primarily from our investments in debt securities, and fee income, which is primarily comprised of commitment and facility fees. Interest income is recognized in accordance with the contractual terms of the loan agreement to the extent that such amounts are expected to be collected. Fees generated in connection with our debt investments are recognized over the life of the loan or, in some cases, recognized as earned. In addition, we generate revenue in the form of capital gains, if any, on warrants or other equity securities that we acquire from our portfolio companies. Our investments generally range from $15.0 million to $40.0 million, although we may make investments in amounts above or below that range. As of December 31, 2022, our debt investments generally have a term of between two and five years and typically bear interest at a rate ranging from approximately 6.0% to approximately 15.0%. In addition to the cash yields received on our debt investments, in some instances our debt investments may also include any of the following: exit fees, balloon payment fees, commitment fees, success fees, PIK provisions or prepayment fees which may be required to be included in income prior to receipt.

Interest on debt securities is generally payable monthly, with amortization of principal typically occurring over the term of the investment. In addition, our loans may include an interest-only period ranging from three to eighteen months or longer. In limited instances in which we choose to defer amortization of the loan for a period of time from the date of the initial investment, the principal amount of the debt securities and any accrued but unpaid interest become due at the maturity date.

Loan origination and commitment fees, which are generally received in full at the inception of a loan, are deferred and amortized into fee income as an enhancement to the related loan’s yield over the contractual life of the loan. We recognize nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. As of December 31, 2022 and 2021, unamortized capitalized fee income was recorded as follows:

(in millions)

As of December 31,

 

 

2022

 

 

2021

 

Offset against debt investment cost

$

43.1

 

 

$

36.5

 

Deferred obligation contingent on funding or other milestone

 

10.9

 

 

 

6.4

 

Total Unamortized Fee Income

$

54.0

 

 

$

42.9

 

Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. As of December 31, 2022 and 2021, loan exit fees receivable were recorded as follows:

(in millions)

As of December 31,

 

 

2022

 

 

2021

 

Included within debt investment cost

$

32.5

 

 

$

29.6

 

Deferred receivable related to expired commitments

 

5.0

 

 

 

5.4

 

Total Exit Fees Receivable

$

37.5

 

 

$

35.0

 

Additionally, we have debt investments in our portfolio that earn PIK interest. The PIK interest, computed at the contractual rate specified in each loan agreement, is recorded as interest income and added to the principal balance of the loan on specified capitalization dates. To maintain our status as a RIC, the non-cash PIK income must be distributed to stockholders with other sources of income in the form of dividend distributions even though we have not yet collected any cash from the borrower. Amounts necessary to pay these distributions may come from available cash or the liquidation of certain investments. In the years ended December 31, 2022 and December 31, 2021, we recorded approximately $20.5 million and $11.2 million of PIK income, respectively.

 

55


 

Portfolio Yield

We report our financial results on a GAAP basis. We monitor the performance of our total investment portfolio and total debt portfolio using both GAAP and Non-GAAP financial measures. In particular, we evaluate performance through monitoring the portfolio yields as we consider them to be effective indicators, for both management and stockholders, of the financial performance of our total investment portfolio and total debt portfolio. The key metrics that we monitor with respect to yields are as described below:

“Total Yield” - The total yield is derived by dividing GAAP basis 'Total investment income' by the weighted average GAAP basis value of investment portfolio assets outstanding during the year, including non-interest earning assets such as warrants and equity investments at amortized cost.
“Effective Yield” on total debt investments - The effective yield is derived by dividing GAAP basis 'Total investment income' by the weighted average GAAP basis value of debt investment portfolio assets at amortized cost outstanding during the year.
“Core Yield” on total debt investments – The core yield is a Non-GAAP financial measure. The core yield is derived by dividing “Core investment income” by the weighted average GAAP basis value of debt investment portfolio assets at amortized cost outstanding during the year. “Core investment income” adjusts GAAP basis 'Total investment income' to exclude fee and other income accelerations attributed to early payoffs, deal restructuring, loan modifications, and other one-time income events, but includes income from expired commitments.

 

 

December 31, 2022

 

 

December 31, 2021

 

Total Yield

 

 

11.9

%

 

 

11.9

%

Effective Yield

 

 

12.7

%

 

 

12.9

%

Core Yield (Non-GAAP)

 

 

12.3

%

 

 

11.4

%

We believe that these measures are useful for our stockholders as it provides the yield of our portfolio to allow a more meaningful comparison with our competitors. As noted above, Core Yield, a Non-GAAP financial measure, is derived by dividing Core investment income, as defined above, by the weighted average GAAP basis value of debt investment portfolio assets at amortized cost outstanding. The reconciliation to calculate “Core investment income” from GAAP basis 'Total investment income' are as follows:

(in thousands)

 

For the year ended

 

 

 

December 31, 2022

 

 

December 31, 2021

 

GAAP Basis:

 

 

 

 

 

 

Total investment income

 

$

321,688

 

 

$

280,976

 

Less: fee and income accelerations attributed to early payoffs, restructuring, loan modifications, and other one-time events except income from expired commitments

 

 

(12,340

)

 

 

(32,420

)

Non-GAAP Basis:

 

 

 

 

 

 

Core investment income

 

$

309,348

 

 

$

248,556

 

We believe the Core Yield is useful for our investors as it provides the yield at which our debt investments are originated and eliminates one-off items that can fluctuate significantly from period to period, thereby allowing for a more meaningful comparison over time.

Although the Core Yield, a Non-GAAP financial measure, is intended to enhance our stockholders’ understanding of our performance, the Core Yield should not be considered in isolation from or as an alternative to the GAAP financial metrics presented. The aforementioned Non-GAAP financial measure may not be comparable to similar Non-GAAP financial measures used by other companies.

Another financial measure that we monitor is the total return for our investors, which was approximately (10.1)% and 25.6% during the years ended December 31, 2022 and 2021, respectively. The total return equals the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. The total return does not reflect any sales load that may be paid by investors. See “Note 10 – Financial Highlights” included in the notes to our consolidated financial statements appearing elsewhere in this report.

 

56


 

Portfolio Composition

Our portfolio companies are primarily privately held companies and public companies which are active in sectors characterized by high margins, high growth rates, consolidation, and product and market extension opportunities.

The following table presents the fair value of the Company’s portfolio by industry sector as of December 31, 2022 and December 31, 2021:

(in thousands)

December 31, 2022

 

 

December 31, 2021

 

 

Investments at
 Fair Value

 

 

Percentage of
 Total Portfolio

 

 

Investments at
 Fair Value

 

 

Percentage of
 Total Portfolio

 

Drug Discovery & Development

$

1,150,707

 

 

 

38.8

%

 

$

967,383

 

 

 

39.7

%

Software

 

798,264

 

 

 

26.9

%

 

 

585,622

 

 

 

24.1

%

Consumer & Business Services

 

439,384

 

 

 

14.8

%

 

 

395,506

 

 

 

16.3

%

Healthcare Services, Other

 

198,763

 

 

 

6.7

%

 

 

121,003

 

 

 

5.0

%

All other industries (1)

 

376,837

 

 

 

12.8

%

 

 

365,008

 

 

 

14.9

%

Total

$

2,963,955

 

 

 

100.0

%

 

$

2,434,522

 

 

 

100.0

%

(1)
See “Note 4 – Investments” for complete list of industry sectors and corresponding amounts of investments at fair value as a percentage of the total portfolio. As of December 31, 2022 the fair value as a percentage of total portfolio does not exceed 5.0% for any individual industry sector other than “Drug Discovery & Development”, “Software”, “Consumer & Business Services”, or "Healthcare Services, Other".

Industry and sector concentrations vary as new loans are recorded and loans are paid off. Loan revenue, consisting of interest, fees, and recognition of gains on equity and warrants or other equity interests, can fluctuate materially when a loan is paid off or a warrant or equity interest is sold. Revenue recognition in any given year can be highly concentrated in several portfolio companies.

For the years ended December 31, 2022 and 2021, our ten largest portfolio companies represented approximately 29.0% and 30.5% of the total fair value of our investments in portfolio companies, respectively. As of December 31, 2022 and December 31, 2021, we had eight and six investments that represented 5% or more of our net assets, respectively. As of December 31, 2022 and December 31, 2021, we had four and six equity investments representing approximately 39.8% and 49.6%, respectively, of the total fair value of our equity investments, and each represented 5% or more of the total fair value of our equity investments. No single portfolio investment represents more than 10% of the fair value of our total investments as of December 31, 2022 and 2021.

As of December 31, 2022 and 2021, approximately 95.3% and 94.0%, respectively, of the debt investment portfolio was priced at floating interest rates or floating interest rates with a Prime, LIBOR, SOFR, Eurodollar, or BSBY-based interest rate floor. Changes in interest rates, including Prime, LIBOR, SOFR, Eurodollar, or BSBY rates, may affect the interest income and the value of our investment portfolio for portfolio investments with floating rates.

Our investments in Structured Debt generally have detachable equity enhancement features in the form of warrants or other equity securities designed to provide us with an opportunity for capital appreciation. These features are treated as OID and are accreted into interest income over the term of the loan as a yield enhancement. Our warrant coverage generally ranges from 3% to 20% of the principal amount invested in a portfolio company, with a strike price generally equal to the most recent equity financing round. As of December 31, 2022, we held warrants in 110 portfolio companies, with a fair value of approximately $30.6 million. The fair value of our warrant portfolio decreased by approximately $7.8 million, as compared to a fair value of $38.4 million as of December 31, 2021, primarily related to the decrease in fair value of the portfolio companies.

Our existing warrant holdings would require us to invest approximately $71.9 million to exercise such warrants as of December 31, 2022. Warrants may appreciate or depreciate in value depending largely upon the underlying portfolio company’s performance and overall market conditions. As attractive investment opportunities arise, we may exercise certain of our warrants to purchase stock, and could ultimately monetize our investments. Of the warrants that we have monetized since inception, we have realized multiples in the range of approximately 1.02x to 42.71x based on the historical rate of return on our investments. We may also experience losses from our warrant portfolio in the event that warrants are terminated or expire unexercised.

Portfolio Grading

We use an investment grading system, which grades each debt investment on a scale of 1 to 5 to characterize and monitor our expected level of risk on the debt investments in our portfolio with 1 being the highest quality. See “Item 1. Business—Investment Process—Loan and Compliance Administration.” The following table shows the distribution of our outstanding debt investments on the 1 to 5 investment grading scale at fair value as of December 31, 2022 and 2021, respectively:

(in thousands)

 

December 31, 2022

 

 

December 31, 2021

 

Investment Grading

 

Number of Companies

 

Debt Investments
at Fair Value

 

 

Percentage of
Total Portfolio

 

 

Number of Companies

 

Debt Investments
at Fair Value

 

 

Percentage of
Total Portfolio

 

1

 

20

 

$

549,135

 

 

 

19.6

%

 

15

 

$

408,975

 

 

 

18.5

%

2

 

55

 

 

1,171,632

 

 

 

41.9

%

 

47

 

 

1,208,323

 

 

 

54.7

%

3

 

40

 

 

1,015,199

 

 

 

36.3

%

 

28

 

 

581,424

 

 

 

26.3

%

4

 

4

 

 

57,807

 

 

 

2.1

%

 

1

 

 

8,269

 

 

 

0.4

%

5

 

1

 

 

1,671

 

 

 

0.1

%

 

1

 

 

2,608

 

 

 

0.1

%

 

 

120

 

$

2,795,444

 

 

 

100.0

%

 

92

 

$

2,209,599

 

 

 

100.0

%

 

 

57


 

As of December 31, 2022, our debt investments had a weighted average investment grading of 2.23 on a cost basis, as compared to 2.10 as of December 31, 2021. Changes in a portfolio company's investment grading may be a result of changes in portfolio company's performance and/or timing of expected liquidity events. For instance, we may downgrade a portfolio company if it is not meeting our financing criteria or are underperforming relative to their respective business plans. We may also downgrade a portfolio company as it approaches a point in time when it will require additional equity capital to continue operations. Conversely, we may upgrade a portfolio company's investment grading when it is exceeding our financial performance expectations and/or is expected to mature/repay in full due to a liquidity event. The overall downgrade of the portfolio's weighted average investment grading is reflective of the impact of the current macroeconomic environment.

As macroeconomic events evolve and cause disruption in the capital markets and to businesses, we are continuing to monitor and work with the management teams and stakeholders of our portfolio companies to navigate the significant market, operational, and economic challenges created by these events. This includes remaining proactive in our assessments of credit performance to manage potential risks across our investment portfolio.

Non-accrual Investments

The following table shows the amortized cost of our performing and non-accrual investments as of December 31, 2022 and December 31, 2021:

(in millions)

 

As of December 31,

 

 

 

2022

 

 

2021

 

 

 

Amortized Cost

 

 

Percentage of Total Portfolio at Amortized Cost

 

 

Amortized Cost

 

 

Percentage of Total Portfolio at Amortized Cost

 

Performing

 

$

2,988

 

 

 

99.4

%

 

$

2,367

 

 

 

99.0

%

Non-accrual

 

 

18

 

 

 

0.6

%

 

 

24

 

 

 

1.0

%

Total Investments

 

$

3,006

 

 

 

100.0

%

 

$

2,391

 

 

 

100.0

%

Debt investments are placed on non-accrual status when it is probable that principal, interest or fees will not be collected according to contractual terms. When a debt investment is placed on non-accrual status, we cease to recognize interest and fee income until the portfolio company has paid all principal and interest due or demonstrated the ability to repay our current and future contractual obligations. We may not apply the non-accrual status to a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is in the process of collection. Interest collected on non-accrual investments are generally applied to principal.

Results of Operations

Our operating results for the years ended December 31, 2022 and 2021, were as follows:

(in thousands, except per share data)

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

Total investment income

 

$

321,688

 

 

$

280,976

 

Total expenses

 

 

133,620

 

 

 

131,008

 

Net investment income

 

 

188,068

 

 

 

149,968

 

Net realized gain (loss):

 

 

(924

)

 

 

20,876

 

Net change in unrealized appreciation (depreciation):

 

 

(85,063

)

 

 

3,311

 

Net increase (decrease) in net assets resulting from operations

 

$

102,081

 

 

$

174,155

 

 

 

 

 

 

 

 

Net investment income before gains and losses per common share:

 

 

 

 

 

 

Basic

 

$

1.48

 

 

$

1.29

 

 

 

 

 

 

 

 

Change in net assets resulting from operations per common share:

 

 

 

 

 

 

Basic

 

$

0.80

 

 

$

1.50

 

Diluted

 

$

0.79

 

 

$

1.49

 

Our operating results can vary substantially from period to period due to various factors, including changes in the level of investments held, changes in our investment yields, recognition of realized gains and losses, and changes in net unrealized appreciation and depreciation, among other factors. As a result, comparison of the net increase (decrease) in net assets resulting from operations may not be meaningful.

Investment Income

Total investment income for the year ended December 31, 2022 was approximately $321.7 million as compared to approximately $281.0 million for the year ended December 31, 2021. Investment income is primarily composed of interest income earned on our debt investments and fee income from commitments, facilities, and other loan related fees.

 

58


 

Interest Income

The following table summarizes the components of interest income for the years ended December 31, 2022 and 2021:

(in thousands)

Year Ended December 31,

 

 

2022

 

 

2021

 

Contractual interest income

$

249,375

 

 

$

200,682

 

Exit fee interest income

 

32,063

 

 

 

37,494

 

PIK interest income

 

20,455

 

 

 

11,210

 

Other interest income (1)

 

5,365

 

 

 

3,974

 

Total interest income

$

307,258

 

 

$

253,360

 

(1)
Other interest income includes OID interest income and interest recorded on other assets.

Interest income for the year ended December 31, 2022 totaled approximately $307.3 million as compared to approximately $253.4 million for the year ended December 31, 2021. The increase in interest income for the year ended December 31, 2022 as compared to the year ended December 31, 2021 is primarily attributable to an increase in the weighted average principal and an increase in core yield due to increases in the benchmark rates of our debt investment portfolio outstanding between the periods.

Interest income is comprised of recurring interest income from the contractual servicing of loans and non-recurring interest income that is related to the acceleration of income due to early loan repayments and other one-time events during the period. The following table summarizes recurring and non-recurring interest income for the years ended December 31, 2022 and December 31, 2021:

(in thousands)

Year Ended December 31,

 

 

2022

 

 

2021

 

Recurring interest income

$

300,013

 

 

$

238,067

 

Non-recurring interest income

 

7,245

 

 

 

15,293

 

Total interest income

$

307,258

 

 

$

253,360

 

The following table shows the PIK related activity for the years ended December 31, 2022 and 2021, at cost:

(in thousands)

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

Beginning PIK interest receivable balance

 

$

11,801

 

 

$

14,817

 

PIK interest income during the period

 

 

20,455

 

 

 

11,210

 

Payments received from PIK loans

 

 

(6,176

)

 

 

(14,047

)

Realized gain (loss)

 

 

(367

)

 

 

(179

)

Ending PIK interest receivable balance

 

$

25,713

 

 

$

11,801

 

The increase in PIK interest income during the year ended December 31, 2022, as compared to the year ended December 31, 2021 is due to an increase in the weighted average principal outstanding for debt investments which earn PIK interest. Payments on PIK loans are normally received only in the event of payoffs. The PIK receivable for both December 31, 2022 and December 31, 2021, represented approximately 1% of total debt investments.

Fee Income

Fee income from commitment, facility, and loan related fees for the year ended December 31, 2022 totaled approximately $14.4 million as compared to approximately $27.6 million for the year ended December 31, 2021. The decrease in fee income for year ended December 31, 2022 is primarily due to a decrease in the acceleration of unamortized fees, and one-time fees as a result of a lower volume of early repayments on our loan portfolio.

Fee income is comprised or recurring fee income from commitment, facility, and loan related fees, acceleration of fee income due to expired commitments, and acceleration of fee income due to early loan repayments during the period. The following table summarizes the components of fee income for the years ended December 31, 2022 and December 31, 2021:

(in thousands)

Year Ended December 31,

 

 

2022

 

 

2021

 

Recurring fee income

$

7,834

 

 

$

7,458

 

Accelerated fee income - expired commitments

 

1,502

 

 

 

3,031

 

Accelerated fee income - early repayments

 

5,094

 

 

 

17,127

 

Total fee income

$

14,430

 

 

$

27,616

 

In certain investment transactions, we may earn income from advisory services; however, we had no income from advisory services in the years ended December 31, 2022 and 2021, respectively.

Operating Expenses

Our operating expenses are comprised of interest and fees on our debt borrowings, general and administrative expenses, and employee compensation and benefits. During the years ended December 31, 2022 and 2021, our operating expenses totaled approximately $133.6 million and $131.0 million, respectively.

 

59


 

Interest and Fees on our Debt

Interest and fees on our debt totaled approximately $62.3 million and $63.1 million for the years ended December 31, 2022 and 2021, respectively. Our lower weighted average borrowing costs during the year ended December 31, 2022, resulted in a decline of interest and fee expenses as compared to the year ended December 31, 2021.

We had a weighted average cost of debt of approximately 4.2% and 4.9% for the years ended December 31, 2022 and 2021, respectively. The weighted average cost of debt includes interest and fees on our debt, but excludes the impact of fee acceleration due to extinguishment of debt. The decrease in the weighted average cost of debt during 2022 as compared to 2021, was attributable to our debt refinancing activities completed over recent years.

General and Administrative Expenses and Tax Expenses

General and administrative expenses include legal fees, consulting fees, accounting fees, printer fees, insurance premiums, taxes, rent, expenses associated with the workout of underperforming investments and various other expenses. Our general and administrative expenses increased to $16.9 million from $16.1 million for the years ended December 31, 2022 and 2021, respectively. The increase in general and administrative expenses for the year ended December 31, 2022 is primarily attributable to an increase in information technology related expenses. Tax expenses primarily relate to excise tax accruals. Tax expenses were $5.4 million and $7.9 million for the years ended December 31, 2022 and December 31, 2021, respectively.

Employee Compensation

Employee compensation and benefits totaled approximately $43.9 million for the year ended December 31, 2022, as compared to approximately $37.0 million for the year ended December 31, 2021. The increase between comparative periods was primarily due to increased variable compensation.

Employee stock-based compensation totaled approximately $13.4 million for the year ended December 31, 2022, as compared to approximately $11.9 million for the year ended December 31, 2021. The increase between comparative periods was primarily attributable to the issuance of additional stock-based compensation awards and higher weighted average grant date fair value.

Expenses allocated to the Adviser Subsidiary

In March 2021, we entered into a shared services agreement with the Adviser Subsidiary (the “Sharing Agreement”), pursuant to which the Adviser Subsidiary utilizes our human capital resources, including deal professional, finance, and administrative functions, as well as other resources including infrastructure assets such as office space and technology. Under the terms of the Sharing Agreement, we allocate the related expenses of shared services to the Adviser Subsidiary. Our total net operating expenses for the years ended December 31, 2022 and 2021, are net of expenses allocated to the Adviser Subsidiary of $8.3 million and $5.0 million, respectively. The increase in expenses allocated to the Adviser Subsidiary is a result of higher average assets under management and higher allocations to the Adviser Funds. As of December 31, 2022 and 2021, $0.1 million and $0.1 million, respectively, was due from the Adviser Subsidiary.

Net Realized Gains and Losses and Net Change in Unrealized Appreciation and Depreciation

Realized gains or losses on investments are measured by the difference between the net proceeds from the repayment or sale and the cost basis of an investment without regard to unrealized appreciation or depreciation previously recognized, and includes investments written off during the period, net of recoveries. Realized loss on debt extinguishment relates to additional fees, costs, and accelerated recognition of remaining debt issuance costs, which are recognized in the event debt is extinguished before its stated maturity. The net change in unrealized appreciation or depreciation on investments primarily reflects the change in portfolio investment values during the reporting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

A summary of net realized gains and losses for the years ended December 31, 2022 and 2021 is as follows:

(in thousands)

Year Ended December 31,

 

 

2022

 

 

2021

 

Realized gains

$

12,264

 

 

$

91,617

 

Realized losses

 

(11,798

)

 

 

(66,322

)

Realized foreign exchange gains (losses)

 

2,296

 

 

 

 

Realized loss on debt extinguishment

 

(3,686

)

 

 

(4,419

)

Net realized gains (losses)

$

(924

)

 

$

20,876

 

 

 

60


 

During the year ended December 31, 2022, we recognized net realized losses of $0.9 million. The net realized losses included gross realized gains of approximately $12.3 million primarily from the sale of our equity position in Black Crow AI, Inc and Peerless Network Holdings, Inc. Our gains were offset by gross realized losses of $11.8 million, primarily from the write-off of our investments in Regent Education, Medrobotics Corporation, Genocea Biosciences, Inc, Kaleido Biosciences, Inc., and Pineapple Energy LLC during the year. Additionally, during the year ended December 31, 2022, we repaid £19.4 million of principal borrowings under our SMBC Facility and realized a $2.3 million foreign exchange gain. Moreover, as part of the retirement of the 2022 Notes in Q1 2022, we incurred a $3.7 million loss on debt extinguishment. The realized loss on debt extinguishment was related to fees, accrued interest, and the acceleration of debt issuance costs amortization, and is included as a realized loss within the “Loss on debt extinguishment” on the Consolidated Statement of Operations.

During the year ended December 31, 2021, we recognized net realized gains of $20.9 million. Net realized gains included gross realized gains of approximately $91.6 million, primarily from the sale of DoorDash, Inc. Palantir Technologies, Ology Bioservices, and TransMedics Group, Inc. Our gains were offset by gross realized losses of $66.3 million, primarily from the write-off of our investments in Intent (p.k.a. Intent Media, Inc.) and Solar Spectrum Holdings, LLC. Additionally, during the year ended December 31, 2021, we fully redeemed and repaid the April 2025 Notes, 2027 Asset-Backed Notes, and 2028 Asset-Backed Notes. As a result, we accelerated recognition of $4.4 million of debt issuance costs associated with the extinguishment of the debt, which is included as a realized loss within the “Loss on debt extinguishment” on the Consolidated Statement of Operations for the year ended December 31, 2021.

The net change in unrealized appreciation and depreciation of our investments is derived from the changes in fair value of each investment as determined in good faith by our Valuation Committee and approved by the Board. The following table summarizes the change in net unrealized appreciation or depreciation of investments for the years ended December 31, 2022, and 2021:

(in thousands)

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

Gross unrealized appreciation on portfolio investments

 

$

106,130

 

 

$

178,947

 

Gross unrealized depreciation on portfolio investments

 

 

(190,450

)

 

 

(154,635

)

Reversal of prior period net unrealized appreciation (depreciation) upon a realization event

 

 

2,408

 

 

 

(19,461

)

Net unrealized appreciation (depreciation) on portfolio investments

 

 

(81,912

)

 

 

4,851

 

Other net unrealized appreciation (depreciation)

 

 

(3,151

)

 

 

(1,540

)

Total net unrealized appreciation (depreciation) on investments

 

$

(85,063

)

 

$

3,311

 

During the years ended December 31, 2022 and 2021, we recorded approximately $85.1 million of net unrealized depreciation and $3.3 million of net unrealized appreciation on our debt, equity, warrant, and investment funds, respectively. The following table summarizes the key drivers of change in net unrealized appreciation (depreciation) of investments for the years ended December 31, 2022, and 2021:

(in thousands)

Year Ended December 31,

 

 

2022

 

 

2021

 

 

Debt

 

Equity, Warrants
and
Investment Funds

 

Total

 

 

Debt

 

Equity, Warrants
and
Investment Funds

 

Total

 

Valuation appreciation (depreciation)

$

(10,539

)

 

(73,781

)

$

(84,320

)

 

$

(3,847

)

$

28,159

 

$

24,312

 

Reversal of prior period net unrealized appreciation (depreciation) upon a realization event

 

999

 

 

1,409

 

 

2,408

 

 

 

(1,150

)

 

(18,311

)

 

(19,461

)

Other net unrealized appreciation (depreciation)

 

(2,586

)

 

(565

)

 

(3,151

)

 

 

 

 

(1,540

)

 

(1,540

)

Net realized appreciation (depreciation)

$

(12,126

)

$

(72,937

)

$

(85,063

)

 

$

(4,997

)

$

8,308

 

$

3,311

 

Income and Excise Taxes

We account for income taxes in accordance with the provisions of ASC Topic 740 Income Taxes, under which income taxes are provided for amounts currently payable and for amounts deferred based upon the estimated future tax effects of differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized. We intend to timely distribute to our stockholders substantially all of our annual taxable income for each year, except that we may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, we may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.

Because federal income tax regulations differ from U.S. GAAP, distributions in accordance with tax regulations may differ from net investment income and realized gains recognized for financial reporting purposes. Differences may be permanent or temporary. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future.

 

61


 

Hercules Adviser LLC

The Adviser Subsidiary has entered into investment management agreements (the “IMAs”) with the Adviser Funds. Pursuant to the IMAs, the Adviser Subsidiary provides investment advisory and management services to the Adviser Funds in exchange for an asset-based fee and certain incentive fees. The Adviser Funds are privately offered investment funds exempt from registration under the 1940 Act that invest in debt and equity investments in venture or institutionally backed technology related and life sciences companies.

Hercules Adviser LLC, the Adviser Subsidiary, receives fee income for the services provided to the Adviser Funds. The Adviser Subsidiary’s contribution to our net investment income is derived from dividend income declared by the Adviser Subsidiary and interest income earned on loans to the Adviser Subsidiary. For the years ended December 31, 2022 and 2021, no dividends were declared by the Adviser Subsidiary.

For the years ended December 31, 2021 and December 31, 2020

A comparison of the fiscal years ended December 31, 2021 and December 31, 2020 can be found in our Form 10-K for the fiscal year ended December 31, 2021 within “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.”, which is incorporated herein by reference.

Financial Condition, Liquidity, Capital Resources and Obligations

Our liquidity and capital resources are derived from our debt borrowings and cash flows from operations, including investment sales and repayments, and income earned. Our primary use of funds from operations includes investments in portfolio companies and payments of fees and other operating expenses we incur. We have used, and expect to continue to use, our debt and the proceeds from the turnover of our portfolio and from public and private offerings of securities to finance our investment objectives. We may also raise additional equity or debt capital through registered offerings off a shelf registration, At-the-Market (“ATM”), and private offerings of securities, by securitizing a portion of our investments, or by borrowing from the SBA through our SBIC subsidiary. This “Financial Condition, Liquidity and Capital Resources” section should be read in conjunction with the “Macroeconomic Market Developments” section above.

During the year ended December 31, 2022, we principally funded our operations from (i) cash receipts from interest, dividend, and fee income from our investment portfolio, (ii) cash proceeds from the realization of portfolio investments through the repayments of debt investments and the sale of debt and equity investments, (iii) debt offerings along with borrowings on our credit facilities, and (iv) equity offerings.

During the year ended December 31, 2022, our operating activities used $424.8 million of cash and cash equivalents, compared to $128.6 million provided during the year ended December 31, 2021. The $553.4 million increase in cash used in operating activities was primarily due to a $652.6 million decrease in principal, fee repayments, and proceeds received from the sale of debt investments, $96.7 million fewer proceeds received from the sale of equity investments, which was offset by a decrease of $207.0 million in net purchases of investments due to increased assignments to the Adviser Funds.

During the year ended December 31, 2022, our investing activities used approximately $114 thousand of cash, compared to $106 thousand used during the year ended December 31, 2021. The $8 thousand increase in cash used by investing activities was due to an increase in purchases of capital equipment.

During the year ended December 31, 2022, our financing activities provided $314.5 million of cash, compared to $229.9 million used during the year ended December 31, 2021. The $544.4 million increase in cash flows from financing activities was due to $574.5 million of new debt issuances related to the issuance of our January 2027 Notes, June 2025 3-Year Notes, 2031 Asset-Backed Notes, and SBA Debenture borrowings during the year ended December 31, 2022. The debt issuances were used in our operating activities and to repay the $230.0 million of 2022 Convertible Notes and $150.0 million to retire the 2022 Notes. Additionally, we issued $229.7 million of ATM equity (net of offering costs) during the year ended December 31, 2022, which is compared to $10.6 million of common stock during the year ended December 31, 2021. These amounts offset the $69.6 million increase in dividend distributions, which totaled $245.1 million during the year ended December 31, 2022, compared to $175.5 million during the year ended December 31, 2021.

As of December 31, 2022, net assets totaled $1.4 billion, with a NAV per share of $10.53. We intend to continue to operate in order to generate cash flows from operations, including income earned from investments in our portfolio companies. Our primary use of funds will be investments in portfolio companies and cash distributions to holders of our common stock.

 

62


 

Available liquidity and capital resources as of December 31, 2022

As of December 31, 2022, we had $606.8 million in available liquidity, including $15.8 million in cash, cash equivalents. Our restricted cash is available to fund eligible new investments and commitments. We had available borrowing capacity of $153.0 million under the SMBC Facility and $438.0 million under the MUFG Bank Facility. In addition, the MUFG Bank Facility had an accordion provision through which the available borrowing capacity can be increased by $55.0 million, subject to certain conditions. Subsequently, on January 13, 2023, we entered into a letter of credit agreement with SMBC, which provides for a letter of credit facility of up to $100.0 million. Coterminously, we amended the existing MUFG Bank Facility decreasing the current maximum revolver to $400.0 million while increasing the accordion provision to $200.0 million. Refer to “Note 5 – Debt” and “Note 14 – Subsequent Events” included in the notes to our consolidated financial statements appearing elsewhere in this report for additional discussion.

The 1940 Act permits BDCs to incur borrowings, issue debt securities, or issue preferred stock unless immediately after the borrowings or issuance the ratio of total assets (less total liabilities other than indebtedness) to total indebtedness plus preferred stock is less than 200% (or 150% if certain requirements are met). On September 4, 2018 and December 6, 2018, our Board, including a “required majority” (as such term is defined in Section 57(o) of the 1940 Act) and our stockholders, respectively, approved the application to us of the 150% minimum asset coverage ratio set forth in Section 61(a)(2) of the 1940 Act. As of December 31, 2022, our asset coverage ratio under our regulatory requirements as a BDC was 198.5% excluding our SBA debentures. Our exemptive order from the SEC allows us to exclude all SBA leverage from our asset coverage ratio. As a result of the SEC exemptive order, our ratio of total assets on a consolidated basis to outstanding indebtedness may be less than 150%, which while providing increased investment flexibility, also may increase our exposure to risks associated with leverage. Total asset coverage when including our SBA debentures was 187.7% as of December 31, 2022.

As of December 31, 2022, we had $179.0 million outstanding under our Credit Facilities, which are floating interest rate obligations. As of December 31, 2022, the remaining $1,415.0 million of debt outstanding were all fixed interest rate debt obligations.

During the year ended December 31, 2022, we issued $350.0 million in aggregate principal amount of January 2027 Notes, which generated net proceeds of approximately $343.4 million. The net proceeds from the January 2027 Notes generated was primarily used to repay the 2022 Convertible Notes and to retire the 2022 Notes. In addition, we issued $150.0 million and $50.0 million in aggregate principal which generated net proceeds of approximately $147.7 million and $49.5 million related to the 2031 Asset- Backed Notes and June 2025 3-Year Notes, respectively. We also borrowed the remaining $24.5 million of capital available through our SBIC, and raised $229.7 million through ATM equity offerings of common shares.

Lastly, as of December 31, 2022, $10.1 million of cash was classified as restricted cash. Our restricted cash relates to amounts that are held as collateral securing certain of the Company’s financing transactions, including collections of interest and principal payments on assets that are securitized related to the 2031 Asset-Backed Notes. Based on current characteristics of the securitized debt investment portfolios, the restricted funds may be used to pay monthly interest and principal on the securitized debt with any excess distributed to us or available for our general operations. Refer to “Note 5 – Debt” included in the notes to our consolidated financial statements appearing elsewhere in this report for additional discussion of our debt obligations.

As detailed above, our diverse and well-structured balance sheet is designed to provide a long-term focused and sustainable investment platform. Currently, we believe we have ample liquidity to support our near-term capital requirements. As the impact of the macro-economic events, including the COVID-19 pandemic, the war in Ukraine, and the related disruption to markets and business continues to impact the economy, we will continue to evaluate our overall liquidity position and take proactive steps to maintain the appropriate liquidity position based upon the current circumstances.

Equity Offerings

We may from time-to-time issue and sell shares of our common stock through public or ATM offerings. We currently sell shares through our equity distribution agreement with JMP Securities LLC (“JMP”) and Jefferies LLC (“Jeffries”) (the “2022 Equity Distribution Agreement”). The 2022 Equity Distribution Agreement provides that we may offer and sell up to 17.5 million shares of our common stock from time to time through JMP or Jeffries, as our sales agents. Sales of our common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

During the year ended December 31, 2022, we issued and sold 14.6 million shares of our common stock receiving total accumulated net proceeds of approximately $229.7 million. This is an increase from the year ended December 31, 2021, where we issued and sold 0.6 million shares of our common stock receiving total accumulated net proceeds of approximately $10.6 million.

We generally use net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of December 31, 2022, approximately 8.5 million shares remain available for issuance and sale under the current equity distribution agreement.

 

63


 

Stock Repurchase

We may from time to time seek to retire or repurchase our common stock through cash purchases, as well as retire, cancel or purchase our outstanding debt through cash purchases and/or exchanges, in open market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will depend on prevailing market conditions, our liquidity requirements, contractual and regulatory restrictions and other factors. The amounts involved may be material. We had no common stock repurchases during the years ended 2020, 2021, or 2022.

Commitments and Obligations

Our significant cash requirements generally relate to our debt obligations. As of December 31, 2022, we had $1,594.0 million of debt outstanding, none of which was due within the next year, $382.0 million being due within 1 to 3 years, and $1,212.0 million being due beyond 3 years.

In addition to our debt obligations, in the normal course of business, we are party to financial instruments with off-balance sheet risk. These consist primarily of unfunded contractual commitments to extend credit, in the form of loans, to our portfolio companies. Unfunded contractual commitments to provide funds to portfolio companies are not reflected on our balance sheet.

Our unfunded contractual commitments may be significant from time to time. A portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, our credit agreements contain customary lending provisions which allow us relief from funding obligations for previously made unfunded commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as are the on-balance sheet financial instruments that we hold. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash requirements. As such, our disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by milestones. Refer to “Note 11 – Commitments and Contingencies” included in the notes to our consolidated financial statements appearing elsewhere in this report for additional discussion of our unfunded commitments.

As of December 31, 2022, we had approximately $628.9 million of available unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by future or unachieved milestones, as well as uncalled capital commitments to make investments in private equity funds. In order to draw a portion of the Company's available unfunded commitments, a portfolio company must submit to the Company a formal funding request that complies with the applicable advance notice and other operational requirements. The available unfunded commitments excludes unfunded commitments (i) for which, with respect to a portfolio company's agreement, a milestone was achieved after the last day on which the portfolio company could have requested a drawdown funding to be completed within the reporting period; and (ii) $173.5 million of unfunded commitments which represent the portion of portfolio company commitments assigned to or directly committed by the Adviser Funds.

Additionally, we had approximately $136.1 million of non-binding term sheets outstanding to four new companies and two existing companies, which generally convert to contractual commitments within approximately 90 days of signing. Non-binding outstanding term sheets are subject to completion of our due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

The fair value of our unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations imbedded in the borrowing agreements.

 

64


 

Critical Accounting Policies and Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and revenues and expenses during the period reported. On an ongoing basis, our management evaluates its estimates and assumptions, which are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in our estimates and assumptions could materially impact our results of operations and financial condition.

For a description of our critical accounting policies, refer to “Note 2 – Summary of Significant Accounting Policies” included in the notes to our consolidated financial statements appearing elsewhere in this report. We consider the most significant accounting policies to be those related to our Valuation of Investments, Fair Valuation Measurements, Income Recognition, and Income Taxes. The valuation of investments is our most significant critical estimate. The most significant input to this estimate is the yield interest rate, which includes the hypothetical market yield plus premium or discount adjustment, used in determining the fair value of our debt investments. The following table shows the approximate increase (decrease) to the fair value of our debt investments from hypothetical change to the yield interest rates used for each valuation, assuming no other changes:

(in thousands)

 

Change in unrealized

 

Basis Point Change

 

appreciation (depreciation)

 

(100)

 

$

38,253

 

(50)

 

$

19,378

 

50

 

$

(19,776

)

100

 

$

(39,630

)

For a further discussion and disclosure of key inputs and considerations related to this estimate, refer to "Note 3 - Fair Value of Financial Instruments" included in the notes to our consolidated financial statements appearing elsewhere in this report.

 

65


 

Item 7A. Quantitative and Qualitative Disclosure About Market Risk

We are subject to financial market risks, including changes in interest rates. Interest rate risk is defined as the sensitivity of our current and future earnings to interest rate volatility, variability of spread relationships, the difference in re-pricing intervals between our assets and liabilities and the effect that interest rates may have on our cash flows. Changes in interest rates may affect both our cost of funding and our interest income from portfolio investments, cash and cash equivalents and idle fund investments. Our investment income will be affected by changes in various interest rates, including Prime, LIBOR, SOFR, Eurodollar, and BSBY rates, to the extent our debt investments include variable interest rates. As of December 31, 2022, approximately 95.3% of the loans in our portfolio had variable rates based on floating Prime, LIBOR, SOFR, Eurodollar, or BSBY rates with a floor. As of December 31, 2022, approximately 10.2% of our debt investments have variable rates based on LIBOR and 13.3% of our debt investments have variable rates based on SOFR, BSBY, or Eurodollar rates. Additionally, all of our LIBOR rate based debt securities have interest rate floors. We are actively considering and discussing the preferred alternative benchmark with our portfolio companies and prioritize the inclusion of LIBOR fallback language in our documentation. The Alternative Reference Rates Committee ("ARRC") has recommended for US based debt securities to use the SOFR rate as the alternative benchmark. Our debt borrowings under the Credit Facilities bear interest at a floating rate, all other outstanding debt borrowings bear interest at a fixed rate. Changes in interest rates can also affect, among other things, our ability to acquire and originate loans and securities and the value of our investment portfolio.

Based on our Consolidated Statement of Assets and Liabilities as of December 31, 2022, the following table shows the approximate annualized increase (decrease) in components of net assets resulting from operations of hypothetical base rate changes in interest rates, assuming no changes in our investments and debt.

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basis Point Change

 

Interest Income

 

 

Interest Expense

 

 

Net Income

 

 

EPS

 

(75)

 

 

 

(18,661

)

 

 

 

(1,215

)

 

 

 

(17,446

)

 

 

 

(0.13

)

(50)

 

 

 

(12,441

)

 

 

 

(810

)

 

 

 

(11,631

)

 

 

 

(0.09

)

(25)

 

 

 

(6,176

)

 

 

 

(405

)

 

 

 

(5,771

)

 

 

 

(0.04

)

25

 

 

 

6,176

 

 

 

 

405

 

 

 

 

5,771

 

 

 

 

0.04

 

50

 

 

 

12,352

 

 

 

 

810

 

 

 

 

11,542

 

 

 

 

0.09

 

75

 

 

 

18,528

 

 

 

 

1,215

 

 

 

 

17,313

 

 

 

 

0.13

 

100

 

 

 

24,644

 

 

 

 

1,619

 

 

 

 

23,025

 

 

 

 

0.18

 

200

 

 

 

48,748

 

 

 

 

3,239

 

 

 

 

45,509

 

 

 

 

0.35

 

We do not currently engage in any hedging activities. However, we may, in the future, hedge against interest rate fluctuations and foreign currency by using standard hedging instruments such as futures, options, and forward contracts. While hedging activities may insulate us against changes in interest rates and foreign currency, they may also limit our ability to participate in the benefits of lower interest rates with respect to our borrowed funds and higher interest rates with respect to our portfolio of investments. During the year ended December 31, 2022, we did not engage in interest rate or foreign currency hedging activities.

Although we believe that the foregoing analysis is indicative of our sensitivity to interest rate changes, it does not adjust for potential changes in the credit market, credit quality, size and composition of the assets in our portfolio. It also does not adjust for other business developments, including our debt borrowings and use of our Credit Facilities that could affect the net increase in net assets resulting from operations, or net income. It also does not assume any repayments from our portfolio companies. Accordingly, no assurances can be given that actual results would not differ materially from the statement above.

Because we currently borrow, and plan to borrow in the future, money to make investments, our net investment income is dependent upon the difference between the rate at which we borrow funds and the rate at which we invest the funds borrowed. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. In periods of rising interest rates, our cost of funds would increase, which could reduce our net investment income if there is not a corresponding increase in interest income generated by variable rate assets in our investment portfolio. For additional information regarding the interest rate associated with each of our debt borrowings, refer to “Note 5 – Debt” included in the notes to our consolidated financial statements in this report on Form 10-K.

 

66


 

 

Item 8. Financial Statements and Supplementary Data

INDEX TO FINANCIAL STATEMENTS

 

Report of Independent Registered Public Accounting Firm

68

Consolidated Statements of Assets and Liabilities as of December 31, 2022 and December 2021

70

Consolidated Statements of Operations for the three years ended December 31,2022

71

Consolidated Statements of Changes in Net Assets for the three years ended December 31,2022

72

Consolidated Statements of Cash Flows for the three years ended December 31, 2022

73

Consolidated Schedule of Investments as of December 31, 2022

74

Consolidated Schedule of Investments as of December 31, 2021

85

Notes to Consolidated Financial Statements

95

Consolidated Schedule of Investments in and Advances to Affiliates as of December 31, 2022

137

Consolidated Schedule of Investments in and Advances to Affiliates as of December 31, 2021

138

 

 

67


 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of Hercules Capital, Inc.

 

Opinions on the Financial Statements and Internal Control over Financial Reporting

 

We have audited the accompanying consolidated statements of assets and liabilities, including the consolidated schedules of investments, of Hercules Capital, Inc. and its subsidiaries (the “Company”) as of December 31, 2022 and 2021, and the related consolidated statements of operations, changes in net assets and cash flows for each of the three years in the period ended December 31, 2022, including the related notes and financial statement schedule listed in the accompanying index (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

 

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations, changes in its net assets and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.

 

We have also previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated statements of assets and liabilities, including the consolidated schedules of investments, of Hercules Capital, Inc. and its subsidiaries as of December 31, 2020, 2019, 2018, 2017, 2016, 2015, 2014, and 2013, and the related consolidated statements of operations, changes in net assets and cash flows for each of the years ended December 31, 2013 through 2019 (none of which are presented herein), and we expressed unqualified opinions on those consolidated financial statements. In our opinion, the information set forth in the Senior Securities table of Hercules Capital, Inc. and its subsidiaries for each of the ten years in the period ended December 31, 2022, is fairly stated, in all material respects, in relation to the consolidated financial statements from which it has been derived.

 

Basis for Opinions

 

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

 

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our procedures included confirmation of securities owned as of December 31, 2022 and 2021 by correspondence with the custodians, agent banks and portfolio company investees; when replies were not received, we performed other auditing procedures. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

 

 

68


 

Definition and Limitations of Internal Control over Financial Reporting

 

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Critical Audit Matters

 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Valuation of Investments - Level 3 Investments in Senior Secured Debt, Unsecured Debt, Preferred Stock, Common Stock

 

As described in Notes 2 and 3 to the consolidated financial statements, approximately 96.6% of the Company’s $2,964 million total investments in securities as of December 31, 2022 represents investments in level 3 senior secured debt, unsecured debt, preferred stock, and common stock whose fair value, as disclosed by management, is determined in good faith by the Board of Directors. Management applied significant judgment in determining the fair value of these level 3 investments, which involved the use of significant unobservable inputs related to i) hypothetical market yields, premiums/(discounts) and the probability weighting of alternative outcomes for debt securities; and ii) the revenue and/or EBITDA multiples, market equity adjustments, discounts for lack of marketability, tangible book value multiple, and cash flow discount rate for equity securities.

 

The principal considerations for our determination that performing procedures relating to the valuation of level 3 investments in senior secured debt, unsecured debt, preferred stock and common stock, is a critical audit matter are the significant judgment by management to determine the fair value of these level 3 investments, including the use of the hypothetical market yields, premiums/(discounts), the probability weighting of alternative outcomes, discounts for lack of marketability, tangible book value multiple and cash flow discount rate, which in turn led to a high degree of auditor judgment, subjectivity, and effort in performing audit procedures and evaluating the audit evidence obtained relating to the significant unobservable inputs. The audit effort involved the use of professionals with specialized skill and knowledge to assist in performing procedures and evaluating the audit evidence obtained.

 

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the valuation of level 3 investments in senior secured debt, unsecured debt, preferred stock, and common stock, including controls over the Company’s methods and significant unobservable inputs. These procedures also included, among others, (i) testing the completeness and accuracy of data provided by management, evaluating the appropriateness of management’s methods, and evaluating the reasonableness of significant unobservable inputs used in those methods related to the hypothetical market yields, premiums/(discounts), and the probability weighting of alternative outcomes for debt securities; and discounts for lack of marketability, tangible book value multiple, and cash flow discount rate for equity securities, and (ii) the involvement of professionals with specialized skill and knowledge to assist in developing an independent fair value range for a sample of securities and comparison of management’s estimate to the independently developed fair value range. Developing the independent fair value range involved testing the completeness and accuracy of data provided by management and developing independent significant unobservable inputs in order to evaluate the reasonableness of management’s fair value estimate of these certain level 3 investments.

/s/ PricewaterhouseCoopers LLP

San Francisco, California

February 16, 2023

 

We have served as the Company’s auditor since 2010.

 

69


 

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES

 

(in thousands, except per share data)

 

 

 

 

 

 

 

 

December 31, 2022

 

 

December 31, 2021

 

Assets

 

 

 

 

 

 

Investments, at fair value:

 

 

 

 

 

 

Non-control/Non-affiliate investments (cost of $2,918,425 and $2,293,398, respectively)

 

$

2,887,497

 

 

$

2,351,560

 

Control investments (cost of $87,271 and $84,039, respectively)

 

 

76,458

 

 

 

73,504

 

Affiliate investments (cost of $0 and $13,547, respectively)

 

 

 

 

 

9,458

 

 Total investments, at fair value (cost of $3,005,696 and $2,390,984, respectively; fair value amounts related to a VIE $236,585 and $0, respectively)

 

 

2,963,955

 

 

 

2,434,522

 

Cash and cash equivalents

 

 

15,797

 

 

 

133,115

 

Restricted cash (amounts related to a VIE $10,079 and $0, respectively)

 

 

10,079

 

 

 

3,150

 

Interest receivable

 

 

31,682

 

 

 

17,365

 

Right of use asset

 

 

4,986

 

 

 

6,761

 

Other assets

 

 

2,356

 

 

 

5,100

 

Total assets

 

$

3,028,855

 

 

$

2,600,013

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

Debt (net of debt issuance costs - Note 5; amounts related to a VIE $147,957 and $0, respectively)

 

$

1,574,351

 

 

$

1,236,303

 

Accounts payable and accrued liabilities

 

 

47,539

 

 

 

47,781

 

Operating lease liability

 

 

5,506

 

 

 

7,382

 

Total liabilities

 

$

1,627,396

 

 

$

1,291,466

 

 

 

 

 

 

 

 

Commitments and contingencies (Note 11)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net assets consist of:

 

 

 

 

 

 

Common stock, par value

 

$

134

 

 

$

117

 

Capital in excess of par value

 

 

1,341,416

 

 

 

1,091,907

 

Total distributable earnings

 

 

59,909

 

 

 

216,523

 

Total net assets

 

$

1,401,459

 

 

$

1,308,547

 

Total liabilities and net assets

 

$

3,028,855

 

 

$

2,600,013

 

 

 

 

 

 

 

 

Shares of common stock outstanding ($0.001 par value and 200,000 authorized)

 

 

133,045

 

 

 

116,619

 

Net asset value per share

 

$

10.53

 

 

$

11.22

 

 

 

See notes to consolidated financial statements.

70

 


 

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

 

(in thousands, except per share data)

 

For the Year Ended December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

Investment income:

 

 

 

 

 

 

 

 

 

Interest and dividend income:

 

 

 

 

 

 

 

 

 

Non-control/Non-affiliate investments

 

$

301,433

 

 

$

249,341

 

 

$

259,989

 

Control investments

 

 

4,621

 

 

 

4,009

 

 

 

2,857

 

Affiliate investments

 

 

1,204

 

 

 

10

 

 

 

533

 

Total interest and dividend income

 

 

307,258

 

 

 

253,360

 

 

 

263,379

 

Fee income:

 

 

 

 

 

 

 

 

 

Non-control/Non-affiliate investments

 

 

14,362

 

 

 

27,557

 

 

 

23,858

 

Control investments

 

 

68

 

 

 

59

 

 

 

21

 

Total fee income

 

 

14,430

 

 

 

27,616

 

 

 

23,879

 

Total investment income

 

 

321,688

 

 

 

280,976

 

 

 

287,258

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Interest

 

 

54,749

 

 

 

54,447

 

 

 

59,605

 

Loan fees

 

 

7,598

 

 

 

8,657

 

 

 

7,269

 

General and administrative

 

 

16,948

 

 

 

16,111

 

 

 

18,910

 

Tax expenses

 

 

5,416

 

 

 

7,928

 

 

 

4,285

 

Employee compensation:

 

 

 

 

 

 

 

 

 

Compensation and benefits

 

 

43,852

 

 

 

36,970

 

 

 

28,996

 

Stock-based compensation

 

 

13,378

 

 

 

11,930

 

 

 

11,053

 

Total employee compensation

 

 

57,230

 

 

 

48,900

 

 

 

40,049

 

Total gross operating expenses

 

 

141,941

 

 

 

136,043

 

 

 

130,118

 

Expenses allocated to the Adviser Subsidiary

 

 

(8,321

)

 

 

(5,035

)

 

 

 

Total net operating expenses

 

 

133,620

 

 

 

131,008

 

 

 

130,118

 

Net investment income

 

 

188,068

 

 

 

149,968

 

 

 

157,140

 

Net realized gain (loss) and net change in unrealized appreciation (depreciation):

 

 

 

 

 

 

 

 

 

Net realized gain (loss):

 

 

 

 

 

 

 

 

 

Non-control/Non-affiliate investments

 

 

1,004

 

 

 

87,438

 

 

 

(41,956

)

Affiliate investments

 

 

1,758

 

 

 

(62,143

)

 

 

(14,149

)

Loss on extinguishment of debt

 

 

(3,686

)

 

 

(4,419

)

 

 

 

Total net realized gain (loss)

 

 

(924

)

 

 

20,876

 

 

 

(56,105

)

Net change in unrealized appreciation (depreciation):

 

 

 

 

 

 

 

 

 

Non-control/Non-affiliate investments

 

 

(88,874

)

 

 

(57,818

)

 

 

128,238

 

Control investments

 

 

(278

)

 

 

(2,677

)

 

 

(2,271

)

Affiliate investments

 

 

4,089

 

 

 

63,806

 

 

 

259

 

Total net change in unrealized appreciation (depreciation)

 

 

(85,063

)

 

 

3,311

 

 

 

126,226

 

Total net realized gain (loss) and net change in unrealized appreciation (depreciation)

 

 

(85,987

)

 

 

24,187

 

 

 

70,121

 

Net increase (decrease) in net assets resulting from operations

 

$

102,081

 

 

$

174,155

 

 

$

227,261

 

 

 

 

 

 

 

 

 

 

 

Net investment income before gains and losses per common share:

 

 

 

 

 

 

 

 

 

Basic

 

$

1.48

 

 

$

1.29

 

 

$

1.39

 

Change in net assets resulting from operations per common share:

 

 

 

 

 

 

 

 

 

Basic

 

$

0.80

 

 

$

1.50

 

 

$

2.02

 

Diluted

 

$

0.79

 

 

$

1.49

 

 

$

2.01

 

Weighted average shares outstanding:

 

 

 

 

 

 

 

 

 

Basic

 

 

125,189

 

 

 

114,742

 

 

 

111,985

 

Diluted

 

 

126,659

 

 

 

115,955

 

 

 

112,267

 

Distributions paid per common share:

 

 

 

 

 

 

 

 

 

Basic

 

$

1.97

 

 

$

1.55

 

 

$

1.38

 

 

See notes to consolidated financial statements.

71

 


 

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(amounts in thousands)

 

 

 

 

 

Capital in

 

Distributable

 

 

 

 

 

Common Stock

 

excess

 

Earnings

 

Net

 

 

 

Shares

 

Par Value

 

of par value

 

(loss)

 

Assets

 

Balance as of December 31, 2019

 

 

107,364

 

$

108

 

$

1,145,106

 

$

(12,165

)

$

1,133,049

 

Net increase in net assets resulting from operations

 

 

 

 

 

 

 

 

227,261

 

 

227,261

 

Public offering, net of offering expenses

 

 

6,272

 

 

6

 

 

77,174

 

 

 

 

77,180

 

Issuance of common stock due to stock option exercises

 

 

54

 

 

 

 

662

 

 

 

 

662

 

Retired shares from net issuance of stock options exercises

 

 

(47

)

 

 

 

(682

)

 

 

 

(682

)

Issuance of common stock under restricted stock plan

 

 

862

 

 

1

 

 

(1

)

 

 

 

 

Retired shares for restricted stock vesting

 

 

(59

)

 

 

 

(1,817

)

 

 

 

(1,817

)

Distributions reinvested in common stock

 

 

280

 

 

 

 

3,339

 

 

 

 

3,339

 

Distributions

 

 

 

 

 

 

 

 

(155,761

)

 

(155,761

)

Stock-based compensation (1)

 

 

 

 

 

 

8,473

 

 

 

 

8,473

 

Tax reclassification of stockholders' equity in accordance with generally accepted accounting principles

 

 

 

 

 

 

(74,056

)

 

74,056

 

 

 

Balance as of December 31, 2020

 

 

114,726

 

$

115

 

$

1,158,198

 

$

133,391

 

$

1,291,704

 

Net increase in net assets resulting from operations

 

 

 

 

 

 

 

 

174,155

 

 

174,155

 

Public offering, net of offering expenses

 

 

639

 

 

1

 

 

10,619

 

 

 

 

10,620

 

Issuance of common stock due to stock option exercises

 

 

284

 

 

 

 

3,903

 

 

 

 

3,903

 

Retired shares from net issuance of stock options exercises

 

 

(69

)

 

 

 

(1,205

)

 

 

 

(1,205

)

Issuance of common stock under restricted stock plan

 

 

1,027

 

 

1

 

 

(1

)

 

 

 

 

Retired shares for restricted stock vesting

 

 

(236

)

 

 

 

(5,514

)

 

 

 

(5,514

)

Distributions reinvested in common stock

 

 

248

 

 

 

 

4,074

 

 

 

 

4,074

 

Distributions

 

 

 

 

 

 

 

 

(179,575

)

 

(179,575

)

Stock-based compensation (1)

 

 

 

 

 

 

10,385

 

 

 

 

10,385

 

Tax reclassification of stockholders' equity in accordance with generally accepted accounting principles

 

 

 

 

 

 

(88,552

)

 

88,552

 

 

 

Balance as of December 31, 2021

 

 

116,619

 

$

117

 

$

1,091,907

 

$

216,523

 

$

1,308,547

 

Net increase in net assets resulting from operations

 

 

 

 

 

 

 

 

102,081

 

 

102,081

 

Public offering, net of offering expenses

 

 

14,559

 

 

15

 

 

229,644

 

 

 

 

229,659

 

Issuance of common stock due to stock option exercises

 

 

59

 

 

 

 

720

 

 

 

 

720

 

Retired shares from net issuance of stock options exercises

 

 

(14

)

 

 

 

(208

)

 

 

 

(208

)

Issuance of common stock under restricted stock plan

 

 

863

 

 

1

 

 

763

 

 

 

 

764

 

Retired shares for restricted stock vesting

 

 

(281

)

 

 

 

(5,808

)

 

 

 

(5,808

)

Distributions reinvested in common stock

 

 

259

 

 

 

 

3,953

 

 

 

 

3,953

 

Issuance of Convertible Notes

 

 

981

 

 

1

 

 

(1

)

 

 

 

 

Distributions

 

 

 

 

 

 

 

 

(249,077

)

 

(249,077

)

Stock-based compensation (1)

 

 

 

 

 

 

10,828

 

 

 

 

10,828

 

Tax reclassification of stockholders' equity in accordance with generally accepted accounting principles

 

 

 

 

 

 

9,618

 

 

(9,618

)

 

 

Balance as of December 31, 2022

 

 

133,045

 

$

134

 

$

1,341,416

 

$

59,909

 

$

1,401,459

 

 

 

(1)
Stock-based compensation includes $149 thousand, $125 thousand, and $106 thousand of restricted stock and option expense related to director compensation for the years ended December 31, 2022, 2021 and 2020, respectively.

 

See notes to consolidated financial statements.

72

 


 

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(in thousands)

 

For the Year Ended December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

Cash flows from (used in) operating activities:

 

 

 

 

 

 

 

 

 

Net increase in net assets resulting from operations

 

$

102,081

 

 

$

174,155

 

 

$

227,261

 

Adjustments to reconcile net increase in net assets resulting from
operations to net cash provided by (used in) operating activities:

 

 

 

 

 

 

 

 

 

Purchases of investments

 

 

(1,465,035

)

 

 

(1,467,129

)

 

 

(761,258

)

Fundings assigned to Adviser Funds

 

 

330,164

 

 

 

125,295

 

 

 

 

Principal and fee repayments received and proceeds from the sale of debt investments

 

 

530,441

 

 

 

1,183,014

 

 

 

781,240

 

Proceeds from the sale of equity investments

 

 

15,201

 

 

 

111,890

 

 

 

32,777

 

Net change in unrealized (appreciation) depreciation

 

 

85,063

 

 

 

(3,311

)

 

 

(126,226

)

Net realized (gain) loss

 

 

(2,762

)

 

 

(25,295

)

 

 

56,105

 

Accretion of paid-in-kind principal

 

 

(20,455

)

 

 

(11,210

)

 

 

(9,039

)

Accretion of loan discounts

 

 

(4,697

)

 

 

(3,842

)

 

 

(4,356

)

Accretion of loan discount on convertible notes

 

 

112

 

 

 

671

 

 

 

671

 

Accretion of loan exit fees

 

 

(24,532

)

 

 

(23,512

)

 

 

(25,648

)

Change in loan income, net of collections

 

 

26,687

 

 

 

35,045

 

 

 

16,780

 

Unearned fees related to unfunded commitments

 

 

2,201

 

 

 

(2,034

)

 

 

(291

)

Realized loss on debt extinguishment

 

 

364

 

 

 

4,419

 

 

 

 

Amortization of debt fees and issuance costs

 

 

5,562

 

 

 

6,368

 

 

 

5,154

 

Depreciation and amortization

 

 

204

 

 

 

317

 

 

 

415

 

Stock-based compensation and amortization of restricted stock grants (1)

 

 

10,828

 

 

 

10,385

 

 

 

8,473

 

Change in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

Interest receivable

 

 

(14,212

)

 

 

1,712

 

 

 

1,130

 

Other assets

 

 

406

 

 

 

2,175

 

 

 

802

 

Accounts payable

 

 

 

 

 

 

 

 

(16

)

Accrued liabilities

 

 

(2,420

)

 

 

9,508

 

 

 

3,828

 

Net cash provided by (used in) operating activities

 

 

(424,799

)

 

 

128,621

 

 

 

207,802

 

Cash flows used in investing activities:

 

 

 

 

 

 

 

 

 

Purchases of capital equipment

 

 

(114

)

 

 

(106

)

 

 

(137

)

Net cash (used in) investing activities

 

 

(114

)

 

 

(106

)

 

 

(137

)

Cash flows provided by (used in) financing activities:

 

 

 

 

 

 

 

 

 

Issuance of common stock

 

 

232,090

 

 

 

10,829

 

 

 

77,478

 

Offering expenses

 

 

(2,431

)

 

 

(209

)

 

 

(298

)

Retirement of employee shares, net

 

 

(4,532

)

 

 

(2,816

)

 

 

(1,837

)

Distributions paid

 

 

(245,124

)

 

 

(175,501

)

 

 

(152,422

)

Issuance of debt

 

 

1,274,237

 

 

 

1,736,975

 

 

 

824,474

 

Repayment of debt

 

 

(931,198

)

 

 

(1,787,043

)

 

 

(827,405

)

Debt issuance costs

 

 

(6,742

)

 

 

(5,632

)

 

 

(1,419

)

Fees paid for credit facilities and debentures

 

 

(1,776

)

 

 

(6,475

)

 

 

(3,610

)

Net cash provided by (used in) financing activities

 

 

314,524

 

 

 

(229,872

)

 

 

(85,039

)

Net increase (decrease) in cash, cash equivalents and restricted cash

 

 

(110,389

)

 

 

(101,357

)

 

 

122,626

 

Cash, cash equivalents and restricted cash at beginning of period

 

 

136,265

 

 

 

237,622

 

 

 

114,996

 

Cash, cash equivalents and restricted cash at end of period

 

$

25,876

 

 

$

136,265

 

 

$

237,622

 

 

 

 

 

 

 

 

 

 

 

Supplemental disclosures of cash flow information and non-cash investing and financing activities:

 

Interest paid

 

$

52,075

 

 

$

51,469

 

 

$

58,274

 

Income tax, including excise tax, paid

 

$

7,376

 

 

$

3,759

 

 

$

2,458

 

Distributions reinvested

 

$

3,953

 

 

$

4,074

 

 

$

3,339

 

 

(1)
Stock-based compensation includes $149 thousand, $125 thousand, and $106 thousand of restricted stock and option expense related to director compensation for the years ended December 31, 2022, 2021, and 2020, respectively.

The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Statements of Assets and Liabilities that sum to the total of the same such amounts in the Consolidated Statements of Cash Flows:

(in thousands)

 

For the Year Ended December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

Cash and cash equivalents

 

$

15,797

 

 

$

133,115

 

 

$

198,282

 

Restricted cash

 

 

10,079

 

 

 

3,150

 

 

 

39,340

 

Total cash, cash equivalents and restricted cash presented in the Consolidated Statements of Cash Flows

 

$

25,876

 

 

$

136,265

 

 

$

237,622

 

See “Note 2 – Summary of Significant Accounting Policies” for a description of cash, cash equivalents and restricted cash.

See notes to consolidated financial statements.

73

 


HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2022

(dollars in thousands)
 

 

Portfolio Company

 

Type of
Investment

 

Maturity Date

 

Interest Rate and Floor (1)